OrphaCode,Name,Prevalence,ExpertLink
166024,Multiple epiphyseal dysplasia-macrocephaly-facial dysmorphism syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166024
58,Alexander disease,0.037 (Japan); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=58
166032,Multiple epiphyseal dysplasia-miniepiphyses syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166032
61,Alpha-mannosidosis,0.1 (Europe); 0.09 (Australia); 0.13 (Norway); 0.09 (Netherlands); 0.12 (Portugal); 0.38 (Czech Republic); 0.07 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=61
166029,Multiple epiphyseal dysplasia-severe proximal femoral dysplasia syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166029
166038,"Metaphyseal chondrodysplasia, Kaitila type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166038
93,Aspartylglucosaminuria,0.2 (Australia); 0.0 (Worldwide); 0.62 (Sweden); 3.35 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93
166035,Brachydactyly-short stature-retinitis pigmentosa syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166035
585,Multiple sulfatase deficiency,154.0 (Worldwide); 0.2 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585
118,Beta-mannosidosis,0.14 (Europe); 0.16 (Czech Republic); 0.13 (Netherlands); 0.12 (Portugal); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=118
141,Canavan disease,0.0 (Worldwide); 7.0 (Specific population); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141
166063,Pontocerebellar hypoplasia type 4,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166063
166078,Von Willebrand disease type 1,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166078
166073,Pontocerebellar hypoplasia type 6,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166073
213,Cystinosis,0.75 (Worldwide); 0.5 (Europe); 0.31 (France); 0.59 (Germany); 2.1 (United Kingdom); 0.52 (Australia); 1.5 (Europe); 0.87 (Denmark); 0.38 (Sweden); 1.6 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213
166084,Von Willebrand disease type 2A,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166084
333,Farber disease,96.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=333
166081,Von Willebrand disease type 2,0.935 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166081
349,Fucosidosis,161.0 (Worldwide); 0.0 (Worldwide); 0.1 (Sweden); 0.63 (Cuba),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=349
166090,Von Willebrand disease type 2M,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166090
365,Glycogen storage disease due to acid maltase deficiency,0.8 (Europe); 0.17 (Portugal); 0.83 (Italy); 2.25 (Netherlands); 0.37 (Czech Republic); 11.5 (Austria); 2.5 (United States); 0.68 (Australia); 2.0 (China); 0.0 (Worldwide); 0.72 (Sweden); 2.3 (Israel); 4.8 (Specific population); 3.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=365
166087,Von Willebrand disease type 2B,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166087
366,Glycogen storage disease due to glycogen debranching enzyme deficiency,1.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=366
166093,Von Willebrand disease type 2N,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166093
368,Glycogen storage disease due to muscle glycogen phosphorylase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=368
166096,Von Willebrand disease type 3,0.1865 (Worldwide); 0.037 (Austria); 0.24 (Finland); 0.016 (France); 0.044 (Greece); 0.16 (Israel); 0.055 (Italy); 0.037 (Netherlands); 0.25 (Norway); 0.022 (Portugal); 0.011 (Spain); 0.312 (Sweden); 0.027 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166096
367,Glycogen storage disease due to glycogen branching enzyme deficiency,0.1 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=367
371,Glycogen storage disease due to muscle phosphofructokinase deficiency,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=371
166105,FASTKD2-related infantile mitochondrial encephalomyopathy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166105
369,Glycogen storage disease due to liver glycogen phosphorylase deficiency,0.0 (Worldwide); 2.3 (Israel); 4.8 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369
447,Paroxysmal nocturnal hemoglobinuria,0.35 (United Kingdom); 3.81 (United Kingdom); 2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447
166108,Birk-Barel syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166108
166113,Bazex syndrome,145.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166113
535,Rare cutaneous lupus erythematosus,50.0 (Europe); 4.3 (United States); 73.0 (United States); 4.0 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=535
166119,Isolated osteopoikilosis,2.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166119
487,Krabbe disease,0.327 (United States); 1.0 (Europe); 0.7 (Worldwide); 1.0 (Europe); 0.7 (France); 0.71 (Australia); 1.35 (Netherlands); 1.21 (Portugal); 0.6 (Germany); 1.0 (Turkey); 0.4 (Czech Republic); 1.9 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=487
166260,Dentinogenesis imperfecta type 2,14.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166260
166265,Dentinogenesis imperfecta type 3,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166265
583,Mucopolysaccharidosis type 6,"0.16 (Europe); 0.23 (Germany); 0.15 (Netherlands); 0.42 (Portugal); 0.23 (Sweden); 3.3 (Sweden); 0.07 (Norway); 2.2 (Norway); 0.05 (Denmark); 3.7 (Denmark); 0.05 (Czech Republic); 0.37 (Australia); 0.1 (Canada); 0.14 (Taiwan, Province of China); 0.27 (Estonia); 0.059 (Colombia); 0.16 (Europe); 2.3 (Turkey); 0.0132 (Poland); 7.85 (Saudi Arabia); 0.28 (Brazil); 0.03 (Japan); 0.11 (Switzerland); 0.3 (Tunisia); 0.019 (Korea, Republic of); 0.04 (United States); 0.011 (United States)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=583
166272,Odontochondrodysplasia,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166272
576,Mucolipidosis type II,0.34 (Europe); 0.0 (Europe); 0.81 (Portugal); 0.16 (Netherlands); 16.2 (Specific population); 0.05 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=576
166277,Wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166277
812,Sialidosis type 1,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=812
166282,Familial sick sinus syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166282
578,Mucolipidosis type IV,0.0 (Worldwide); 0.1 (Sweden); 2.5 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=578
166286,Porokeratotic eccrine ostial and dermal duct nevus,45.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166286
577,Mucolipidosis type III,0.985 (Europe); 0.08 (Netherlands); 1.68 (Portugal); 29.55 (Europe); 2.4 (Netherlands); 50.4 (Portugal),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=577
166291,Dirofilariasis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166291
166308,Benign infantile focal epilepsy with midline spikes and waves during sleep,36.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166308
166305,Benign infantile seizures associated with mild gastroenteritis,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166305
2912,Poliomyelitis,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2912
796,Sandhoff disease,1.49 (Portugal); 0.34 (Netherlands); 0.19 (Czech Republic); 0.26 (Australia); 0.95 (Turkey); 0.3 (United States); 0.67 (Europe); 0.0 (Europe); 0.38 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=796
801,Scleroderma,1.41 (Worldwide); 42.0 (Worldwide); 1.5 (Australia); 23.0 (Australia); 469.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=801
461,Recessive X-linked ichthyosis,15.0 (Europe); 16.6 (Europe); 9.9 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=461
584,Mucopolysaccharidosis type 7,0.01 (Europe); 0.24 (Netherlands); 0.02 (Brazil); 0.02 (Czech Republic); 0.02 (Japan); 0.038 (Switzerland); 0.047 (Australia); 0.007 (United States); 0.027 (United States); 0.29 (Canada),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=584
881,Turner syndrome,5.5 (Europe); 7.5 (Austria); 7.9 (Belgium); 10.5 (Bulgaria); 3.6 (Croatia); 10.4 (Denmark); 7.1 (France); 8.0 (Germany); 3.2 (Hungary); 7.1 (Ireland); 3.4 (Italy); 1.1 (Malta); 14.0 (Netherlands); 4.2 (Norway); 3.6 (Poland); 2.8 (Portugal); 2.8 (Spain); 22.4 (Switzerland); 10.1 (United Kingdom); 2.3 (Ukraine); 70.0 (Japan); 42.5 (Singapore); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=881
95,Friedreich ataxia,2.0 (Europe); 2.3 (France); 2.8 (Italy); 1.1 (Italy); 6.2 (Spain); 4.3 (Spain); 1.0 (Finland); 0.13 (Finland); 0.7 (Denmark); 0.9 (Portugal); 1.8 (United Kingdom); 0.9 (Greece); 1.0 (Norway); 2.1 (Germany); 0.24 (Sweden); 0.27 (Czech Republic); 3.03 (Russian Federation),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95
848,Beta-thalassemia,1.0 (Worldwide); 0.5 (France); 10.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=848
846,Alpha-thalassemia,0.0 (Europe); 10.3 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=846
586,Cystic fibrosis,19.3912 (Europe); 11.1319 (Europe); 28.5714 (Austria); 8.39 (Austria); 35.0877 (Belgium); 20.1429 (Belgium); 40.0 (Bulgaria); 2.26 (Bulgaria); 12.6358 (Cyprus); 3.35 (Cyprus); 15.29 (Czech Republic); 8.7775 (Czech Republic); 17.41 (Denmark); 9.9946 (Denmark); 22.2222 (Estonia); 6.18 (Estonia); 4.0 (Finland); 1.1027 (Finland); 21.15 (France); 12.1416 (France); 19.5017 (Germany); 11.1954 (Germany); 28.5714 (Greece); 5.21 (Greece); 0.0 (Hungary); 4.09 (Hungary); 36.36 (Ireland); 20.8733 (Ireland); 17.809 (Italy); 10.2236 (Italy); 0.0 (Latvia); 1.04 (Latvia); 0.0 (Lithuania); 1.3 (Lithuania); 0.0 (Luxembourg); 4.31 (Luxembourg); 0.0 (Malta); 5.79 (Malta); 16.58 (Netherlands); 9.5181 (Netherlands); 11.5474 (Norway); 6.629 (Norway); 17.4881 (Poland); 10.0394 (Poland); 12.549 (Portugal); 7.204 (Portugal); 48.6381 (Romania); 1.06 (Romania); 9.7119 (Russian Federation); 5.5753 (Russian Federation); 15.38 (Slovakia); 8.8292 (Slovakia); 33.3333 (Slovenia); 3.28 (Slovenia); 16.5048 (Spain); 9.4749 (Spain); 17.9285 (Sweden); 10.2922 (Sweden); 41.9991 (United Kingdom); 13.7 (United Kingdom); 13.1995 (Brazil); 0.7786 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=586
262,Duchenne and Becker muscular dystrophy,0.23 (United Kingdom); 0.0 (Europe); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=262
261,Emery-Dreifuss muscular dystrophy,0.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261
550,MELAS,0.18 (Japan); 0.0 (Worldwide); 0.6 (Europe); 1.63 (Finland); 236.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=550
269,Facioscapulohumeral dystrophy,4.5 (Europe); 4.4 (Italy); 3.95 (United Kingdom); 2.0 (Japan); 12.0 (Netherlands); 0.3 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269
480,Kearns-Sayre syndrome,2.0 (Europe); 0.8 (Finland); 1.0 (United Kingdom); 0.3 (Israel),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480
593,Myofibrillar myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=593
551,MERRF,0.494 (Sweden); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=551
597,Central core disease,0.4 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597
607,Nemaline myopathy,2.0 (Europe); 0.2 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=607
163746,Peripheral demyelinating neuropathy-central dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschsprung disease,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163746
684,Paramyotonia congenita of Von Eulenburg,0.0 (Worldwide); 0.17 (United Kingdom); 0.94 (Netherlands); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=684
273,Steinert myotonic dystrophy,"5.0 (Europe); 12.5 (Worldwide); 10.4 (United Kingdom); 7.9 (Iceland); 5.3 (Serbia); 9.13 (Japan); 0.46 (Taiwan, Province of China); 14.3 (South Africa); 76.3 (Specific population); 210.5 (Specific population); 0.2 (Serbia); 9.31 (Italy); 11.95 (Ireland); 20.0 (Specific population); 5.7 (Specific population); 18.1 (Croatia)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=273
163937,"X-linked intellectual disability, Najm type",35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163937
163934,Atopic keratoconjunctivitis,15.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163934
614,Thomsen and Becker disease,1.0 (Worldwide); 0.0 (Europe); 7.3 (Finland); 0.9 (Italy); 0.52 (United Kingdom); 0.75 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=614
163921,Posttransplant acute limbic encephalitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163921
163966,"X-linked dominant chondrodysplasia, Chassaing-Lacombe type",10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163966
163971,"X-linked intellectual disability, Cilliers type",0.0 (Worldwide); 4.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163971
163976,"X-linked intellectual disability, Van Esch type",0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163976
163979,X-linked intellectual disability-craniofacioskeletal syndrome,0.0 (Worldwide); 9.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163979
163956,"X-linked intellectual disability, Nascimento type",8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163956
163961,X-linked cerebral-cerebellar-coloboma syndrome,0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163961
324,Fabry disease,6.66 (Worldwide); 6.96 (Australia); 0.21 (Netherlands); 0.12 (Portugal); 0.52 (Czech Republic); 0.015 (Turkey); 0.15 (United Kingdom); 0.25 (Japan); 0.0 (Europe); 1.11 (Sweden); 0.118 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324
163985,Hyperekplexia-epilepsy syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163985
778,Rett syndrome,5.0 (Europe); 10.0 (Europe); 0.0 (France); 0.0 (Worldwide); 5.0 (Sweden); 0.0 (Japan); 0.0 (United States); 1.6 (United Kingdom); 3.05 (Australia); 0.0 (Australia); 0.0 (Hong Kong),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=778
72,Angelman syndrome,7.5 (Worldwide); 1.3 (Europe); 0.0 (Europe); 2.5 (Australia); 0.0 (Australia); 5.0 (Spain); 8.3 (Spain); 1.8 (Estonia); 0.0 (Estonia); 10.0 (Denmark); 0.5 (Denmark); 4.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=72
307,Juvenile myoclonic epilepsy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=307
1941,Juvenile absence epilepsy,7.5 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1941
892,Von Hippel-Lindau disease,2.3 (United Kingdom); 1.1 (United Kingdom); 0.0 (Europe); 2.13 (Denmark); 3.66 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=892
731,Autosomal recessive polycystic kidney disease,5.0 (Germany); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=731
138,CHARGE syndrome,3.5 (Canada); 6.5 (Worldwide); 0.0 (Worldwide); 9.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=138
558,Marfan syndrome,25.0 (Europe); 15.0 (Worldwide); 20.0 (Europe); 10.2 (United Kingdom); 7.0 (United Kingdom); 10.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=558
165805,Familial mesial temporal lobe epilepsy with febrile seizures,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=165805
803,Amyotrophic lateral sclerosis,"2.2 (Europe); 5.2 (Europe); 3.85 (Worldwide); 1.35 (Worldwide); 1.06 (United Kingdom); 4.9 (United Kingdom); 2.1 (Ireland); 4.7 (Ireland); 2.4 (Finland); 6.4 (Finland); 2.0 (Canada); 4.9 (Canada); 1.46 (United States); 1.37 (Uruguay); 1.9 (Uruguay); 1.4 (Denmark); 3.1 (Denmark); 3.0 (Italy); 7.9 (Italy); 2.0 (France); 1.4 (Spain); 5.4 (Spain); 2.2 (Norway); 4.0 (Norway); 0.51 (Taiwan, Province of China); 1.97 (Taiwan, Province of China); 2.6 (Faroe Islands); 0.42 (Iran, Islamic Republic of); 1.57 (Iran, Islamic Republic of); 2.5 (Specific population); 10.8 (Specific population); 1.4 (Specific population); 6.0 (Specific population)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=803
100,Ataxia-telangiectasia,10.0 (Norway); 0.4 (Norway); 1.7 (United States); 0.49 (Europe); 0.15 (Portugal); 0.25 (France); 0.25 (United Kingdom); 1.19 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100
733,Familial adenomatous polyposis,0.0 (Worldwide); 6.0 (Europe); 19.0 (Denmark); 4.65 (Denmark); 8.6 (Sweden); 3.2 (Sweden); 15.8 (Finland); 2.63 (Finland); 11.6 (United Kingdom); 5.3 (United Kingdom); 0.24 (Australia); 2.8 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=733
399,Huntington disease,"4.0 (Greece); 0.38 (Worldwide); 2.7 (Worldwide); 12.0 (Europe); 10.6 (Ireland); 0.61 (United Kingdom); 5.4 (United Kingdom); 0.11 (Italy); 6.35 (Italy); 0.69 (Canada); 0.3 (United States); 1.9 (United States); 0.65 (Japan); 0.65 (Australia); 6.3 (Australia); 0.046 (China); 0.37 (China); 5.2 (Slovenia); 0.08 (Taiwan, Province of China); 0.42 (Taiwan, Province of China); 0.14 (Iceland); 1.0 (Iceland); 6.7 (Norway); 4.7 (Sweden); 0.33 (Greece); 0.5 (Finland); 21.0 (Egypt); 4.64 (Cyprus); 0.12 (Cyprus); 5.8 (Denmark); 4.94 (Spain); 0.35 (Spain)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399
501,Lafora disease,0.1 (France); 0.0 (Europe); 300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=501
870,Down syndrome,95.0 (Worldwide); 0.0 (Worldwide); 101.0 (Europe); 57.0 (Europe); 63.7 (France); 98.3 (Germany); 70.0 (Belgium); 74.0 (Italy); 91.2 (Netherlands); 110.0 (Norway); 69.0 (Spain); 38.0 (Portugal); 91.6 (United Kingdom); 98.0 (Switzerland); 66.0 (Poland); 59.0 (Denmark); 44.0 (Croatia); 75.0 (Hungary); 235.0 (Ireland); 100.0 (Ukraine); 174.0 (Japan); 66.0 (United Kingdom); 126.0 (United States); 130.0 (South Africa),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=870
512,Metachromatic leukodystrophy,1.47 (Europe); 0.1 (Europe); 1.42 (Netherlands); 1.85 (Portugal); 0.6 (Germany); 1.43 (Turkey); 1.09 (Australia); 0.69 (Czech Republic); 0.38 (Poland); 2.5 (United States); 0.0 (Worldwide); 1.73 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=512
567,22q11.2 deletion syndrome,9.6 (Europe); 10.3 (France); 37.5 (Worldwide); 16.8 (United States); 0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=567
166016,"Multiple epiphyseal dysplasia, Lowry type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166016
232,Sickle cell anemia,42.0 (France); 25.0 (Germany); 30.0 (United States); 47.5 (Belgium); 41.7 (United Kingdom); 10.0 (Europe); 32.8 (United States); 344.8 (Guadeloupe); 248.75 (Martinique); 467.3 (Guyana); 20.15 (Reunion); 21.6262 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=232
536,Systemic lupus erythematosus,"47.0 (France); 64.2 (Martinique); 14.7 (New Zealand); 20.6 (Korea, Republic of); 53.6 (United States); 37.0 (Taiwan, Province of China); 0.0 (Europe); 28.0 (Finland); 5.14 (Worldwide); 43.7 (Worldwide); 81.84 (Poland)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=536
534,Oculocerebrorenal syndrome of Lowe,0.2 (Worldwide); 0.2 (Europe); 0.2 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=534
790,Retinoblastoma,"0.05 (Europe); 4.6 (Taiwan, Province of China); 5.9 (Korea, Republic of); 1.05 (Europe); 6.0 (Worldwide); 5.05 (Japan); 0.0 (Europe); 0.018 (Austria); 0.073 (Belgium); 0.035 (Bulgaria); 0.04 (Croatia); 0.018 (Estonia); 0.053 (Finland); 0.033 (Germany); 0.043 (Iceland); 0.071 (Ireland); 0.045 (Italy); 0.016 (Latvia); 0.017 (Lithuania); 0.094 (Malta); 0.071 (Norway); 0.038 (Poland); 0.047 (Portugal); 0.042 (Slovakia); 0.038 (Slovenia); 0.048 (Spain); 0.039 (Switzerland); 0.071 (United Kingdom); 0.107 (Netherlands)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=790
652,Multiple endocrine neoplasia type 1,3.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=652
908,Fragile X syndrome,32.5 (Worldwide); 20.0 (Europe); 9.7 (United States); 1.3 (France); 19.0 (Spain); 16.11 (Canada); 2.4 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=908
3099,Rheumatic fever,5.0 (Europe); 12.5 (Canada); 12.5 (Spain); 100.0 (Australia); 30.0 (India); 100.0 (Mexico); 5.0 (Latin America); 7.6 (New Zealand); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3099
739,Prader-Willi syndrome,0.0 (Worldwide); 0.0 (Worldwide); 3.1 (Europe); 0.0 (Europe); 3.7 (Belgium); 1.3 (Belgium); 3.4 (United Kingdom); 1.9 (United Kingdom); 6.6 (Japan); 0.0 (Japan); 4.0 (Australia); 0.0 (Australia); 6.2 (United States); 0.0 (United States); 4.76 (France); 0.229 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=739
47,X-linked agammaglobulinemia,"0.1 (Europe); 0.22 (Worldwide); 0.18 (France); 0.21 (Italy); 0.08 (United Kingdom); 0.06 (Spain); 0.03 (Germany); 0.09 (Poland); 0.13 (Croatia); 0.16 (Hungary); 0.25 (North Macedonia); 0.1 (Slovenia); 0.09 (Serbia); 0.04 (Ukraine); 0.06 (Belarus); 0.03 (Romania); 0.26 (United States); 0.07 (United States); 0.11 (Korea, Republic of)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=47
580,Mucopolysaccharidosis type 2,"0.7 (Europe); 0.31 (Sweden); 9.1 (Denmark); 0.43 (Czech Republic); 0.71 (Ireland); 1.07 (Taiwan, Province of China); 0.74 (Australia); 2.16 (Estonia); 0.1 (Canada); 0.2 (Europe); 1.09 (Portugal); 0.64 (Germany); 1.21 (Italy); 0.67 (Netherlands); 6.5 (Sweden); 0.13 (Norway); 4.4 (Norway); 0.27 (Denmark); 0.68 (Worldwide); 0.46 (Poland); 0.84 (Japan); 0.46 (Switzerland); 0.74 (Korea, Republic of); 0.29 (Tunisia); 0.26 (United States); 0.37 (Brazil); 0.07 (United States)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=580
579,Mucopolysaccharidosis type 1,"1.0 (Europe); 0.69 (Germany); 1.33 (Portugal); 1.19 (Netherlands); 0.67 (Sweden); 8.7 (Sweden); 1.85 (Norway); 31.0 (Norway); 0.54 (Denmark); 7.4 (Denmark); 3.8 (Ireland); 1.07 (United Kingdom); 0.63 (Tunisia); 0.11 (Taiwan, Province of China); 0.58 (Canada); 1.14 (Australia); 0.72 (Czech Republic); 0.5 (Europe); 0.82 (Worldwide); 0.22 (Poland); 0.23 (Japan); 0.19 (Switzerland); 3.62 (Saudi Arabia); 0.21 (Korea, Republic of); 0.24 (Brazil); 0.34 (United States); 1.0 (Israel); 1.1 (Specific population)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=579
905,Wilson disease,2.25 (Worldwide); 6.0 (Europe); 2.02 (Worldwide); 1.5 (France); 0.94 (Italy); 3.0 (Japan); 10.0 (China); 13.5 (Specific population); 37.04 (Specific population); 1.37 (Ireland); 2.9 (Germany); 0.016 (Finland); 0.45 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=905
792,X-linked retinoschisis,5.0 (Denmark); 5.0 (Netherlands); 5.0 (Worldwide); 3.6 (France); 4.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=792
163525,Subacute cutaneous lupus erythematosus,0.63 (United States); 1.4805 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163525
827,Stargardt disease,13.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=827
906,Wiskott-Aldrich syndrome,"0.1 (Europe); 0.18 (France); 0.2 (Switzerland); 0.55 (Norway); 0.07 (Australia); 0.03 (Korea, Republic of); 0.2 (United States); 0.0278 (China)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=906
904,Williams syndrome,13.3 (Norway); 4.2 (Hong Kong); 13.3 (Norway); 4.2 (Hong Kong),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=904
280,Wolf-Hirschhorn syndrome,2.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280
15,Achondroplasia,"4.73 (Worldwide); 3.62 (Europe); 5.645 (France); 3.7 (Italy); 4.195 (Sweden); 2.6466 (Spain); 2.37 (Denmark); 3.2 (Latin America); 3.8 (Australia); 3.63 (Switzerland); 3.7877 (United Kingdom); 6.0 (Ukraine); 79.05 (Iraq); 36.73 (Iran, Islamic Republic of); 12.92 (Kuwait); 25.87 (Lebanon); 48.14 (Saudi Arabia); 10.51 (United Arab Emirates); 16.53 (Cameroon); 4.0 (North America); 4.42 (Cuba); 6.75 (Mexico); 4.75 (Argentina); 14.25 (Venezuela); 4.76 (Germany); 6.35 (Malta); 3.01 (Netherlands); 2.39 (Norway); 4.47 (Poland); 18.11 (Nigeria); 0.0 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=15
96,Ataxia with vitamin E deficiency,0.33 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96
101,Dentatorubral pallidoluysian atrophy,0.48 (Japan); 0.71 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101
783,Rubinstein-Taybi syndrome,0.9 (Netherlands); 0.0 (Netherlands); 0.7 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=783
163649,Spondyloepiphyseal dysplasia-craniosynostosis-cleft palate-cataracts-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163649
631,Non-acquired isolated growth hormone deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631
276,T-B+ severe combined immunodeficiency due to gamma chain deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276
163654,Spondyloepiphyseal dysplasia-brachydactyly-speech disorder syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163654
481,Kennedy disease,0.09 (Italy); 1.6 (Italy); 0.0 (Italy); 7.6 (Finland); 3.8 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=481
664,Ornithine transcarbamylase deficiency,1.0 (Europe); 1.4 (Italy); 1.29 (Australia); 1.6 (Finland); 0.88 (Canada); 1.77 (United States); 1.77 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=664
163668,"Spondyloepiphyseal dysplasia, MacDermot type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163668
163662,"Spondyloepiphyseal dysplasia, Reardon type",1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163662
394,Homocystinuria due to cystathionine beta-synthase deficiency,0.3 (Worldwide); 1.65 (Europe); 1.5 (Ireland); 0.77 (Germany); 15.6 (Norway); 5.0 (Denmark); 1.7 (Australia); 55.5 (Qatar); 0.11 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=394
163665,"Spondyloepiphyseal dysplasia tarda, Kohn type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163665
508,Leprechaunism,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508
436,Hypophosphatasia,0.0 (Worldwide); 0.0208 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436
163596,Hb Bart's hydrops fetalis,275.0 (South East Asia); 0.0 (Worldwide); 7.6 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163596
429,Hypochondroplasia,3.0303 (Worldwide); 3.0303 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=429
437,Hypophosphatemic rickets,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=437
104,Leber hereditary optic neuropathy,2.6 (Netherlands); 4.3 (Worldwide); 2.3 (Europe); 3.22 (United Kingdom); 2.0 (Finland); 1.85 (Denmark); 1.9743 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=104
2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,1.7 (Worldwide); 1.7 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2182
163634,Maffucci syndrome,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163634
636,Neurofibromatosis type 1,21.0 (United Kingdom); 24.46 (Finland); 47.5 (New Zealand); 21.3 (Europe); 36.65 (United States); 36.9 (United Kingdom); 33.3 (Worldwide); 50.0 (Finland); 6.7 (Canada); 20.0 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=636
163703,Febrile infection-related epilepsy syndrome,0.1 (Germany); 0.0 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163703
649,Norrie disease,400.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=649
163727,Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163727
163684,Leukoencephalopathy-dystonia-motor neuropathy syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163684
163681,CNTNAP2-related developmental and epileptic encephalopathy,0.0 (Worldwide); 28.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163681
379,Chronic granulomatous disease,"0.46 (Worldwide); 0.0 (Worldwide); 0.5 (United States); 0.0 (United States); 0.5 (Europe); 0.0 (Europe); 0.75 (United Kingdom); 0.0 (United Kingdom); 0.57 (France); 0.0 (France); 0.22 (Sweden); 0.0 (Sweden); 0.1 (Italy); 0.0 (Italy); 0.7 (Denmark); 0.0 (Denmark); 0.48 (Netherlands); 0.0 (Netherlands); 0.08 (Australia); 0.35 (Japan); 0.0 (Japan); 0.34 (Korea, Republic of); 0.0 (Korea, Republic of); 0.99 (Latin America); 0.0 (Latin America); 0.53 (Israel); 0.0 (Israel)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=379
16,Blue cone monochromatism,1.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=16
644,NARP syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=644
637,Full NF2-related schwannomatosis,1.7 (Europe); 3.0 (United Kingdom); 1.78 (United Kingdom); 2.56 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=637
163696,Action myoclonus-renal failure syndrome,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163696
181,X-linked hypohidrotic ectodermal dysplasia,0.75 (Europe); 0.0 (Europe); 12.7 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=181
163693,2p21 microdeletion syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163693
163690,Hypotonia-cystinuria syndrome,0.0 (Worldwide); 22.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163690
337,Fibrodysplasia ossificans progressiva,0.05 (Worldwide); 0.061 (United Kingdom); 0.087 (Spain); 0.036 (Spain); 0.078 (Europe); 0.136 (France); 0.085 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=337
377,Gorlin syndrome,"2.0 (Europe); 5.3 (United Kingdom); 3.2 (United Kingdom); 0.39 (Italy); 0.61 (Australia); 0.007 (Korea, Republic of); 1.1 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=377
648,Noonan syndrome,70.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=648
281,Monosomy 5p syndrome,7.0 (Japan); 2.22 (Denmark); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281
752,"46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency",0.68 (Netherlands); 0.68 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=752
214,Cystinuria,50.0 (United Kingdom); 8.0 (Canada); 5.5 (Japan); 40.0 (Specific population); 14.0 (Worldwide); 1.0 (Sweden); 25.0 (Australia); 5.9 (United States); 5.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=214
510,Lesch-Nyhan syndrome,0.43 (Italy); 0.34 (Europe); 0.42 (Spain); 0.0 (Spain); 0.18 (Canada); 0.0 (Canada); 0.0 (Italy); 0.18 (United Kingdom); 0.5 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=510
524,Li-Fraumeni syndrome,7.0 (United Kingdom); 5.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=524
699,Pearson syndrome,0.0 (Worldwide); 194.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=699
640,Hereditary neuropathy with liability to pressure palsies,3.5 (Europe); 16.0 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=640
60,Alpha-1-antitrypsin deficiency,47.5 (Ireland); 20.0 (Europe); 25.0 (Germany); 17.0 (United States); 33.0 (Specific population); 63.5 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60
895,Waardenburg syndrome type 2,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=895
896,Waardenburg syndrome type 3,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=896
857,Townes-Brocks syndrome,0.42 (Spain); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=857
894,Waardenburg syndrome type 1,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=894
682,Hyperkalemic periodic paralysis,0.5 (Europe); 0.17 (United Kingdom); 0.06 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=682
800,Schwartz-Jampel syndrome,129.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=800
628,Diastrophic dysplasia,1.2 (Europe); 0.3 (Europe); 3.03 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=628
673,Malaria,73.0 (Worldwide); 3.0 (Europe); 12.0 (France); 1.2 (Europe); 1.62 (Denmark); 0.75 (Iceland); 0.8 (Austria); 2.1 (Belgium); 0.16 (Bulgaria); 0.1 (Croatia); 0.52 (Cyprus); 0.32 (Czech Republic); 0.2 (Estonia); 0.74 (Finland); 0.68 (Greece); 0.14 (Hungary); 1.7 (Ireland); 0.18 (Latvia); 0.22 (Lithuania); 0.84 (Luxembourg); 1.54 (Malta); 1.84 (Netherlands); 0.08 (Poland); 1.44 (Portugal); 0.16 (Romania); 0.06 (Slovakia); 0.28 (Slovenia); 1.5 (Spain); 1.88 (Sweden); 2.38 (United Kingdom); 1.62 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=673
681,Hypokalemic periodic paralysis,1.0 (Europe); 0.13 (United Kingdom); 0.53 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=681
126,Blepharophimosis-ptosis-epicanthus inversus syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=126
107,BOR syndrome,2.5 (Canada); 2.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=107
774,Hereditary hemorrhagic telangiectasia,16.0 (Europe); 43.5 (France); 2.5 (United Kingdom); 15.6 (Denmark); 16.25 (Japan); 6.1 (United States); 19.4 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=774
794,Saethre-Chotzen syndrome,3.0 (Europe); 0.0 (Europe); 1.0 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=794
710,Pfeiffer syndrome,1.0 (Europe); 0.0 (Worldwide); 0.3 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=710
2869,Peutz-Jeghers syndrome,2.2 (Worldwide); 0.4 (Europe); 0.65 (Uruguay),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2869
893,WAGR syndrome,0.2 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=893
912,Zellweger syndrome,0.0 (Worldwide); 8.2 (Specific population); 4.6 (Israel); 8.2 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=912
50,Aicardi syndrome,1.07 (Netherlands); 0.95 (United States); 0.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50
53,Albers-Schönberg osteopetrosis,1.0 (Worldwide); 5.5 (Denmark); 0.2 (Brazil); 5.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53
14,Abetalipoproteinemia,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=14
52,Alagille syndrome,1.4 (Australia); 0.0 (Australia); 0.8 (Europe); 2.7 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52
167,Chédiak-Higashi syndrome,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=167
195,Cat-eye syndrome,1.35 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=195
207,Crouzon syndrome,0.9 (Europe); 0.0 (Europe); 1.65 (Canada); 2.6 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=207
205,Crigler-Najjar syndrome,0.1 (Europe); 1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=205
160148,Cap polyposis,67.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=160148
201,Cowden syndrome,0.45 (Netherlands); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=201
192,Coffin-Lowry syndrome,1.5 (Worldwide); 1.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=192
2442,X-linked lymphoproliferative disease,0.05 (Europe); 0.0347 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2442
169802,Severe hemophilia A,2.8 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169802
562,McCune-Albright syndrome,0.55 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=562
565,Menkes disease,0.33 (Europe); 0.28 (Japan); 2.5 (Australia); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=565
2443,Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies,9.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2443
474,Jeune syndrome,1.4 (Europe); 0.89 (Australia); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=474
540,Familial hemophagocytic lymphohistiocytosis,2.0 (Sweden); 0.0 (Worldwide); 0.104 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=540
568,"Microphthalmia, Lenz type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=568
564,Meckel syndrome,1.3 (France); 0.0 (France); 11.0 (Finland); 4.0 (Worldwide); 0.0 (Worldwide); 2.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=564
289,Ellis Van Creveld syndrome,500.0 (Specific population); 0.4 (Europe); 1.1 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289
258,Laminin subunit alpha 2-related congenital muscular dystrophy,0.3 (Europe); 0.6 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=258
1247,Schistosomiasis,0.0 (Europe); 0.0 (Africa),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1247
112,Bartter syndrome,0.1 (Europe); 0.12 (Sweden); 1.7 (Kuwait); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=112
1646,Chromosome Y microdeletion syndrome,20.8 (Worldwide); 20.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1646
169464,Primary CD59 deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169464
99,Autosomal dominant cerebellar ataxia,2.7 (Worldwide); 3.0 (Netherlands); 0.9 (Italy); 5.6 (Portugal); 5.6 (Europe); 12.6 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99
116,Beckwith-Wiedemann syndrome,3.5 (Europe); 1.3 (Spain); 5.25 (Japan); 7.4 (Jamaica); 10.0 (Italy); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=116
87,Apert syndrome,0.0 (Europe); 0.0 (Worldwide); 0.0 (Worldwide); 1.1 (Spain); 1.1 (Spain); 1.2 (United States); 1.2 (United States); 1.47 (Canada); 1.47 (Canada); 1.6 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=87
97,Familial paroxysmal ataxia,0.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97
313,Lamellar ichthyosis,0.0 (Europe); 0.35 (Spain); 1.1 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313
169799,Mild hemophilia B,0.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169799
169796,Moderate hemophilia B,0.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169796
169793,Severe hemophilia B,0.8 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169793
1000,Ocular albinism with late-onset sensorineural deafness,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1000
999,Ermine phenotype,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=999
171430,Severe congenital nemaline myopathy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171430
171433,Intermediate nemaline myopathy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171433
171436,Typical nemaline myopathy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171436
171439,Childhood-onset nemaline myopathy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171439
55,Oculocutaneous albinism,5.9 (Worldwide); 3.9 (Denmark); 45.0 (South Africa),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=55
171442,Adult-onset nemaline myopathy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171442
171607,X-linked spastic paraplegia type 34,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171607
2771,Bruck syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2771
171612,Autosomal dominant spastic paraplegia type 37,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171612
171617,Autosomal dominant spastic paraplegia type 38,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171617
1349,Mitochondrial DNA-related cardiomyopathy and hearing loss,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1349
171622,Autosomal recessive spastic paraplegia type 32,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171622
171629,Autosomal recessive spastic paraplegia type 35,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171629
861,Treacher-Collins syndrome,0.63 (France); 0.0 (France); 6.9 (Japan); 0.0 (Japan); 2.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=861
308,Progressive myoclonic epilepsy type 1,5.0 (Finland); 2.0 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=308
1991,Cleft lip with or without cleft palate,0.0 (Worldwide); 190.5 (Japan); 77.5 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1991
199,Cornelia de Lange syndrome,1.24 (Europe); 0.65 (France); 0.5 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199
2162,Holoprosencephaly,"13.4 (Europe); 5.5 (United States); 21.6 (Latin America); 15.0 (United Kingdom); 60.6 (Taiwan, Province of China); 502.0 (Japan); 0.0 (Worldwide); 10.9 (Specific population)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2162
930,Idiopathic achalasia,"0.0 (Europe); 8.0 (Worldwide); 10.82 (Canada); 6.29 (Korea, Republic of); 13.5 (Ireland); 8.7 (Iceland); 1.8 (Singapore); 1.59 (Italy); 0.73 (Iceland); 0.3 (Singapore); 0.39 (Korea, Republic of); 1.63 (Canada); 0.77 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=930
998,Albinism-deafness syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=998
1727,22q11.2 duplication syndrome,216.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1727
169079,Cernunnos-XLF deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169079
1715,Trisomy 18p syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1715
3380,Trisomy 18 syndrome,16.7 (Worldwide); 9.8 (Austria); 4.4 (Hungary); 25.3 (Ireland); 4.1 (Italy); 11.4 (Netherlands); 11.2 (Norway); 10.4 (Europe); 0.0 (Europe); 5.8 (France); 8.9 (Belgium); 5.8 (Germany); 48.2 (Malta); 4.4 (Poland); 9.5 (Portugal); 1.9 (Spain); 24.6 (Switzerland); 13.0 (United Kingdom); 6.5 (Ukraine); 14.6 (Croatia); 38.8 (Denmark); 18.0 (Japan); 0.0 (Japan); 19.1 (United States); 12.6 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3380
168984,CLAPO syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168984
168999,Malignant melanoma of the mucosa,0.26 (Europe); 0.0 (Europe); 1.5 (Europe); 0.32 (Belgium); 0.23 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168999
3378,Trisomy 13 syndrome,3.7 (Europe); 2.9 (Belgium); 4.8 (Germany); 7.2 (Ireland); 24.1 (Malta); 4.8 (Norway); 2.2 (Poland); 5.0 (United Kingdom); 3.3 (Ukraine); 18.0 (Japan); 15.9 (Japan); 12.6 (United States); 1.9 (France); 9.8 (Austria); 1.1 (Hungary); 1.4 (Italy); 11.4 (Netherlands); 5.2 (Portugal); 2.5 (Spain); 13.2 (Switzerland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3378
169100,Immunodeficiency due to CD25 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169100
169105,Good syndrome,0.0 (Worldwide); 241.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169105
169090,Combined immunodeficiency due to CRAC channel dysfunction,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169090
236,Trisomy 9p syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=236
169095,Severe combined immunodeficiency due to FOXN1 deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169095
169085,Susceptibility to respiratory infections associated with CD8alpha chain mutation,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169085
168829,Primary peritoneal carcinoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168829
168816,Peritoneal inclusion cyst,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168816
753,"46,XY difference of sex development due to 5-alpha-reductase 2 deficiency",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=753
868,Triose phosphate-isomerase deficiency,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=868
168811,Malignant peritoneal mesothelioma,0.2 (France); 0.0 (Europe); 0.5 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168811
218,Darier disease,3.0 (United Kingdom); 1.0 (Denmark); 3.8 (Slovenia); 3.4 (Europe); 0.31 (Singapore),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=218
168796,"Heart-hand syndrome, Slovenian type",14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168796
1465,Coffin-Siris syndrome,190.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1465
168782,Childhood disintegrative disorder,2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168782
1642,Distal deletion 9p syndrome,89.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1642
168966,Composite lymphoma,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168966
168960,Refractory anemia with excess blasts in transformation,0.04 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168960
8,"47,XYY syndrome",0.0 (Denmark); 50.0 (Europe); 14.1 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=8
168956,Hypereosinophilic syndrome,0.027 (United States); 0.0 (Europe); 3.3 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168956
1600,Monosomy 18q syndrome,2.5 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1600
1598,Monosomy 18p syndrome,0.0 (Europe); 2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1598
2773,Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2773
2772,Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2772
2609,Isolated complex I deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2609
626,Large/giant congenital melanocytic nevus,2.75 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=626
773,Refsum disease,0.1 (Europe); 60.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=773
11,Pentasomy X syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=11
169154,T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency,0.15 (Worldwide); 0.0 (Worldwide); 0.04 (Chile),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169154
370,Glycogen storage disease due to phosphorylase kinase deficiency,1.0 (Europe); 0.0 (Europe); 0.3 (Israel); 0.5 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370
169160,T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169160
385,Neurodegeneration with brain iron accumulation,0.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=385
169157,T-B+ severe combined immunodeficiency due to CD45 deficiency,0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169157
1947,"Progressive epilepsy-intellectual disability syndrome, Finnish type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1947
352,Galactosemia,2.0 (Europe); 2.1 (Europe); 1.3 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352
596,X-linked centronuclear myopathy,1.0 (France); 0.0 (Worldwide); 0.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=596
610,Bethlem muscular dystrophy,0.77 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=610
169186,Autosomal recessive centronuclear myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169186
464,Incontinentia pigmenti,0.62 (United States); 1.2 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464
3307,Tetrasomy 18p syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3307
169189,Autosomal dominant centronuclear myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169189
44,Neonatal adrenoleukodystrophy,1.2 (Italy); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=44
56,Alkaptonuria,0.0 (Worldwide); 0.0 (Europe); 0.15 (France); 0.0 (France); 0.25 (United States); 0.0 (United States); 5.3 (Slovakia); 0.0 (Slovakia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=56
963,Acromegaly,"0.47 (Worldwide); 3.6 (Spain); 9.7 (Italy); 8.6 (United Kingdom); 0.19 (Belgium); 12.0 (Belgium); 0.4 (Ireland); 6.3 (Ireland); 0.34 (Finland); 0.39 (Korea, Republic of); 2.79 (Korea, Republic of); 0.77 (Iceland); 13.4 (Iceland); 7.8 (United States); 1.1 (United States); 8.5 (Denmark); 0.31 (Malta); 12.5 (Malta); 0.35 (Sweden); 0.38 (Denmark); 0.0 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=963
1059,Blue rubber bleb nevus,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1059
1006,Alopecia antibody deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1006
1046,Lethal hemolytic anemia-genital anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1046
22,Succinic semialdehyde dehydrogenase deficiency,450.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=22
29,Mevalonic aciduria,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=29
245,Nager syndrome,100.0 (Worldwide); 0.0 (Worldwide); 0.3 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=245
30,Hereditary orotic aciduria,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=30
36,Acrocallosal syndrome,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36
915,Aarskog-Scott syndrome,0.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=915
2614,Nail-patella syndrome,2.2 (United Kingdom); 0.0 (Worldwide); 0.2 (Europe); 1.0 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2614
33,Isovaleric acidemia,1.0 (Europe); 1.55 (Germany); 0.28 (Australia); 0.63 (Italy); 0.53 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33
819,Smith-Magenis syndrome,0.0 (Worldwide); 4.0 (Worldwide); 5.35 (Europe); 0.0 (United States); 5.35 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=819
3085,Retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3085
9,Tetrasomy X syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=9
168615,Hereditary persistence of alpha-fetoprotein,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168615
168612,Congenital deficiency in alpha-fetoprotein,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168612
1442,Ring chromosome 18 syndrome,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1442
168621,"Dysplasia of head of femur, Meyer type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168621
1452,Cleidocranial dysplasia,0.1 (Worldwide); 0.4 (Europe); 1.2 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1452
168624,"Familial scaphocephaly syndrome, McGillivray type",11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168624
193,Cohen syndrome,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=193
1488,Cooper-Jabs syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1488
200,Isolated corpus callosum agenesis,0.0 (United States); 0.0 (Hungary); 1.37 (United States); 3.2 (Hungary),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=200
1334,Chronic mucocutaneous candidiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1334
168583,Hereditary North American Indian childhood cirrhosis,36.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168583
1369,Congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1369
168577,Hereditary cryohydrocytosis with reduced stomatin,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168577
168593,Sudden infant death-dysgenesis of the testes syndrome,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168593
1406,Charlie M syndrome,0.0 (Worldwide); 4.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1406
168588,Hyperandrogenism due to cortisone reductase deficiency,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168588
1414,Cholestasis-lymphedema syndrome,47.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1414
168598,Methionine adenosyltransferase I/III deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168598
168606,Seborrhea-like dermatitis with psoriasiform elements,44.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168606
168549,Axial spondylometaphyseal dysplasia,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168549
168552,Spondylometaphyseal dysplasia-bowed forearms-facial dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168552
1154,Arthrogryposis-oculomotor limitation-electroretinal anomalies syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1154
168555,"Spondylometaphyseal dysplasia, A4 type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168555
168558,"46,XY difference of sex development-adrenal insufficiency due to CYP11A1 deficiency",9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168558
168563,"46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168563
124,Diamond-Blackfan anemia,0.67 (Europe); 0.5 (United Kingdom); 0.65 (Italy); 0.75 (United States); 0.0 (Worldwide); 0.194 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=124
168566,Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168566
1310,Caffey disease,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1310
168569,H syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168569
168572,Native American myopathy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168572
125,Bloom syndrome,2.08 (Specific population); 300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=125
90,Argininemia,0.04 (Finland); 0.27 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90
168443,Spondyloepimetaphyseal dysplasia-hypotrichosis syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168443
1065,Aniridia-cerebellar ataxia-intellectual disability syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1065
168451,Spondyloepimetaphyseal dysplasia-abnormal dentition syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168451
168454,"Spondyloepimetaphyseal dysplasia, Geneviève type",6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168454
1146,Distal arthrogryposis type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1146
1143,Neurogenic arthrogryposis multiplex congenita,4.3 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1143
168544,"Spondylometaphyseal dysplasia, Golden type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168544
1147,Sheldon-Hall syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1147
246,Postaxial acrofacial dysostosis,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=246
1770,XY type gonadal dysgenesis-associated anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1770
1775,Dyskeratosis congenita,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1775
1764,Familial dysautonomia,0.0 (Europe); 18.5 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1764
235,Dubowitz syndrome,0.2 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=235
239,Dyggve-Melchior-Clausen disease,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=239
1672,Diencephalic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1672
833,Encephalopathy due to sulfite oxidase deficiency,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=833
167714,Unclassified acute myeloid leukemia,0.49 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=167714
167635,Scleromyxedema,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=167635
765,Pyruvate dehydrogenase deficiency,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=765
395,Homocystinuria due to methylene tetrahydrofolate reductase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=395
408,Isolated glycerol kinase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=408
148,Multiple carboxylase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=148
147,Carbamoyl-phosphate synthetase 1 deficiency,0.0 (Worldwide); 0.19 (Finland); 0.0 (Worldwide); 0.077 (United States); 0.125 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=147
23,Argininosuccinic aciduria,0.46 (United States); 0.69 (Finland); 1.0 (Europe); 1.05 (Austria),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=23
45,Adenosine monophosphate deaminase deficiency,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=45
226,Dihydropteridine reductase deficiency,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=226
217,Isolated Dandy-Walker malformation,1.0 (Europe); 2.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217
1556,Cutis marmorata telangiectatica congenita,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1556
1538,Craniosynostosis-Dandy-Walker malformation-hydrocephalus syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1538
1496,Corpus callosum agenesis-neuronopathy syndrome,0.0 (Worldwide); 47.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1496
417,Neonatal severe primary hyperparathyroidism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=417
2233,Hypogonadism-mitral valve prolapse-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2233
2248,Hypoplastic left heart syndrome,18.0 (Worldwide); 16.2 (United States); 15.1 (Europe); 49.1 (Austria); 29.1 (Belgium); 56.8 (Croatia); 21.3 (Denmark); 11.8 (France); 23.8 (Germany); 19.9 (Hungary); 18.1 (Ireland); 9.9 (Italy); 49.8 (Malta); 5.8 (Netherlands); 16.4 (Norway); 9.2 (Poland); 5.5 (Portugal); 12.5 (Switzerland); 16.6 (United Kingdom); 22.3 (Ukraine); 1.9 (Spain); 0.0 (Worldwide); 8.0 (China); 11.6 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2248
446,Neonatal hemochromatosis,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=446
2135,Cutaneous mastocytosis-deafness-microtia syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2135
2140,Congenital diaphragmatic hernia,30.0 (Worldwide); 21.2 (Europe); 39.3 (Austria); 14.6 (Belgium); 11.4 (Croatia); 19.8 (Denmark); 23.6 (France); 5.9 (Germany); 23.2 (Hungary); 21.7 (Ireland); 22.6 (Italy); 49.8 (Malta); 29.2 (Netherlands); 22.9 (Norway); 8.2 (Poland); 18.9 (Portugal); 9.4 (Spain); 38.9 (Switzerland); 19.7 (United Kingdom); 22.3 (Ukraine); 33.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2140
2185,Congenital hydrocephalus,59.0 (United States); 0.0 (Worldwide); 46.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2185
2116,Hartnup disease,4.2 (Worldwide); 3.3 (Australia); 3.85 (United States); 1.9 (Specific population); 4.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2116
2118,Hawkinsinuria,0.0 (Worldwide); 5.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2118
351,Galactosialidosis,0.0 (Worldwide); 0.14 (Sweden); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=351
2020,Congenital fiber-type disproportion myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2020
2053,Freeman-Sheldon syndrome,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2053
295,Fetal parvovirus syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=295
1933,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1933
1880,Ebstein malformation of the tricuspid valve,"1.25 (Europe); 3.5 (Europe); 7.8 (France); 19.5 (Austria); 3.1 (Belgium); 16.5 (Croatia); 18.2 (Denmark); 11.6 (Germany); 1.1 (Hungary); 3.6 (Ireland); 4.1 (Italy); 24.1 (Malta); 5.7 (Netherlands); 1.0 (Poland); 0.6 (Spain); 27.2 (Switzerland); 3.5 (United Kingdom); 6.5 (Ukraine); 4.7 (Taiwan, Province of China); 6.0 (United States); 6.6 (Specific population); 9.8 (Norway)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1880
255,Dopa-responsive dystonia,0.3 (Europe); 0.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=255
1915,Fetal alcohol syndrome,1.6 (Europe); 9.8 (Austria); 5.8 (Belgium); 14.8 (Germany); 1.1 (Hungary); 8.1 (Ireland); 1.4 (Italy); 1.6 (Norway); 13.2 (Switzerland); 1.9 (United Kingdom); 6800.0 (South Africa); 13.6 (France); 0.5 (Poland); 1.2 (Spain); 80.8 (Ukraine); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1915
1885,Isolated ectopia lentis,0.0 (Worldwide); 90.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1885
1851,Multicystic dysplastic kidney,23.26 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1851
660,Omphalocele,11.7 (Europe); 0.0 (Europe); 19.6 (Austria); 0.0 (Austria); 14.6 (Belgium); 0.0 (Belgium); 10.9 (Croatia); 0.0 (Croatia); 19.8 (Denmark); 0.0 (Denmark); 13.6 (France); 0.0 (France); 11.6 (Germany); 0.0 (Germany); 6.6 (Hungary); 0.0 (Hungary); 25.3 (Ireland); 0.0 (Ireland); 11.0 (Italy); 0.0 (Italy); 48.2 (Malta); 0.0 (Malta); 22.9 (Netherlands); 0.0 (Netherlands); 11.2 (Norway); 0.0 (Norway); 12.1 (Poland); 0.0 (Poland); 6.9 (Spain); 0.0 (Spain); 12.3 (Switzerland); 0.0 (Switzerland); 11.6 (United Kingdom); 0.0 (United Kingdom); 16.2 (Ukraine); 0.0 (Ukraine); 10.0 (Czech Republic); 0.0 (Czech Republic); 6.3 (Japan); 0.0 (Japan); 15.2 (China); 18.6 (United States); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=660
635,Neuroblastoma,11.0 (Europe); 5.8 (Europe); 2.5 (United States); 14.0 (Germany); 1.26 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=635
2612,Linear nevus sebaceus syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2612
2635,Metatropic dysplasia,81.0 (Worldwide); 0.0 (Worldwide); 0.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2635
2655,Thanatophoric dysplasia,3.5 (Europe); 0.0 (Europe); 2.8 (France); 3.5 (Italy); 1.7 (Sweden); 3.8 (Denmark); 8.0 (Ireland); 4.7 (Latin America); 4.3 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2655
606,Proximal myotonic myopathy,1.0 (Germany); 1.0 (Europe); 10.0 (Finland); 0.17 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=606
705,Pendred syndrome,7.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=705
2801,Juvenile Paget disease,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2801
884,Tetrasomy 12p syndrome,4.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=884
2785,Osteopetrosis with renal tubular acidosis,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2785
2744,Horizontal gaze palsy with progressive scoliosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2744
2746,Opsismodysplasia,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2746
2971,Peroxisomal acyl-CoA oxidase deficiency,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2971
2970,Prune belly syndrome,2.4 (Italy); 0.38 (United Kingdom); 3.42 (Canada); 3.8 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2970
744,Proteus syndrome,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=744
2903,Familial spontaneous pneumothorax,54.64 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2903
2901,Neuralgic amyotrophy,1.64 (United States); 0.0 (Europe); 3.0 (United Kingdom); 30.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2901
718,Isolated Pierre Robin sequence,0.0 (United Kingdom); 8.0 (France); 0.0 (France); 12.4 (Germany); 3.5 (Denmark); 0.0 (Denmark); 4.5 (Sweden); 0.0 (Sweden); 5.9 (United Kingdom); 7.9 (United States); 0.0 (United States); 5.0 (Europe); 0.0 (Europe); 6.4 (Netherlands); 18.8 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=718
290,Congenital rubella syndrome,0.0 (Worldwide); 0.29 (France); 0.24 (Germany); 0.8 (Italy); 0.64 (Netherlands); 0.27 (Austria); 2.18 (Romania); 0.22 (Spain); 0.02 (Turkey); 0.03 (Europe); 0.35 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=290
3071,Costello syndrome,300.0 (Worldwide); 0.08 (Japan); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3071
763,Pycnodysostosis,0.13 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=763
2983,Difference of sex development-intellectual disability syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2983
2301,Congenital short bowel syndrome,43.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2301
469,Hereditary fructose intolerance,5.0 (Europe); 5.0 (Switzerland); 0.0 (Switzerland); 5.0 (United Kingdom); 0.0 (United Kingdom); 3.8 (Germany); 0.0 (Germany); 0.0 (Poland); 3.2 (Poland); 7.5 (Finland); 0.753 (United States); 0.38 (Specific population); 0.1981 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=469
2308,Jacobsen syndrome,1.5 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2308
2318,Joubert syndrome with oculorenal defect,0.0 (Worldwide); 17.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2318
2253,Foveal hypoplasia-presenile cataract syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2253
2300,Multiple intestinal atresia,0.0 (Worldwide); 4.05 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2300
180226,Embryonal carcinoma,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=180226
502,Trichorhinophalangeal syndrome type 2,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=502
180229,Polyembryoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=180229
2370,Larsen-like osseous dysplasia-short stature syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2370
477,KID syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477
2346,Angioosteohypertrophic syndrome,0.8 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2346
506,Leigh syndrome,2.8 (Europe); 1.3 (Australia); 0.0 (Worldwide); 2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=506
2414,Congenital pulmonary lymphangiectasia,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2414
180234,Mixed germ cell tumor,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=180234
2377,Laurence-Moon syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2377
2374,Isolated congenital laryngeal web,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2374
180242,Malignant tumor of fallopian tubes,1.0 (Europe); 0.11 (United Kingdom); 0.15 (Denmark); 0.16 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=180242
2466,MASA syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2466
180275,Paget disease of the nipple,0.51 (Europe); 0.065 (Finland); 0.096 (Poland); 0.179 (Austria); 0.433 (Belgium); 0.235 (Bulgaria); 0.192 (Croatia); 0.287 (Czech Republic); 0.434 (Estonia); 0.29 (Germany); 0.682 (Iceland); 0.487 (Ireland); 0.421 (Italy); 0.254 (Latvia); 0.215 (Lithuania); 0.345 (Malta); 0.709 (Norway); 0.209 (Portugal); 0.21 (Slovakia); 0.457 (Slovenia); 0.415 (Spain); 0.394 (Switzerland); 0.335 (Netherlands); 0.637 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=180275
560,Marshall syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=560
570,Moebius syndrome,300.0 (Worldwide); 0.0 (Worldwide); 2.12 (Netherlands); 0.27 (Italy); 0.06 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=570
1505,Short rib-polydactyly syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1505
2444,Congenital pulmonary airway malformation,8.2 (Europe); 2.9 (Belgium); 17.7 (France); 5.9 (Germany); 1.0 (Hungary); 7.2 (Ireland); 1.4 (Italy); 17.1 (Netherlands); 4.9 (Norway); 0.7 (Poland); 3.8 (Spain); 12.3 (Switzerland); 18.1 (United Kingdom); 3.2 (Ukraine); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2444
612,Potassium-aggravated myotonia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=612
716,Phenylketonuria,"6.0 (France); 10.99 (France); 11.4 (Europe); 11.5079 (Europe); 3.4 (United Kingdom); 10.0 (United Kingdom); 22.0 (Ireland); 22.0 (Ireland); 0.0 (Finland); 0.8928 (Finland); 5.577 (United States); 4.0 (United States); 9.8 (Latin America); 3.5999 (Latin America); 5.5 (Brazil); 4.0 (Brazil); 2.266 (Australia); 8.89 (Australia); 11.9 (Iceland); 11.9 (Iceland); 1.16 (Japan); 0.8 (Japan); 4.412 (China); 6.2798 (China); 2.68 (Thailand); 0.4399 (Thailand); 9.95 (Turkey); 14.99 (Turkey); 7.6 (United Arab Emirates); 6.89 (United Arab Emirates); 20.0 (Jordan); 2.6 (Jordan); 5.4644 (India); 2.439 (Korea, Republic of); 0.862 (Philippines); 1.2 (Singapore); 1.6999 (Taiwan, Province of China); 4.5 (Bahrain); 20.0 (Iran, Islamic Republic of); 6.9998 (Iraq); 15.603 (Israel); 7.02 (Saudi Arabia); 20.0 (Egypt); 13.0005 (Tunisia); 17.349 (Austria); 13.0005 (Belarus); 10.0 (Bosnia and Herzegovina); 3.746 (Bulgaria); 12.0004 (Croatia); 7.6923 (Cyprus); 19.1534 (Czech Republic); 7.4437 (Denmark); 13.9997 (Estonia); 18.6567 (Germany); 9.5969 (Greece); 11.1111 (Hungary); 25.0 (Italy); 12.2399 (Latvia); 10.7526 (Lithuania); 13.5998 (Moldova, Republic of); 8.661 (Netherlands); 8.7282 (Norway); 12.3051 (Poland); 8.0 (Portugal); 10.0 (Romania); 12.9634 (Russian Federation); 8.13 (Serbia); 17.3822 (Slovakia); 4.9 (Slovenia); 9.8366 (Spain); 7.8858 (Sweden); 12.5 (Switzerland); 14.0016 (Ukraine); 6.6666 (Canada); 6.2798 (New Caledonia); 6.2798 (New Zealand); 6.3633 (Argentina); 5.1999 (Chile); 2.0333 (Costa rica); 3.5999 (Mexico); 2.129 (Peru); 2.0 (Cuba); 4.1366 (Worldwide); 13.34 (India); 22.7 (Pakistan); 6.8 (Saudi Arabia); 8.75 (Austria); 16.6 (Estonia); 9.316 (Germany); 4.25 (Greece); 8.5 (Hungary); 7.933 (Italy); 24.6 (North Macedonia); 7.85 (Poland); 6.0 (Portugal); 16.9 (Slovakia); 6.6 (Spain); 7.55 (Chile); 7.271 (Iran, Islamic Republic of); 5.5 (Canada); 5.1 (Korea, Republic of); 1.433 (Taiwan, Province of China); 6.4 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=716
287,Classical Ehlers-Danlos syndrome,5.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=287
1020,Early-onset autosomal dominant Alzheimer disease,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1020
63,Alport syndrome,0.0 (Europe); 1.9 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63
54,X-linked recessive ocular albinism,0.58 (Europe); 0.0 (Europe); 0.84 (Denmark); 0.0 (Denmark); 1.0 (United States); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54
154,Familial isolated dilated cardiomyopathy,2.91 (Europe); 17.5 (Europe); 6.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=154
84,Fanconi anemia,3.3 (Specific population); 0.3 (Europe); 0.62 (Europe); 2.2 (Israel); 2.5 (Specific population); 2.5 (Specific population); 0.111 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84
70,Proximal spinal muscular atrophy,2.6 (Europe); 20.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70
69,Amyloidosis,"0.0 (Worldwide); 1.91 (Korea, Republic of)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69
191,Cockayne syndrome,0.5 (Europe); 0.2 (Europe); 0.09 (Germany); 0.18 (France); 0.2 (Italy); 0.45 (Netherlands); 0.38 (United Kingdom); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=191
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,25.0 (Europe); 15.95 (United Kingdom); 61.0 (Norway); 28.2 (Spain); 17.5 (Italy); 19.55 (Sweden); 6.1 (Denmark); 12.0 (Iceland); 10.8 (Japan); 16.0 (Cyprus); 9.7 (Serbia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166
834,Free sialic acid storage disease,0.0 (Worldwide); 130.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=834
799,Schizencephaly,1.48 (United Kingdom); 1.54 (United States); 0.0 (Europe); 1.0 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=799
3151,Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3151
178566,Mycosis fungoides and variants,0.59 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178566
813,Silver-Russell syndrome,15.5 (Europe); 0.0 (United Kingdom); 1.0 (United Kingdom); 0.7 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=813
3169,Sirenomelia,0.98 (Worldwide); 0.01 (Worldwide); 0.71 (Europe); 0.009 (Europe); 1.04 (France); 0.62 (Italy); 0.64 (Spain); 0.54 (Netherlands); 0.7 (Finland); 0.31 (Slovakia); 0.33 (Hungary); 0.74 (United States); 1.6 (Canada); 0.83 (China); 0.79 (Australia); 2.36 (Mexico); 1.36 (Latin America); 12.0 (Colombia); 0.98 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3169
816,Sjögren-Larsson syndrome,"0.6 (Sweden); 16.0 (Taiwan, Province of China); 0.0 (Europe)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=816
821,Sotos syndrome,7.1 (Worldwide); 0.0 (Worldwide); 0.5 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=821
3173,Infantile spasms-broad thumbs syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3173
3204,Stormorken-Sjaastad-Langslet syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3204
3205,Sturge-Weber syndrome,3.5 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3205
3320,Thrombocytopenia-absent radius syndrome,0.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3320
3346,Tracheal agenesis,2.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3346
858,Congenital toxoplasmosis,"33.0 (Europe); 30.0 (France); 1.0 (Greece); 2.2 (United Kingdom); 7.3 (Sweden); 30.0 (Denmark); 50.0 (Switzerland); 130.0 (Germany); 113.0 (Poland); 40.0 (Brazil); 138.0 (Italy); 55.0 (United States); 0.0 (Worldwide); 640.0 (Iran, Islamic Republic of)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=858
887,VACTERL/VATER association,6.25 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=887
291,Congenital varicella syndrome,130.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=291
909,Cerebrotendinous xanthomatosis,2.0 (Specific population); 0.056 (Spain); 4.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=909
3447,Weaver syndrome,48.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3447
1422,Chondrodysplasia-difference of sex development syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1422
178478,Infant botulism,0.2 (Europe); 0.3 (Europe); 2.1 (United States); 2.2 (Argentina); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178478
178481,Intestinal botulism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178481
178475,Wound botulism,0.1 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178475
178461,X-linked myopathy with postural muscle atrophy,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178461
178464,Hereditary myopathy with early respiratory failure,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178464
178396,Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178396
178400,Distal myopathy with anterior tibial onset,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178400
178382,Congenital vertical talus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178382
178389,Osteopetrosis-hypogammaglobulinemia syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178389
62,Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3,0.07 (United Kingdom); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=62
178364,Syndromic microphthalmia type 5,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178364
715,Glycogen storage disease due to muscle phosphorylase kinase deficiency,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=715
178377,Osteosclerosis-developmental delay-craniosynostosis syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178377
348,"Fructose-1,6-bisphosphatase deficiency",0.67 (Italy); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=348
178345,Aromatase excess syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178345
178355,Smith-McCort dysplasia,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178355
178338,UV-sensitive syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178338
3137,Alpha-N-acetylgalactosaminidase deficiency,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3137
117,Behçet disease,"0.66 (Spain); 0.24 (Italy); 5.2 (United States); 0.58 (Iran, Islamic Republic of); 7.1 (France); 3.8 (Italy); 11.1 (United Kingdom); 1.2 (Sweden); 1.5 (Portugal); 10.0 (Japan); 225.0 (Turkey); 16.7 (Iran, Islamic Republic of); 15.2 (Israel); 1.4 (Taiwan, Province of China); 0.8 (Taiwan, Province of China); 20.0 (Saudi Arabia); 0.0 (Europe); 1.51 (Korea, Republic of)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=117
732,Polymyositis,0.585 (Europe); 7.1 (Europe); 0.75 (Argentina); 7.2 (Argentina); 0.41 (Australia); 7.2 (Australia); 0.39 (Spain); 0.76 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=732
221,Dermatomyositis,0.1 (Australia); 1.97 (Australia); 0.32 (Argentina); 10.2 (Argentina); 0.49 (Spain); 1.1 (United States); 13.0 (United States); 4.9172 (Norway); 0.32 (Sweden); 3.8 (Sweden); 3.5 (Germany); 11.3 (Germany); 0.9704 (Worldwide); 7.5312 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221
598,Multiminicore myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=598
204,Sporadic Creutzfeldt-Jakob disease,"0.125 (Australia); 0.0937 (Australia); 0.152 (Austria); 0.114 (Austria); 0.117 (Belgium); 0.087 (Belgium); 0.105 (Canada); 0.078 (Canada); 0.12 (Czech Republic); 0.09 (Czech Republic); 0.104 (Cyprus); 0.078 (Cyprus); 0.147 (Denmark); 0.11 (Denmark); 0.032 (Estonia); 0.024 (Estonia); 0.141 (Finland); 0.105 (Finland); 0.16 (France); 0.12 (France); 0.133 (Germany); 0.099 (Germany); 0.062 (Greece); 0.0465 (Greece); 0.0107 (Hungary); 0.08 (Hungary); 0.142 (Italy); 0.1065 (Italy); 0.123 (Netherlands); 0.092 (Netherlands); 0.102 (Norway); 0.0765 (Norway); 0.0086 (Slovakia); 0.0645 (Slovakia); 0.146 (Slovenia); 0.1095 (Slovenia); 0.128 (Spain); 0.096 (Spain); 0.142 (Sweden); 0.1065 (Sweden); 0.173 (Switzerland); 0.129 (Switzerland); 0.055 (Taiwan, Province of China); 0.041 (Taiwan, Province of China); 0.124 (United Kingdom); 0.093 (United Kingdom); 0.122 (United States); 0.0915 (United States); 0.088 (Worldwide); 0.118 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=204
178517,Localized pagetoid reticulosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178517
178512,Folliculotropic mycosis fungoides,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178512
178509,Perry syndrome,53.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178509
178506,"Brain calcification, Rajab type",8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178506
611,Inclusion body myositis,0.5 (Europe); 2.5 (Sweden); 0.49 (Netherlands); 1.2 (Australia); 1.1 (United States); 0.1 (Turkey); 3.2 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=611
178487,Adult intestinal botulism,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178487
177926,Bleeding disorder in hemophilia A carriers,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=177926
581,Mucopolysaccharidosis type 3,"0.21 (Brazil); 0.87 (Europe); 1.57 (Germany); 0.84 (Portugal); 1.89 (Netherlands); 1.42 (Australia); 0.91 (Czech Republic); 0.84 (Sweden); 1.63 (Sweden); 0.27 (Norway); 0.88 (Norway); 0.43 (Denmark); 0.92 (Denmark); 0.36 (Ireland); 0.29 (Canada); 0.39 (Taiwan, Province of China); 0.7 (Tunisia); 0.0 (Worldwide); 0.3 (Europe); 0.86 (Poland); 0.26 (Japan); 0.38 (Switzerland); 1.8 (Saudi Arabia); 0.25 (Korea, Republic of); 1.62 (Estonia); 2.4 (Israel); 4.8 (Specific population); 0.071 (United States); 0.26 (United States)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=581
177929,Bleeding disorder in hemophilia B carriers,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=177929
685,Hereditary spastic paraplegia,4.8 (Europe); 9.6 (Spain); 4.1 (Portugal); 1.3 (Sweden); 4.2 (Worldwide); 5.75 (Tunisia); 7.4 (Norway); 2.7 (Italy); 4.4 (Estonia); 2.1 (Libyan Arab Jamahiriya),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=685
666,Osteogenesis imperfecta,8.06 (Worldwide); 6.4 (France); 0.4 (Latin America); 1.5 (Ireland); 6.95 (United States); 7.4 (Sweden); 0.375 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=666
178029,Arginine vasopressin deficiency,4.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178029
423,Malignant hyperthermia of anesthesia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423
418,Congenital adrenal hyperplasia,"13.35 (Europe); 10.0 (Europe); 6.7 (Europe); 8.6 (France); 6.65 (Italy); 12.8 (Germany); 10.2 (Sweden); 5.6 (United Kingdom); 7.65 (Netherlands); 4.0 (Belgium); 9.3 (Switzerland); 5.35 (Japan); 6.9 (New Zealand); 6.3 (Cuba); 6.7 (Taiwan, Province of China); 38.8 (India); 4.8 (United States); 1.36 (China); 7.98 (Czech Republic)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=418
216,Neuronal ceroid lipofuscinosis,0.0 (Worldwide); 0.12 (Italy); 0.98 (Italy); 0.56 (Italy); 4.0 (Norway); 2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216
364,Glycogen storage disease due to glucose-6-phosphatase deficiency,0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=364
355,Gaucher disease,1.7 (Europe); 1.0 (Europe); 1.3 (Worldwide); 0.67 (Spain); 5.7 (Austria); 2.6 (France); 2.0 (France); 0.74 (France); 1.7 (Australia); 1.13 (Czech Republic); 1.35 (Portugal); 1.16 (Netherlands); 7.5 (Hungary); 0.45 (Turkey); 2.11 (Sweden); 0.224 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=355
388,Hirschsprung disease,"13.2 (Europe); 21.0 (United States); 13.2 (Europe); 15.0 (Worldwide); 22.0 (Taiwan, Province of China); 15.0 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=388
177107,Syndromic hypothyroidism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=177107
448,Hemophilia,6.25 (Europe); 7.7 (Europe); 6.46 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=448
304,Epidermolysis bullosa simplex,0.656 (Worldwide); 0.58 (Australia); 1.19 (Netherlands); 0.197 (Romania),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=304
354,GM1 gangliosidosis,0.75 (Europe); 27.0 (Malta); 5.9 (Brazil); 0.0 (Worldwide); 0.34 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=354
178320,Acute lung injury,25.0 (Europe); 0.0 (Europe); 25.0 (Australia); 65.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178320
178333,Åland Islands eye disease,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178333
760,Purine nucleoside phosphorylase deficiency,72.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=760
270,Oculopharyngeal muscular dystrophy,167.0 (Specific population); 1.0 (France); 0.0 (Europe); 100.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=270
178303,8q22.1 microdeletion syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178303
244,Primary ciliary dyskinesia,44.0 (Pakistan); 5.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=244
178307,Reticulate acropigmentation of Kitamura,130.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178307
589,Myasthenia gravis,"1.7 (Europe); 20.0 (Europe); 7.77 (Worldwide); 0.9 (United States); 20.0 (Canada); 2.1 (Spain); 40.0 (United Kingdom); 1.11 (United Kingdom); 15.0 (United Kingdom); 1.33 (Serbia); 17.0 (United States); 31.8 (Serbia); 1.94 (Italy); 15.7 (Austria); 2.5 (Australia); 18.5 (Italy); 2.1 (Taiwan, Province of China); 11.7 (Australia); 0.74 (Greece); 14.0 (Taiwan, Province of China); 0.65 (Croatia); 7.8 (Estonia); 7.1 (Greece); 9.9 (Croatia); 3.2 (Egypt); 0.53 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589
805,Tuberous sclerosis complex,"1.58 (Taiwan, Province of China); 5.62 (Germany); 0.0 (Worldwide); 3.87 (Hong Kong); 5.38 (Sweden); 4.45 (United Kingdom)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=805
886,Usher syndrome,4.53 (Worldwide); 5.0 (Denmark); 6.2 (Germany); 6.2 (United Kingdom); 3.6 (Norway); 4.2 (Spain); 3.5 (Finland); 4.4 (United States); 3.2 (Colombia); 3.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=886
3440,Waardenburg syndrome,0.37 (Europe); 1.74 (United States); 2.4 (Netherlands); 0.0 (Netherlands); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3440
702,Pelizaeus-Merzbacher disease,0.25 (Europe); 0.35 (United States); 0.13 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=702
738,Porphyria,5.25 (Worldwide); 0.7 (Japan); 0.52 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=738
768,Familial long QT syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=768
791,Retinitis pigmentosa,"30.0 (Europe); 26.7 (Worldwide); 25.4 (Denmark); 22.5 (Norway); 21.0 (United States); 20.5 (United Kingdom); 26.4 (China); 16.7 (Slovenia); 11.09 (Korea, Republic of)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=791
375,Anti-glomerular basement membrane disease,0.08 (Europe); 0.179 (New Zealand); 0.06 (China); 0.0 (Worldwide); 0.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=375
183,Eosinophilic granulomatosis with polyangiitis,1.56 (Europe); 0.09 (Sweden); 1.13 (France); 1.4 (Sweden); 0.09 (United Kingdom); 1.3 (Norway); 0.09 (Spain); 2.23 (Australia); 0.18 (Europe); 1.5 (Worldwide); 0.05 (Norway); 0.11 (Germany); 0.13 (Lithuania); 0.12 (France); 0.06 (Turkey); 0.014 (Peru); 2.4 (Germany); 1.78 (Japan); 0.4 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183
1164,Allergic bronchopulmonary aspergillosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1164
2406,Locked-in syndrome,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2406
509,Leptospirosis,0.12 (Europe); 0.0 (Europe); 0.92 (France); 0.12 (Austria); 0.12 (Belgium); 0.18 (Bulgaria); 1.13 (Croatia); 0.22 (Czech Republic); 0.12 (Denmark); 0.24 (Estonia); 0.02 (Finland); 0.12 (Germany); 0.22 (Greece); 0.16 (Hungary); 0.36 (Ireland); 0.1 (Italy); 0.14 (Latvia); 0.3 (Lithuania); 0.04 (Luxembourg); 0.42 (Malta); 0.36 (Netherlands); 0.38 (Portugal); 0.38 (Romania); 0.12 (Slovakia); 0.52 (Slovenia); 0.04 (Sweden); 0.1 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=509
761,Immunoglobulin A vasculitis,"55.9 (Korea, Republic of); 30.0 (France); 6.79 (Croatia); 13.0 (United Kingdom); 6.1 (Netherlands); 17.55 (Sweden); 12.9 (Taiwan, Province of China); 0.0 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=761
2131,Alternating hemiplegia of childhood,0.94 (Denmark); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2131
171901,Primary cutaneous T-cell lymphoma,5.2 (Europe); 24.0 (Europe); 0.09 (Croatia); 0.097 (Latvia); 0.02 (Poland); 0.577 (Austria); 0.539 (Belgium); 0.158 (Bulgaria); 0.341 (Czech Republic); 0.185 (Estonia); 0.326 (Germany); 0.767 (Iceland); 0.647 (Ireland); 0.323 (Lithuania); 0.431 (Norway); 0.355 (Portugal); 0.273 (Slovakia); 0.225 (Slovenia); 0.594 (Spain); 0.231 (Switzerland); 0.441 (Netherlands); 0.197 (United Kingdom); 1.163 (Italy); 1.57 (Malta),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171901
713,Glycogen storage disease due to phosphoglycerate kinase 1 deficiency,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=713
171915,B-cell non-Hodgkin lymphoma,17.45 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171915
57,Glycogen storage disease due to aldolase A deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=57
249,Fibrous dysplasia of bone,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=249
2334,Autosomal dominant keratitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2334
171918,T-cell non-Hodgkin lymphoma,0.99 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171918
171929,Trisomy 10p syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171929
187,Citrullinemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=187
46,Adenylosuccinate lyase deficiency,56.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46
442,Congenital hypothyroidism,"38.0 (Europe); 0.0 (Europe); 10.0 (France); 0.0 (France); 57.0 (United Kingdom); 0.0 (United Kingdom); 45.5 (Italy); 57.0 (Greece); 55.5 (Cyprus); 15.5 (Latvia); 0.0 (Latvia); 49.1 (China); 0.0 (China); 30.2 (Germany); 0.0 (Germany); 29.4 (Denmark); 25.0 (Poland); 0.0 (Poland); 35.0 (Estonia); 0.0 (Estonia); 54.8 (Lebanon); 150.0 (Iran, Islamic Republic of); 73.35 (Brazil); 43.0 (Turkey); 0.0 (Turkey); 35.4 (Australia); 0.0 (Australia); 63.7 (United Arab Emirates); 76.9 (Bangladesh); 62.5 (Pakistan); 50.2 (Taiwan, Province of China); 43.0 (Mexico); 0.0 (Mexico); 25.3 (Bosnia and Herzegovina); 0.0 (Bosnia and Herzegovina); 33.7 (Bahrain); 0.0 (Bahrain); 36.0 (New Zealand); 0.0 (New Zealand); 16.0 (Thailand); 0.0 (Thailand); 0.0 (United States); 44.0 (United States); 37.3 (Specific population); 97.0873 (Brazil); 34.76 (Czech Republic); 45.0 (Ireland)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=442
43,X-linked adrenoleukodystrophy,0.8 (Israel); 0.8 (Norway); 2.0639 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=43
3166,Sialuria,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3166
2882,Sitosterolemia,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2882
810,Shigellosis,0.0 (Worldwide); 1.68 (Europe); 0.78 (Austria); 8.18 (Bulgaria); 0.33 (Croatia); 0.04 (Cyprus); 1.6 (Czech Republic); 2.08 (Denmark); 1.38 (Estonia); 1.82 (Finland); 2.54 (France); 0.7 (Germany); 0.74 (Greece); 0.38 (Hungary); 1.12 (Ireland); 0.34 (Latvia); 1.12 (Lithuania); 2.6 (Luxembourg); 0.34 (Malta); 2.4 (Netherlands); 0.02 (Poland); 0.08 (Portugal); 1.18 (Romania); 6.1 (Slovakia); 1.02 (Slovenia); 0.44 (Spain); 3.68 (Sweden); 3.32 (United Kingdom); 0.3 (Iceland); 2.06 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=810
3165,Eosinophilic fasciitis,0.0 (Worldwide); 1.4 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3165
2420,Primary pulmonary lymphoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2420
727,Microscopic polyangiitis,1.0 (Europe); 0.26 (Germany); 4.2843 (Worldwide); 1.16 (Spain); 9.4 (Sweden); 0.5 (Australia); 2.5 (France); 0.27 (Norway); 3.7 (New Zealand); 0.74 (United Kingdom); 6.3 (United Kingdom); 2.8 (Germany); 3.91 (Australia); 1.38 (Japan); 2.4 (Kuwait); 1.82 (Japan); 0.71 (Canada); 1.02 (Greece); 0.3 (Lithuania); 1.01 (Sweden); 1.6 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=727
900,Granulomatosis with polyangiitis,"0.85 (Europe); 9.0 (Europe); 1.0 (United Kingdom); 16.0 (Sweden); 0.86 (Germany); 2.37 (France); 1.19 (Sweden); 0.49 (Spain); 9.51 (Norway); 1.0 (Norway); 9.5 (Australia); 9.35 (New Zealand); 0.93 (Finland); 2.6 (United States); 1.94 (China); 0.21 (Lithuania); 0.66 (Greece); 0.24 (Italy); 0.46 (Canada); 0.21 (Japan); 0.037 (Taiwan, Province of China); 0.23 (Japan); 3.43 (Italy); 10.0 (Denmark); 1.3 (United States)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=900
863,Trichinellosis,0.0 (Europe); 0.06 (Europe); 0.48 (Bulgaria); 0.067 (Croatia); 0.04 (Estonia); 0.04 (Italy); 1.06 (Latvia); 0.6 (Lithuania); 0.64 (Romania); 0.08 (Slovakia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=863
134,Beta-ketothiolase deficiency,0.0 (Worldwide); 0.72 (Australia); 0.43 (United States); 0.98 (China); 0.53 (Viet Nam),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=134
171700,Diffuse panbronchiolitis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171700
171703,Microcephaly-polymicrogyria-corpus callosum agenesis syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171703
171706,Short stature-delayed bone age due to thyroid hormone metabolism deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171706
171719,Cutis laxa-Marfanoid syndrome,0.0 (Worldwide); 18.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171719
1163,Aspergillosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1163
3467,Hereditary xanthinuria,150.0 (Worldwide); 9.05 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3467
171673,Limbal stem cell deficiency,20.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171673
511,Maple syrup urine disease,"0.67 (Worldwide); 0.78 (United States); 0.79 (Italy); 7.3 (Tunisia); 0.19 (Japan); 1.15 (Portugal); 0.6 (Australia); 0.86 (Taiwan, Province of China); 0.0 (Europe); 4.8 (Israel); 10.2 (Specific population); 0.396 (China); 0.34 (Czech Republic)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=511
171680,Lissencephaly due to TUBA1A mutation,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171680
32,Glutathione synthetase deficiency,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=32
26,Methylmalonic acidemia with homocystinuria,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=26
171863,Autosomal dominant spastic paraplegia type 42,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171863
171871,Renal pseudohypoaldosteronism type 1,1.51 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171871
322,Exstrophy-epispadias complex,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=322
171866,"Spondyloepimetaphyseal dysplasia, aggrecan type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171866
2368,Gastroschisis,16.9 (Europe); 29.4 (Austria); 14.6 (Belgium); 22.7 (Croatia); 21.3 (Denmark); 17.7 (France); 41.6 (Germany); 6.2 (Hungary); 18.1 (Ireland); 9.9 (Italy); 25.8 (Malta); 17.5 (Netherlands); 36.0 (Norway); 11.6 (Poland); 11.0 (Portugal); 5.6 (Spain); 12.3 (Switzerland); 36.3 (United Kingdom); 9.5 (Ukraine); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2368
171881,Cap myopathy,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171881
2512,Autosomal recessive primary microcephaly,0.1 (Specific population); 0.0 (Worldwide); 1.0 (Pakistan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2512
171876,Generalized pseudohypoaldosteronism type 1,0.6 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171876
795,Rare form of salmonellosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=795
797,Sarcoidosis,"60.0 (United States); 0.0 (Worldwide); 48.1 (Ireland); 3.3 (Croatia); 20.0 (Europe); 5.0 (United Kingdom); 30.2 (France); 4.5 (Spain); 28.2 (Finland); 4.68 (Denmark); 7.0 (Switzerland); 0.0 (Switzerland); 1.07 (Greece); 5.89 (Greece); 3.84 (Iceland); 4.0 (Czech Republic); 63.0 (Czech Republic); 5.35 (Australia); 1.01 (Japan); 3.7 (Japan); 0.125 (Korea, Republic of); 0.56 (Singapore); 49.0 (Italy); 4.9 (France); 160.0 (Sweden); 11.5 (Sweden); 2.17 (Taiwan, Province of China); 0.2 (Portugal); 26.7 (Norway); 14.4 (Norway); 10.5 (Canada); 21.0 (Guadeloupe); 2.3 (Guadeloupe); 0.4 (Uruguay)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=797
92,Juvenile idiopathic arthritis,13.0 (Czech Republic); 1.5 (Europe); 4.7 (France); 8.9 (United States); 21.0 (Czech Republic); 20.5 (Worldwide); 74.6 (Specific population); 7.8 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=92
171829,6q16 microdeletion syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171829
1201,Small bowel atresia,9.0 (Europe); 9.0 (Spain); 11.0 (Ireland); 10.0 (Portugal); 14.5 (Italy); 22.0 (Reunion); 9.0 (Switzerland); 10.0 (Austria); 14.0 (Germany); 19.0 (Denmark); 12.0 (Malta); 18.0 (France); 18.0 (United Kingdom); 15.0 (Belgium); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1201
171844,Blindness-scoliosis-arachnodactyly syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171844
171839,Craniosynostosis-hydrocephalus-Arnold-Chiari malformation type I-radioulnar synostosis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171839
1202,Larynx atresia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1202
1199,Esophageal atresia,24.3 (Europe); 0.0 (Europe); 19.5 (Austria); 17.5 (Belgium); 11.4 (Croatia); 42.5 (Denmark); 11.8 (France); 23.8 (Germany); 26.6 (Hungary); 10.8 (Ireland); 18.4 (Italy); 24.9 (Malta); 17.1 (Netherlands); 34.4 (Norway); 9.7 (Poland); 18.9 (Portugal); 15.7 (Spain); 25.1 (Switzerland); 22.4 (United Kingdom); 22.3 (Ukraine); 21.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1199
171851,MEDNIK syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171851
171848,Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171848
1304,Brucellosis,0.09 (Europe); 0.03 (France); 0.04 (Austria); 0.05 (Germany); 1.13 (Greece); 0.03 (Ireland); 0.22 (Italy); 0.01 (Lithuania); 0.03 (Luxembourg); 0.05 (Malta); 0.05 (Norway); 0.35 (Portugal); 0.12 (Spain); 0.15 (Sweden); 0.02 (United Kingdom); 0.01 (Romania); 0.02 (Slovakia); 0.02 (Slovenia); 0.02 (Netherlands); 0.01 (Poland); 0.04 (Belgium); 0.11 (Bulgaria); 0.02 (Croatia); 0.004 (Czech Republic); 0.008 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1304
173,Cholera,0.0 (Europe); 0.0 (United States); 0.0 (Europe); 0.0 (United Kingdom); 0.0 (Germany); 0.0 (Austria); 0.0 (Belgium); 0.0 (Czech Republic); 0.0 (Denmark); 0.0 (France); 0.0 (Norway); 0.0 (Spain); 0.0 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=173
3303,Tetralogy of Fallot,"34.0 (Worldwide); 29.3 (Europe); 39.3 (Austria); 40.8 (Belgium); 11.4 (Croatia); 39.7 (Denmark); 13.8 (France); 11.9 (Germany); 34.3 (Hungary); 14.5 (Ireland); 26.8 (Italy); 48.2 (Malta); 29.2 (Netherlands); 31.1 (Norway); 16.2 (Poland); 23.7 (Portugal); 63.0 (Taiwan, Province of China); 11.9 (Spain); 25.1 (Switzerland); 32.0 (United Kingdom); 25.4 (Ukraine); 47.0 (United States); 40.0 (China); 0.0 (Worldwide); 0.0 (Europe)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3303
200418,Immunodeficiency with factor I anomaly,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=200418
730,Autosomal dominant polycystic kidney disease,39.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=730
486,Autosomal dominant severe congenital neutropenia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=486
1209,Tricuspid atresia,"5.5625 (Europe); 0.0 (Europe); 5.9 (Belgium); 9.0 (France); 3.0 (Germany); 10.5 (Ireland); 6.5 (Italy); 4.0 (Netherlands); 3.3 (Norway); 1.5 (Poland); 1.9 (Spain); 11.1 (Portugal); 12.6 (Switzerland); 5.0 (United Kingdom); 9.7 (Ukraine); 4.6 (Taiwan, Province of China); 8.0 (Malta); 6.0 (Czech Republic); 3.0 (Slovakia)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1209
98,Autosomal recessive spastic ataxia of Charlevoix-Saguenay,0.0 (Worldwide); 51.76 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98
1478,Interatrial communication,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1478
330,Congenital factor XII deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330
1959,Evans syndrome,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1959
284,Alveolar echinococcosis,0.16 (Europe); 0.26 (Switzerland); 0.014 (Poland); 2.8 (Austria); 0.026 (France); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284
1177,Early-onset cerebellar ataxia with retained tendon reflexes,2.08 (Italy); 1.0 (Italy); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1177
828,Stickler syndrome,1.0 (Europe); 0.0 (Europe); 0.65 (France); 0.0 (France); 12.2 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=828
1431,Paroxysmal dyskinesia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1431
293,Congenital herpes simplex virus infection,6.6 (Sweden); 0.0 (Worldwide); 1.6 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293
199340,"Muscular dystrophy, Selcen type",12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199340
199337,Pancreatic insufficiency-anemia-hyperostosis syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199337
234,Dubin-Johnson syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=234
199348,Thiamine-responsive encephalopathy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199348
3287,Takayasu arteritis,"0.084 (Europe); 1.34 (Europe); 0.06 (United Kingdom); 4.0 (Japan); 0.1 (Sweden); 0.98 (Sweden); 0.47 (United Kingdom); 0.04 (Denmark); 0.0 (Worldwide); 0.07 (Germany); 0.78 (Kuwait); 0.15 (Japan); 0.13 (Lithuania); 0.22 (Kuwait); 0.26 (United States); 0.15 (Norway); 2.56 (Norway); 2.82 (Korea, Republic of); 0.24 (Korea, Republic of); 0.46 (Poland); 0.092 (Poland)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3287
199343,EAST syndrome,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199343
2800,Extramammary Paget disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2800
199326,"Isolated autosomal dominant hypomagnesemia, Glaudemans type",21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199326
1928,Congenital lobar emphysema,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1928
199332,Endocrine-cerebro-osteodysplasia syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199332
199329,"Congenital myopathy, Paradas type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199329
3463,Wolfram syndrome,0.13 (United Kingdom); 0.12 (India); 0.13 (Worldwide); 1.83 (Specific population); 0.13 (Japan); 0.62 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3463
549,Legionnaires disease,1.4 (Europe); 2.5 (France); 1.82 (Austria); 1.38 (Belgium); 0.8 (Croatia); 0.42 (Cyprus); 1.24 (Czech Republic); 3.18 (Denmark); 0.84 (Estonia); 0.32 (Finland); 1.18 (Germany); 0.3 (Greece); 0.5 (Hungary); 0.83 (Iceland); 0.28 (Ireland); 2.72 (Italy); 1.5 (Latvia); 0.28 (Lithuania); 1.02 (Luxembourg); 1.88 (Malta); 2.48 (Netherlands); 0.96 (Norway); 0.06 (Poland); 2.42 (Portugal); 0.26 (Slovakia); 4.38 (Slovenia); 2.16 (Spain); 1.52 (Sweden); 0.62 (United Kingdom); 0.02 (Romania); 5.4 (New Zealand),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=549
704,Pemphigus vulgaris,0.13 (France); 18.0 (Europe); 0.7 (United Kingdom); 0.076 (Finland); 0.47 (Bulgaria); 0.42 (United States); 0.25 (Tunisia); 9.482 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=704
199354,Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199354
199351,Adult-onset dystonia-parkinsonism,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199351
356,Gerstmann-Straussler-Scheinker syndrome,0.0 (Worldwide); 0.0055 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=356
466,Fatal familial insomnia,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466
199293,Congenital microgastria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199293
3452,Whipple disease,0.0 (Europe); 0.0 (Worldwide); 0.29 (Italy); 0.98 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3452
199282,Harlequin syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199282
199285,Hereditary hypercarotenemia and vitamin A deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199285
2331,Kawasaki disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2331
2102,GTP cyclohydrolase I deficiency,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2102
3002,Immune thrombocytopenia,25.0 (Europe); 9.5 (United States); 3.9 (United Kingdom); 6.75 (Europe); 2.68 (Denmark); 45.0 (Denmark); 2.9 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3002
199267,Infantile digital fibromatosis,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199267
2040,Congenital respiratory-biliary fistula,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2040
199318,15q13.3 microdeletion syndrome,246.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199318
2357,Bronchogenic cyst,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2357
274,Bernard-Soulier syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=274
1195,Congenital atransferrinemia,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1195
199302,Isolated cleft lip,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199302
199306,Cleft lip/palate,0.0 (Europe); 56.0 (United States); 98.0 (France); 80.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199306
926,Acatalasemia,3.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=926
3020,Ramsay Hunt syndrome,5.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3020
1531,Craniosynostosis,24.3 (Europe); 47.6 (France); 49.4 (Australia); 43.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1531
1675,Dihydropyrimidine dehydrogenase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1675
189427,Cushing syndrome due to bilateral macronodular adrenocortical disease,0.08 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=189427
976,Adenine phosphoribosyltransferase deficiency,1.5 (Specific population); 3.7 (Japan); 6.7 (Iceland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=976
3129,Sarcosinemia,0.28 (United States); 2.0 (Worldwide); 0.0 (Worldwide); 2.3 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3129
415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,0.0 (Worldwide); 0.0 (Europe); 111.0 (Worldwide); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=415
13,6-pyruvoyl-tetrahydropterin synthase deficiency,0.0 (Worldwide); 0.0 (Europe); 0.0854 (Brazil); 0.3094 (China); 2.5258 (Hong Kong),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=13
2494,Ménétrier disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2494
171,Primary sclerosing cholangitis,0.77 (Europe); 7.84 (Europe); 8.1 (Worldwide); 0.65 (Worldwide); 0.77 (United States); 8.81 (United States); 1.3 (Norway); 8.5 (Norway); 1.22 (Sweden); 16.2 (Sweden); 0.66 (United Kingdom); 8.28 (United Kingdom); 0.5 (Netherlands); 6.0 (Netherlands); 0.9 (Canada); 0.07 (Spain); 0.22 (Spain); 1.3 (Singapore),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=171
199247,Corticosteroid-binding globulin deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199247
199241,Pulmonary capillary hemangiomatosis,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199241
2134,Atypical hemolytic uremic syndrome,0.2 (United States); 1.0 (Europe); 0.0278 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2134
17,Fatal infantile lactic acidosis with methylmalonic aciduria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=17
3006,Pyridoxine-dependent epilepsy,0.2 (Europe); 0.13 (United Kingdom); 0.25 (Netherlands); 5.0 (Germany); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3006
780,Rhabdomyosarcoma,0.59 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=780
3111,Rotor syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3111
2382,Lennox-Gastaut syndrome,0.1 (Europe); 15.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2382
2806,Subacute sclerosing leukoencephalitis,0.0 (Europe); 0.003 (United States); 2.0 (India),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2806
2467,Systemic mastocytosis,0.3 (Italy); 0.0 (Worldwide); 0.9 (Denmark); 9.6 (Denmark); 0.6 (Europe); 13.0 (Netherlands); 11.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2467
1934,Early infantile epileptic encephalopathy,1.0 (Japan); 2.0 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1934
845,Tay-Sachs disease,27.8 (Specific population); 0.5 (Specific population); 0.31 (Europe); 3.13 (Portugal); 0.3 (Czech Republic); 0.5 (Australia); 0.28 (Worldwide); 0.41 (Netherlands); 0.29 (Canada); 0.74 (United Arab Emirates); 0.23 (Turkey); 0.48 (Sweden); 0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=845
1942,Myoclonic-astatic epilepsy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1942
1943,Early-onset progressive encephalopathy with migrant continuous myoclonus,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1943
3451,Infantile epileptic spasms syndrome,"6.0 (Europe); 3.5 (Europe); 3.7 (Worldwide); 2.5 (Finland); 2.5 (Iceland); 4.5 (Sweden); 2.9 (United States); 31.0 (Singapore); 25.0 (Korea, Republic of); 3.25 (Japan)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3451
3299,Tetanus,0.014 (France); 0.024 (Europe); 0.044 (Malta); 0.01 (Slovakia); 0.014 (Bulgaria); 0.028 (Croatia); 0.004 (Czech Republic); 0.014 (Denmark); 0.032 (Estonia); 0.036 (Greece); 0.024 (Hungary); 0.016 (Ireland); 0.076 (Italy); 0.07 (Lithuania); 0.008 (Netherlands); 0.012 (Norway); 0.032 (Poland); 0.008 (Portugal); 0.032 (Romania); 0.118 (Slovenia); 0.016 (Spain); 0.02 (Sweden); 0.01 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3299
2302,Asbestos intoxication,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2302
770,Rabies,0.0 (Europe); 0.0 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=770
3386,American trypanosomiasis,0.0 (Europe); 0.0 (France); 0.0 (Germany); 0.0 (Italy); 0.0 (Netherlands); 0.0 (Portugal); 0.0 (Spain); 0.0 (Switzerland); 0.0 (United Kingdom); 0.0 (Belgium); 95.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3386
267,Calpain-3-related limb-girdle muscular dystrophy R1,1.0 (Europe); 0.6 (United Kingdom); 4.8 (Reunion); 1.65 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=267
1329,Complete atrioventricular septal defect,0.0 (Worldwide); 20.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1329
582,Mucopolysaccharidosis type 4,"0.07 (Sweden); 0.76 (Norway); 24.2 (Norway); 0.48 (Denmark); 31.0 (Denmark); 0.73 (Czech Republic); 0.45 (Tunisia); 0.33 (Taiwan, Province of China); 0.45 (Europe); 0.36 (Netherlands); 0.14 (Poland); 27.6 (Europe); 0.15 (Japan); 0.38 (Switzerland); 3.62 (Saudi Arabia); 0.13 (Korea, Republic of); 0.14 (Brazil); 0.6 (Portugal); 0.038 (United States); 0.14 (United States); 0.07 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=582
2137,Autoimmune hepatitis,0.0 (Europe); 1.2 (Worldwide); 23.5 (Worldwide); 0.75 (Europe); 1.9 (Norway); 16.9 (Norway); 0.85 (Sweden); 24.5 (New Zealand); 0.95 (Spain); 11.6 (Spain); 10.7 (Sweden); 0.67 (Israel); 11.0 (Israel); 1.68 (Denmark); 23.9 (Denmark); 4.0 (Singapore); 42.9 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2137
186,Primary biliary cholangitis,2.57 (Europe); 21.05 (Worldwide); 3.0 (Worldwide); 25.0 (Europe); 0.9 (France); 1.7 (Spain); 19.5 (Spain); 2.5 (Iceland); 38.3 (Iceland); 1.1 (Netherlands); 13.2 (Netherlands); 1.7 (Denmark); 12.0 (Denmark); 1.7 (Finland); 18.0 (Finland); 25.0 (United Kingdom); 4.5 (United States); 40.2 (United States); 3.0 (Canada); 22.7 (Canada); 5.1 (Australia); 5.5 (Israel); 4.9 (China); 1.0 (Brunei Darussalam); 2.6 (Brunei Darussalam); 36.5 (Greece); 2.1 (Greece); 2.3 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=186
397,Giant cell arteritis,8.9 (Germany); 0.35 (United States); 2.8 (Italy); 7.7 (Sweden); 11.2 (United Kingdom); 0.0 (Europe); 30.4 (Italy); 16.8 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397
2932,Chronic inflammatory demyelinating polyneuropathy,3.7 (Europe); 0.36 (Italy); 2.6 (United Kingdom); 3.86 (Italy); 7.7 (Norway); 12.0 (Egypt); 0.48 (Japan); 1.61 (Japan); 0.15 (Australia); 1.9 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2932
2398,Multiple symmetric lipomatosis,0.0 (Worldwide); 2.0 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2398
1656,Dermatitis herpetiformis,27.0 (Europe); 0.9 (Italy); 1.5 (Ireland); 17.6 (Ireland); 1.1 (Sweden); 21.0 (Sweden); 0.98 (United States); 11.2 (United States); 3.5 (Finland); 75.3 (Finland); 11.5 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1656
3198,Stiff person spectrum disorder,"0.0 (Europe); 0.15 (United Kingdom); 0.09 (Tanzania, United Republic of)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3198
2929,Juvenile polyposis syndrome,3.85 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2929
131,Budd-Chiari syndrome,"1.5 (Europe); 0.08 (Sweden); 0.14 (Sweden); 0.05 (Denmark); 0.02 (Japan); 0.24 (Japan); 0.04 (France); 0.21 (Italy); 0.087 (Korea, Republic of); 0.529 (Korea, Republic of); 0.1 (Worldwide); 1.1 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=131
646,Niemann-Pick disease type C,1.0 (Europe); 0.77 (France); 0.75 (United Kingdom); 0.75 (Germany); 0.35 (Netherlands); 2.2 (Portugal); 0.47 (Australia); 0.91 (Czech Republic); 0.48 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=646
654,Nephroblastoma,0.14 (Europe); 0.0 (Europe); 3.65 (Europe); 0.144 (United Kingdom); 10.0 (Europe); 0.072 (Bulgaria); 0.006 (Czech Republic); 0.089 (Germany); 0.043 (Iceland); 0.065 (Latvia); 0.066 (Portugal); 0.121 (Austria); 0.195 (Belgium); 0.155 (Croatia); 0.139 (Estonia); 0.158 (Finland); 0.17 (Ireland); 0.111 (Italy); 0.12 (Lithuania); 0.157 (Malta); 0.131 (Norway); 0.111 (Poland); 0.162 (Slovakia); 0.144 (Slovenia); 0.113 (Spain); 0.135 (Switzerland); 0.176 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=654
1489,Whooping cough,8.9 (Europe); 9.76 (Austria); 10.08 (Belgium); 1.08 (Bulgaria); 0.88 (Cyprus); 10.7 (Czech Republic); 19.16 (Denmark); 4.66 (Estonia); 5.1 (Finland); 15.4 (Germany); 0.38 (Greece); 0.16 (Hungary); 2.34 (Croatia); 5.3 (Iceland); 3.58 (Ireland); 1.2 (Italy); 8.48 (Latvia); 2.22 (Lithuania); 2.14 (Luxembourg); 0.52 (Malta); 31.72 (Netherlands); 47.24 (Norway); 10.6 (Poland); 2.1 (Portugal); 0.42 (Romania); 10.5 (Slovakia); 9.5 (Slovenia); 8.3 (Spain); 6.2 (Sweden); 8.5 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1489
2764,Osteochondritis dissecans,35.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2764
3389,Tuberculosis,4.0 (Greece); 5.0 (Iceland); 6.0 (Israel); 15.0 (Spain); 24.0 (Portugal); 8.0 (Belgium); 4.0 (Austria); 90.0 (Algeria); 23.0 (Poland); 42.0 (Latvia); 59.0 (Lithuania); 49.0 (Bosnia and Herzegovina); 17.0 (Croatia); 101.0 (Romania); 97.0 (Russian Federation); 139.0 (Worldwide); 16.0 (Europe); 3.4 (United States); 20.0 (Japan); 6.0 (Australia); 4.0 (France); 8.0 (Finland); 18.0 (Hungary); 181.0 (India); 7.0 (Netherlands); 14.0 (United Kingdom); 6.0 (Norway); 7.0 (Sweden); 75.0 (China); 47.0 (Latin America); 993.0 (South Africa); 7.1 (Denmark); 6.0 (Czech Republic); 5.0 (Germany); 10.7 (Ireland); 3.0 (Italy); 25.0 (Estonia); 24.0 (Turkey); 89.0 (Ukraine); 9.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3389
1679,Diphtheria,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1679
1267,Botulism,0.022 (Europe); 0.0 (Worldwide); 0.255 (France); 0.35 (United States); 0.026 (Austria); 0.006 (Belgium); 0.028 (Bulgaria); 0.04 (Croatia); 0.01 (Czech Republic); 0.024 (Denmark); 0.012 (Finland); 0.006 (Germany); 0.052 (Hungary); 0.012 (Ireland); 0.052 (Italy); 0.086 (Lithuania); 0.002 (Netherlands); 0.038 (Poland); 0.018 (Portugal); 0.104 (Romania); 0.02 (Slovenia); 0.004 (Spain); 0.01 (Sweden); 0.008 (United Kingdom); 0.098 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1267
2897,Pityriasis rubra pilaris,48.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2897
2103,Guillain-Barré syndrome,1.45 (Worldwide); 1.72 (United States); 3.5 (Europe); 25.0 (Denmark); 1.4 (Europe); 12.0 (Egypt); 2.42 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2103
183669,Agammaglobulinemia,0.13 (Europe); 0.287 (France); 0.134 (Spain); 0.192 (Netherlands); 0.045 (Turkey); 0.094 (United Kingdom); 0.205 (Italy); 0.077 (Germany); 0.071 (Poland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183669
2070,Eosinophilic gastroenteritis,280.0 (Worldwide); 0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2070
183707,Infantile LAD-like disease due to RAC2 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183707
2314,Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency,0.1 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2314
183678,Hermansky-Pudlak syndrome due to AP-3 deficiency,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183678
449,Hepatoblastoma,0.02 (Europe); 0.009 (Austria); 0.019 (Belgium); 0.008 (Bulgaria); 0.042 (Croatia); 0.005 (Czech Republic); 0.046 (Estonia); 0.031 (Finland); 0.021 (Germany); 0.043 (Ireland); 0.017 (Italy); 0.022 (Latvia); 0.004 (Lithuania); 0.031 (Malta); 0.033 (Norway); 0.023 (Poland); 0.008 (Portugal); 0.032 (Slovakia); 0.025 (Slovenia); 0.009 (Spain); 0.011 (Switzerland); 0.032 (Netherlands); 0.028 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449
183675,Recurrent infections associated with rare immunoglobulin isotypes deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183675
2177,Hydranencephaly,0.0 (Worldwide); 0.0 (Worldwide); 2.1 (Japan); 2.8 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2177
533,Listeriosis,0.0 (Worldwide); 0.43 (Europe); 0.337 (Worldwide); 0.31 (United States); 0.48 (Austria); 1.07 (Belgium); 0.09 (Bulgaria); 0.05 (Croatia); 0.05 (Cyprus); 0.36 (Czech Republic); 0.98 (Denmark); 0.4 (Estonia); 1.1 (Finland); 0.57 (France); 0.68 (Germany); 0.15 (Greece); 0.28 (Hungary); 0.29 (Ireland); 0.24 (Italy); 0.28 (Latvia); 0.25 (Lithuania); 0.4 (Luxembourg); 0.38 (Malta); 0.47 (Netherlands); 0.23 (Poland); 0.29 (Portugal); 0.05 (Romania); 0.31 (Slovakia); 0.67 (Slovenia); 0.9 (Spain); 0.92 (Sweden); 0.3 (United Kingdom); 0.56 (Iceland); 0.46 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=533
183713,OBSOLETE:Bacterial susceptibility due to TLR signaling pathway deficiency,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183713
2380,Legg-Calvé-Perthes disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2380
683,Progressive supranuclear palsy,0.65 (Worldwide); 5.26 (Worldwide); 14.0 (Europe); 1.39 (United States); 3.2 (Italy); 14.0 (Guadeloupe); 3.75 (United Kingdom); 0.3 (Libyan Arab Jamahiriya); 0.63 (United States); 0.4 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=683
677,Pancreatoblastoma,60.0 (Worldwide); 0.0 (Europe); 0.0 (Worldwide); 0.008 (Bulgaria); 0.013 (Czech Republic); 0.005 (Germany); 0.001 (Italy); 0.016 (Latvia); 0.004 (Lithuania); 0.008 (Poland); 0.002 (Portugal); 0.001 (Netherlands); 0.001 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=677
183660,Severe combined immunodeficiency,1.65 (Europe); 1.6 (France); 1.7 (Greece); 1.75 (Australia); 1.28 (Chile); 3.79 (Costa rica); 0.0 (Worldwide); 1.72 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183660
897,Waardenburg-Shah syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=897
808,Seckel syndrome,50.0 (Worldwide); 0.0 (Worldwide); 0.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=808
844,Lown-Ganong-Levine syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=844
3027,Caudal regression syndrome,0.0 (Worldwide); 0.0 (Worldwide); 1.75 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3027
676,Hereditary chronic pancreatitis,0.3 (France); 0.57 (Denmark); 0.43 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=676
643,Giant axonal neuropathy,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=643
634,Netherton syndrome,0.5 (Europe); 0.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=634
140,Campomelic dysplasia,3.0E-4 (Worldwide); 1.875 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140
2828,Young-onset Parkinson disease,15.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2828
642,Hereditary sensory and autonomic neuropathy type 4,0.14 (Japan); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=642
627,Nance-Horan syndrome,196.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=627
638,Neurofibromatosis-Noonan syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=638
326,Congenital factor V deficiency,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=326
526,Liddle syndrome,72.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=526
650,LCAT deficiency,125.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=650
427,Familial hypoaldosteronism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=427
215,Congenital stationary night blindness,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=215
342,Familial Mediterranean fever,175.0 (Turkey); 200.0 (Armenia); 2.5 (Sweden); 0.23 (Japan); 0.0 (Europe); 14.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=342
180,Choroideremia,2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=180
754,Androgen insensitivity syndrome,1.01 (Netherlands); 0.0 (Worldwide); 4.1 (Denmark); 0.04 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=754
253,Spondyloepiphyseal dysplasia and spondyloepimetaphyseal dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=253
327,Congenital factor VII deficiency,0.33 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=327
183518,Hereditary ataxia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183518
373,Simpson-Golabi-Behmel syndrome,0.0 (Worldwide); 250.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=373
403,Familial hyperaldosteronism type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=403
574,21q deletion syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=574
653,Multiple endocrine neoplasia type 2,2.9 (Europe); 1.25 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=653
146,Differentiated thyroid carcinoma,5.25 (Worldwide); 2.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=146
1331,Familial prostate cancer,9.4 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1331
157,Carnitine palmitoyltransferase II deficiency,300.0 (Worldwide); 0.0 (Worldwide); 0.2 (United States); 1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157
847,X-linked alpha-thalassemia-intellectual disability syndrome,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=847
1446,Ring chromosome 22 syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1446
183435,Inherited ichthyosis,1.33 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183435
2268,ICF syndrome,66.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2268
475,Joubert syndrome,0.47 (Italy); 1.6666 (Worldwide); 0.0 (Worldwide); 5.0 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=475
392,Holt-Oram syndrome,0.7 (Europe); 0.95 (Hungary); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=392
113,Bazex-Dupré-Christol syndrome,143.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=113
243,"46,XX gonadal dysgenesis",0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=243
183422,Polymalformative genetic syndrome with increased risk of developing cancer,10.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=183422
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,3.0 (Europe); 2.0 (United Kingdom); 3.0 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=136
182114,Rare urogenital tumor,0.13 (Europe); 0.21 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=182114
48,Congenital bilateral absence of vas deferens,50.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48
182130,Tumor of endocrine glands,3.75 (Europe); 64.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=182130
528,Congenital generalized lipodystrophy,0.5 (Europe); 0.01 (United States); 0.86 (Peru); 0.1 (Norway); 0.5 (Lebanon); 0.2 (Portugal); 4.0 (Oman); 0.6812 (Worldwide); 0.05 (Turkey); 3.23 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=528
275,Severe combined immunodeficiency due to DCLRE1C deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275
182090,Pulmonary arterial hypertension,2.0 (Europe); 1.6 (Spain); 0.37 (Spain); 1.5 (France); 0.24 (France); 1.09 (United States); 1.07 (Czech Republic); 2.24 (Czech Republic); 1.55 (Switzerland); 0.35 (Switzerland); 0.72 (United Kingdom); 5.2 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=182090
182095,Interstitial lung disease,4.1 (Denmark); 5.4 (Europe); 7.6 (Spain); 4.63 (Greece); 17.3 (Greece),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=182095
184,Cherubism,0.0 (Worldwide); 300.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=184
1047,Sideroblastic anemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1047
71,Chylomicron retention disease,55.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71
182067,Glial tumor,5.26 (United States); 26.0 (Europe); 5.7 (Greece); 6.2 (Croatia); 5.35 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=182067
1949,Self-limited neonatal epilepsy,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1949
189,Hidrotic ectodermal dysplasia,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=189
1473,Uveal coloboma-cleft lip and palate-intellectual disability,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1473
1344,Atrial standstill,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1344
182050,MYH9-related disease,0.29 (Italy); 0.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=182050
3103,Roberts syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3103
709,Peters plus syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=709
776,Lujan-Fryns syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=776
902,Werner syndrome,0.5 (Europe); 0.5 (United States); 2.0 (Japan); 2.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=902
888,Van der Woude syndrome,"1.7 (Finland); 1.3 (France); 0.0 (France); 1.4 (Australia); 0.85 (Taiwan, Province of China); 0.0 (Taiwan, Province of China); 0.9 (United States); 0.0 (United States); 0.0 (Europe); 0.7 (Australia)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=888
871,Familial progressive cardiac conduction defect,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=871
1597,Distal deletion 17q syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1597
1590,Distal deletion 13q syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1590
1587,Monosomy 13q14 syndrome,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1587
1621,3q13 microdeletion syndrome,42.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1621
1620,Distal deletion 3p syndrome,34.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1620
1627,Deletion 5q35 syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1627
1699,Trisomy 12p syndrome,40.0 (Worldwide); 2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1699
500,Noonan syndrome with multiple lentigines,296.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500
507,Leishmaniasis,0.1 (Europe); 25.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=507
548,Leprosy,0.0 (Worldwide); 3.7 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=548
233,Duane retraction syndrome,10.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=233
657,Congenital isolated hyperinsulinism,2.24 (Czech Republic); 5.25 (Japan); 3.52 (United Kingdom); 2.0 (Netherlands); 40.0 (Saudi Arabia); 3.67 (Worldwide); 0.0 (Worldwide); 23.2 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=657
2495,Meningioma,4.15 (Germany); 0.0 (Europe); 8.14 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2495
569,Familial or sporadic hemiplegic migraine,10.0 (Europe); 10.0 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=569
2014,Cleft palate,"53.6 (Europe); 0.0 (Europe); 19.6 (Austria); 0.0 (Austria); 40.8 (Belgium); 0.0 (Belgium); 56.8 (Croatia); 0.0 (Croatia); 127.6 (Denmark); 0.0 (Denmark); 25.5 (France); 0.0 (France); 47.5 (Germany); 0.0 (Germany); 67.5 (Hungary); 0.0 (Hungary); 54.2 (Ireland); 0.0 (Ireland); 39.6 (Italy); 0.0 (Italy); 74.7 (Malta); 0.0 (Malta); 11.7 (Netherlands); 0.0 (Netherlands); 65.4 (Norway); 0.0 (Norway); 36.5 (Poland); 0.0 (Poland); 14.2 (Portugal); 0.0 (Portugal); 30.7 (Spain); 0.0 (Spain); 25.1 (Switzerland); 0.0 (Switzerland); 60.2 (United Kingdom); 0.0 (United Kingdom); 57.2 (Ukraine); 0.0 (Ukraine); 101.2 (Australia); 0.0 (Australia); 52.0 (Chile); 0.0 (Chile); 27.0 (Sudan); 0.0 (Sudan); 26.0 (Iran, Islamic Republic of); 0.0 (Iran, Islamic Republic of); 27.0 (Mexico); 0.0 (Mexico); 4.0 (Bolivia); 0.0 (Bolivia); 68.0 (Specific population); 0.0 (Specific population); 40.0 (Taiwan, Province of China); 0.0 (Taiwan, Province of China)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2014
240,Léri-Weill dyschondrosteosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=240
2311,Autosomal recessive spondylocostal dysostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2311
358,Gitelman syndrome,2.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=358
242,"46,XY complete gonadal dysgenesis",0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=242
2052,Fraser syndrome,0.2 (Europe); 0.0 (Worldwide); 0.43 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2052
1354,Heart defects-limb shortening syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1354
1358,Carey-Fineman-Ziter syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1358
557,Non-syndromic anorectal malformation,20.0 (Worldwide); 24.0 (Europe); 78.0 (Austria); 26.2 (Belgium); 11.4 (Croatia); 21.3 (Denmark); 23.6 (France); 53.5 (Germany); 43.2 (Hungary); 28.9 (Ireland); 11.3 (Italy); 29.2 (Netherlands); 29.5 (Norway); 11.6 (Poland); 4.7 (Portugal); 13.8 (Spain); 49.0 (Switzerland); 21.6 (United Kingdom); 28.6 (Ukraine); 60.8 (Saudi Arabia); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=557
111,Barth syndrome,0.22 (Europe); 0.29 (United States); 0.15 (France); 0.71 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=111
10,"48,XXYY syndrome",1.9 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=10
1308,C syndrome,0.11 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1308
150,Nasopharyngeal carcinoma,0.2 (China); 0.0 (Worldwide); 2.0 (Europe); 0.36 (Europe); 0.337 (Austria); 0.317 (Belgium); 0.766 (Bulgaria); 0.423 (Croatia); 0.437 (Czech Republic); 0.24 (Estonia); 0.177 (Finland); 0.35 (Germany); 0.383 (Iceland); 0.207 (Ireland); 0.618 (Italy); 0.254 (Latvia); 0.228 (Lithuania); 0.264 (Norway); 0.426 (Poland); 0.62 (Portugal); 0.491 (Slovakia); 0.394 (Slovenia); 0.779 (Spain); 0.462 (Switzerland); 0.288 (Netherlands); 0.211 (United Kingdom); 1.256 (Malta),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=150
133,Chronic beryllium disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=133
1552,Currarino syndrome,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1552
1450,Ring chromosome 8 syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1450
1448,Ring chromosome 6 syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1448
1580,Distal deletion 10p syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1580
1437,Ring chromosome 1 syndrome,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1437
172,Progressive familial intrahepatic cholestasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=172
1447,Ring chromosome 4 syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1447
1444,Ring chromosome 20 syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1444
1439,Ring chromosome 12 syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1439
1438,Ring chromosome 10 syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1438
3306,Inverted duplicated chromosome 15 syndrome,3.33 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3306
3375,Trisomy X syndrome,42.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3375
3310,Tetrasomy 9p syndrome,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3310
3000,Familial peripheral male-limited precocious puberty,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3000
3176,Spina bifida-hypospadias syndrome,6.1 (Spain); 6.1 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3176
1708,Mosaic trisomy 16 syndrome,0.0 (Worldwide); 226.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1708
1711,Mosaic trisomy 17 syndrome,31.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1711
3376,Triploidy syndrome,12.6 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3376
1692,Mosaic trisomy 1 syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1692
1698,Mosaic trisomy 12 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1698
1706,Mosaic trisomy 15 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1706
916,Aase-Smith syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=916
920,Ablepharon macrostomia syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=920
1445,Ring chromosome 21 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1445
7,3C syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=7
931,Isolated acheiropodia,0.0 (Worldwide); 0.4 (Brazil); 0.03 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=931
929,Achalasia-microcephaly syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=929
869,Triple A syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=869
2297,Insulin-resistance syndrome type A,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2297
922,Familial nasal acilia,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=922
921,Abruzzo-Erickson syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=921
27,Vitamin B12-unresponsive methylmalonic acidemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=27
939,3-hydroxyisobutyric aciduria,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=939
31,Oxoglutaric aciduria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31
935,Short-limb skeletal dysplasia with severe combined immunodeficiency,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=935
932,Achondrogenesis,2.8 (France); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=932
37,Acrodermatitis enteropathica,0.2 (Denmark); 0.0 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=37
950,Acrodysostosis,0.0 (Worldwide); 80.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=950
949,Acrocraniofacial dysostosis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=949
945,Acalvaria,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=945
957,Acropectorovertebral dysplasia,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=957
958,Acro-renal-mandibular syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=958
955,Hajdu-Cheney syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=955
952,"Acrofacial dysostosis, Weyers type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=952
1713,17p11.2 microduplication syndrome,170.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1713
1738,Trisomy 4p syndrome,85.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1738
1742,Trisomy 5p syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1742
1745,Distal duplication 6p syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1745
1752,Trisomy 8q syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1752
1762,Proximal Xq28 duplication syndrome,0.0 (Europe); 0.65 (Australia); 0.07 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1762
1878,TRIM32-related limb-girdle muscular dystrophy R8,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1878
1876,Oculogastrointestinal muscular dystrophy,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1876
1948,Epilepsy-microcephaly-skeletal dysplasia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1948
1946,Amelocerebrohypohidrotic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1946
1951,Epilepsy-telangiectasia syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1951
381,Griscelli syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=381
2604,Familial visceral myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2604
156,Carnitine palmitoyl transferase 1A deficiency,60.0 (Worldwide); 0.0 (Worldwide); 0.3 (Israel); 0.5 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=156
2597,Mitochondrial myopathy-lactic acidosis-deafness syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2597
2598,Mitochondrial myopathy and sideroblastic anemia,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2598
1078,Thumb stiffness-brachydactyly-intellectual disability syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1078
1077,Dental ankylosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1077
1074,Ankyloblepharon filiforme adnatum-imperforate anus syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1074
1072,Ankyloblepharon filiforme adnatum-cleft palate syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1072
1071,Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1071
1069,Aniridia-absent patella syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1069
1068,Aniridia-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1068
1067,Aniridia-ptosis-intellectual disability-familial obesity syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1067
1064,Aniridia-renal agenesis-psychomotor retardation syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1064
1062,Hereditary neurocutaneous malformation,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1062
1053,Vein of Galen aneurysmal malformation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1053
1052,Mosaic variegated aneuploidy syndrome,41.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1052
1040,Metaphyseal anadysplasia,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1040
1041,Hydrops fetalis,134.0 (Ireland); 380.0 (Turkey); 180.0 (Thailand); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1041
1037,Arthrogryposis multiplex congenita,5.7 (Europe); 8.3 (Australia); 0.0 (Canada); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1037
1126,Aprosencephaly cerebellar dysgenesis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1126
1125,"Ocular motor apraxia, Cogan type",50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1125
1121,Radial deficiency-tibial hypoplasia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1121
1120,Lung agenesis-heart defect-thumb anomalies syndrome,0.0 (Worldwide); 9.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1120
1122,Ulnar hypoplasia-split foot syndrome,0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1122
1116,Aplasia cutis congenita-intestinal lymphangiectasia syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1116
1118,Fibular aplasia-ectrodactyly syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1118
1117,Aplasia cutis-myopia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1117
1110,Aortic arch anomaly-facial dysmorphism-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1110
1113,Aphalangy-syndactyly-microcephaly syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1113
1112,Aphalangy-hemivertebrae-urogenital-intestinal dysgenesis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1112
1106,Microphthalmia with limb anomalies,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1106
83,Antley-Bixler syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83
1104,Anophthalmia plus syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1104
1094,Anonychia-microcephaly syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1094
991,PAGOD syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=991
990,Agnathia-holoprosencephaly-situs inversus syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=990
989,Hypoglossia-hypodactyly syndrome,47.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=989
994,Fetal akinesia deformation sequence,0.6 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=994
51,Aicardi-Goutières syndrome,10.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=51
981,Internal carotid absence,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=981
978,ADULT syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=978
977,Adrenomyodystrophy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=977
983,Testicular regression syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=983
970,Hereditary sensory and autonomic neuropathy type 2,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=970
971,Acrorenal syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=971
40,"Acromesomelic dysplasia, Maroteaux type",50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=40
969,Acromicric dysplasia,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=969
974,Adams-Oliver syndrome,0.0 (Worldwide); 398.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=974
973,"Isolated absence/hypoplasia of fingers excluding thumb, unilateral",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=973
959,Acro-renal-ocular syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=959
968,"Acromesomelic dysplasia, Hunter-Thompson type",10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=968
139411,Carney triad,0.0 (Worldwide); 150.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139411
139414,Congenital panfollicular nevus,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139414
1028,Amelo-onycho-hypohidrotic syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1028
139417,Acute transverse myelitis,8.6 (United States); 7.9 (United States); 4.72 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139417
1031,Enamel-renal syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1031
139423,Idiopathic acute transverse myelitis,0.25 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139423
139426,Perioral myoclonia with absences,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139426
139431,Epilepsy with eyelid myoclonia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139431
1035,Beta-mercaptolactate cysteine disulfiduria,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1035
139436,Multicentric reticulohistiocytosis,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139436
1021,Amaurosis-hypertrichosis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1021
64,Alström syndrome,0.0 (Europe); 950.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64
1023,"Congenital generalized hypertrichosis, Ambras type",40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1023
139396,X-linked cerebral adrenoleukodystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139396
139402,Drug reaction with eosinophilia and systemic symptoms,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139402
139406,Encephalopathy due to prosaposin deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139406
1008,Alopecia-epilepsy-pyorrhea-intellectual disability syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1008
701,Alopecia universalis,25.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=701
1010,Autosomal dominant palmoplantar keratoderma and congenital alopecia,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1010
1014,Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1014
1001,2q37 microdeletion syndrome,115.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1001
59,Allan-Herndon-Dudley syndrome,320.0 (Worldwide); 0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=59
1003,Scalp defects-postaxial polydactyly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1003
1005,Alopecia-contractures-dwarfism-intellectual disability syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1005
1253,Ascher syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1253
1252,Blepharonasofacial malformation syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1252
1248,Maxillonasal dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1248
127,Borjeson-Forssman-Lehmann syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=127
1264,Tricho-retino-dento-digital syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1264
1262,Böök syndrome,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1262
1263,Boomerang dysplasia,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1263
1259,Blepharoptosis-myopia-ectopia lentis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1259
1261,Bonnemann-Meinecke-Reich syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1261
1234,Bartsocas-Papas syndrome,24.0 (Worldwide); 0.0 (Worldwide); 0.15 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1234
1231,Barber-Say syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1231
1229,Congenital intrauterine infection-like syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1229
109,Bannayan-Riley-Ruvalcaba syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=109
1228,Banki syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1228
1241,Bencze syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1241
1237,Beemer-Ertbruggen syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1237
114,Auriculoosteodysplasia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=114
115,Congenital contractural arachnodactyly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=115
1236,Severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1236
137622,Intractable diarrhea-choanal atresia-eye anomalies syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137622
1292,Brachymorphism-onychodysplasia-dysphalangism syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1292
137628,Cardiac anomalies-heterotaxy syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137628
1293,Brachyolmia,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1293
137625,Glycogen storage disease due to muscle and heart glycogen synthase deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137625
1299,Branchioskeletogenital syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1299
1300,Autosomal dominant popliteal pterygium syndrome,0.0 (Worldwide); 200.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1300
137667,Capillary malformation-arteriovenous malformation,261.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137667
137634,Overgrowth-macrocephaly-facial dysmorphism syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137634
1295,Brachytelephalangy-dysmorphism-Kallmann syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1295
137631,"Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137631
1296,Lambert syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1296
1297,Branchio-oculo-facial syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1297
137639,Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137639
137577,Neonatal hypoxic and ischemic brain injury,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137577
137583,Vulvar intraepithelial neoplasia,20.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137583
1276,Brachydactyly-arterial hypertension syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1276
1275,Brachydactyly-elbow wrist dysplasia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1275
1270,Bowen-Conradi syndrome,60.0 (Worldwide); 0.0 (Worldwide); 281.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1270
137605,Legius syndrome,2.2 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137605
137596,Neurotrophic keratopathy,0.0 (Worldwide); 4.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137596
1278,Brachydactyly-preaxial hallux varus syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1278
137599,Herpes simplex virus stromal keratitis,4.2091 (Worldwide); 5.4 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137599
1166,Congenital unilateral hypoplasia of depressor anguli oris,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1166
1168,Ataxia-oculomotor apraxia type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1168
1160,Chylous ascites,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1160
137817,Arachnoiditis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137817
1174,Cerebellar ataxia-ectodermal dysplasia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1174
137839,Lemierre syndrome,10.0 (Europe); 36.0 (Denmark); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137839
137834,Frank-Ter Haar syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137834
137831,X-linked intellectual disability-cerebellar hypoplasia syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137831
1170,Autosomal recessive cerebelloparenchymal disorder type 3,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1170
1178,Ataxia-tapetoretinal degeneration syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1178
1175,X-linked progressive cerebellar ataxia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1175
1180,Ataxia-hypogonadism-choroidal dystrophy syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1180
1179,Benign paroxysmal tonic upgaze of childhood with ataxia,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1179
1173,Cerebellar ataxia-hypogonadism syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1173
137867,Madras motor neuron disease,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137867
137681,Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137681
1133,AREDYLD syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1133
137675,Histiocytoid cardiomyopathy,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137675
1131,X-linked mandibulofacial dysostosis,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1131
137678,Spondyloepiphyseal dysplasia with metatarsal shortening,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137678
137698,Cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk,25.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137698
137754,Aminoacylase 1 deficiency,0.0 (Worldwide); 15.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137754
1145,Infantile-onset X-linked spinal muscular atrophy,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1145
1144,Arthrogryposis-like hand anomaly-sensorineural deafness syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1144
137686,Asherman syndrome,44.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137686
137776,Lethal congenital contracture syndrome type 2,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137776
1150,Arthrogryposis multiplex congenita-whistling face syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1150
1149,Kuskokwim syndrome,0.0 (Worldwide); 8.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1149
137807,Primary cutaneous amyloidosis,"9.8 (Taiwan, Province of China); 0.0 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137807
1159,Progressive pseudorheumatoid dysplasia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1159
137783,Lethal congenital contracture syndrome type 3,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137783
1214,Progressive hemifacial atrophy,0.0 (Worldwide); 0.143 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1214
1215,Autosomal dominant optic atrophy plus syndrome,0.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1215
138044,Rare disease with Pierre Robin syndrome,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=138044
1221,Cheilitis glandularis,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1221
1225,Baller-Gerold syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1225
1226,Bamforth-Lazarus syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1226
1227,Bangstad syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1227
1184,Ataxia-photosensitivity-short stature syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1184
1182,Spastic ataxia with congenital miosis,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1182
137888,Auriculocondylar syndrome,0.0 (Europe); 50.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137888
1186,Infantile-onset spinocerebellar ataxia,29.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1186
1185,Spinocerebellar ataxia-dysmorphism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1185
137898,Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome,127.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137898
1188,Ataxia-deafness-intellectual disability syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1188
1187,Lethal ataxia with deafness and optic atrophy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1187
1190,Atelosteogenesis type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1190
137908,Hypotonia with lactic acidemia and hyperammonemia,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137908
137914,Choanal atresia,8.6 (Europe); 0.0 (Europe); 9.8 (Austria); 14.6 (Belgium); 21.3 (Denmark); 15.7 (France); 5.9 (Germany); 10.0 (Hungary); 7.2 (Ireland); 5.7 (Italy); 11.7 (Netherlands); 4.9 (Norway); 2.2 (Poland); 6.3 (Spain); 12.6 (Switzerland); 8.9 (United Kingdom); 3.2 (Ukraine),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137914
1193,Atkin-Flaitz syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1193
137917,"Choanal atresia, unilateral",0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137917
1200,Burn-McKeown syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1200
137920,"Choanal atresia, bilateral",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137920
1198,Colonic atresia,5.0 (Worldwide); 0.0 (Worldwide); 1.5 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1198
1203,Duodenal atresia,9.0 (Europe); 9.0 (Europe); 9.0 (Belgium); 0.0 (Belgium); 4.0 (Spain); 0.0 (Spain); 6.0 (Ireland); 0.0 (Ireland); 7.0 (Italy); 0.0 (Italy); 11.0 (United Kingdom); 0.0 (United Kingdom); 5.0 (Malta); 0.0 (Malta); 9.0 (Denmark); 0.0 (Denmark); 11.0 (France); 0.0 (France); 7.0 (Reunion); 0.0 (Reunion); 3.0 (Portugal); 0.0 (Portugal); 9.0 (Germany); 0.0 (Germany); 5.0 (Austria); 0.0 (Austria); 3.0 (Switzerland); 0.0 (Switzerland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1203
1208,Pulmonary atresia-intact ventricular septum syndrome,4.5 (United Kingdom); 4.2 (Sweden); 0.0 (United Kingdom); 0.0 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1208
1449,Ring chromosome 7 syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1449
1453,Cleidorhizomelic syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1453
1440,Ring chromosome 14 syndrome,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1440
1443,Ring chromosome 19 syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1443
141258,Tessier number 4 facial cleft,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141258
1458,CODAS syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1458
141253,Oblique facial cleft,0.31 (United States); 0.0 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141253
1454,Joubert syndrome with hepatic defect,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1454
190,Coats disease,0.09 (United Kingdom); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=190
1426,Greenberg dysplasia,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1426
141184,Rapidly involuting congenital hemangioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141184
1427,Autosomal recessive otospondylomegaepiphyseal dysplasia,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1427
1435,Xq21 microdeletion syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1435
1436,X-linked skeletal dysplasia-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1436
1433,Choroidal atrophy-alopecia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1433
1484,Contractures-ectodermal dysplasia-cleft lip/palate syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1484
141333,Biemond syndrome type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141333
1490,Corneal dystrophy-perceptive deafness syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1490
1487,Cooks syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1487
1486,Lethal congenital contracture syndrome type 1,0.0 (Finland); 3.96 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1486
1466,COFS syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1466
1471,Coloboma of macula-brachydactyly type B syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1471
141291,Cleft lip and alveolus,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141291
141091,Polyrrhinia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141091
141083,Nasolacrimal duct cyst,25.7 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141083
1410,Uncombable hair syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1410
141099,Proboscis lateralis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141099
141096,Supernumerary nostril,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141096
1412,Tarsal-carpal coalition syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1412
1416,Familial calcium pyrophosphate deposition,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1416
1394,Cerebrofaciothoracic dysplasia,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1394
1397,Hydrocephaly-cerebellar agenesis syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1397
1398,Isolated cerebellar agenesis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1398
1399,Richards-Rundle syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1399
141077,Epignathus,0.0017 (Worldwide); 1.68 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141077
1401,CHAND syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1401
141152,Isolated congenital hypoglossia/aglossia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141152
174,"Metaphyseal chondrodysplasia, Schmid type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=174
141163,Glossopalatine ankylosis,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141163
1425,Desbuquois syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1425
141179,Non-involuting congenital hemangioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141179
141127,Congenital tracheal stenosis,0.0 (Canada); 1.6 (Canada),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141127
141132,Oculo-auriculo-vertebral spectrum,0.0 (Worldwide); 0.0 (Worldwide); 4.0 (Japan); 0.65 (France); 11.7 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141132
141145,Hemifacial hyperplasia,1.16 (United States); 1.16 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141145
141148,Hemifacial myohyperplasia,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141148
156728,"Spondyloepimetaphyseal dysplasia, matrilin-3 type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=156728
1375,Cataract-hypertrichosis-intellectual disability syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1375
163,Hereditary hyperferritinemia-cataract syndrome,120.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=163
1373,Cataract-aberrant oral frenula-growth delay syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1373
1368,Cataract-ataxia-deafness syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1368
1366,Autosomal recessive palmoplantar keratoderma and congenital alopecia,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1366
1361,Carnosinase deficiency,24.0 (Worldwide); 0.0 (Worldwide); 0.2 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1361
1393,Cerebrocostomandibular syndrome,75.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1393
157826,Congenital epulis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157826
1390,Night blindness-skeletal anomalies-dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1390
157820,Cold-induced sweating syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157820
1389,Cortical blindness-intellectual disability-polydactyly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1389
157798,Serrated polyposis syndrome,1.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157798
1388,Catel-Manzke syndrome,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1388
157801,Mesoaxial synostotic syndactyly with phalangeal reduction,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157801
1387,Cataract-intellectual disability-hypogonadism syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1387
157791,Epithelioid hemangioendothelioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157791
1381,Cataract-intellectual disability-anal atresia-urinary defects syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1381
1380,Cataract-nephropathy-encephalopathy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1380
1377,Cataract-microcornea syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1377
157215,Hereditary hypophosphatemic rickets with hypercalciuria,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157215
1325,Camptodactyly-taurinuria syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1325
1326,"Camptodactyly syndrome, Guadalajara type 2",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1326
1327,"Camptodactyly syndrome, Guadalajara type 1",8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1327
1328,Camurati-Engelmann disease,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1328
1323,Camptodactyly-joint contractures-facial skeletal defects syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1323
156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,14.9 (Germany); 0.0 (Europe); 3.3 (United States); 42.1 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=156152
1314,Symmetrical thalamic calcifications,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1314
1318,"Campomelia, Cumming type",8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1318
1319,Camptobrachydactyly,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1319
1305,Feingold syndrome,123.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1305
1307,Distal limb deficiencies-micrognathia syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1307
1313,Infantile choroidocerebral calcification syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1313
1350,Heart-hand syndrome type 2,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1350
1355,Congenital heart defect-round face-developmental delay syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1355
1352,Atrioventricular defect-blepharophimosis-radial and anal defect syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1352
1345,Cardiomyopathy-cataract-hip spine disease syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1345
1338,Heart defect-tongue hamartoma-polysyndactyly syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1338
1340,Cardiofaciocutaneous syndrome,0.12 (Japan); 300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1340
2856,Persistent Müllerian duct syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2856
1336,Hyperkeratosis-hyperpigmentation syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1336
1335,Pentalogy of Cantrell,0.55 (Europe); 0.0 (Europe); 0.67 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1335
1682,Arterial dissection-lentiginosis syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1682
1757,Fibular dimelia-diplopodia syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1757
1756,Caudal duplication,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1756
1766,Dysequilibrium syndrome,0.0 (Worldwide); 51.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1766
1777,Temtamy syndrome,56.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1777
1780,Thakker-Donnai syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1780
1772,"45,X/46,XY mixed gonadal dysgenesis",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1772
1784,Acrofrontofacionasal dysostosis,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1784
1782,Dysosteosclerosis,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1782
1790,Hypomandibular faciocranial dysostosis,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1790
1786,"Acrofacial dysostosis, Catania type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1786
1788,"Acrofacial dysostosis, Rodríguez type",13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1788
859,Transcobalamin deficiency,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=859
139441,Hypomyelination with atrophy of basal ganglia and cerebellum,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139441
3196,Steroid dehydrogenase deficiency-dental anomalies syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3196
139444,Leukoencephalopathy with bilateral anterior temporal lobe cysts,29.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139444
139447,Progressive cavitating leukoencephalopathy,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139447
1573,Hypotrichosis with juvenile macular degeneration,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1573
726,Alpers-Huttenlocher syndrome,0.7 (Europe); 0.07 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=726
139450,Microtia-eye coloboma-imperforation of the nasolacrimal duct syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139450
139455,Autosomal recessive bestrophinopathy,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139455
1574,Retinal degeneration-nanophthalmos-glaucoma syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1574
139466,SERKAL syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139466
1596,Distal deletion 15q syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1596
139471,Microphthalmia with brain and digit anomalies,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139471
139474,17q11.2 microduplication syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139474
1617,Developmental delay-language impairment-dopa responsive dystonia-parkinsonism syndrome due to 2q24 microdeletion,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1617
1606,1p36 deletion syndrome,15.0 (United States); 15.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1606
139480,Autosomal recessive spastic paraplegia type 39,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139480
1647,Oculocerebrocutaneous syndrome,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1647
139485,Autosomal recessive ataxia due to ubiquinone deficiency,31.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139485
1653,Dentin dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1653
139515,Charcot-Marie-Tooth disease type 4J,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139515
139512,Neuropathy with hearing impairment,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139512
1657,"Dermatoosteolysis, Kirghizian type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1657
139525,Distal hereditary motor neuropathy type 2,0.0 (Worldwide); 4.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139525
1658,Absence of fingerprints-congenital milia syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1658
1659,Dermatoleukodystrophy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1659
139547,Distal spinal muscular atrophy type 3,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139547
1660,Dermoodontodysplasia,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1660
139557,X-linked distal spinal muscular atrophy type 3,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139557
1661,X-linked corneal dermoid,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1661
1662,Restrictive dermopathy,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1662
139552,"Distal hereditary motor neuropathy, Jerash type",30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139552
139573,Hereditary sensory and autonomic neuropathy with deafness and global delay,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139573
139564,Hereditary sensory and autonomic neuropathy type 1B,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139564
139583,X-linked hereditary sensory and autonomic neuropathy with deafness,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139583
1667,Wolcott-Rallison syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1667
139578,Mutilating hereditary sensory neuropathy with spastic paraplegia,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139578
1671,Split cord malformation type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1671
140917,Stapes ankylosis with broad thumbs and toes,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140917
1548,Cryptorchidism-arachnodactyly-intellectual disability syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1548
1547,Cryptomicrotia-brachydactyly-excess fingertip arch syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1547
140922,Titin-related limb-girdle muscular dystrophy R10,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140922
1545,Crisponi syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1545
1540,Jackson-Weiss syndrome,0.0 (Worldwide); 200.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1540
140874,Joubert syndrome and related disorders,1.1 (Worldwide); 1.0 (United States); 1.0 (Netherlands); 666.67 (North America); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140874
140896,Severe acute respiratory syndrome,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140896
1532,Gómez-López-Hernández syndrome,36.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1532
140952,Syndactyly-telecanthus-anogenital and renal malformations syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140952
140957,Autosomal dominant macrothrombocytopenia,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140957
140944,CLOVES syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140944
140949,Low-flow priapism,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140949
1555,Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1555
140936,Lelis syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140936
140941,Short stature due to primary acid-labile subunit deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140941
1553,Curry-Jones syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1553
140927,Self-limited neonatal-infantile epilepsy,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140927
140933,Linear atrophoderma of Moulin,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140933
140989,Primary angiitis of the central nervous system,0.24 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140989
1566,Dandy-Walker malformation-postaxial polydactyly syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1566
140976,RHYNS syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140976
1563,Dahlberg-Borer-Newcomer syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1563
140969,Saldino-Mainzer syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140969
140966,"Palmoplantar keratoderma, Nagashima type",40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140966
140963,Bilateral microtia-deafness-cleft palate syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140963
382,Guanidinoacetate methyltransferase deficiency,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=382
742,Prolidase deficiency,90.0 (Worldwide); 0.0 (Worldwide); 0.08 (Canada),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=742
1979,Lipodystrophy due to peptidic growth factors deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1979
1571,Knobloch syndrome,119.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1571
141007,Orofaciodigital syndrome type 9,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141007
1551,Familial benign copper deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1551
1568,X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1568
141000,Orofaciodigital syndrome type 11,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=141000
1497,X-linked complicated corpus callosum dysgenesis,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1497
1493,Vici syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1493
140286,Secondary hypoparathyroidism due to impaired parathormon secretion,24.75 (Europe); 0.0 (Europe); 0.8 (Denmark); 1.7 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140286
1495,Intellectual disability-hypoplastic corpus callosum-preauricular tag syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1495
1509,Coxopodopatellar syndrome,47.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1509
1512,Crane-Heise syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1512
1506,Thin ribs-tubular bones-dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1506
1508,Coxoauricular syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1508
1507,Autosomal recessive Robinow syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1507
1517,Cantú syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1517
1519,SPECC1L-related hypertelorism syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1519
1520,Craniofrontonasal dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1520
1513,Craniodiaphyseal dysplasia,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1513
1514,Craniodigital-intellectual disability syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1514
140481,Autosomal dominant slowed nerve conduction velocity,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=140481
1515,Cranioectodermal dysplasia,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1515
1516,Non-syndromic bilambdoid and sagittal craniosynostosis,14.0 (Worldwide); 0.0 (Worldwide); 0.0 (Worldwide); 0.05 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1516
1527,"Craniosynostosis, Philadelphia type",1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1527
1528,Craniotelencephalic dysplasia,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1528
1529,Craniofacial-deafness-hand syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1529
1521,Craniofrontonasal dysplasia-Poland anomaly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1521
1522,Craniometaphyseal dysplasia,160.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1522
1525,Cranio-osteoarthropathy,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1525
1969,Facial dysmorphism-anorexia-cachexia-eye and skin anomalies syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1969
1968,Flat face-microstomia-ear anomaly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1968
1970,Facial dysmorphism-macrocephaly-myopia-Dandy-Walker malformation syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1970
1973,Faciocardiorenal syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1973
1972,Lethal faciocardiomelic dysplasia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1972
1974,Autosomal recessive faciodigitogenital syndrome,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1974
1962,Exostoses-anetodermia-brachydactyly type E syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1962
1964,Extrasystoles-short stature-hyperpigmentation-microcephaly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1964
1822,Dysplasia epiphysealis hemimelica,0.1 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1822
1824,Lowry-Wood syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1824
1952,Epiphyseal stippling-osteoclastic hyperplasia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1952
1954,Congenital lethal erythroderma,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1954
1955,Spinocerebellar ataxia type 34,0.0 (Worldwide); 45.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1955
1926,Diabetic embryopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1926
2209,Maternal phenylketonuria,0.0 (Europe); 10.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2209
1927,Emery-Nelson syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1927
1937,Eng-Strom syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1937
1920,Toluene embryopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1920
1919,Phenobarbital embryopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1919
1917,Fetal methylmercury syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1917
1923,Methimazole embryofetopathy,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1923
1912,Fetal hydantoin syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1912
1918,Fetal minoxidil syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1918
1911,Cocaine embryofetopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1911
1910,Fetal iodine syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1910
1916,Diethylstilbestrol syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1916
294,Fetal cytomegalovirus syndrome,40.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=294
1914,Vitamin K antagonist embryofetopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1914
1913,Fetal trimethadione syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1913
1896,EEC syndrome,1.11 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1896
1897,EEM syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1897
1908,Aminopterin/methotrexate embryofetopathy,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1908
1909,Indomethacin embryofetopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1909
1906,Fetal valproate spectrum disorder,0.0 (Worldwide); 1.02 (Europe); 11.7 (Reunion); 0.5 (Belgium); 1.7 (Netherlands); 1.3 (Switzerland); 1.2 (Germany); 1.3 (Ireland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1906
1895,Edinburgh malformation syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1895
1891,Intellectual disability-spasticity-ectrodactyly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1891
1892,Ectrodactyly-polydactyly syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1892
1816,Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1816
1807,Focal facial dermal dysplasia type III,0.0 (Worldwide); 20.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1807
1818,"Ectodermal dysplasia, trichoodontoonychial type",7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1818
1883,Ectodermal dysplasia-sensorineural deafness syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1883
1882,Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1882
1875,Congenital muscular dystrophy-infantile cataract-hypogonadism syndrome,0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1875
1873,Jalili syndrome,"8.3 (Palestinian Territory, occupied); 49.0 (Worldwide); 0.0 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1873
1879,Melorheostosis with osteopoikilosis,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1879
1867,"Hereditary bullous dystrophy, macular type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1867
1872,Cone rod dystrophy,2.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1872
1871,Progressive cone dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1871
1860,Thanatophoric dysplasia type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1860
1861,Thoracic dysplasia-hydrocephalus syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1861
1865,"Dyssegmental dysplasia, Silverman-Handmaker type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1865
1858,Skeletal dysplasia-epilepsy-short stature syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1858
254,Spondylometaphyseal dysplasia,1.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254
1852,X-linked retinal dysplasia,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1852
1842,"Bone dysplasia, lethal Holmgren type",7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1842
1839,Hereditary mucoepithelial dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1839
1837,"Metaphyseal chondrodysplasia, Rosenberg type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1837
1836,"Mesomelic dysplasia, Kantaputra type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1836
1834,Axial mesodermal dysplasia spectrum,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1834
1830,Schimke immuno-osseous dysplasia,133.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1830
1825,Epiphyseal dysplasia-hearing loss-dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1825
251,Multiple epiphyseal dysplasia,5.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251
1811,Odontomicronychial dysplasia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1811
1812,Ectodermal dysplasia-intellectual disability-central nervous system malformation syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1812
1808,"Hidrotic ectodermal dysplasia, Christianson-Fourie type",6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1808
1809,"Hidrotic ectodermal dysplasia, Halal type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1809
1806,Ectodermal dysplasia-blindness syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1806
1802,Ghosal hematodiaphyseal dysplasia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1802
1803,Thoracomelic dysplasia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1803
1798,Craniofacial dysostosis-diaphyseal hyperplasia syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1798
1799,Familial developmental dysphasia,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1799
1794,Oculomaxillofacial dysostosis,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1794
2130,Non-syndromic hemimelia,4.15 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2130
2136,Hennekam syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2136
2138,"46,XX ovotesticular difference of sex development",500.0 (Worldwide); 2.5 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2138
2139,Hernández-Aguirre Negrete syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2139
2141,Diaphragmatic defect-limb deficiency-skull defect syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2141
2143,Donnai-Barrow syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2143
2145,"Craniosynostosis, Herrmann-Opitz type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2145
2149,Nodular neuronal heterotopia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2149
2148,Lissencephaly type 1 due to doublecortin gene mutation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2148
158048,Hemophagocytic syndrome associated with an infection,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158048
158057,Acquired hemophagocytic lymphohistiocytosis associated with malignant disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158057
2108,Hallermann-Streiff syndrome,150.0 (Worldwide); 0.0 (Worldwide); 3.6 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2108
158061,Macrophage activation syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158061
2107,Hall-Riggs syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2107
2110,Hallux varus-preaxial polysyndactyly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2110
2109,Hallermann-Streiff-like syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2109
2111,Cystic hamartoma of lung and kidney,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2111
158266,Huntington disease-like syndrome,1.85 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158266
2115,Harrod syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2115
2114,"Hip dysplasia, Beukes type",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2114
2994,Short stature-craniofacial anomalies-genital hypoplasia syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2994
2117,Hartsfield syndrome,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2117
2119,HEC syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2119
2123,Multifocal infantile hemangioma with extracutenous involvement,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2123
157997,Benign cephalic histiocytosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157997
2090,GMS syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2090
157991,Generalized eruptive histiocytosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157991
2091,Multinodular goiter-cystic kidney-polydactyly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2091
376,Gordon syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=376
2092,Focal dermal hypoplasia,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2092
158000,Juvenile xanthogranuloma,0.005 (Germany); 0.0225 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158000
2098,"Acromesomelic dysplasia, Grebe type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2098
158025,Hereditary progressive mucinous histiocytosis,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158025
380,Greig cephalopolysyndactyly syndrome,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=380
2095,Gorlin-Chaudhry-Moss syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2095
158014,Rosaï-Dorfman disease,1000.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158014
2097,Grant syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2097
2101,Grubben-de Cock-Borghgraef syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2101
2104,Dysmorphism-pectus carinatum-joint laxity syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2104
158032,Hemophagocytic syndrome,0.0 (Worldwide); 0.198 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158032
158029,Sea-blue histiocytosis,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158029
2069,Gastrocutaneous syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2069
157846,Neuroferritinopathy,90.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157846
157832,Craniorhiny,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157832
2067,GAPO syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2067
157835,Paroxysmal hemicrania,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157835
2065,Galloway-Mowat syndrome,159.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2065
2075,Genitopalatocardiac syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2075
2074,Gemignani syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2074
157850,Pantothenate kinase-associated neurodegeneration,0.15 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157850
2072,Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2072
157954,ANE syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157954
157962,"Oculoauricular syndrome, Schorderet type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157962
157946,Huntington disease-like 3,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157946
2078,Geroderma osteodysplastica,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2078
2077,German syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2077
157973,Congenital muscular dystrophy due to LMNA mutation,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157973
2085,Glaucoma-sleep apnea syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2085
2084,Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2084
157965,SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157965
2083,Prominent glabella-microcephaly-hypogenitalism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2083
1791,Frontofacionasal dysplasia,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1791
1826,Frontometaphyseal dysplasia,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1826
2047,Flynn-Aird syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2047
2048,Foix-Chavany-Marie syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2048
2050,Cole-Carpenter syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2050
2063,Splenogonadal fusion-limb defects-micrognathia syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2063
2064,Posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2064
250,Frontonasal dysplasia,0.0 (Europe); 0.7 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=250
2057,Blepharophimosis-ptosis-esotropia-syndactyly-short stature syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2057
2059,Fryns syndrome,7.0 (France); 0.0 (Worldwide); 7.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2059
2026,Gingival fibromatosis-hypertrichosis syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2026
2025,Gingival fibromatosis-facial dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2025
2028,Juvenile hyaline fibromatosis,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2028
2027,Gingival fibromatosis-progressive deafness syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2027
2021,Fibrochondrogenesis,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2021
2019,Femur-fibula-ulna complex,1.5 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2019
2024,Hereditary gingival fibromatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2024
2022,Endocardial fibroelastosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2022
2824,Paraplegia-intellectual disability-hyperkeratosis syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2824
2045,FLOTCH syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2045
2044,Floating-Harbor syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2044
2031,Hepatic fibrosis-renal cysts-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2031
2036,Scalp-ear-nipple syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2036
2006,Median cleft lip/mandible,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2006
2007,Alar cartilages hypoplasia-coloboma-telecanthus syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2007
2003,Cleft lip/palate-deafness-sacral lipoma syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2003
158687,Lethal acantholytic erosive disorder,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158687
158684,Epidermolysis bullosa simplex with pyloric atresia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158684
2004,Laryngotracheoesophageal cleft,7.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2004
2001,Cleft lip/palate-intestinal malrotation-cardiopathy syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2001
158681,Epidermolysis bullosa simplex with circinate migratory erythema,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158681
158676,"Localized dystrophic epidermolysis bullosa, nails only",0.0 (Worldwide); 10.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158676
158673,"Localized dystrophic epidermolysis bullosa, acral form",10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158673
158668,Ectodermal dysplasia-skin fragility syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158668
2016,Cleft palate-lateral synechia syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2016
2017,Sternal cleft,2.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2017
2013,Cleft palate-large ears-small head syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2013
2010,Cleft palate-stapes fixation-oligodontia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2010
158775,Smoldering systemic mastocytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158775
2008,Acrocardiofacial syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2008
1986,Gollop-Wolfgang complex,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1986
1980,Bilateral striopallidodentate calcinosis,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1980
1997,Blepharo-cheilo-odontic syndrome,55.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1997
1995,Cleft lip-retinopathy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1995
1993,Pai syndrome,67.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1993
1988,Femoral-facial syndrome,62.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1988
2348,"Familial partial lipodystrophy, Dunnigan type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2348
247775,Mayer-Rokitansky-Küster-Hauser syndrome type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247775
2351,Kousseff syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2351
247768,Müllerian aplasia and hyperandrogenism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247768
2353,Schilbach-Rott syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2353
247790,FTH1-related iron overload,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247790
247794,Juvenile cataract-microcornea-renal glucosuria syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247794
247815,Autosomal recessive ataxia due to PEX10 deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247815
2363,Lacrimoauriculodentodigital syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2363
247691,Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247691
2340,Keratosis follicularis spinulosa decalvans,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2340
247685,Odontohypophosphatasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247685
2342,Haim-Munk syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2342
247709,Multiple endocrine neoplasia type 2B,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247709
485,Kniest dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=485
247762,Lipoblastoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247762
2347,Lethal Kniest-like dysplasia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2347
247585,Citrullinemia type II,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247585
2333,Kenny-Caffey syndrome,65.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2333
247598,Neonatal intrahepatic cholestasis due to citrin deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247598
2332,KBG syndrome,164.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2332
247604,Juvenile primary lateral sclerosis,4.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247604
247623,Perinatal lethal hypophosphatasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247623
247638,Prenatal benign hypophosphatasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247638
2337,"Diffuse palmoplantar keratoderma, Bothnian type",2.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2337
247651,Infantile hypophosphatasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247651
247667,Childhood-onset hypophosphatasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247667
2339,Keratosis follicularis-dwarfism-cerebral atrophy syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2339
247676,Adult hypophosphatasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247676
494,Keratoderma hereditarium mutilans,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494
2322,Kabuki syndrome,1.16 (New Zealand); 1.16 (Australia); 3.1 (Europe); 3.1 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2322
247378,Autosomal recessive secondary polycythemia not associated with VHL gene,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247378
2321,Jung syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2321
2324,Osteopenia-intellectual disability-sparse hair syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2324
247511,Autosomal dominant secondary polycythemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247511
2323,Sanjad-Sakati syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2323
247522,Primary ciliary dyskinesia-retinitis pigmentosa syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247522
247525,Citrullinemia type I,"2.4 (Europe); 1.28 (Austria); 4.5 (Korea, Republic of); 0.84 (Taiwan, Province of China); 1.13 (United States)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247525
2325,Epidermolysis bullosa simplex with anodontia/hypodontia,0.0 (Worldwide); 5.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2325
2329,Karsch-Neugebauer syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2329
247582,Citrin deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247582
2328,Kapur-Toriello syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2328
2408,Lowe-Kohn-Cohen syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2408
2409,Lowry-MacLean syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2409
2405,Thickened earlobes-conductive deafness syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2405
2407,Laryngo-onycho-cutaneous syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2407
2412,Dislocation of the hip-dysmorphism syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2412
2575,Cystic fibrosis-gastritis-megaloblastic anemia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2575
2410,Hypergonadotropic hypogonadism-cataract syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2410
2399,Nasopalpebral lipoma-coloboma syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2399
2400,Peripheral motor neuropathy-dysautonomia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2400
2396,Encephalocraniocutaneous lipomatosis,77.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2396
2388,Choreoacanthocytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2388
248111,Juvenile Huntington disease,0.04 (Europe); 0.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=248111
2386,Leukoencephalopathy-palmoplantar keratoderma syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2386
248095,Primary hypertrophic osteoarthropathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=248095
2379,Early-onset parkinsonism-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2379
2391,Congenitally short costocoracoid ligament,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2391
2390,Lichtenstein syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2390
247834,Occult macular dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247834
2371,Lethal Larsen-like syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2371
2369,Limb body wall complex,3.0 (Australia); 0.0 (Europe); 2.5 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2369
247820,Ectodermal dysplasia-pili torti-cutaneous syndactyly syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247820
247827,Ectodermal dysplasia-hyperhidrosis-cutaneous syndactyly syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247827
2378,Laurin-Sandrow syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2378
247868,NLRP12-associated hereditary periodic fever syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247868
2375,Laryngeal abductor paralysis-intellectual disability syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2375
2457,Mandibuloacral dysplasia,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2457
2451,Mucocutaneous venous malformations,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2451
2439,Patterson-Stevenson-Fontaine syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2439
244305,Dominant hypophosphatemia with nephrolithiasis or osteoporosis,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=244305
244283,Biliary atresia with splenic malformation syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=244283
2440,Isolated split hand-split foot malformation,5.4 (Europe); 16.4 (China); 5.1 (Canada); 6.0 (Hungary); 6.0 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2440
244310,RFT1-CDG,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=244310
244242,HELLP syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=244242
296,Ollier disease,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=296
2437,Czeizel-Losonci syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2437
244275,De novo thrombotic microangiopathy after kidney transplantation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=244275
243343,Dimethylglycine dehydrogenase deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=243343
2435,Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2435
2429,Macrocephaly-spastic paraplegia-dysmorphism syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2429
2432,Macrosomia-microphthalmia-cleft palate syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2432
2489,Upper limb defect-eye and ear abnormalities syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2489
247353,Generalized pustular psoriasis,0.18 (France); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247353
247262,Hyperphosphatasia-intellectual disability syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247262
2487,Lower limb malformation-hypospadias syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2487
247257,Inhalational anthrax,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247257
247245,Superficial siderosis,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247245
2485,Melorheostosis,0.09 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2485
247234,Sporadic adult-onset ataxia of unknown etiology,7.6 (Europe); 6.9 (Italy); 8.4 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247234
2483,Melkersson-Rosenthal syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2483
247203,Collecting duct carcinoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247203
2484,Melnick-Needles syndrome,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2484
247198,Progressive cerebello-cerebral atrophy,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247198
2481,Neurocutaneous melanocytosis,1.25 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2481
2482,Melhem-Fahl syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2482
247165,Infantile mercury poisoning,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247165
2475,White forelock with malformations,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2475
2476,Dysraphism-cleft lip/palate-limb reduction defects syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2476
2473,McKusick-Kaufman syndrome,0.0 (Worldwide); 90.0 (Worldwide); 10.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2473
2471,McDonough syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2471
2470,Matthew-Wood syndrome,43.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2470
561,Marshall-Smith syndrome,74.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=561
2464,"Marfanoid syndrome, De Silva type",6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2464
559,Marinesco-Sjögren syndrome,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=559
2463,Marfanoid habitus-autosomal recessive intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2463
2462,Shprintzen-Goldberg syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2462
2461,Marden-Walker syndrome,50.0 (Worldwide); 0.0 (Worldwide); 2.5 (Belgium),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2461
251630,Anaplastic oligodendroglioma,0.09 (Europe); 0.11 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251630
2172,Microcephaly-glomerulonephritis-marfanoid habitus syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2172
251636,Ependymoma,0.16 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251636
251639,Subependymoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251639
2176,Infantile systemic hyalinosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2176
251643,Myxopapillary ependymoma,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251643
251646,Anaplastic ependymoma,0.04 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251646
251651,Oligoastrocytic tumor,0.11 (Europe); 0.19 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251651
2181,Hydrocephaly-tall stature-joint laxity syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2181
2180,Hydrocephalus-costovertebral dysplasia-Sprengel anomaly syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2180
2186,Hydrocephalus-blue sclerae-nephropathy syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2186
251671,Angiocentric glioma,52.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251671
2189,Hydrolethalus,5.0 (Finland); 0.0 (Finland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2189
251679,Astroblastoma,0.02 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251679
312,Autosomal dominant epidermolytic ichthyosis,0.4317 (Japan); 0.0 (Worldwide); 0.29 (Denmark); 0.65 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=312
2196,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement,72.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2196
251852,Embryonal tumor of neuroepithelial tissue,0.22 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251852
251576,Gliosarcoma,0.03 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251576
2150,Hirschsprung disease-type D brachydactyly syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2150
251582,Gliomatosis cerebri,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251582
251579,Giant cell glioblastoma,0.02 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251579
2152,Mowat-Wilson syndrome,0.0 (Worldwide); 1.7 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2152
2153,Hirschsprung disease-nail hypoplasia-dysmorphism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2153
251589,Anaplastic astrocytoma,0.4 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251589
251598,Protoplasmic astrocytoma,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251598
2155,Hirschsprung disease-deafness-polydactyly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2155
251595,Diffuse astrocytoma,0.48 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251595
2158,Histidinuria-renal tubular defect syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2158
251612,Pilocytic astrocytoma,0.36 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251612
2163,Holoprosencephaly-craniosynostosis syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2163
251607,Pleomorphic xanthoastrocytoma,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251607
2165,Holoprosencephaly-caudal dysgenesis syndrome,0.9 (Spain); 0.0 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2165
2166,Holoprosencephaly-postaxial polydactyly syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2166
251627,Oligodendroglioma,0.25 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251627
2167,Holzgreve syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2167
2169,Methylcobalamin deficiency type cblE,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2169
2222,Hypertrichosis lanuginosa congenita,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2222
2220,Hypertrichosis cubiti,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2220
1051,Ramos-Arroyo syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1051
2228,Hypodontia-dysplasia of nails syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2228
2224,Hypertryptophanemia,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2224
2232,Primary hypergonadotropic hypogonadism-partial alopecia syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2232
2230,Hypogonadotropic hypogonadism-frontoparietal alopecia syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2230
2229,Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2229
2238,Familial isolated hypoparathyroidism,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2238
2237,Hypoparathyroidism-sensorineural deafness-renal disease syndrome,0.0 (Worldwide); 180.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2237
2235,Hypogonadotropic hypogonadism-retinitis pigmentosa syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2235
2234,Male hypergonadotropic hypogonadism-intellectual disability-skeletal anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2234
251863,Desmoplastic/nodular medulloblastoma,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251863
2198,Palmoplantar keratoderma-esophageal carcinoma syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2198
2206,Ankylosing vertebral hyperostosis with tylosis,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2206
2201,Palmoplantar keratoderma-spastic paralysis syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2201
2202,Palmoplantar keratoderma-deafness syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2202
251870,Central nervous system embryonal tumor,0.07 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251870
251899,Choroid plexus carcinoma,0.01 (Europe); 0.0 (Europe); 0.35 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251899
2213,Hypertelorism-microtia-facial clefting syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2213
251896,Choroid plexus tumor,0.05 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251896
2211,Hypertelorism-hypospadias-polysyndactyly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2211
2218,Cervical hypertrichosis-peripheral neuropathy syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2218
251909,Pineoblastoma,0.02 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251909
2215,Multiple pterygium-malignant hyperthermia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2215
251019,2q32q33 microdeletion syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251019
2266,"Hypotrichosis-intellectual disability, Lopes type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2266
251028,SATB2-associated syndrome due to a chromosomal rearrangement,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251028
2269,Ichthyosis-alopecia-eclabion-ectropion-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2269
251038,3q29 microduplication syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251038
250999,1q41q42 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=250999
2261,"Hypospadias-intellectual disability, Goldblatt type syndrome",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2261
251004,Paternal uniparental disomy of chromosome 1 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251004
251009,Maternal uniparental disomy of chromosome 1 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251009
672,Pallister-Hall syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=672
251014,2q31.1 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251014
455,Superficial epidermolytic ichthyosis,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=455
251061,7q31 microdeletion syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251061
251066,8p11.2 deletion syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251066
2272,Ichthyosis-oral and digital anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2272
251071,8p23.1 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251071
2274,Ichthyosis-hepatosplenomegaly-cerebellar degeneration syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2274
251076,8p23.1 duplication syndrome,1.72 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251076
2273,Ichthyosis follicularis-alopecia-photophobia syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2273
251043,Ring chromosome 5 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251043
165,Neutral lipid storage disease,0.0 (Worldwide); 50.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=165
139,CHILD syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139
251046,6p22 microdeletion syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251046
457,Harlequin ichthyosis,0.0 (Worldwide); 200.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457
2271,Congenital ichthyosis-microcephalus-tetraplegia syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2271
251056,6q25.2q25.3 microdeletion syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251056
2246,Cerebellar hypoplasia-tapetoretinal degeneration syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2246
2249,Ulna hypoplasia-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2249
2239,Familial isolated hypoparathyroidism due to agenesis of parathyroid gland,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2239
2241,Megacystis-microcolon-intestinal hypoperistalsis syndrome,230.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2241
250984,Autosomal recessive Stickler syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=250984
2256,Fibulo-ulnar hypoplasia-renal anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2256
250977,AICA-ribosiduria,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=250977
250994,1q21.1 microduplication syndrome,46.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=250994
250989,1q21.1 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=250989
2250,Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2250
250923,Isolated aniridia,1.31 (Europe); 1.38 (Norway); 1.38 (Sweden); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=250923
2251,Thumb deformity-alopecia-pigmentation anomaly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2251
2252,Radial hypoplasia-triphalangeal thumbs-hypospadias-maxillary diastema syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2252
250972,Polymicrogyria with optic nerve hypoplasia,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=250972
2255,Pancreatic hypoplasia-diabetes-congenital heart disease syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2255
251380,Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome,10.6 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251380
2306,Isotretinoin-like syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2306
251383,CK syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251383
2305,Isotretinoin syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2305
251370,Sickle cell-hemoglobin D disease syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251370
251375,Sickle cell-hemoglobin E disease syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251375
251359,Sickle cell-beta-thalassemia disease syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251359
251365,Sickle cell-hemoglobin C disease syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251365
2295,Familial articular hypermobility syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2295
2319,Juberg-Hayward syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2319
251523,Hyperzincemia and hypercalprotectinemia,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251523
2316,Johnson neuroectodermal syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2316
2315,Johanson-Blizzard syndrome,0.4 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2315
251510,"46,XY partial gonadal dysgenesis",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251510
251515,Distal arthrogryposis type 10,53.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251515
2310,Absence deformity of leg-cataract syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2310
2309,Pachyonychia congenita,1000.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2309
251393,Localized junctional epidermolysis bullosa,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251393
2307,IVIC syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2307
251295,Pigmented paravenous retinochoroidal atrophy,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251295
251290,Parietal foramina with clavicular hypoplasia,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251290
2282,Dysmorphism-short stature-deafness-difference of sex development syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2282
251287,Benign concentric annular macular dystrophy,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251287
251282,Autosomal dominant spastic ataxia type 1,0.0 (Worldwide); 53.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251282
251279,Microphthalmia-retinitis pigmentosa-foveoschisis-optic disc drusen syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251279
251274,Familial hyperaldosteronism type III,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251274
2278,Ichthyosis-intellectual disability-dwarfism-renal impairment syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2278
251262,Familial osteochondritis dissecans,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251262
251347,Ataxia-telangiectasia-like disorder,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251347
2289,Neuronal intranuclear inclusion disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2289
2290,Microvillus inclusion disease,0.0 (Europe); 137.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2290
2285,Primary basilar invagination,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2285
251307,Idiopathic recurrent pericarditis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251307
251304,Infantile onset panniculitis with uveitis and systemic granulomatosis,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=251304
2674,Cyprus facial-neuromusculoskeletal syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2674
2673,Neurofaciodigitorenal syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2673
2672,Neuhauser-Eichner-Opitz syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2672
2678,Familial isolated café-au-lait macules,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2678
2668,Nephropathy-deafness-hyperparathyroidism syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2668
2663,Nathalie syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2663
2662,Keipert syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2662
2671,Neu-Laxova syndrome,91.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2671
1475,Renal coloboma syndrome,180.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1475
2670,Pierson syndrome,98.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2670
2669,Nephrosis-deafness-urinary tract-digital malformations syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2669
254930,Combined oxidative phosphorylation defect type 7,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254930
254925,Combined oxidative phosphorylation defect type 4,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254925
2697,Arthrogryposis-renal dysfunction-cholestasis syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2697
254920,Combined oxidative phosphorylation defect type 2,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254920
2695,Bifid nose,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2695
255182,Pyruvate dehydrogenase E3-binding protein deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=255182
2701,Noonan syndrome-like disorder with loose anagen hair,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2701
255138,Pyruvate dehydrogenase E1-beta deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=255138
255132,Adult-onset autosomal recessive sideroblastic anemia,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=255132
2698,Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2698
2699,Median nodule of the upper lip,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2699
254875,"Mitochondrial DNA depletion syndrome, myopathic form",45.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254875
2690,Neutropenia-monocytopenia-deafness syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2690
254898,Deafness-encephaloneuropathy-obesity-valvulopathy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254898
2712,Oculofaciocardiodental syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2712
2714,Oculo-palato-cerebral syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2714
2713,Oculoosteocutaneous syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2713
2715,Severe oculo-renal-cerebellar syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2715
2718,Oculotrichodysplasia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2718
2717,Oculotrichoanal syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2717
2704,Urofacial syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2704
2703,Port-wine nevi-mega cisterna magna-hydrocephalus syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2703
255210,Mitochondrial DNA-associated Leigh syndrome,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=255210
255229,Navajo neurohepatopathy,49.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=255229
2707,"Oculocerebrofacial syndrome, Kaufman type",19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2707
255235,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=255235
2710,Oculodentodigital dysplasia,243.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2710
2709,"Oculodental syndrome, Rutherfurd type",1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2709
2728,"Blepharophimosis-intellectual disability syndrome, Ohdo type",30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2728
2730,Postaxial tetramelic oligodactyly,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2730
2732,Olivopontocerebellar atrophy-deafness syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2732
2733,Omodysplasia,0.0 (Worldwide); 30.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2733
2719,"Oculocerebral hypopigmentation syndrome, Cross type",14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2719
2720,"Oculocerebral hypopigmentation syndrome, Preus type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2720
2721,Odonto-onycho-dermal dysplasia,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2721
2722,Odonto-onycho dysplasia-alopecia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2722
2723,Odontotrichomelic syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2723
2724,Odontomatosis-aortae esophagus stenosis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2724
2755,Orofaciodigital syndrome type 8,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2755
2754,Orofaciodigital syndrome type 6,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2754
252164,Benign schwannoma,6.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=252164
2753,Orofaciodigital syndrome type 4,29.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2753
2751,Orofaciodigital syndrome type 2,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2751
2750,Orofaciodigital syndrome type 1,0.65 (France); 1.2 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2750
252057,Tumor of cranial and spinal nerves,1.89 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=252057
2743,Ophthalmoplegia-intellectual disability-lingua scrotalis syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2743
2741,Ophthalmomandibulomelic dysplasia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2741
252028,Primary melanocytic tumor of central nervous system,0.01 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=252028
661,Congenital central hypoventilation syndrome,0.5 (France); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=661
2736,Lethal omphalocele-cleft palate syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2736
254367,Rare lichen planus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254367
2776,Autosomal recessive distal osteolysis syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2776
2777,Osteomesopyknosis,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2777
254361,Plectin-related limb-girdle muscular dystrophy R17,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254361
2774,Multicentric carpo-tarsal osteolysis with or without nephropathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2774
254351,Distal 7q11.23 microdeletion syndrome,41.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254351
2769,"Familial osteodysplasia, Anderson type",0.0 (Worldwide); 4.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2769
254346,19p13.12 microdeletion syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254346
2770,Nasu-Hakola disease,0.0 (Europe); 0.15 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2770
254343,Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254343
2767,Carpotarsal osteochondromatosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2767
254334,Autosomal recessive intermediate Charcot-Marie-Tooth disease type B,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254334
2768,Blount disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2768
252212,Malignant triton tumor,170.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=252212
2763,Osteocraniostenosis,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2763
2759,Imperforate oropharynx-costovertebral anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2759
2760,OSLAM syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2760
252175,Vestibular schwannoma,2.0 (Denmark); 1.2 (United States); 0.8 (Specific population); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=252175
254516,Temple syndrome,53.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254516
2793,Otoonychoperoneal syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2793
254519,Kagami-Ogata syndrome,84.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254519
254525,Temple syndrome due to paternal 14q32.2 microdeletion,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254525
2798,Pachygyria-intellectual disability-epilepsy syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2798
2796,Pachydermoperiostosis,204.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2796
254528,Kagami-Ogata syndrome due to maternal 14q32.2 microdeletion,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254528
254478,Lichen planus pemphigoides,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254478
2789,Lateral meningocele syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2789
2788,Osteoporosis-pseudoglioma syndrome,0.05 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2788
254492,Frontal fibrosing alopecia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254492
2791,Otodental syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2791
254504,Inhalational botulism,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254504
2790,"Endosteal hyperostosis, Worth type",6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2790
254509,Iatrogenic botulism,180.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254509
254411,Annular atrophic lichen planus,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254411
254424,Annular lichen planus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254424
2783,Autosomal dominant osteopetrosis type 1,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2783
254449,Atrophic lichen planus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254449
2786,Osteoporosis-oculocutaneous hypopigmentation syndrome,0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2786
254463,Lichen planus pigmentosus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254463
2780,Osteopathia striata-cranial sclerosis syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2780
2779,Osteopathia striata-pigmentary dermopathy-white forelock syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2779
254379,Linear lichen planus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254379
254395,Actinic lichen planus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254395
667,Autosomal recessive malignant osteopetrosis,0.75 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=667
2815,Spastic paraparesis-deafness syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2815
2818,Spastic paraplegia-glaucoma-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2818
2808,Laryngeal abductor paralysis,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2808
2812,Parana hard skin syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2812
2805,Partial pancreatic agenesis,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2805
254698,Epithelioid trophoblastic tumor,0.0 (Worldwide); 0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254698
254693,Partial hydatidiform mole,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254693
675,Annular pancreas,1.8 (Europe); 29.4 (Austria); 2.9 (Belgium); 21.3 (Denmark); 7.9 (France); 5.9 (Germany); 1.0 (Hungary); 3.6 (Ireland); 5.7 (Italy); 24.9 (Malta); 17.1 (Netherlands); 0.7 (Poland); 3.1 (Spain); 0.8 (United Kingdom); 3.2 (Ukraine); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=675
678,Papillon-Lefèvre syndrome,0.25 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=678
254704,Genetic hyperferritinemia without iron overload,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254704
254534,Kagami-Ogata syndrome due to maternal 14q32.2 hypermethylation,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254534
2802,X-linked sideroblastic anemia and spinocerebellar ataxia,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2802
254531,Temple syndrome due to paternal 14q32.2 hypomethylation,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254531
254688,Complete hydatidiform mole,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=254688
2804,W syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2804
2491,Müllerian duct anomalies-limb anomalies syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2491
2492,FATCO syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2492
2499,Metachondromatosis,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2499
2496,Mesomelia-synostoses syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2496
2497,"Upper limb mesomelic dysplasia, type Fryns",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2497
2502,Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2502
2501,"Metaphyseal chondrodysplasia, Spahr type",18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2501
2504,Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2504
2511,Microbrachycephaly-ptosis-cleft lip syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2511
2510,Micro syndrome,203.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2510
2508,Corpus callosum agenesis-abnormal genitalia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2508
2516,Microcephaly-cardiac defect-lung malsegmentation syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2516
2515,Microcephaly-cardiomyopathy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2515
2513,Microcephaly-albinism-digital anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2513
2521,Microcephaly-cleft palate-abnormal retinal pigmentation syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2521
2524,Pontocerebellar hypoplasia type 2,81.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2524
2523,Microcephaly-brain defect-spasticity-hypernatremia syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2523
2522,Microcephaly-cervical spine fusion anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2522
2526,Microcephaly-lymphedema-chorioretinopathy syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2526
2528,"Microcephaly-microcornea syndrome, Seemanova type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2528
2533,Microcephaly-deafness-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2533
2536,Microcornea-glaucoma-absent frontal sinuses syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2536
2551,Microspherophakia-metaphyseal dysplasia syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2551
2554,Ear-patella-short stature syndrome,67.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2554
2556,Microphthalmia with linear skin defects syndrome,55.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2556
2558,Mikati-Najjar-Sahli syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2558
2557,Mietens syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2557
2561,Pyramidal molars-abnormal upper lip syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2561
2560,Moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2560
2564,Tetramelic monodactyly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2564
2563,MOMO syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2563
2565,Mononen-Karnes-Senac syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2565
2574,Moynahan syndrome,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2574
575,Muckle-Wells syndrome,200.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=575
2572,Spastic ataxia-corneal dystrophy syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2572
2573,Moyamoya disease,"0.74 (Japan); 6.2 (Japan); 0.43 (China); 3.92 (China); 0.048 (Taiwan, Province of China); 0.44 (Taiwan, Province of China); 0.086 (United States); 0.33 (France); 0.035 (Europe); 0.0 (Europe)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2573
2570,Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2570
2571,X-linked immunoneurologic disorder,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2571
261183,15q11.2 microdeletion syndrome,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261183
261144,FOXG1 syndrome due to 14q12 microdeletion,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261144
261120,14q11.2 microdeletion syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261120
2578,Mayer-Rokitansky-Küster-Hauser syndrome type 2,1.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2578
2579,Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2579
261102,Distal 7q11.23 microduplication syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261102
2576,Mulibrey nanism,150.0 (Worldwide); 0.0 (Worldwide); 2.7 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2576
261236,16p13.11 microdeletion syndrome,7.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261236
261243,16p13.11 microduplication syndrome,162.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261243
2608,N syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2608
261222,Distal 16p11.2 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261222
1359,Carney complex,750.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1359
261229,14q11.2 microduplication syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261229
2590,Spinal muscular atrophy-progressive myoclonic epilepsy syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2590
261204,16p11.2p12.2 microduplication syndrome,0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261204
261211,16p11.2p12.2 microdeletion syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261211
2589,Myoclonus-cerebellar ataxia-deafness syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2589
261190,Cleft palate-congenital heart defect-intellectual disability syndrome due to 15q14 microdeletion,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261190
2588,Myhre syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2588
261197,Proximal 16p11.2 microdeletion syndrome,20.0 (Europe); 20.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261197
261295,20p12.3 microdeletion syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261295
261304,Paternal 20q13.2q13.3 microdeletion syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261304
261279,17q23.1q23.2 microdeletion syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261279
261290,Trisomy 17p syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261290
2617,"Microcephalic primordial dwarfism, Montreal type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2617
261265,17q12 microdeletion syndrome,0.0 (Worldwide); 0.16 (Denmark); 103.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261265
261272,17q12 microduplication syndrome,118.0 (Worldwide); 0.0 (Worldwide); 0.46 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261272
2616,3M syndrome,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2616
261250,16q24.3 microdeletion syndrome,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261250
2613,Nail-patella-like renal disease,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2613
261257,Distal 17p13.3 microdeletion syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261257
261344,Trisomy 1q syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261344
261337,Distal 22q11.2 microduplication syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261337
261476,Xp21 deletion syndrome,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261476
261349,2p15p16.1 microdeletion syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261349
261318,Trisomy 20p syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261318
261311,20q13.33 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261311
2623,Geleophysic dysplasia,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2623
261330,Distal 22q11.2 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261330
261323,21q22.11q22.12 microdeletion syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261323
261524,Paternal uniparental disomy of chromosome X syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261524
261519,Maternal uniparental disomy of chromosome X syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261519
261534,"49,XXXYY syndrome",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261534
261529,Ring chromosome Y syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261529
2631,Mesomelic dwarfism-cleft palate-camptodactyly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2631
261494,Kleefstra syndrome,114.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261494
261483,Xq27.3q28 duplication syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261483
2632,Langer mesomelic dysplasia,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2632
261501,Atypical Norrie disease due to Xp11.3 microdeletion,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261501
2634,"Mesomelic dwarfism, Reinhardt-Pfeiffer type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2634
2645,Osteoglosphonic dysplasia,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2645
261600,Alagille syndrome due to 20p12 microdeletion,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261600
2643,"Microcephalic primordial dwarfism, Toriello type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2643
2636,Microcephalic osteodysplastic primordial dwarfism types I and III,53.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2636
2658,Lenz-Majewski hyperostotic dwarfism,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2658
261638,Okihiro syndrome due to 20q13 microdeletion,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261638
261652,Kleefstra syndrome due to a point mutation,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=261652
264200,14q22q23 microdeletion syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=264200
3057,Monoamine oxidase A deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3057
3055,X-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3055
3052,X-linked intellectual disability-seizures-psoriasis syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3052
3047,"Blepharophimosis-intellectual disability syndrome, SBBYS type",122.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3047
3044,Intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3044
3042,Intellectual disability-cataracts-calcified pinnae-myopathy syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3042
3041,Intellectual disability-balding-patella luxation-acromicria syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3041
3038,Delayed speech-facial asymmetry-strabismus-ear lobe creases syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3038
263665,NK-cell enteropathy,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263665
3035,Growth delay-hydrocephaly-lung hypoplasia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3035
263662,Familial multiple meningioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263662
3034,Delayed membranous cranial ossification,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3034
263548,Peeling skin syndrome type A,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263548
3033,Renal tubular dysgenesis,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3033
263553,Peeling skin syndrome type B,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263553
3032,NPHP3-related Meckel-like syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3032
263534,Acral peeling skin syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263534
263543,Generalized peeling skin syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263543
263516,Progressive myoclonic epilepsy type 3,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263516
263524,Acute necrotizing encephalopathy of childhood,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263524
263501,COG4-CDG,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263501
3026,Radial ray hypoplasia-choanal atresia syndrome,0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3026
263508,COG1-CDG,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263508
263482,"Spondyloepimetaphyseal dysplasia, Maroteaux type",10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263482
3021,RAPADILINO syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3021
263479,Fuchs heterochromic iridocyclitis,0.2 (Finland); 0.5 (Finland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263479
263494,DPM3-CDG,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263494
3023,External auditory canal atresia-vertical talus-hypertelorism syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3023
263487,COG5-CDG,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263487
263458,Hyperinsulinism due to INSR deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263458
263455,Congenital hyperinsulinism due to HNF4A deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263455
1832,Osteosclerotic bone dysplasia,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1832
3018,Retinal ischemic syndrome-digestive tract small vessel hyalinosis-diffuse cerebral calcifications syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3018
3019,Ramon syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3019
263463,CHST3-related skeletal dysplasia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263463
263432,Nevus of Ito,1.17 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263432
263425,Nevus of Ota,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263425
3015,Radio-renal syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3015
263440,Neuroacanthocytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263440
263435,Congenital smooth muscle hamartoma,38.5 (Israel); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263435
3016,Absent radius-anogenital anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3016
263410,Infantile spasms-psychomotor retardation-progressive brain atrophy-basal ganglia disease syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263410
3010,Qazi-Markouizos syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3010
3011,Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3011
769,Rabson-Mendenhall syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=769
263413,Angiosarcoma,0.0 (Europe); 0.02 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263413
3003,Pyknoachondrogenesis,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3003
263335,Moderately-differentiated thymic neuroendocrine carcinoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263335
263339,Poorly differentiated thymic neuroendocrine carcinoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263339
3005,Pyle disease,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3005
263347,MRCS syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263347
263352,Postcardiotomy right ventricular failure,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263352
3004,Mirror polydactyly-vertebral segmentation-limbs defects syndrome,0.3 (Spain); 0.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3004
263310,Thymoma type A,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263310
2997,Ptosis-vocal cord paralysis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2997
263317,Thymoma type B,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263317
263324,Thymoma type AB,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263324
2999,Ptosis-strabismus-ectopic pupils syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2999
263331,Well-differentiated thymic neuroendocrine carcinoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263331
2990,Autosomal recessive multiple pterygium syndrome,0.0 (Worldwide); 64.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2990
263297,Glycogen storage disease with severe cardiomyopathy due to glycogenin deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263297
2987,Antecubital pterygium syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2987
2985,Pseudoprogeria syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2985
2988,Pterygium colli-intellectual disability-digital anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2988
3138,Ulnar-mammary syndrome,128.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3138
3145,Arginine vasopressin resistance-intracranial calcification-short stature-facial dysmorphism syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3145
3143,Autoimmune polyendocrinopathy type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3143
3144,Schneckenbecken dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3144
3132,Say-Barber-Miller syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3132
3130,Satoyoshi syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3130
798,Schinzel-Giedion syndrome,0.0 (Worldwide); 0.0 (Europe); 46.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=798
262941,Partial duplication of the long arm of chromosome 14 syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=262941
3134,SCARF syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3134
3121,Ruvalcaba syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3121
2909,Rothmund-Thomson syndrome,400.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2909
3110,Rombo syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3110
3101,Richieri Costa-da Silva syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3101
3102,Richieri Costa-Pereira syndrome,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3102
3104,Robin sequence-oligodactyly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3104
3107,Autosomal dominant Robinow syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3107
3109,Mayer-Rokitansky-Küster-Hauser syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3109
3086,Autosomal dominant vitreoretinochoroidopathy,3.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3086
3088,Revesz syndrome,4.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3088
3097,Meacham syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3097
3098,"Rhizomelic syndrome, Urbach type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3098
3078,"Severe X-linked intellectual disability, Gustavson type",7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3078
3077,X-linked intellectual disability-psychosis-macroorchidism syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3077
3080,"Intellectual disability, Wolff type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3080
3079,"Intellectual disability, Buenos-Aires type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3079
3063,"X-linked intellectual disability, Snyder type",21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3063
3068,Intellectual disability-myopathy-short stature-endocrine defect syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3068
268843,"Malformation of the neurenteric canal, spinal cord and column",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268843
2886,TARP syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2886
268861,Primary tethered cord syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268861
2885,Piebald trait-neurologic defects syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2885
2884,Piebaldism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2884
2881,Cutaneous photosensitivity-lethal colitis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2881
2879,"Phocomelia, Schinzel type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2879
268826,Parietal encephalocele,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268826
268829,Basal encephalocele,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268829
268920,Isolated megalencephaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268920
268882,Arnold-Chiari malformation type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268882
2892,Pilodental dysplasia-refractive errors syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2892
2891,Pili torti-developmental delay-neurological abnormalities syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2891
2889,Pili torti,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2889
2890,Pili torti-onychodysplasia syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2890
268865,Neurenteric cyst,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268865
2888,Pierre Robin syndrome-faciodigital anomaly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2888
268868,Isolated amyelia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268868
2865,Short stature-webbed neck-heart disease syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2865
2866,Short stature-deafness-neutrophil dysfunction-dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2866
2863,Short stature-wormian bones-dextrocardia syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2863
268744,Spinal dysraphism with a posterior meningocele,33.0 (Saudi Arabia); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268744
268823,Occipital encephalocele,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268823
2876,PHAVER syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2876
268820,Cranial meningocele,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268820
268817,Cephalocele,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268817
2874,Phakomatosis pigmentokeratotica,0.0 (Worldwide); 34.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2874
268813,Myelocystocele,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268813
268810,Isolated posterior meningocele,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268810
2871,Pfeiffer-Palm-Teller syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2871
2872,"Cardiocranial syndrome, Pfeiffer type",7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2872
2867,"Short stature, Brussels type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2867
2868,Short stature-valvular heart disease-characteristic facies syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2868
2846,Congenital pericardium anomaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2846
2842,Penoscrotal transposition,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2842
2848,Camptodactyly-arthropathy-coxa-vara-pericarditis syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2848
2847,Pericardial and diaphragmatic defect,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2847
268357,Neural tube closure defect,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268357
2838,Renal caliceal diverticuli-deafness syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2838
268322,Hereditary thrombocytopenia with normal platelets,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268322
2840,Pelvic dysplasia-arthrogryposis of lower limbs syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2840
2839,Pelvis-shoulder dysplasia,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2839
2855,Perrault syndrome,124.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2855
2854,Fuhrmann syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2854
708,Peters anomaly,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=708
268363,Open iniencephaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268363
268366,Closed iniencephaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268366
2850,Alopecia-intellectual disability syndrome,0.0 (Worldwide); 15.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2850
268369,Open spinal dysraphism,51.5 (Germany); 0.0 (Worldwide); 50.0 (France); 400.0 (Ireland); 62.0 (Latin America); 400.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268369
268114,RAS-associated autoimmune leukoproliferative disease,0.0 (Worldwide); 20.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268114
2825,PARC syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2825
2826,Spastic paraplegia-precocious puberty syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2826
268139,Intraocular medulloepithelioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268139
268129,Spheroid body myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268129
2819,Spastic paraplegia-facial-cutaneous lesions syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2819
2820,Spastic paraplegia-nephritis-deafness syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2820
2821,Spastic paraplegia-neuropathy-poikiloderma syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2821
2822,Autosomal recessive spastic paraplegia type 11,0.26 (Portugal),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2822
2835,Pectus excavatum-macrocephaly-dysplastic nails syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2835
268261,DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268261
2836,PEHO syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2836
268249,Mycophenolate mofetil embryopathy,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268249
268316,Complication in hemodialysis,13.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268316
268162,Intermediate maple syrup urine disease,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268162
2832,Short tarsus-absence of lower eyelashes syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2832
268145,Classic maple syrup urine disease,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268145
268184,Thiamine-responsive maple syrup urine disease,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268184
2833,Stiff skin syndrome,54.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2833
2834,Wrinkly skin syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2834
268173,Intermittent maple syrup urine disease,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268173
2969,Proteus-like syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2969
2962,De Barsy syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2962
2972,Non-eruption of teeth-maxillary hypoplasia-genu valgum syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2972
750,Pseudoachondroplasia,3.3 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=750
2976,"Pseudoleprechaunism syndrome, Patterson type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2976
2975,"46,XX difference of sex development-skeletal anomalies syndrome",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2975
2980,Acrootoocular syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2980
2978,Chronic intestinal pseudoobstruction,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2978
2946,Brachydactyly-long thumb syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2946
1848,"Renal agenesis, bilateral",1.7 (Europe); 4.5 (France); 5.8 (Germany); 1.4 (Italy); 5.7 (Netherlands); 10.8 (Ireland); 3.2 (Norway); 1.2 (Poland); 0.6 (Spain); 2.2 (Hungary); 19.0 (Denmark); 9.7 (Austria); 3.0 (Belgium); 13.6 (Croatia); 24.1 (Malta); 1.2 (United Kingdom); 3.2 (Ukraine); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1848
2951,Absent thumb-short stature-immunodeficiency syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2951
2947,Triphalangeal thumbs-brachyectrodactyly syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2947
264978,Drug or radiation exposure-related interstitial lung disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=264978
2956,Acrodysplasia scoliosis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2956
2952,"Adducted thumbs-arthrogryposis syndrome, Christian type",9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2952
740,Hutchinson-Gilford progeria syndrome,0.025 (Worldwide); 0.005 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=740
2959,Progeria-short stature-pigmented nevi syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2959
2957,Guttmacher syndrome,0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2957
2958,X-linked intellectual disability-dysmorphism-cerebral atrophy syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2958
2924,Isolated polycystic liver disease,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2924
2926,Digital extensor muscle aplasia-polyneuropathy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2926
2928,Polyneuropathy-intellectual disability-acromicria-premature menopause syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2928
2930,Cronkhite-Canada syndrome,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2930
2935,Crossed polysyndactyly,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2935
2934,Polysyndactyly-cardiac malformation syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2934
2941,Porencephaly-cerebellar hypoplasia-internal malformations syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2941
2940,Porencephaly,0.0 (Worldwide); 3.5 (United States); 5.2 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2940
2896,Pitt-Hopkins syndrome,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2896
2900,Leri pleonosteosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2900
2905,POEMS syndrome,0.0 (Europe); 0.33 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2905
2907,Hereditary acrokeratotic poikiloderma,0.0 (Worldwide); 41.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2907
2911,Poland syndrome,3.1 (Canada); 0.0 (Canada); 1.5 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2911
264580,Glycogen storage disease due to liver phosphorylase kinase deficiency,1.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=264580
2916,Postaxial polydactyly-dental and vertebral anomalies syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2916
2917,Polydactyly-myopia syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2917
2919,Orofaciodigital syndrome type 5,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2919
264675,Hereditary pulmonary alveolar proteinosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=264675
2920,Oliver syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2920
264691,Isolated pulmonary capillaritis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=264691
2921,Preaxial polydactyly-colobomata-intellectual disability syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2921
264688,Congenital chylothorax,0.0 (Worldwide); 4.17 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=264688
3374,Unilateral ocular duplication,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3374
275803,Pulmonary arterial hypertension associated with congenital heart disease,0.17 (France); 0.026 (France); 0.95 (United Kingdom); 0.2 (United Kingdom); 0.3 (Spain); 0.46 (Czech Republic); 0.22 (Czech Republic); 0.0 (Netherlands); 0.57 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275803
275808,Pulmonary arterial hypertension associated with HIV infection,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275808
275813,Pulmonary arterial hypertension associated with portal hypertension,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275813
3377,Trismus-pseudocamptodactyly syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3377
275823,Pulmonary arterial hypertension associated with schistosomiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275823
3368,Trigonocephaly-bifid nose-acral anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3368
275777,Heritable pulmonary arterial hypertension,0.08 (Europe); 0.08 (France); 0.8 (Czech Republic),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275777
275786,Drug- or toxin-induced pulmonary arterial hypertension,0.0 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275786
275791,Pulmonary arterial hypertension associated with another disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275791
3369,Trigonocephaly-short stature-developmental delay syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3369
275798,Pulmonary arterial hypertension associated with connective tissue disease,0.23 (France); 0.036 (France); 0.25 (Spain); 1.25 (United Kingdom); 0.25 (United Kingdom); 0.25 (Czech Republic); 0.12 (Czech Republic); 0.25 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275798
3363,Trichomegaly-retina pigmentary degeneration-dwarfism syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3363
275761,Lysosomal acid lipase deficiency,0.27 (Czech Republic); 2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275761
3366,Non-syndromic metopic craniosynostosis,6.7 (Europe); 10.2979 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3366
3365,Trigonocephaly-broad thumbs syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3365
275766,Idiopathic pulmonary arterial hypertension,0.0 (Worldwide); 0.59 (France); 0.1 (France); 0.56 (Spain); 0.12 (Spain); 1.4 (Czech Republic); 0.62 (Czech Republic); 0.86 (Switzerland); 0.12 (Switzerland); 0.25 (United Kingdom); 1.7 (United Kingdom); 0.11 (United States); 0.17 (Belgium); 0.14 (Israel); 0.8 (Israel); 1.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275766
3361,Trichodysplasia-xeroderma syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3361
3408,Upington disease,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3408
3409,Urban-Rogers-Meyer syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3409
276145,Malignant epithelial tumor of salivary glands,0.73 (Europe); 0.85 (Austria); 0.986 (Germany); 0.809 (Iceland); 0.737 (Ireland); 0.98 (Latvia); 0.817 (Malta); 0.864 (Norway); 0.937 (Poland); 0.899 (Portugal); 0.99 (Slovakia); 0.657 (Slovenia); 0.919 (Spain); 0.906 (Switzerland); 0.786 (Netherlands); 0.906 (United Kingdom); 1.121 (Belgium); 1.026 (Bulgaria); 1.261 (Croatia); 1.113 (Czech Republic); 1.127 (Estonia); 1.093 (Finland); 1.227 (Italy); 1.213 (Lithuania),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276145
276161,Multiple endocrine neoplasia,0.05 (Ireland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276161
3412,VACTERL with hydrocephalus,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3412
276152,Multiple endocrine neoplasia type 4,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276152
3403,Uhl anomaly,84.0 (Worldwide); 1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3403
3404,Ulbright-Hodes syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3404
276066,Bile acid CoA ligase deficiency and defective amidation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276066
275872,Frontotemporal dementia with motor neuron disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275872
3383,Humerus trochlea aplasia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3383
3384,Common arterial trunk,4.3 (Worldwide); 4.8 (Europe); 5.8 (Belgium); 9.8 (France); 5.8 (Germany); 5.5 (Hungary); 3.6 (Ireland); 2.8 (Italy); 5.8 (Netherlands); 3.3 (Norway); 2.2 (Poland); 1.9 (Spain); 12.6 (Switzerland); 7.7 (United Kingdom); 6.4 (Ukraine); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3384
275864,Behavioral variant of frontotemporal dementia,4.0 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275864
275944,Hemolytic disease of the newborn with Kell alloimmunization,116.0 (United Kingdom); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275944
3387,Isolated anterior cervical hypertrichosis,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3387
3388,Neural tube defect,55.0 (United States); 91.05 (Europe); 88.75 (Belgium); 76.8 (Austria); 74.7 (Czech Republic); 47.9 (Croatia); 109.6 (Denmark); 86.7 (Finland); 120.2 (France); 138.25 (Germany); 67.2 (Hungary); 87.4 (Ireland); 54.65 (Italy); 109.5 (Malta); 84.2 (Netherlands); 92.7 (Norway); 92.5 (Poland); 47.3 (Portugal); 98.5 (Spain); 101.7 (Switzerland); 115.5 (United Kingdom); 1387.0 (China); 31.0 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3388
1723,Mosaic trisomy 2 syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1723
275828,Pulmonary arterial hypertension associated with chronic hemolytic anemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275828
1724,Mosaic trisomy 20 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1724
1747,Mosaic trisomy 7 syndrome,31.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1747
3329,Tibial aplasia-ectrodactyly syndrome,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3329
3328,Absent tibia-polydactyly-arachnoid cyst syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3328
3327,Thyrocerebrorenal syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3327
3326,Thymic-renal-anal-lung dysplasia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3326
3322,Hoyeraal-Hreidarsson syndrome,0.0 (Worldwide); 33.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3322
3317,Thoracolaryngopelvic dysplasia,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3317
3316,Thomas syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3316
3314,"Thiemann disease, familial form",33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3314
3355,Trichoodontoonychial dysplasia,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3355
275555,Preeclampsia,45.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275555
275543,L1 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275543
3353,Trichodermodysplasia-dental alterations syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3353
275523,Dianzani autoimmune lymphoproliferative disease,0.0 (Worldwide); 30.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275523
3351,Trichodental syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3351
275517,Autoimmune lymphoproliferative syndrome-recurrent viral infections due to CASP8 deficiency,0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=275517
3352,Tricho-dento-osseous syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3352
3350,Tremor-nystagmus-duodenal ulcer syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3350
3344,Weismann-Netter syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3344
3347,Mounier-Kühn syndrome,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3347
3341,Torticollis-keloids-cryptorchidism-renal dysplasia syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3341
3342,Arterial tortuosity syndrome,102.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3342
3339,Oculoectodermal syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3339
271861,Hereditary ATTR amyloidosis,"0.2222 (Worldwide); 0.1474 (Argentina); 0.147 (Australia); 0.1511 (Austria); 0.1484 (Bangladesh); 0.1504 (Belgium); 0.5694 (Bulgaria); 0.1476 (Canada); 0.1481 (China); 4.25 (Cyprus); 0.1509 (Czech Republic); 0.1403 (Denmark); 0.149 (Ecuador); 0.1454 (Finland); 0.7514 (France); 0.1486 (Germany); 0.1481 (Greece); 0.153 (Hungary); 0.1481 (India); 0.1578 (Ireland); 0.1428 (Israel); 0.9046 (Italy); 0.1473 (Poland); 19.9126 (Portugal); 0.1464 (Romania); 0.1485 (Russian Federation); 0.1428 (Slovenia); 0.1487 (Spain); 0.1476 (Sri Lanka); 2.5816 (Sweden); 0.1445 (Switzerland); 0.1489 (Taiwan, Province of China); 0.0317 (Turkey); 0.149 (United Kingdom); 0.0968 (Japan); 0.1482 (Korea, Republic of); 0.1666 (Luxembourg); 0.1485 (Malaysia); 0.148 (Mexico); 0.2662 (Netherlands); 0.1521 (New Zealand)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=271861
3338,Toriello-Carey syndrome,59.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3338
3469,XK aprosencephaly syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3469
3472,Yunis-Varon syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3472
3471,Young syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3471
3319,Congenital amegakaryocytic thrombocytopenia,0.0 (Worldwide); 100.0 (Worldwide); 0.15 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3319
3473,Zimmermann-Laband syndrome,52.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3473
3459,Wilson-Turner syndrome,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3459
3464,Woodhouse-Sakati syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3464
3466,WT limb-blood syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3466
3465,Worster-Drought syndrome,3.7 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3465
2749,Oromandibular-limb hypogenesis syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2749
2995,Baraitser-Winter cerebrofrontofacial syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2995
3200,Arthrogryposis-ectodermal dysplasia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3200
1570,Symbrachydactyly of hands and feet,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1570
3243,Sweet syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3243
1827,Acromelic frontonasal dysplasia,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1827
2076,X-linked intellectual disability-epilepsy syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2076
268980,Isolated focal cortical dysplasia type Ib,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268980
268987,Isolated focal cortical dysplasia type Ic,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268987
3424,Velo-facial-skeletal syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3424
268973,Isolated focal cortical dysplasia type Ia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268973
269008,Isolated focal cortical dysplasia type IIb,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269008
3433,Microcephaly-brachydactyly-kyphoscoliosis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3433
268994,Isolated focal cortical dysplasia type II,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268994
3429,Verloove Vanhorick-Brubakk syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3429
269001,Isolated focal cortical dysplasia type IIa,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269001
2460,Van den Ende-Gupta syndrome,29.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2460
268940,Bilateral polymicrogyria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268940
268943,Unilateral polymicrogyria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268943
3416,Hyperostosis corticalis generalisata,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3416
268926,Midline cerebral malformation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268926
268936,Isolated arhinencephaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268936
268961,Isolated focal cortical dysplasia type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268961
268947,Unilateral focal polymicrogyria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268947
3417,Van den Bosch syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3417
268950,Cerebral cortical dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268950
269229,Pontine tegmental cap dysplasia,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269229
3453,Autoimmune polyendocrinopathy type 1,4.0 (Finland); 0.5 (France); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3453
269224,Global cerebellar malformation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269224
3448,Weaver-Williams syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3448
269221,Isolated bilateral hemispheric cerebellar hypoplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269221
3449,Weill-Marchesani syndrome,1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3449
269218,Isolated unilateral hemispheric cerebellar hypoplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269218
3456,Wildervanck syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3456
269510,Congenital non-communicating hydrocephalus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269510
3454,Wieacker-Wolff syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3454
3455,Wiedemann-Rautenstrauch syndrome,37.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3455
269505,Congenital communicating hydrocephalus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269505
269203,Isolated cerebellar vermis agenesis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269203
269197,Glioependymal/ependymal cyst,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269197
3434,MMEP syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3434
269215,Isolated Dandy-Walker malformation without hydrocephalus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269215
269212,Isolated Dandy-Walker malformation with hydrocephalus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269212
269209,Isolated partial cerebellar vermis agenesis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269209
269206,Isolated total cerebellar vermis agenesis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=269206
1856,Spondyloperipheral dysplasia-short ulna syndrome,0.0 (Worldwide); 10.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1856
280302,Autoimmune pancreatitis type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280302
280333,Alpha-dystroglycan-related limb-girdle muscular dystrophy R16,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280333
280325,Distal deletion 12p syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280325
280293,Pelizaeus-Merzbacher-like disease due to AIMP1 mutation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280293
280288,Pelizaeus-Merzbacher-like disease due to HSPD1 mutation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280288
3194,Corneodermatoosseous syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3194
280365,Autosomal semi-dominant severe lipodystrophic laminopathy,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280365
280379,Erythropoietic uroporphyria associated with myeloid malignancy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280379
3197,Hereditary hyperekplexia,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3197
3199,Stimmler syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3199
3184,Steatocystoma multiplex-natal teeth syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3184
3186,Holoprosencephaly-radial heart renal anomalies syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3186
3191,Subaortic stenosis-short stature syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3191
3193,Supravalvular aortic stenosis,4.0 (Europe); 13.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3193
280356,PLIN1-related familial partial lipodystrophy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280356
3214,"Deaf blind hypopigmentation syndrome, Yemenite type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3214
280403,Familial omphalocele syndrome with facial dysmorphism,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280403
280406,Familial steroid-resistant nephrotic syndrome with sensorineural deafness,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280406
3201,Ventricular extrasystoles with syncopal episodes-perodactyly-Robin sequence syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3201
280384,Recessive intellectual disability-motor dysfunction-multiple joint contractures syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280384
280397,Familial Alzheimer-like prion disease,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280397
280576,Nestor-Guillermo progeria syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280576
3220,Deafness-enamel hypoplasia-nail defects syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3220
3219,Fountain syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3219
3222,Phosphoribosylpyrophosphate synthetase superactivity,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3222
280586,"Chondrodysplasia with joint dislocations, gPAPP type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280586
3217,Deafness-small bowel diverticulosis-neuropathy syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3217
280553,Fatal infantile hypertonic myofibrillar myopathy,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280553
280558,Warsaw breakage syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280558
3216,Conductive deafness-malformed external ear syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3216
3218,Deafness-epiphyseal dysplasia-short stature syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3218
647,Nijmegen breakage syndrome,1.0 (Worldwide); 0.0 (Worldwide); 0.7 (Russian Federation); 3.1 (Poland); 3.1 (Czech Republic); 2.6 (Slovakia); 2.3 (Belarus); 1.3 (Ukraine),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=647
280062,Calciphylaxis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280062
279947,Postorgasmic illness syndrome,0.0 (Worldwide); 45.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279947
279943,Hereditary neutrophilia,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279943
279934,"Mitochondrial DNA depletion syndrome, hepatocerebral form due to DGUOK deficiency",0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279934
3152,Sclerosteosis,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3152
280142,Severe combined immunodeficiency due to LCK deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280142
3164,"Omphalocele syndrome, Shprintzen-Goldberg type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3164
3168,Sillence syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3168
280133,Complement component 3 deficiency,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280133
3163,SHORT syndrome,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3163
1479,Atrial septal defect-atrioventricular conduction defects syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1479
3156,Senior-Loken syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3156
280071,ALG11-CDG,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280071
3157,Septo-optic dysplasia spectrum,10.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3157
3180,Spondylocamptodactyly syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3180
280210,"Pelizaeus-Merzbacher disease, connatal form",0.03 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280210
280219,"Pelizaeus-Merzbacher disease, classic form",0.17 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280219
280200,Microform holoprosencephaly,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280200
3177,Spinocerebellar degeneration-corneal dystrophy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3177
280205,Laryngotracheoesophageal cleft type 0,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280205
3175,X-linked spasticity-intellectual disability-epilepsy syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3175
280195,Septopreoptic holoprosencephaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280195
3172,Eyebrow duplication-syndactyly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3172
280183,Methylmalonic aciduria due to transcobalamin receptor defect,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280183
280282,Pelizaeus-Merzbacher-like disease due to GJC2 mutation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280282
280270,Pelizaeus-Merzbacher-like disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280270
280234,Null syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280234
1855,Spondyloenchondrodysplasia,36.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1855
280224,"Pelizaeus-Merzbacher disease, transitional form",0.03 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280224
1797,Autosomal dominant spondylocostal dysostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1797
280229,Pelizaeus-Merzbacher disease in female carriers,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280229
276580,Autosomal dominant hyperinsulinism due to Kir6.2 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276580
3258,Cenani-Lenz syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3258
276575,Autosomal dominant hyperinsulinism due to SUR1 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276575
3262,Dobrow syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3262
276598,Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276598
276608,Non-insulinoma pancreatogenous hypoglycemia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276608
3265,Isolated humero-radial synostosis,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3265
276603,Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276603
3266,Isolated humero-radio-ulnar synostosis,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3266
276621,Sporadic pheochromocytoma/secreting paraganglioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276621
3268,Radioulnar synostosis-microcephaly-scoliosis syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3268
276630,Symptomatic form of Coffin-Lowry syndrome in female carriers,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276630
3270,Radioulnar synostosis-developmental delay-hypotonia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3270
3275,Spondylocarpotarsal synostosis,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3275
425,Apolipoprotein A-I deficiency,30.0 (Worldwide); 0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=425
3291,Teebi-Shaltout syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3291
3293,Telecanthus-hypertelorism-strabismus-pes cavus syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3293
3292,Tel Hashomer camptodactyly syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3292
279882,Spasmus nutans,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279882
3294,Extensor tendons of finger anomalies,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3294
279888,Acute endophthalmitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279888
279891,Chronic endophthalmitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279891
279894,Toxic maculopathy due to antimalarial drugs,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279894
3301,Tetraamelia-multiple malformations syndrome,0.0 (Worldwide); 5.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3301
279897,Primary oculocerebral lymphoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279897
279904,Primary intraocular lymphoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279904
3304,Fallot complex-intellectual disability-growth delay syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3304
3312,Thalidomide embryopathy,0.77 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3312
279914,Intermediate uveitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=279914
276198,Spinocerebellar ataxia type 36,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276198
276193,Spinocerebellar ataxia type 35,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276193
276183,Spinocerebellar ataxia type 32,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276183
3224,Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3224
276174,Idiopathic recurrent stupor,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276174
276238,Machado-Joseph disease type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276238
276234,Non-syndromic male infertility due to sperm motility disorder,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276234
3230,Deafness-oligodontia syndrome,0.0 (Worldwide); 5.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3230
3231,Deafness-onychodystrophy syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3231
276244,Machado-Joseph disease type 3,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276244
276241,Machado-Joseph disease type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276241
3235,Progressive deafness with stapes fixation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3235
3236,Conductive deafness-ptosis-skeletal anomalies syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3236
3232,Deafness-ear malformation-facial palsy syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3232
3233,Cochleosaccular degeneration-cataract syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3233
3241,Deafness-craniofacial syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3241
276280,Hemihyperplasia-multiple lipomatosis syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276280
276399,Familial multinodular goiter,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276399
3239,Deafness-vitiligo-achalasia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3239
3238,Cardiospondylocarpofacial syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3238
3237,Multiple synostoses syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3237
3246,Symphalangism with multiple anomalies of hands and feet,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3246
276413,10q22.3q23.3 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276413
3242,Renpenning syndrome,64.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3242
276405,Hyperbiliverdinemia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276405
3250,Proximal symphalangism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3250
3248,Isolated distal symphalangism,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3248
276422,10q22.3q23.3 microduplication syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276422
276429,Hypnic headache,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276429
3255,Filippi syndrome,29.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3255
276556,Hyperinsulinism due to UCP2 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276556
276432,Ogden syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276432
3253,Cleft lip/palate-ectodermal dysplasia syndrome,0.0 (Worldwide); 50.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3253
276435,Lower motor neuron syndrome with late-adult onset,55.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276435
911,Combined immunodeficiency due to ZAP70 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=911
3325,Heparin-induced thrombocytopenia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3325
746,Mitochondrial trifunctional protein deficiency,100.0 (Worldwide); 0.0 (Worldwide); 1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=746
943,Malonic aciduria,34.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=943
621,Hereditary methemoglobinemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=621
2089,Glycogen storage disease due to hepatic glycogen synthase deficiency,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2089
412,Dysbetalipoproteinemia,7.8 (Europe); 10.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412
743,Severe hereditary thrombophilia due to congenital protein S deficiency,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=743
424,Familial hyperthyroidism due to mutations in TSH receptor,0.0 (Worldwide); 28.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424
325,Congenital factor II deficiency,0.05 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=325
343,Hyperimmunoglobulinemia D with periodic fever,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=343
572,Immunodeficiency by defective expression of MHC class II,179.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572
1930,Herpes simplex virus encephalitis,0.3 (Worldwide); 0.3 (United Kingdom); 0.3 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1930
158,Systemic primary carnitine deficiency,3.2 (Europe); 3.2 (United States); 2.5 (Japan); 0.83 (Australia); 77.0 (Faroe Islands); 138.9 (Faroe Islands); 0.0069 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=158
2056,Essential fructosuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2056
206436,Infantile Krabbe disease,0.254 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206436
820,Sneddon syndrome,0.4 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=820
206428,Hypoxanthine-guanine phosphoribosyltransferase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206428
1945,Self-limited epilepsy with centrotemporal spikes,0.0 (Worldwide); 20.0 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1945
832,Succinyl-CoA:3-oxoacid CoA transferase deficiency,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=832
6,3-methylcrotonyl-CoA carboxylase deficiency,"2.65 (Europe); 1.9 (United States); 3.3 (Germany); 1.36 (Taiwan, Province of China); 0.0 (Worldwide); 0.0 (Europe)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=6
20,3-hydroxy-3-methylglutaric aciduria,0.0 (Worldwide); 0.8 (Portugal); 0.0 (United States); 0.0 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=20
712,Hemolytic anemia due to glucophosphate isomerase deficiency,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=712
2831,"Rhizomelic dysplasia, Patterson-Lowry type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2831
1129,Arachnodactyly-abnormal ossification-intellectual disability syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1129
206546,Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206546
1383,Cataract-deafness-hypogonadism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1383
206538,Malignant non-dysgerminomatous germ cell tumor of ovary,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206538
206554,Fukutin-related limb-girdle muscular dystrophy R13,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206554
1524,Craniomicromelic syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1524
206549,Anoctamin-5-related limb-girdle muscular dystrophy R12,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206549
1123,Caudal appendage-deafness syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1123
206564,POMGNT1-related limb-girdle muscular dystrophy R15,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206564
206559,POMT2-related limb-girdle muscular dystrophy R14,0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206559
206572,Overlap myositis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206572
206569,Immune-mediated necrotizing myopathy,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206569
206580,Autosomal recessive lower motor neuron disease with childhood onset,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206580
3439,Von Voss-Cherstvoy syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3439
1217,Spinal atrophy-ophthalmoplegia-pyramidal syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1217
2680,Hypomyelination neuropathy-arthrogryposis syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2680
1681,Diprosopus,33.0 (Worldwide); 0.0 (Worldwide); 0.2 (Argentina),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1681
1655,Müllerian derivatives-lymphangiectasia-polydactyly syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1655
633,Laron syndrome,0.3 (Europe); 4.86 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=633
478,Kallmann syndrome,3.75 (Europe); 5.0 (France); 2.1 (Finland); 0.6 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=478
822,Hereditary spherocytosis,50.0 (Germany); 20.0 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=822
910,Xeroderma pigmentosum,0.1 (United States); 4.5 (Japan); 0.23 (Europe); 0.19 (United Kingdom); 0.41 (Netherlands); 0.16 (Italy); 0.34 (France); 0.18 (Germany); 1.75 (Libyan Arab Jamahiriya),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=910
777,X-linked non-syndromic intellectual disability,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=777
766,Hemolytic anemia due to red cell pyruvate kinase deficiency,5.1 (Specific population); 5.0 (Europe); 0.96 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=766
28,Vitamin B12-responsive methylmalonic acidemia,192.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=28
206973,Congenital myotonia,1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206973
206594,Subacute inflammatory demyelinating polyneuropathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206594
206599,Isolated asymptomatic elevation of creatine phosphokinase,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206599
3206,Stüve-Wiedemann syndrome,0.0 (Worldwide); 56.0 (Worldwide); 20.0 (United Arab Emirates),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3206
206583,Adult polyglucosan body disease,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206583
65,Leber congenital amaurosis,0.0 (Europe); 2.5 (Worldwide); 1.23 (United States); 2.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65
321,Multiple osteochondromas,100.0 (Specific population); 0.9 (United Kingdom); 1.35 (Netherlands); 3.0 (Europe); 2.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=321
144,Lynch syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=144
206647,Myotonic dystrophy,189.0 (Specific population); 6.7 (Worldwide); 8.78 (Europe); 2.1 (Italy); 5.5 (Japan); 8.4 (Ireland); 13.3 (Croatia); 11.6 (New Zealand); 20.0 (Finland); 1.22 (Norway); 10.9 (Spain); 2.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=206647
110,Bardet-Biedl syndrome,7.4 (Specific population); 0.5 (Europe); 0.64 (Tunisia); 1.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=110
2326,Kallmann syndrome-heart disease syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2326
1130,Arachnodactyly-intellectual disability-dysmorphism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1130
3207,White matter hypoplasia-corpus callosum agenesis-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3207
2058,Fryns-Smeets-Thiry syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2058
2538,Microgastria-limb reduction defect syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2538
1192,Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1192
2062,Progressive non-infectious anterior vertebral fusion,67.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2062
2015,Cleft palate-short stature-vertebral anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2015
2427,Macrocephaly-short stature-paraplegia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2427
2898,X-linked intellectual disability-plagiocephaly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2898
2349,Muscular pseudohypertrophy-hypothyroidism syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2349
1423,Lethal recessive chondrodysplasia,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1423
2183,Hydrocephalus-obesity-hypogonadism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2183
1114,Aplasia cutis congenita,0.0 (Worldwide); 10.0 (Worldwide); 7.69 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1114
209004,Axonal polyneuropathy associated with IgG/IgM/IgA monoclonal gammopathy,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209004
1101,Anophthalmia-megalocornea-cardiopathy-skeletal anomalies syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1101
2184,Hydrocephaly-low insertion umbilicus syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2184
208650,NLRP3-associated autoinflammatory disease,0.28 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=208650
1272,Aymé-Gripp syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1272
208513,Spinocerebellar ataxia type 29,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=208513
1485,"Arthrogryposis-hyperkeratosis syndrome, lethal form",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1485
3051,Nicolaides-Baraitser syndrome,61.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3051
1134,Isolated arrhinia,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1134
1768,Familial caudal dysgenesis,0.0 (Worldwide); 4.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1768
2204,"Dysplastic cortical hyperostosis, Kozlowski-Tsuruta type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2204
2963,"Progeroid syndrome, Petty type",1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2963
2619,"Brachydactylous dwarfism, Mseleni type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2619
1541,"Craniosynostosis, Boston type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1541
1415,Hardikar syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1415
209335,Autosomal dominant adult-onset proximal spinal muscular atrophy,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209335
209341,DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy,0.0 (Worldwide); 37.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209341
3167,Siegler-Brewer-Carey syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3167
1277,Brachydactyly-mesomelia-intellectual disability-heart defects syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1277
2547,Microphthalmia-microtia-fetal akinesia syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2547
1778,Facial dysmorphism-shawl scrotum-joint laxity syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1778
3074,Intellectual disability-short stature-hypertelorism syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3074
210110,Intermediate osteopetrosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210110
3405,Umbilical cord ulceration-intestinal atresia syndrome,66.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3405
210115,Sterile multifocal osteomyelitis with periostitis and pustulosis,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210115
1884,Ectopia lentis-chorioretinal dystrophy-myopia syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1884
209981,IRIDA syndrome,75.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209981
209989,Non-papillary transitional cell carcinoma of the bladder,37.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209989
1459,Celiac disease-epilepsy-cerebral calcification syndrome,170.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1459
210133,Leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210133
210136,Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210136
2582,Myalgia-eosinophilia syndrome associated with tryptophan,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2582
210122,Congenital alveolar capillary dysplasia,1.2 (Canada); 40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210122
210128,Urocanic aciduria,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210128
2254,Pontocerebellar hypoplasia type 1,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2254
209959,Phacoanaphylactic uveitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209959
209964,Solitary rectal ulcer syndrome,1.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209964
209951,Autosomal spastic paraplegia type 18,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209951
209956,Idiopathic uveal effusion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209956
209973,Benign nocturnal alternating hemiplegia of childhood,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209973
209967,Episodic ataxia type 6,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209967
209970,Episodic ataxia type 7,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209970
2795,Fowler urethral sphincter dysfunction syndrome,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2795
209908,Isolated childhood apraxia of speech,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209908
209905,Brain-lung-thyroid syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209905
209902,Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209902
2666,Adult familial nephronophthisis-spastic quadriparesia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2666
209943,IRVAN syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209943
209932,Cone dystrophy with supernormal rod response,45.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209932
209919,Idiopathic copper-associated cirrhosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209919
209916,Extraskeletal myxoid chondrosarcoma,0.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209916
2519,Microcephaly-seizures-intellectual disability-heart disease syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2519
209370,Severe neonatal-onset encephalopathy with microcephaly,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209370
209867,Autosomal dominant rhegmatogenous retinal detachment,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209867
210571,Dystonia 16,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210571
3286,Catecholaminergic polymorphic ventricular tachycardia,10.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3286
210272,Mal de débarquement,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210272
210548,Macrocephaly-intellectual disability-autism syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210548
210159,Adult hepatocellular carcinoma,3.22 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210159
3283,His bundle tachycardia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3283
210163,"Congenital lethal myopathy, Compton-North type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210163
3240,Early-onset progressive leukoencephalopathy-central nervous system calcification-deafness-visual impairment syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3240
210141,Inherited congenital spastic tetraplegia,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210141
210144,"Lethal polymalformative syndrome, Boissel type",10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210144
1546,Cryptococcosis,11.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1546
67,Amoebiasis due to Entamoeba histolytica,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67
210584,Spindle cell hemangioma,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210584
2023,Undifferentiated pleomorphic sarcoma,0.9 (Europe); 0.9 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2023
416,Primary hyperoxaluria,0.2 (Germany); 0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=416
599,Distal myopathy,0.33 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599
3392,Tularemia,0.2 (Europe); 0.0 (United Kingdom); 0.0 (Netherlands); 4.0 (Sweden); 1.27 (Czech Republic); 9.1 (Finland); 0.1 (Austria); 0.005 (Belgium); 0.05 (Denmark); 0.3 (Croatia); 0.6 (Bulgaria); 0.075 (Estonia); 0.08 (France); 0.02 (Germany); 0.035 (Italy); 0.145 (Latvia); 0.07 (Lithuania); 0.01 (Poland); 0.01 (Romania); 0.01 (Slovenia); 0.25 (Switzerland); 0.75 (Spain); 1.83 (Norway); 2.0 (Europe); 0.5 (Hungary); 0.1 (Slovakia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3392
1063,Tufted angioma,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1063
2737,Onchocerciasis,0.0 (Specific population); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2737
211067,Episodic ataxia type 5,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=211067
3343,Toxocariasis,3.3 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3343
211062,Hereditary episodic ataxia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=211062
2034,Filariasis,0.0 (Europe); 0.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2034
2583,Mycetoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2583
1685,Distomatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1685
211017,Spinocerebellar ataxia type 30,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=211017
1902,Ehrlichiosis,50.0 (Worldwide); 0.25 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1902
656,Hereditary steroid-resistant nephrotic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=656
655,Nephronophthisis,1.25 (Finland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=655
2415,Rare lymphatic malformation,12.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2415
2122,Kaposiform hemangioendothelioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2122
2591,Infantile myofibromatosis,0.67 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2591
35,Propionic acidemia,"100.0 (Canada); 1.5 (Worldwide); 0.2 (Europe); 0.6 (Italy); 4.0 (Germany); 33.0 (Saudi Arabia); 5.7 (Japan); 1.23 (Korea, Republic of); 0.0278 (China)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35
407,Glycine encephalopathy,0.17 (Europe); 1.8 (Finland); 1.59 (Canada); 1.0 (Saudi Arabia); 2.0 (Portugal); 0.13 (Portugal); 3.8 (Israel); 8.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=407
2968,Leukocyte adhesion deficiency,350.0 (Worldwide); 0.0 (Latin America); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2968
663,Mitochondrial DNA-related progressive external ophthalmoplegia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=663
137,Congenital disorder of glycosylation,1.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=137
220,Denys-Drash syndrome,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,1.0 (Europe); 0.4 (Australia); 0.4 (United States); 0.5 (Germany); 2.0 (Sweden); 0.84 (Poland); 1.09 (Estonia); 0.0 (Worldwide); 8.0 (Europe); 0.5 (Israel); 0.3 (Specific population); 1.24 (Czech Republic),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=5
85,Congenital dyserythropoietic anemia,0.16 (Europe); 0.0 (Europe); 740.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85
25,Glutaryl-CoA dehydrogenase deficiency,333.0 (Specific population); 2.0 (Specific population); 1.0 (Worldwide); 2.85 (Spain); 0.48 (Japan); 0.76 (United States); 0.0 (Worldwide); 2.0 (Israel); 4.3 (Specific population); 0.56 (Czech Republic),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=25
177,Rhizomelic chondrodysplasia punctata,0.7 (Europe); 0.5 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=177
1246,Brachydactyly-nystagmus-cerebellar ataxia syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1246
618,Familial melanoma,1.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=618
359,Pediatric-onset glaucoma of genetic origin,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=359
213500,Ovarian cancer,49.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213500
818,Smith-Lemli-Opitz syndrome,"3.7 (Europe); 1.7 (United Kingdom); 5.85 (Slovakia); 2.6 (Canada); 2.65 (United States); 0.0 (Worldwide); 0.0 (Czech Republic); 1.4314 (Korea, Republic of)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=818
213512,Malignant mixed Müllerian tumor of the ovary,0.12 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213512
213504,Adenocarcinoma of ovary,5.97 (Europe); 5.635 (Austria); 6.773 (Belgium); 6.162 (Bulgaria); 6.103 (Croatia); 7.229 (Czech Republic); 6.881 (Estonia); 5.973 (Finland); 6.593 (Germany); 4.09 (Iceland); 5.079 (Ireland); 5.518 (Italy); 8.353 (Latvia); 7.79 (Lithuania); 5.653 (Malta); 7.116 (Norway); 5.698 (Poland); 2.834 (Portugal); 5.519 (Slovakia); 6.575 (Slovenia); 4.263 (Spain); 6.379 (Switzerland); 5.306 (Netherlands); 6.09 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213504
175,Cartilage-hair hypoplasia,150.0 (Specific population); 4.34 (Finland); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=175
209,Cutis laxa,0.1 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=209
42,Medium chain acyl-CoA dehydrogenase deficiency,"12.0 (Europe); 16.1 (Germany); 7.25 (United Kingdom); 8.5 (Portugal); 4.8 (Spain); 11.49 (Netherlands); 4.3 (Canada); 5.26 (Australia); 1.96 (Japan); 0.38 (Taiwan, Province of China); 11.1 (Denmark); 6.3 (Greece); 5.85 (United States); 6.85 (Worldwide); 4.02 (Austria); 4.35 (Italy); 1.0 (Israel); 0.5 (Specific population); 4.5 (Czech Republic)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=42
213557,Salivary gland type cancer of the breast,0.05 (Europe); 0.038 (Austria); 0.095 (Belgium); 0.024 (Bulgaria); 0.014 (Croatia); 0.068 (Czech Republic); 0.024 (Finland); 0.077 (Germany); 0.037 (Ireland); 0.075 (Italy); 0.043 (Latvia); 0.017 (Lithuania); 0.031 (Malta); 0.06 (Norway); 0.013 (Poland); 0.039 (Portugal); 0.019 (Slovakia); 0.044 (Slovenia); 0.054 (Spain); 0.09 (Switzerland); 0.064 (Netherlands); 0.053 (United Kingdom); 0.323 (Estonia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213557
2066,Gamma-aminobutyric acid transaminase deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2066
213531,Metaplastic carcinoma of the breast,0.06 (Europe); 0.081 (Austria); 0.027 (Bulgaria); 0.059 (Croatia); 0.074 (Estonia); 0.065 (Finland); 0.043 (Iceland); 0.096 (Ireland); 0.084 (Italy); 0.06 (Latvia); 0.031 (Malta); 0.045 (Poland); 0.082 (Portugal); 0.074 (Slovakia); 0.07 (United Kingdom); 0.226 (Belgium); 0.11 (Czech Republic); 0.136 (Germany); 0.108 (Lithuania); 0.104 (Norway); 0.163 (Slovenia); 0.128 (Spain); 0.135 (Switzerland); 0.238 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213531
213528,Rare adenocarcinoma of the breast,3.55 (Europe); 0.898 (Lithuania); 2.325 (Austria); 2.221 (Belgium); 2.397 (Bulgaria); 2.175 (Croatia); 2.717 (Czech Republic); 3.371 (Estonia); 2.615 (Finland); 3.812 (Germany); 2.428 (Iceland); 2.305 (Ireland); 4.103 (Italy); 1.191 (Latvia); 2.199 (Malta); 3.017 (Norway); 1.812 (Poland); 1.697 (Portugal); 2.171 (Slovakia); 2.315 (Slovenia); 2.142 (Spain); 3.187 (Switzerland); 3.264 (Netherlands); 3.638 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213528
3188,Congenital pulmonary veins atresia or stenosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3188
860,Congenitally uncorrected transposition of the great arteries,24.25 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=860
185,Scimitar syndrome,2.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=185
3189,Congenital pulmonary valvar stenosis,27.2 (France); 19.6 (Austria); 29.1 (Belgium); 14.6 (Croatia); 59.5 (Denmark); 63.6 (Germany); 63.1 (Hungary); 3.6 (Ireland); 26.1 (Italy); 48.2 (Malta); 6.3 (Netherlands); 35.3 (Norway); 11.4 (Poland); 23.7 (Portugal); 25.7 (Spain); 98.4 (Switzerland); 42.5 (United Kingdom); 19.4 (Ukraine); 0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3189
1464,Univentricular heart,7.5 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1464
3400,Aorto-ventricular tunnel,130.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3400
213716,Squamous cell carcinoma of the corpus uteri,0.12 (Europe); 0.039 (Belgium); 0.014 (Croatia); 0.012 (Finland); 0.044 (Germany); 0.083 (Ireland); 0.031 (Malta); 0.011 (Norway); 0.045 (Portugal); 0.034 (Slovakia); 0.019 (Slovenia); 0.039 (Spain); 0.056 (Switzerland); 0.018 (Netherlands); 0.041 (United Kingdom); 0.117 (Austria); 0.12 (Bulgaria); 0.177 (Czech Republic); 0.139 (Estonia); 0.113 (Italy); 0.173 (Latvia); 0.228 (Lithuania); 0.106 (Poland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213716
213746,Transitional cell carcinoma of the corpus uteri,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213746
1572,Common variable immunodeficiency,4.0 (Specific population); 2.3 (Netherlands); 0.98 (France); 0.66 (Spain); 0.87 (Netherlands); 0.6 (United Kingdom); 0.72 (Italy); 0.52 (Germany); 0.1 (Turkey); 0.073 (Poland); 0.77 (Australia); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1572
3261,Autoimmune lymphoproliferative syndrome,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3261
2849,Perlman syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2849
213772,Adenocarcinoma of the cervix uteri,1.01 (Europe); 0.762 (Austria); 0.966 (Belgium); 0.968 (Croatia); 0.85 (Estonia); 0.899 (Finland); 0.987 (Germany); 0.789 (Ireland); 0.734 (Italy); 0.774 (Latvia); 0.471 (Malta); 0.766 (Poland); 0.868 (Spain); 0.738 (Switzerland); 0.765 (Netherlands); 0.918 (United Kingdom); 1.108 (Bulgaria); 1.108 (Czech Republic); 1.065 (Iceland); 1.118 (Lithuania); 1.177 (Norway); 1.007 (Portugal); 1.048 (Slovakia); 1.12 (Slovenia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213772
213767,Squamous cell carcinoma of the cervix uteri,4.28 (Europe); 11.822 (Bulgaria); 10.336 (Estonia); 11.192 (Lithuania); 4.104 (Austria); 4.67 (Belgium); 5.539 (Croatia); 8.277 (Czech Republic); 1.885 (Finland); 4.871 (Germany); 3.707 (Iceland); 4.204 (Ireland); 3.307 (Italy); 7.362 (Latvia); 1.759 (Malta); 4.756 (Norway); 7.941 (Poland); 5.478 (Portugal); 8.555 (Slovakia); 7.507 (Slovenia); 2.867 (Spain); 2.657 (Switzerland); 3.063 (Netherlands); 3.312 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213767
213792,Adenosarcoma of the cervix uteri,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213792
213787,Carcinosarcoma of the cervix uteri,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213787
213812,Primitive neuroectodermal tumor of the cervix uteri,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213812
747,Autoimmune pulmonary alveolar proteinosis,0.165 (Japan); 2.66 (Japan); 2.66 (Worldwide); 0.687 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=747
213807,Leiomyosarcoma of the cervix uteri,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213807
2953,Musculocontractural Ehlers-Danlos syndrome,34.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2953
3082,Intellectual disability-polydactyly-uncombable hair syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3082
782,Axenfeld-Rieger syndrome,0.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=782
3269,Isolated radio-ulnar synostosis,350.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3269
3259,Syndactyly-polydactyly-ear lobe syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3259
3309,Tetrasomy 5p syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3309
216675,Transposition of the great arteries,31.7 (Europe); 50.0 (United States); 23.3 (Belgium); 59.5 (Denmark); 33.4 (France); 47.5 (Germany); 28.8 (Hungary); 18.1 (Ireland); 22.6 (Italy); 40.9 (Netherlands); 31.1 (Norway); 14.0 (Poland); 4.7 (Portugal); 15.7 (Spain); 37.7 (Switzerland); 33.9 (United Kingdom); 22.3 (Ukraine); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216675
216694,Congenitally corrected transposition of the great arteries,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216694
216718,Isolated congenitally uncorrected transposition of the great arteries,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216718
216729,Congenitally uncorrected transposition of the great arteries with cardiac malformation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216729
3411,Double uterus-hemivagina-renal agenesis syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3411
882,Tyrosinemia type 1,0.9 (Worldwide); 1.5 (Norway); 1.1 (Finland); 6.7 (Tunisia); 6.25 (Specific population); 54.0 (Specific population); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=882
216796,Osteogenesis imperfecta type 1,0.0 (Worldwide); 5.16 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216796
903,Von Willebrand disease,10.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=903
216804,Osteogenesis imperfecta type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216804
216812,Osteogenesis imperfecta type 3,0.0 (Worldwide); 0.89 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216812
216820,Osteogenesis imperfecta type 4,0.0 (Worldwide); 1.35 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216820
216828,Osteogenesis imperfecta type 5,47.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216828
3474,CHIME syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3474
1441,Ring chromosome 17 syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1441
216978,"Niemann-Pick disease type C, late infantile neurologic onset",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216978
361,Familial glucocorticoid deficiency,0.4953 (Ireland); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=361
216975,"Niemann-Pick disease type C, severe early infantile neurologic onset",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216975
1787,"Acrofacial dysostosis, Palagonia type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1787
216981,"Niemann-Pick disease type C, juvenile neurologic onset",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=216981
217008,Bockenheimer syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217008
217017,Zechi-Ceide syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217017
217012,Spinocerebellar ataxia type 31,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217012
2088,Fanconi-Bickel syndrome,200.0 (Worldwide); 0.0 (Worldwide); 0.3 (Israel); 0.5 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2088
217026,"Microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217026
217266,BNAR syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217266
179,Birdshot chorioretinopathy,0.35 (Worldwide); 0.14 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=179
217260,Progressive multifocal leukoencephalopathy,0.0 (Worldwide); 0.068 (Sweden); 0.11 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217260
292,Congenital enterovirus infection,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=292
217253,NMDA receptor encephalitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217253
767,Polyarteritis nodosa,3.16 (Europe); 3.1 (Sweden); 0.9 (United Kingdom); 3.07 (France); 0.11 (Australia); 0.62 (Spain); 3.3 (Norway); 0.05 (Norway); 0.04 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=767
2584,Classic mycosis fungoides,0.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2584
217093,"Mucopolysaccharidosis type 2, attenuated form",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217093
3162,Sézary syndrome,0.02 (United States); 0.012 (Norway); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3162
217085,"Mucopolysaccharidosis type 2, severe form",0.4 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217085
217080,Pulmonary fungal infections in patients deemed at risk,22.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217080
217074,Rare carcinoma of pancreas,11.79 (Europe); 8.3 (Europe); 15.5 (Europe); 3.9 (Worldwide); 3.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217074
2330,Kasabach-Merritt phenomenon,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2330
217071,Renal cell carcinoma,42.0 (Europe); 8.35 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217071
217067,Pouchitis,22.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217067
2700,Noma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2700
217064,5-fluorouracil poisoning,2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217064
1451,CINCA syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1451
217059,Isolated nail clubbing,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217059
217055,Autosomal recessive intermediate Charcot-Marie-Tooth disease type A,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217055
556,Malakoplakia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=556
217335,RIN2 syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217335
2745,Opitz GBBB syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2745
217340,17q21.31 microduplication syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217340
3260,Idiopathic hypereosinophilic syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3260
217330,REN-related autosomal dominant tubulointerstitial kidney disease,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217330
2086,Optic pathway glioma,0.12 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2086
2566,Chronic Epstein-Barr virus infection syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2566
3385,African trypanosomiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3385
1560,Cysticercosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1560
566,Congenital microcoria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=566
341,Viral hemorrhagic fever,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=341
340,Hemorrhagic fever-renal syndrome,0.74 (Europe); 37.0 (Europe); 0.92 (Austria); 0.78 (Belgium); 0.06 (Bulgaria); 2.2 (Croatia); 0.08 (Czech Republic); 1.36 (Estonia); 29.16 (Finland); 0.18 (France); 1.16 (Germany); 0.08 (Hungary); 0.3 (Latvia); 1.44 (Luxembourg); 0.02 (Poland); 0.02 (Romania); 0.24 (Slovakia); 2.32 (Slovenia); 2.52 (Sweden); 0.5 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=340
2552,Microsporidiosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2552
1171,Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1171
217560,Neuroendocrine cell hyperplasia of infancy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217560
217557,Pulmonary interstitial glycogenosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217557
1686,Cardiac diverticulum,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1686
217563,Neonatal acute respiratory distress syndrome,0.0 (Worldwide); 0.067 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217563
217407,Hereditary hypotrichosis with recurrent skin vesicles,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217407
1456,Middle aortic syndrome,0.17 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1456
1457,Aorta coarctation,35.6 (Europe); 78.5 (Austria); 43.7 (Belgium); 22.7 (Croatia); 21.3 (Denmark); 27.5 (France); 59.4 (Germany); 31.0 (Hungary); 32.5 (Ireland); 39.6 (Italy); 24.9 (Malta); 11.7 (Netherlands); 21.3 (Norway); 8.0 (Poland); 9.5 (Portugal); 16.9 (Spain); 25.1 (Switzerland); 40.1 (United Kingdom); 38.1 (Ukraine); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1457
217390,Combined immunodeficiency due to DOCK8 deficiency,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217390
1132,Aortic arch defects,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1132
217385,17p13.3 microduplication syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217385
217399,Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217399
217396,Progressive polyneuropathy with bilateral striatal necrosis,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217396
982,Pulmonary valve agenesis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=982
217371,Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217371
217346,19q13.11 microdeletion syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217346
980,Absence of the pulmonary artery,0.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=980
217382,Neurodegenerative syndrome due to cerebral folate transport deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217382
1054,Aneurysm of sinus of Valsalva,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1054
217377,Microduplication Xp11.22p11.23 syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217377
217622,Sensorineural deafness with dilated cardiomyopathy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217622
3092,Fixed subaortic stenosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3092
2299,Aortic arch interruption,0.3 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2299
3427,Double outlet left ventricle,0.5 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3427
3426,Double outlet right ventricle,10.0 (Germany); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3426
439,Isolated right ventricular hypoplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439
422,Idiopathic/heritable pulmonary arterial hypertension,0.11 (United States); 0.65 (France); 0.1 (France); 1.4 (Czech Republic); 0.62 (Czech Republic); 1.0 (Europe); 6.25 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=422
2038,Pulmonary arteriovenous malformation,2.5 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2038
2041,Coronary arterial fistula,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2041
282,Frontotemporal dementia,3.0 (Europe); 3.05 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=282
331,Congenital factor XIII deficiency,0.04 (Europe); 0.05 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=331
159,Carnitine-acylcarnitine translocase deficiency,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=159
542,Primary cutaneous lymphoma,0.75 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542
707,Plague,0.0 (Worldwide); 2.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=707
335,Congenital fibrinogen deficiency,0.15 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=335
79,Congenital alpha2-antiplasmin deficiency,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79
217656,Inherited isolated arrhythmogenic cardiomyopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=217656
1070,Anisakiasis,1.6 (Japan); 0.32 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1070
1467,Cogan syndrome,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1467
2157,Histidinemia,2.7 (Sweden); 0.0 (Europe); 8.3 (United States); 11.9 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2157
3124,Saccharopinuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3124
220407,Limited systemic sclerosis,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220407
220386,Semilobar holoprosencephaly,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220386
2203,Hyperlysinemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2203
220393,Diffuse cutaneous systemic sclerosis,"3.8 (Taiwan, Province of China); 1.5 (Taiwan, Province of China)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220393
332,Congenital intrinsic factor deficiency,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=332
220448,Macrothrombocytopenia with mitral valve insufficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220448
220436,Quebec platelet disorder,0.45 (Specific population); 0.15 (Canada),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220436
2195,Dicarboxylic aminoaciduria,0.0 (Specific population); 2.76 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2195
2170,Methylcobalamin deficiency type cblG,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2170
220295,Xeroderma pigmentosum-Cockayne syndrome complex,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220295
414,Gyrate atrophy of choroid and retina,2.0 (Finland); 200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=414
622,Homocystinuria without methylmalonic aciduria,73.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=622
927,Hyperammonemia due to N-acetylglutamate synthase deficiency,0.0 (Europe); 99.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=927
2880,Phosphoenolpyruvate carboxykinase deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2880
941,D-glyceric aciduria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=941
220465,Laron syndrome with immunodeficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220465
220489,Rare hereditary hemochromatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220489
19,2-hydroxyglutaric aciduria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=19
2843,Pentosuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2843
220497,Joubert syndrome with renal defect,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220497
212,Cystathioninuria,7.1 (Canada); 7.1 (Canada); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=212
220493,Joubert syndrome with ocular defect,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=220493
470,Lysinuric protein intolerance,0.0 (Europe); 1.7 (Italy); 1.7 (Finland); 1.75 (Japan); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=470
221074,Marchiafava-Bignami disease,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221074
145,Hereditary breast and/or ovarian cancer syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=145
2965,Prolactinoma,44.4 (United Kingdom); 62.0 (Belgium); 45.7 (Switzerland); 2.05 (Malta); 50.7 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2965
221091,Trigeminal neuralgia,0.0 (Worldwide); 4.3 (United States); 8.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221091
538,Lymphangioleiomyomatosis,0.0135 (Worldwide); 0.15 (Worldwide); 0.015 (United States); 0.17 (United States); 0.01 (France); 0.19 (Germany); 0.21 (Canada); 0.25 (United Kingdom); 0.32 (Switzerland); 0.39 (New Zealand); 0.26 (Australia); 0.25 (Europe); 0.25 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538
221098,Glossopharyngeal neuralgia,0.0 (Worldwide); 0.7 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221098
2942,Postpoliomyelitis syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2942
1578,Pterin-4 alpha-carbinolamine dehydratase deficiency,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1578
3208,Isolated succinate-CoQ reductase deficiency,37.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3208
221008,Rothmund-Thomson syndrome type 1,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221008
24,Fumaric aciduria,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=24
221016,Rothmund-Thomson syndrome type 2,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221016
221039,"Hereditary sclerosing poikiloderma, Weary type",0.0 (Worldwide); 9.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221039
851,Paris-Trousseau thrombocytopenia,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=851
221043,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221043
221046,Poikiloderma with neutropenia,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221046
745,Severe hereditary thrombophilia due to congenital protein C deficiency,0.16 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=745
221054,Acrocephalopolydactyly,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221054
221061,Familial cerebral cavernous malformation,15.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221061
849,Glanzmann thrombasthenia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=849
225154,Familial infantile bilateral striatal necrosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=225154
225123,TFR2-related hemochromatosis,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=225123
225147,Sporadic infantile bilateral striatal necrosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=225147
223727,Bone sarcoma,0.8 (Europe); 9.29 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=223727
221120,Pseudoaminopterin syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221120
221126,Fowler vasculopathy,44.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221126
221139,Combined immunodeficiency with facio-oculo-skeletal anomalies,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221139
221142,Confetti-like macular atrophy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221142
221145,"Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies",21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=221145
228003,Severe combined immunodeficiency due to CORO1A deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228003
3398,Thymic epithelial neoplasm,0.17 (Europe); 1.3 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3398
228000,Idiopathic CD4 lymphocytopenia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228000
547,Non-Hodgkin lymphoma,0.0 (Europe); 11.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=547
842,Testicular seminomatous germ cell tumor,1.71 (Europe); 46.01 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=842
227976,"Autosomal recessive optic atrophy, OPA7 type",0.0 (Worldwide); 17.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=227976
876,Yolk sac tumor,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=876
227972,Toxic oil syndrome,0.0 (Worldwide); 20000.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=227972
227796,Fundus albipunctatus,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=227796
228123,Coccidioidomycosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228123
228119,Fusariosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228119
228116,Hughes-Stovin syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228116
228113,Anal fistula,18.3 (Europe); 18.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228113
3399,Germ cell tumor,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3399
389,Langerhans cell histiocytosis,1.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=389
228012,Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228012
616,Medulloblastoma,0.11 (Europe); 1.0 (Europe); 0.74 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=616
301,Ependymal tumor,0.2 (Europe); 0.0 (Europe); 3.85 (Europe); 0.2 (United Kingdom); 0.43 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=301
541,Primary cutaneous CD30+ T-cell lymphoproliferative disease,0.18 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=541
543,Burkitt lymphoma,0.17 (Europe); 12.5 (Africa); 0.4 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=543
319,Skeletal Ewing sarcoma,0.13 (Europe); 2.33 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319
668,Osteosarcoma,0.23 (Europe); 0.0 (Europe); 3.17 (Europe); 0.4 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=668
227510,"Multiple system atrophy, cerebellar type",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=227510
94,Astrocytoma,4.8 (Europe); 2.5 (Europe); 4.909 (Austria); 5.777 (Belgium); 3.768 (Bulgaria); 4.184 (Croatia); 4.251 (Czech Republic); 4.443 (Estonia); 5.263 (Finland); 5.829 (Germany); 5.538 (Iceland); 5.147 (Ireland); 4.786 (Italy); 3.632 (Latvia); 4.801 (Lithuania); 3.392 (Malta); 5.78 (Norway); 3.543 (Poland); 3.931 (Portugal); 3.707 (Slovakia); 4.523 (Slovenia); 5.087 (Spain); 5.574 (Switzerland); 4.544 (Netherlands); 5.591 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94
360,Glioblastoma,3.0 (Worldwide); 1.0 (Worldwide); 2.52 (Europe); 3.2 (United States); 4.2 (Croatia); 3.7 (Greece); 3.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=360
226292,Permanent congenital hypothyroidism,33.3 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=226292
513,Acute lymphoblastic leukemia,2.75 (Europe); 1.3 (France); 1.6 (United States); 22.0 (United States); 11.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=513
1957,Esthesioneuroblastoma,0.02 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1957
226298,Central congenital hypothyroidism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=226298
2030,Fibrosarcoma,0.01 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2030
2126,Solitary fibrous tumor,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2126
226295,Primary congenital hypothyroidism,37.5 (Europe); 58.62 (United States); 33.0 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=226295
758,Pseudoxanthoma elasticum,2.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=758
419,Hyperprolinemia type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=419
1501,Adrenocortical carcinoma,0.75 (Europe); 0.03 (Europe); 0.082 (Portugal); 0.173 (Austria); 0.18 (Belgium); 0.249 (Bulgaria); 0.547 (Croatia); 0.271 (Czech Republic); 0.314 (Estonia); 0.225 (Finland); 0.173 (Germany); 0.17 (Iceland); 0.133 (Ireland); 0.288 (Italy); 0.514 (Latvia); 0.464 (Lithuania); 0.188 (Malta); 0.226 (Norway); 0.433 (Poland); 0.234 (Slovakia); 0.244 (Slovenia); 0.215 (Spain); 0.141 (Switzerland); 0.167 (Netherlands); 0.183 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1501
226307,Hypothyroidism due to deficient transcription factors involved in pituitary development or function,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=226307
3148,Malignant peripheral nerve sheath tumor,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3148
3273,Synovial sarcoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3273
391,Classic Hodgkin lymphoma,2.463 (Europe); 2.95 (France); 0.0 (Europe); 22.9 (Europe); 2.8 (United States); 0.25 (China); 0.25 (Japan); 2.012 (Austria); 2.443 (Belgium); 2.083 (Bulgaria); 2.923 (Croatia); 2.418 (Czech Republic); 2.392 (Estonia); 2.232 (Finland); 2.333 (Germany); 2.599 (Iceland); 2.355 (Ireland); 3.361 (Italy); 1.868 (Latvia); 2.372 (Lithuania); 2.701 (Malta); 2.267 (Norway); 2.2 (Poland); 2.435 (Portugal); 2.261 (Slovakia); 2.265 (Slovenia); 2.617 (Spain); 3.091 (Switzerland); 2.27 (Netherlands); 2.504 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391
2260,Oligomeganephronia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2260
503,Larsen syndrome,0.65 (France); 0.0 (France); 0.4 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=503
1652,Dent disease,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1652
2542,Isolated microphthalmia-anophthalmia-coloboma,2.18 (France); 3.33 (Sweden); 3.7 (United States); 0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2542
3280,Syringomyelia,8.4 (Europe); 8.4 (United Kingdom); 9.0 (Spain); 1.94 (Japan); 8.2 (New Zealand),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3280
2478,Megalencephalic leukoencephalopathy with subcortical cysts,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2478
3337,Primary Fanconi renotubular syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3337
223,Arginine vasopressin resistance,0.15 (Europe); 0.44 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=223
757,Pseudohypoaldosteronism type 2,180.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=757
228423,GATA2 deficiency spectrum,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228423
521,Chronic myeloid leukemia,1.25 (Europe); 1.25 (France); 6.0 (Europe); 5.63 (Europe); 1.7 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521
228415,5q35 microduplication syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228415
132,Hereditary butyrylcholinesterase deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=132
1172,Autosomal recessive cerebellar ataxia,3.3 (Portugal); 3.3 (Worldwide); 5.3 (France); 2.3 (Norway); 3.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1172
229717,Isolated agammaglobulinemia,0.3 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=229717
228426,Syndromic multisystem autoimmune disease due to Itch deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228426
2345,Isolated Klippel-Feil syndrome,2.0 (Europe); 0.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2345
1333,Familial pancreatic carcinoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1333
228396,Ptosis-upper ocular movement limitation-absence of lacrimal punctum syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228396
228387,Spondylo-megaepiphyseal-metaphyseal dysplasia,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228387
228390,Frontonasal dysplasia-alopecia-genital anomalies syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228390
228410,Cardiac anomalies-short stature-joint hypermobility-facial dysmorphism syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228410
228399,8q12 microduplication syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228399
2781,Osteopetrosis and related disorders,1.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2781
228402,2q23.1 microdeletion syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228402
228384,5q14.3 microdeletion syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228384
228379,Virus-associated trichodysplasia spinulosa,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228379
228374,Charcot-Marie-Tooth disease type 2B5,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228374
228371,Foodborne botulism,0.1 (Europe); 0.0 (Worldwide); 0.01 (United States); 0.18 (Romania),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228371
228290,White fibrous papulosis of the neck,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228290
228293,Pseudoxanthoma elasticum-like papillary dermal elastolysis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228293
228299,Mid-dermal elastolysis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228299
228302,"Carnitine palmitoyl transferase II deficiency, myopathic form",300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228302
228305,"Carnitine palmitoyl transferase II deficiency, severe infantile form",30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228305
228308,"Carnitine palmitoyl transferase II deficiency, neonatal form",20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228308
228312,"Autoimmune hemolytic anemia, cold type",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228312
228240,Elastoderma,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228240
135,CACH syndrome,148.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=135
228247,Acquired pseudoxanthoma elasticum,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228247
228254,Elastoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228254
228264,Papular elastorrhexis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228264
228272,Primary anetoderma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228272
228277,Familial anetoderma,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228277
228285,Acquired cutis laxa,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228285
228190,Patent ductus arteriosus-bicuspid aortic valve-hand anomalies syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228190
3203,Overhydrated hereditary stomatocytosis,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3203
3202,Dehydrated hereditary stomatocytosis,0.0 (Worldwide); 20.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3202
228236,Linear focal elastosis,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228236
228227,Late-onset focal dermal elastosis,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228227
228140,"Idiopathic ventricular fibrillation, non Brugada type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228140
1018,X-linked Alport syndrome-diffuse leiomyomatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1018
228165,Baló concentric sclerosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228165
306,Self-limited infantile epilepsy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306
228157,Marburg acute multiple sclerosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228157
328,Congenital factor X deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=328
228174,Autosomal dominant Charcot-Marie-Tooth disease type 2N,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228174
228169,Autosomal dominant striatal neurodegeneration,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228169
2132,Hemoglobin C disease,166.66 (United States); 3.65 (Belgium),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2132
2133,Hemoglobin E disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2133
228179,Autosomal dominant Charcot-Marie-Tooth disease type 2M,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228179
288,Hereditary elliptocytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=288
231531,Hermansky-Pudlak syndrome due to BLOC-1 deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231531
231512,Hermansky-Pudlak syndrome due to BLOC-2 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231512
1320,Idiopathic camptocormia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1320
256,Early-onset generalized limb-onset dystonia,20.0 (Specific population); 0.2 (United States); 0.4 (Europe); 3.4 (United States); 8.3 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=256
231500,Hermansky-Pudlak syndrome due to BLOC-3 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231500
441,Pure autonomic failure,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=441
1576,Infantile bilateral striatal necrosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1576
231445,Paraparetic variant of Guillain-Barré syndrome,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231445
2073,Narcolepsy type 1,30.0 (Europe); 0.74 (United States); 22.0 (Norway); 26.0 (Finland); 34.0 (China); 28.9 (United States); 40.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2073
231401,Alpha-thalassemia-myelodysplastic syndrome,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231401
1866,"Focal, segmental or multifocal dystonia",2.0 (Europe); 11.7 (Europe); 11.2 (Serbia); 31.2 (Iceland); 29.5 (United States); 13.7 (Japan); 10.0 (Egypt); 14.3 (Thailand),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1866
231393,Beta-thalassemia-X-linked thrombocytopenia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231393
809,Mixed connective tissue disease,0.17 (Norway); 3.0 (Norway); 2.7 (Japan); 0.0 (Europe); 1.9 (United States); 0.8 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=809
1309,Medullary sponge kidney,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1309
231249,Hemoglobin E-beta-thalassemia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231249
231242,Hemoglobin C-beta-thalassemia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231242
2197,Idiopathic hypercalciuria,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2197
231237,Delta-beta-thalassemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231237
231226,Dominant beta-thalassemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231226
18,Distal renal tubular acidosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=18
231222,Beta-thalassemia intermedia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231222
160,Castleman disease,0.0 (Worldwide); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=160
231214,Beta-thalassemia major,0.0 (Worldwide); 0.7 (United States); 160.0 (Bahrain); 40.0 (Oman),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231214
2841,Hailey-Hailey disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2841
231183,Usher syndrome type 3,0.1 (Denmark); 0.0 (Europe); 1.2 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231183
347,Frasier syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=347
231178,Usher syndrome type 2,2.2 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231178
1670,Chronic diarrhea with villous atrophy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1670
231154,Combined immunodeficiency due to partial RAG1 deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231154
231160,Familial cerebral saccular aneurysm,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231160
231169,Usher syndrome type 1,1.5 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231169
231147,Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231147
231080,High-grade dysplasia in patients with Barrett esophagus,36.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231080
231108,Rhabdoid tumor predisposition syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231108
405,Familial hypocalciuric hypercalcemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=405
231111,Drug-induced lupus erythematosus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231111
1223,Balantidiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1223
231040,Familial generalized lentiginosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231040
3318,Essential thrombocythemia,24.0 (United States); 1.55 (Sweden); 30.0 (Sweden); 0.0 (Europe); 0.48 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3318
230857,Ehlers-Danlos/osteogenesis imperfecta syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=230857
230851,Cardiac-valvular Ehlers-Danlos syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=230851
231031,Erythema palmare hereditarium,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231031
913,Zollinger-Ellison syndrome,0.15 (Europe); 0.0 (Europe); 0.15 (Denmark); 0.3 (Switzerland); 0.05 (Ireland); 0.125 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=913
231013,Congenital trigeminal anesthesia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231013
230800,Toxin-mediated infectious botulism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=230800
82,Hereditary thrombophilia due to congenital antithrombin deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=82
230839,Classical-like Ehlers-Danlos syndrome type 1,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=230839
519,Acute myeloid leukemia,2.5 (Worldwide); 10.0 (Europe); 3.39 (Europe); 10.98 (Europe); 4.4 (France); 2.8 (Denmark); 3.7 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=519
235936,Familial hyperaldosteronism,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=235936
238446,15q11q13 microduplication syndrome,0.0 (Worldwide); 30.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238446
238329,Severe X-linked mitochondrial encephalomyopathy,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238329
231573,Congenital erosive and vesicular dermatosis,31.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231573
231580,Primary unilateral adrenal hyperplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231580
231556,Late-onset localized junctional epidermolysis bullosa-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231556
231568,Autosomal dominant generalized dystrophic epidermolysis bullosa,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231568
231637,Rare surgically correctable form of primary aldosteronism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231637
231625,Adrenocortical carcinoma with pure aldosterone hypersecretion,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231625
1900,Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1900
286,Vascular Ehlers-Danlos syndrome,1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=286
285,Hypermobile Ehlers-Danlos syndrome,12.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=285
231736,Microcornea-posterior megalolenticonus-persistent fetal vasculature-coloboma syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231736
231742,Epibulbar lipodermoid-preauricular appendage-polythelia syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231742
257,Epidermolysis bullosa simplex with muscular dystrophy,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=257
1901,Dermatosparaxis Ehlers-Danlos syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1901
231720,Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231720
1899,Arthrochalasia Ehlers-Danlos syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1899
839,"Congenital nephrotic syndrome, Finnish type",0.0 (Worldwide); 12.2 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=839
531,Miller-Dieker syndrome,1.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=531
3394,Soft tissue sarcoma,3.6 (France); 30.0 (Europe); 4.74 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3394
1084,Isolated lissencephaly type 1 without known genetic defects,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1084
1083,Microlissencephaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1083
452,X-linked lissencephaly with abnormal genitalia,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=452
238750,4q21 microdeletion syndrome,0.0 (Worldwide); 14.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238750
238763,Glaucoma secondary to spherophakia/ectopia lentis and megalocornea,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238763
238722,Familial congenital mirror movements,75.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238722
238744,Mammary-digital-nail syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238744
238769,1q44 microdeletion syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238769
238517,Hypotonia-cystinuria type 1 syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238517
238505,Combined immunodeficiency due to CD27 deficiency,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238505
238468,Hypohidrotic ectodermal dysplasia,6.7 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238468
238475,Familial hypercholanemia,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238475
238455,Infantile dystonia-parkinsonism,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238455
238459,SLC35A1-CDG,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238459
238578,Familial clubfoot due to 17q23.1q23.2 microduplication,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238578
238583,Hyperphenylalaninemia due to tetrahydrobiopterin deficiency,0.22 (Japan); 0.2 (Worldwide); 0.21 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238583
238557,Chuvash erythrocytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238557
238569,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections syndrome,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238569
238547,Acquired secondary polycythemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238547
238523,Atypical hypotonia-cystinuria syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238523
238536,Congenital secondary polycythemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238536
238624,Idiopathic intracranial hypertension,14.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238624
238621,Ileal pouch anal anastomosis related faecal incontinence,3.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238621
238606,Primary orthostatic tremor,390.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238606
238593,IgG4-related mesenteritis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238593
238670,Isolated thyrotropin-releasing hormone deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238670
238666,Isolated congenital hypogonadotropic hypogonadism,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238666
238654,"Congenital primary megaureter, nonrefluxing and unobstructed form",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238654
238650,"Congenital primary megaureter, refluxing form",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238650
238646,"Congenital primary megaureter, obstructed form",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238646
238642,"Primary megaureter, adult-onset form",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=238642
240071,Classic progressive supranuclear palsy syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=240071
240112,Progressive supranuclear palsy-progressive non-fluent aphasia syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=240112
240103,Progressive supranuclear palsy-corticobasal syndrome,0.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=240103
240094,Progressive supranuclear palsy-pure akinesia with gait freezing syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=240094
240085,Progressive supranuclear palsy-predominant parkinsonism syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=240085
240760,Nijmegen breakage syndrome-like disorder,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=240760
331226,Susceptibility to infection due to TYK2 deficiency,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=331226
331235,Selective IgM deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=331235
331176,Severe congenital neutropenia due to G6PC3 deficiency,57.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=331176
331187,Immunodeficiency due to MASP-2 deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=331187
331190,Immunodeficiency due to ficolin3 deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=331190
331206,Severe combined immunodeficiency due to complete RAG1/2 deficiency,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=331206
330064,Chronic actinic dermatitis,16.7 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330064
330001,Wild type ATTR amyloidosis,1.72 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330001
329977,Classic neuroendocrine tumor of appendix,0.25 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329977
329984,Goblet cell carcinoma,0.025 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329984
330012,High altitude pulmonary edema,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330012
330015,Lead poisoning,2.3 (Europe); 0.68 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330015
330032,Hemoglobin Lepore-beta-thalassemia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330032
330041,Hemoglobin M disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330041
330021,Mercury poisoning,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330021
330029,Hypotrichosis-deafness syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330029
330058,Hydroa vacciniforme,0.34 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330058
330061,Actinic prurigo,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330061
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330050
330054,Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=330054
329813,Mosaic genome-wide paternal uniparental disomy syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329813
329802,5p13 microduplication syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329802
329883,Non-hypoproteinemic hypertrophic gastropathy,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329883
329874,Idiopathic giant cell myocarditis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329874
329475,Spastic paraplegia-Paget disease of bone syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329475
329481,Lipoprotein glomerulopathy,0.0 (Worldwide); 150.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329481
329478,Adult-onset distal myopathy due to VCP mutation,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329478
329942,Transient neonatal multiple acyl-CoA dehydrogenase deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329942
329971,Generalized juvenile polyposis/juvenile polyposis coli,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329971
329967,Intermittent hydrarthrosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329967
329918,C3 glomerulopathy,0.15 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329918
329903,Immunoglobulin-mediated membranoproliferative glomerulonephritis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329903
329308,Fatty acid hydroxylase-associated neurodegeneration,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329308
329314,Adult-onset multiple mitochondrial DNA deletion syndrome due to DGUOK deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329314
329319,Thrombocythemia with distal limb defects,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329319
329324,Inverse Klippel-Trénaunay syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329324
329284,Beta-propeller protein-associated neurodegeneration,68.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329284
329457,Distal arthrogryposis type 5D,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329457
329466,"Autosomal dominant focal dystonia, DYT25 type",28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329466
329469,Acute megakaryoblastic leukemia in children without Down syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329469
329329,Autosomal recessive frontotemporal pachygyria,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329329
329332,Microcephaly-cerebellar hypoplasia-cardiac conduction defect syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329332
329336,Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329336
329228,Microcephalic primordial dwarfism due to ZNF335 deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329228
329224,Schuurs-Hoeijmakers syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329224
329217,Cerebral sinovenous thrombosis,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329217
329211,Autosomal dominant neovascular inflammatory vitreoretinopathy,99.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329211
329195,Developmental delay with autism spectrum disorder and gait instability,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329195
329191,Tall stature-long halluces-multiple extra-epiphyses syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329191
329178,Congenital muscular dystrophy with intellectual disability and severe epilepsy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329178
329258,Autosomal dominant Charcot-Marie-Tooth disease type 2Q,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329258
329249,Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329249
329242,Congenital chronic diarrhea with protein-losing enteropathy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329242
329235,X-linked central congenital hypothyroidism with late-onset testicular enlargement,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329235
329173,Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329173
329,Congenital factor XI deficiency,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329
1243,Best vitelliform macular dystrophy,1.5 (Denmark); 20.0 (Sweden); 0.0 (Worldwide); 1.5 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1243
324964,Chronic nonbacterial osteomyelitis/Chronic recurrent multifocal osteomyelitis,0.3 (Worldwide); 2.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324964
324972,MAGIC syndrome,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324972
324977,Proteasome-associated autoinflammatory syndrome,0.0 (Worldwide); 40.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324977
324718,ABetaA21G amyloidosis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324718
324713,"ABeta amyloidosis, Italian type",7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324713
324737,SRD5A3-CDG,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324737
324723,"ABeta amyloidosis, Arctic type",1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324723
324648,Invasive non-typhoidal salmonellosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324648
324636,Autoerythrocyte sensitization syndrome,170.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324636
324708,"ABeta amyloidosis, Iowa type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324708
324703,ABetaL34V amyloidosis,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324703
324611,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to KIF5A mutation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324611
324632,Hendra virus infection,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324632
324625,Chikungunya,0.02 (France); 0.0 (Worldwide); 0.12 (Europe); 0.32 (Belgium); 0.06 (Finland); 0.13 (Germany); 0.3 (Italy); 0.02 (Latvia); 0.35 (Spain); 0.16 (Sweden); 0.24 (United Kingdom); 0.4 (Malta); 0.02 (Slovenia); 0.0 (Greece); 0.0 (Hungary); 0.0 (Ireland); 0.0 (Portugal),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324625
324588,Familial dyskinesia and facial myokymia,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324588
324601,X-linked cleft palate and ankyloglossia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324601
324581,Benign Samaritan congenital myopathy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324581
324585,Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324585
324569,Pontocerebellar hypoplasia type 8,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324569
324575,Hyperinsulinism due to HNF1A deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324575
324540,Aphonia-deafness-retinal dystrophy-bifid halluces-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324540
324561,Hypopigmentation-punctate palmoplantar keratoderma syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324561
324530,Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324530
324535,Combined oxidative phosphorylation defect type 11,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324535
324525,Hypertrophic cardiomyopathy with kidney anomalies due to mitochondrial DNA mutation,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324525
324442,Autosomal recessive axonal neuropathy with neuromyotonia,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324442
324416,Muscular hypertrophy-hepatomegaly-polyhydramnios syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324416
324422,ALG13-CDG,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324422
324410,X-linked intellectual disability-cardiomegaly-congestive heart failure syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324410
324381,Hereditary inclusion body myopathy type 4,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324381
324364,Mixed sclerosing bone dystrophy with extra-skeletal manifestations,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324364
324353,Congenital achiasma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324353
324321,Sinoatrial node dysfunction and deafness,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324321
324313,9p13 microdeletion syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324313
324307,Severe lateral tibial bowing-short stature-mild winged scapula-mild facial dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324307
324299,Multiple paragangliomas associated with polycythemia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324299
324294,T-cell immunodeficiency with epidermodysplasia verruciformis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324294
324290,Early-onset Lafora body disease,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324290
324262,Autosomal recessive congenital cerebellar ataxia due to MGLUR1 deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=324262
320360,MT-ATP6-related mitochondrial spastic paraplegia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320360
320355,Autosomal dominant spastic paraplegia type 41,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320355
320370,Autosomal recessive spastic paraplegia type 43,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320370
320365,Autosomal dominant spastic paraplegia type 36,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320365
320380,Autosomal recessive spastic paraplegia type 54,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320380
320375,Autosomal recessive spastic paraplegia type 55,0.0 (Worldwide); 14.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320375
320391,Autosomal recessive spastic paraplegia type 46,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320391
320385,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320385
320401,Autosomal recessive spastic paraplegia type 44,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320401
320396,Autosomal recessive spastic paraplegia type 45,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320396
320411,Autosomal recessive spastic paraplegia type 56,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320411
320406,Spastic paraplegia-optic atrophy-neuropathy syndrome,75.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320406
319543,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to a partial deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319543
319547,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319547
319535,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a complete deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319535
319539,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319539
319519,Combined oxidative phosphorylation defect type 14,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319519
319524,Combined oxidative phosphorylation defect type 15,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319524
319509,Combined oxidative phosphorylation defect type 9,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319509
319514,Combined oxidative phosphorylation defect type 13,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319514
319589,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319589
319595,Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319595
319574,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319574
319581,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,68.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319581
319563,Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319563
319569,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319569
319552,Mendelian susceptibility to mycobacterial diseases due to complete IL12RB1 deficiency,180.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319552
319558,Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency,49.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319558
319651,Constitutional megaloblastic anemia with severe neurologic disease,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319651
319646,PGM1-CDG,46.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319646
319640,Retinal macular dystrophy type 2,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319640
319635,Amyloidosis cutis dyschromia,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319635
319623,X-linked mendelian susceptibility to mycobacterial diseases due to CYBB deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319623
319612,X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319612
319605,X-linked mendelian susceptibility to mycobacterial diseases,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319605
319600,Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319600
319678,Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319678
319675,"Microcephalic primordial dwarfism, Dauber type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319675
319671,Alazami syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319671
319276,Clear cell renal carcinoma,1.99 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319276
319251,Rift valley fever,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319251
319319,Renal medullary carcinoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319319
319298,Papillary renal cell carcinoma,0.14 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319298
319303,Chromophobe renal cell carcinoma,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319303
319332,Autosomal recessive myogenic arthrogryposis multiplex congenita,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319332
319340,Carney complex-trismus-pseudocamptodactyly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319340
319504,Combined oxidative phosphorylation defect type 8,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319504
319195,Chondroectodermal dysplasia with night blindness,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319195
319199,Autosomal recessive spastic paraplegia type 53,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319199
319218,Ebola hemorrhagic fever,28220.0 (Worldwide); 0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319218
319160,Congenital myopathy with internal nuclei and atypical cores,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319160
319171,Distal 17p13.1 microdeletion syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319171
319189,Familial cortical myoclonus,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319189
319182,Wiedemann-Steiner syndrome,84.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=319182
317428,Combined immunodeficiency due to ORAI1 deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=317428
317425,Severe combined immunodeficiency due to DNA-PKcs deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=317425
317430,Combined immunodeficiency due to STIM1 deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=317430
317473,Pancytopenia due to IKZF1 mutations,39.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=317473
317476,XMEN,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=317476
315311,"Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form",2.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=315311
315306,"Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form",7.5 (Europe); 7.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=315306
314993,Cataract-congenital heart disease-neural tube defect syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314993
314978,X-linked non progressive cerebellar ataxia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314978
314970,Lymphocytic hypereosinophilic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314970
314962,Secondary hypereosinophilic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314962
314950,Primary hypereosinophilic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314950
314918,Mild Canavan disease,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314918
314911,Severe Canavan disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314911
314701,Primary systemic amyloidosis,30.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314701
314679,Cerebrofacioarticular syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314679
314667,TMEM165-CDG,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314667
314689,Combined immunodeficiency due to STK4 deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314689
314684,Primary bone lymphoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314684
314652,Variant ABeta2M amyloidosis,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314652
314647,Non-progressive cerebellar ataxia with intellectual disability,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314647
314662,Segmental progressive overgrowth syndrome with fibroadipose hyperplasia,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314662
314655,Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314655
314621,Duplication of the pituitary gland,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314621
314637,Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314637
314632,CLN12 disease,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314632
314802,Short stature due to partial GHR deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314802
314811,Short stature due to GHSR deficiency,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314811
314889,Autosomal dominant proximal renal tubular acidosis,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314889
314777,Familial isolated pituitary adenoma,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314777
314795,SHOX-related short stature,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314795
314718,Lethal arteriopathy syndrome due to fibulin-4 deficiency,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314718
314721,Atypical dentin dysplasia due to SMOC2 deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314721
370127,Medich giant platelet syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370127
370103,"Primary dystonia, DYT17 type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370103
370097,Oculocutaneous albinism type 6,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370097
370091,Oculocutaneous albinism type 5,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370091
370348,Peripheral primitive neuroectodermal tumor,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370348
370334,Extraskeletal Ewing sarcoma,0.077 (Austria); 0.056 (Belgium); 0.01 (Bulgaria); 0.023 (Croatia); 0.052 (Czech Republic); 0.083 (Estonia); 0.071 (Germany); 0.055 (Ireland); 0.068 (Italy); 0.043 (Latvia); 0.05 (Lithuania); 0.076 (Norway); 0.018 (Poland); 0.092 (Portugal); 0.081 (Slovenia); 0.087 (Spain); 0.056 (Switzerland); 0.089 (Netherlands); 0.058 (United Kingdom); 0.112 (Finland); 0.126 (Malta); 0.106 (Slovakia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370334
370131,White platelet syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370131
370046,Didymosis aplasticosebacea,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370046
370034,Familial syringomyelia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370034
370039,Angora hair nevus,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370039
370022,Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370022
370026,Acute myeloid leukemia with t(8;16)(p11;p13) translocation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370026
370015,"Spondyloepimetaphyseal dysplasia, Isidor-Toutain type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370015
370088,Acute infantile liver failure-multisystemic involvement syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370088
370076,Fetal carbamazepine syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370076
370052,SCALP syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370052
371007,Congenital muscular dystrophy with hyperlaxity,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=371007
370997,Muscle-eye-brain disease with bilateral multicystic leucodystrophy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370997
370921,STT3A-CDG,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370921
370924,STT3B-CDG,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370924
370927,SSR4-CDG,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370927
370930,XYLT1-CDG,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370930
370968,Congenital muscular dystrophy with intellectual disability,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370968
370980,Congenital muscular dystrophy without intellectual disability,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370980
370943,Autism spectrum disorder-epilepsy-arthrogryposis syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370943
369929,Primary hyperaldosteronism-seizures-neurological abnormalities syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369929
369920,Pontocerebellar hypoplasia type 9,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369920
369942,CADDS,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369942
369939,Severe motor and intellectual disabilities-sensorineural deafness-dystonia syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369939
369955,"Methylmalonic acidemia with homocystinuria, type cblJ",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369955
369950,Intellectual disability-seizures-macrocephaly-obesity syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369950
369970,Microcornea-myopic chorioretinal atrophy-telecanthus syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369970
369962,"Methylmalonic acidemia with homocystinuria, type cblX",18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369962
369979,Finger hyperphalangy-toe anomalies-severe pectus excavatum syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369979
369992,Severe dermatitis-multiple allergies-metabolic wasting syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369992
370002,Focal palmoplantar keratoderma with joint keratoses,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370002
369999,Diffuse palmoplantar keratoderma with painful fissures,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369999
370010,Intellectual disability-facial dysmorphism-hand anomalies syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370010
369837,Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369837
369840,TRAPPC11-related limb-girdle muscular dystrophy R18,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369840
369847,Intellectual disability-hyperkinetic movement-truncal ataxia syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369847
369852,Congenital neutropenia-myelofibrosis-nephromegaly syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369852
369861,Congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369861
369867,Autosomal recessive intermediate Charcot-Marie-Tooth disease type C,3.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369867
369873,Obesity due to SIM1 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369873
369881,2p21 microdeletion syndrome without cystinuria,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369881
369886,Homozygous 2p21 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369886
369891,Developmental delay-facial dysmorphism syndrome due to MED13L deficiency,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369891
369897,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with variable craniofacial anomalies",20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369897
369913,Combined oxidative phosphorylation defect type 17,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=369913
364055,Severe early-childhood-onset retinal dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=364055
364028,X-linked intellectual disability due to GRIA3 mutations,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=364028
364033,Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=364033
772,Infantile Refsum disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=772
1194,TMEM70-related mitochondrial encephalo-cardio-myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1194
363999,Non-immune hydrops fetalis,42.0 (Worldwide); 0.0 (Worldwide); 300.0 (Thailand),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363999
1048,Isolated anencephaly/exencephaly,"35.0 (Europe); 0.0 (Europe); 20.6 (United States); 210.0 (India); 120.0 (Iran, Islamic Republic of); 26.0 (Thailand); 58.0 (Singapore)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1048
364013,Immune hydrops fetalis,0.0 (Worldwide); 33.3 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=364013
823,Spina bifida and other spinal dysraphisms,18.6 (Europe); 0.0 (Europe); 50.0 (France); 24.8 (United States); 9.8 (Austria); 17.5 (Belgium); 11.4 (Croatia); 21.3 (Denmark); 19.6 (France); 17.8 (Germany); 14.4 (Hungary); 50.6 (Ireland); 12.7 (Italy); 24.9 (Malta); 17.5 (Netherlands); 14.7 (Norway); 24.4 (Poland); 18.9 (Portugal); 5.0 (Spain); 12.6 (Switzerland); 13.1 (United Kingdom); 41.3 (Ukraine),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=823
363992,Ichthyosis-short stature-brachydactyly-microspherophakia syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363992
363976,Giant cell tumor of bone,0.1404 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363976
363981,Charcot-Marie-Tooth disease type 4B3,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363981
363969,Autosomal recessive cerebral atrophy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363969
363965,Koolen-De Vries syndrome due to a point mutation,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363965
363958,17q21.31 microdeletion syndrome,1.82 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363958
363746,Balint syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363746
363741,Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363741
363727,X-linked dyserythropoietic anemia with abnormal platelets and neutropenia,1.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363727
363722,Alexander disease type II,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363722
363717,Alexander disease type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363717
363710,Spinocerebellar ataxia type 37,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363710
363705,Craniofaciofrontodigital syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363705
363694,Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363694
363686,Severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363686
363680,2p13.2 microdeletion syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363680
363677,Childhood-onset autosomal recessive myopathy with external ophthalmoplegia,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363677
364577,Intellectual disability-brachydactyly-Pierre Robin syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=364577
364198,Bipartite talus,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=364198
363417,Temtamy preaxial brachydactyly syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363417
363409,Fetal akinesia-cerebral and retinal hemorrhage syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363409
363412,Hypomyelination with brain stem and spinal cord involvement and leg spasticity,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363412
363429,Autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363429
363432,Autosomal recessive congenital cerebellar ataxia due to GRID2 deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363432
363424,Multiple mitochondrial dysfunctions syndrome type 3,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363424
363396,High myopia-sensorineural deafness syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363396
363400,Severe neurodegenerative syndrome with lipodystrophy,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363400
363203,Ring chromosome syndrome,2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363203
363618,LMNA-related cardiocutaneous progeria syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363618
363623,GMPPB-related limb-girdle muscular dystrophy R19,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363623
363649,Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363649
363654,X-linked parkinsonism-spasticity syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363654
363659,20q11.2 microduplication syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363659
363665,Acroosteolysis-keloid-like lesions-premature aging syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363665
363540,Leukoencephalopathy with mild cerebellar ataxia and white matter edema,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363540
363549,Acute encephalopathy with biphasic seizures and late reduced diffusion,283.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363549
363558,New-onset refractory status epilepticus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363558
363567,Acute encephalopathy with inflammation-mediated status epilepticus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363567
363579,Extragonadal germ cell tumor,0.13 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363579
363611,CTCF-related neurodevelopmental disorder,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363611
363494,Non-seminomatous germ cell tumor of testis,1.21 (Europe); 33.53 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363494
363523,Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363523
363534,"Mitochondrial DNA depletion syndrome, hepatocerebrorenal form",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363534
363528,Intellectual disability-strabismus syndrome,34.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363528
363444,THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363444
363454,BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363454
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,0.0 (Worldwide); 97.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363447
363478,Paratesticular adenocarcinoma,0.01 (Europe); 0.0 (Europe); 0.0 (Europe); 0.003 (Austria); 0.004 (Belgium); 0.003 (Croatia); 0.001 (Czech Republic); 0.001 (Germany); 0.003 (Ireland); 0.001 (Italy); 0.005 (Latvia); 0.003 (Spain); 0.001 (Netherlands); 0.002 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363478
363472,Tumor of testis and paratestis,3.15 (Europe); 87.77 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363472
363489,Sex cord-stromal tumor of testis,0.02 (Europe); 0.44 (Europe); 0.049 (Austria); 0.048 (Belgium); 0.01 (Bulgaria); 0.034 (Croatia); 0.016 (Czech Republic); 0.018 (Estonia); 0.012 (Finland); 0.02 (Germany); 0.018 (Ireland); 0.027 (Italy); 0.016 (Latvia); 0.008 (Lithuania); 0.022 (Norway); 0.013 (Poland); 0.01 (Portugal); 0.037 (Slovakia); 0.006 (Slovenia); 0.021 (Spain); 0.023 (Switzerland); 0.012 (Netherlands); 0.023 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363489
363483,Testicular teratoma,0.04 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=363483
357175,Short ulna-dysmorphism-hypotonia-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357175
357329,Combined immunodeficiency due to IL21R deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357329
357332,Syndactyly-camptodactyly and clinodactyly of fifth fingers-bifid toes syndrome,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357332
357237,Combined immunodeficiency due to CARD11 deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357237
357502,Idiopathic nephrotic syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357502
356978,"D,L-2-hydroxyglutaric aciduria",13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=356978
356947,3q26q27 microdeletion syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=356947
356961,SLC35A2-CDG,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=356961
357008,Hemolytic uremic syndrome with DGKE deficiency,47.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357008
357001,19p13.13 microdeletion syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357001
356996,ANK3-related intellectual disability-sleep disturbance syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=356996
357043,Amyotrophic lateral sclerosis type 4,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357043
357034,Non-hereditary retinoblastoma,0.038 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357034
357027,Hereditary retinoblastoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357027
357158,Mandibulofacial dysostosis-macroblepharon-macrostomia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357158
357154,Oral submucous fibrosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=357154
352654,Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352654
352662,Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352662
352657,Hereditary benign intraepithelial dyskeratosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352657
352641,Autosomal recessive cerebellar ataxia with late-onset spasticity,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352641
352636,Phalangeal microgeodic syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352636
352649,Brain dopamine-serotonin vesicular transport disease,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352649
352596,Progressive myoclonic epilepsy with dystonia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352596
352629,16q24.1 microdeletion syndrome,42.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352629
352577,Bainbridge-Ropers syndrome,77.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352577
352587,Focal epilepsy-intellectual disability-cerebro-cerebellar malformation,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352587
352582,Familial infantile myoclonic epilepsy,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352582
352731,Oculocutaneous albinism type 1,2.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352731
352734,Minimal pigment oculocutaneous albinism type 1,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352734
352737,Temperature-sensitive oculocutaneous albinism type 1,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352737
352712,Facial dysmorphism-immunodeficiency-livedo-short stature syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352712
352718,Progressive retinal dystrophy due to retinol transport defect,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352718
352723,Attenuated Chédiak-Higashi syndrome,100.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352723
352665,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to 9q21.3 microdeletion,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352665
352670,Autosomal dominant intermediate Charcot-Marie-Tooth disease type F,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352670
352675,X-linked Charcot-Marie-Tooth disease type 6,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352675
352682,Cobblestone lissencephaly without muscular or ocular involvement,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352682
353253,Burning mouth syndrome,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353253
353220,Familial primary localized cutaneous amyloidosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353220
352763,Scleredema,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352763
352745,Oculocutaneous albinism type 7,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352745
353334,Congenital retinal arteriovenous communication,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353334
353320,"Pyruvate carboxylase deficiency, benign type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353320
353327,Congenital myasthenic syndromes with glycosylation defect,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353327
353308,"Pyruvate carboxylase deficiency, infantile type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353308
353314,"Pyruvate carboxylase deficiency, severe neonatal type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353314
353298,Roifman syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353298
353284,Rubinstein-Taybi syndrome due to EP300 haploinsufficiency,34.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353284
352403,Spectrin-associated autosomal recessive cerebellar ataxia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352403
352333,Congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352333
352328,MEGDEL syndrome,67.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352328
352447,Progressive external ophthalmoplegia-myopathy-emaciation syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352447
352530,Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352530
352563,Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352563
352540,Oncogenic osteomalacia,400.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352540
352479,ISPD-related limb-girdle muscular dystrophy R20,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352479
352470,DNA2-related mitochondrial DNA deletion syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352470
352490,Autism spectrum disorder due to AUTS2 deficiency,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=352490
294422,Chronic intestinal failure,86.0 (Italy); 42.4691 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=294422
293987,Rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome,96.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293987
294016,Microcephaly-capillary malformation syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=294016
294023,Neonatal inflammatory skin and bowel disease,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=294023
294026,Syndactyly-nystagmus syndrome due to 2q31.1 microduplication,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=294026
293964,Hypoinsulinemic hypoglycemia and body hemihypertrophy,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293964
293967,Hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293967
293978,Deficiency in anterior pituitary function-variable immunodeficiency syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293978
293958,Hypertelorism-preauricular sinus-punctual pits-deafness syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293958
293955,Childhood encephalopathy due to thiamine pyrophosphokinase deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293955
293948,1p21.3 microdeletion syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293948
293939,Distal Xq28 microduplication syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293939
293936,EDICT syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293936
293925,Lethal occipital encephalocele-skeletal dysplasia syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293925
293864,Hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293864
293843,3MC syndrome,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293843
293822,MITF-related melanoma and renal cell carcinoma predisposition syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293822
293825,Congenital dyserythropoietic anemia type IV,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293825
293812,Fixed drug eruption,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293812
293807,Ketamine-induced biliary dilatation,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293807
293725,"Blepharophimosis-intellectual disability syndrome, Verloes type",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293725
293642,Blepharophimosis-intellectual disability syndrome,58.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293642
293707,"Blepharophimosis-intellectual disability syndrome, MKB type",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293707
294975,Isolated absence of upper arm and forearm with hand present,0.62 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=294975
294963,Popliteal pterygium syndrome,0.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=294963
294971,Isolated tetra-amelia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=294971
289863,Atypical glycine encephalopathy,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289863
289877,Transient hyperammonemia of the newborn,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289877
289916,Vitamin B12-unresponsive methylmalonic acidemia type mut0,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289916
289661,Epstein-Barr virus-positive diffuse large B-cell lymphoma,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289661
289857,Neonatal glycine encephalopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289857
289860,Infantile glycine encephalopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289860
289560,Mitochondrial membrane protein-associated neurodegeneration,0.1 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289560
289553,Dysmorphism-conductive hearing loss-heart defect syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289553
289548,Inherited isolated adrenal insufficiency due to partial CYP11A1 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289548
289539,BAP1-related tumor predisposition syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289539
289601,Hereditary arterial and articular multiple calcification syndrome,0.0 (Worldwide); 16.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289601
289596,Juvenile nasopharyngeal angiofibroma,0.0 (Worldwide); 0.6666 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289596
289586,Exfoliative ichthyosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289586
293355,Methylmalonic acidemia without homocystinuria,0.0 (Europe); 0.0555 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293355
293375,Grayson-Wilbrandt corneal dystrophy,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293375
293381,Epithelial recurrent erosion dystrophy,186.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293381
293462,Pre-Descemet corneal dystrophy,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293462
293603,Congenital hereditary endothelial dystrophy type II,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293603
293621,X-linked endothelial corneal dystrophy,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293621
811,Shwachman-Diamond syndrome,0.59 (Italy); 0.5 (United Kingdom); 0.67 (Puerto rico); 1.3 (Canada); 0.0 (Europe); 0.5 (Worldwide); 0.28 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=811
293168,Infantile-onset ascending hereditary spastic paralysis,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293168
293165,Skin fragility-woolly hair-palmoplantar keratoderma syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293165
428,Autosomal dominant hypocalcemia,0.161 (Denmark); 0.0 (Worldwide); 3.9 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=428
293181,Epilepsy of infancy with migrating focal seizures,114.0 (Worldwide); 0.0 (Worldwide); 0.11 (United Kingdom); 0.4 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293181
2298,Insulin-resistance syndrome type B,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2298
2207,Familial primary hyperparathyroidism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2207
293173,Acute generalized exanthematous pustulosis,0.3 (Worldwide); 0.035 (Israel); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293173
293199,Pleomorphic rhabdomyosarcoma,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293199
393,"46,XX testicular difference of sex development",2.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=393
293202,Epithelioid sarcoma,0.0 (Europe); 0.0 (Europe); 0.04 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293202
293284,Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293284
293208,Celiac artery compression syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=293208
2459,Mansonelliasis,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2459
2404,Loiasis,0.0 (Europe); 0.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2404
2394,Pyruvate dehydrogenase E3 deficiency,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2394
2356,Arachnoid cyst,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2356
829,Adult-onset Still disease,0.16 (France); 0.13 (Japan); 3.9 (Japan); 0.4 (Norway); 6.9 (Norway); 0.0 (Europe); 0.62 (Turkey); 6.77 (Turkey),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=829
1929,Rasmussen subacute encephalitis,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1929
1183,Opsoclonus-myoclonus syndrome,0.02 (Europe); 0.0 (Worldwide); 0.018 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1183
2688,Adult idiopathic neutropenia,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2688
2686,Cyclic neutropenia,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2686
890,Hepatic veno-occlusive disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=890
176,Non-rhizomelic chondrodysplasia punctata,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=176
231,Dracunculiasis,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=231
2035,Lymphatic filariasis,0.0 (Specific population); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2035
284448,CLIPPERS,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284448
284454,Acute zonal occult outer retinopathy,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284454
284460,Acute annular outer retinopathy,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284460
284417,"Phosphoserine aminotransferase deficiency, infantile/juvenile form",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284417
284426,Glycogen storage disease due to lactate dehydrogenase M-subunit deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284426
284435,Glycogen storage disease due to lactate dehydrogenase H-subunit deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284435
284984,Aneurysm-osteoarthritis syndrome,45.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284984
284979,Neonatal Marfan syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284979
289365,Familial vesicoureteral reflux,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289365
289347,Infective dermatitis associated with HTLV-1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289347
289356,Primary non-gestational choriocarcinoma of ovary,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289356
289377,Early-onset myopathy with fatal cardiomyopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289377
289380,Myosclerosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289380
289290,Hypermethioninemia encephalopathy due to adenosine kinase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289290
289266,Early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289266
289326,Tropical spastic paraparesis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289326
289307,Developmental delay due to methylmalonate semialdehyde dehydrogenase deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289307
289504,Combined malonic and methylmalonic acidemia,3.3 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289504
289499,Congenital cataract microcornea with corneal opacity,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289499
289494,4H leukodystrophy,0.0 (Worldwide); 200.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289494
289522,Microtriplication 11q24.1 syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289522
289513,12q15q21.1 microdeletion syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289513
289465,Isolated congenital adermatoglyphia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289465
289390,Primary Sjögren syndrome,"11.343 (France); 48.99 (Europe); 86.398 (Greece); 49.745 (Norway); 45.47 (Denmark); 3.95 (United States); 37.15 (Taiwan, Province of China); 207.83 (Turkey); 30.91 (Italy); 165.98 (Brazil); 9.5 (Taiwan, Province of China); 5.3 (Greece); 3.9 (Slovenia); 6.92 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289390
289385,Malignancy diagnosed during pregnancy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289385
289483,Intellectual disability-alacrima-achalasia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289483
289478,PASH syndrome,0.0 (Worldwide); 36.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289478
289176,Autosomal recessive hypophosphatemic rickets,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289176
289157,Hypocalcemic vitamin D-dependent rickets,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=289157
280921,Idiopathic panuveitis,2.0194 (Europe); 0.5051 (Europe); 16.0 (United States); 3.6 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280921
280898,Panuveitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280898
280892,Posterior uveitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280892
280886,Anterior uveitis,185.0 (Denmark); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280886
281103,Keratinopathic ichthyosis,0.11 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281103
281097,Autosomal recessive congenital ichthyosis,0.5 (United States); 0.5 (Europe); 0.77 (Spain); 1.1 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281097
281090,Syndromic recessive X-linked ichthyosis,1.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281090
281085,Inherited ichthyosis syndromic form,0.19 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281085
281082,Inherited non-syndromic ichthyosis,1.13 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281082
281190,Congenital reticular ichthyosiform erythroderma,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281190
281201,Keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281201
281139,Annular epidermolytic ichthyosis,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281139
281122,Self-improving collodion baby,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281122
281127,Acral self-healing collodion baby,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=281127
280628,Familial progressive hyper- and hypopigmentation,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280628
280633,Multiple congenital anomalies-hypotonia-seizures syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280633
280615,Hemoglobinopathy Toms River,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280615
280598,Hereditary sensorimotor neuropathy with hyperelastic skin,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280598
280620,Progressive myoclonic epilepsy type 6,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280620
280671,Megaconial congenital muscular dystrophy,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280671
280640,Occipital pachygyria and polymicrogyria,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280640
280654,Autosomal recessive nail dysplasia,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280654
280779,Cutaneous collagenous vasculopathy,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280779
280785,Bullous diffuse cutaneous mastocytosis,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280785
280794,Pseudoxanthomatous diffuse cutaneous mastocytosis,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280794
280679,Moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280679
280763,Severe intellectual disability and progressive spastic paraplegia,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280763
280774,Generalized essential telangiectasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=280774
284149,Craniosynostosis-dental anomalies,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284149
284139,"Larsen-like syndrome, B3GAT3 type",14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284139
284180,Xp22.13p22.2 duplication syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284180
284169,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to 10p11.21p12.31 microdeletion,0.0 (Worldwide); 19.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284169
284160,8q21.11 microdeletion syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284160
284247,Familial retinal arterial macroaneurysm,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284247
284232,Autosomal dominant Charcot-Marie-Tooth disease type 2O,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284232
284227,TEMPI syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284227
284271,Autosomal recessive cerebellar ataxia-psychomotor delay syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284271
284264,IgG4-related disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284264
284324,Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284324
284282,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to WWOX deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284282
284289,Adult-onset autosomal recessive cerebellar ataxia,0.0 (Worldwide); 14.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284289
284343,DICER1 tumor-predisposition syndrome,0.007 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284343
284332,Infantile-onset autosomal recessive nonprogressive cerebellar ataxia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284332
284339,Pontocerebellar hypoplasia type 7,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284339
284388,Reversible cerebral vasoconstriction syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284388
284395,Well-differentiated fetal adenocarcinoma of the lung,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284395
284400,Small cell carcinoma of the bladder,0.14 (United States); 0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=284400
282166,Inherited Creutzfeldt-Jakob disease,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=282166
309854,Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309854
314029,High bone mass osteogenesis imperfecta,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314029
314022,Gastric adenocarcinoma and proximal polyposis of the stomach,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314022
314017,Idiopathic linear interstitial keratitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314017
314002,Contractures-webbed neck-micrognathia-hypoplastic nipples syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314002
313947,2q23.1 microduplication syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313947
313936,PENS syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313936
313920,Epstein-Barr virus-associated gastric carcinoma,1.2 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313920
313906,Congenital pancreatic cyst,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313906
313892,Developmental and speech delay due to SOX5 deficiency,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313892
313884,12p12.1 microdeletion syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313884
313855,FGFR2-related bent bone dysplasia,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313855
313850,Infantile cerebellar-retinal degeneration,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313850
313846,Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313846
313838,Coats plus syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313838
313800,Retinal dystrophy-optic nerve edema-splenomegaly-anhidrosis-migraine headache syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313800
313808,Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313808
313781,20p13 microdeletion syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313781
313795,Jawad syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313795
313772,Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=313772
314603,Autosomal recessive spastic ataxia with leukoencephalopathy,54.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314603
314597,Chudley-McCullough syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314597
314613,Growing teratoma syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314613
314575,Intellectual disability-hypotonia-brachycephaly-pyloric stenosis-cryptorchidism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314575
314572,Autosomal recessive leukoencephalopathy-ischemic stroke-retinitis pigmentosa syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314572
314588,Distal triplication 15q syndrome,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314588
314585,15q overgrowth syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314585
314485,Young adult-onset distal hereditary motor neuropathy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314485
314566,Primary progressive apraxia of speech,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314566
314555,Facial dysmorphism-ocular anomalies-osteopenia-intellectual disability-dental anomalies syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314555
314466,Atypical Meigs syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314466
314459,Pseudo-Meigs syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314459
314478,Ovarian fibrothecoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314478
314473,Ovarian fibroma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314473
314422,Ameloblastic carcinoma,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314422
314432,Spigelian hernia-cryptorchidism syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314432
314451,Meigs syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314451
314394,Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314394
314399,Autosomal dominant aplasia and myelodysplasia,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314399
314404,Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314404
314419,Ameloblastoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314419
314373,Chronic infantile diarrhea due to guanylate cyclase 2C overactivity,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314373
314376,Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314376
314381,Hereditary sensory and autonomic neuropathy type 6,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314381
314389,Xq12-q13.3 duplication syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314389
314034,7p22.1 microduplication syndrome,0.0 (Worldwide); 5.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314034
314041,Marfanoid habitus-inguinal hernia-advanced bone age syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314041
314051,Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=314051
306674,Kufor-Rakeb syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306674
306669,Hemiparkinsonism-hemiatrophy syndrome,0.0 (Worldwide); 68.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306669
306741,Hemidystonia-hemiatrophy syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306741
306734,"Primary dystonia, DYT21 type",16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306734
306731,Sydenham chorea,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306731
308166,Erythrokeratoderma variabilis progressiva,0.046 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=308166
308386,Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=308386
308410,Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=308410
308425,Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=308425
307766,Curly hair-acral keratoderma-caries syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=307766
307936,Hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=307936
309111,Combined pancreatic lipase-colipase deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309111
309031,Pancreatic triacylglycerol lipase deficiency,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309031
309108,Pancreatic colipase deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309108
309025,Mevalonate kinase deficiency,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309025
309015,Familial lipoprotein lipase deficiency,0.1 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309015
309020,Familial apolipoprotein C-II deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309020
178,Chordoma,0.06 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178
2637,Microcephalic osteodysplastic primordial dwarfism type II,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2637
592,Macrophagic myofasciitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=592
308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset","3.0 (Taiwan, Province of China); 0.72 (Netherlands); 0.0 (Europe)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=308552
309271,"Metachromatic leukodystrophy, adult form",0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309271
309246,"GM2 gangliosidosis, AB variant",10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309246
309256,"Metachromatic leukodystrophy, late infantile form",0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309256
309263,"Metachromatic leukodystrophy, juvenile form",0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309263
309324,"Free sialic acid storage disease, infantile form",0.0 (Worldwide); 0.14 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309324
309334,Salla disease,0.0 (Worldwide); 1.59 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309334
309294,Sialidosis,0.05 (Netherlands); 0.02 (Australia); 0.0 (Europe); 0.05 (Europe); 0.07 (Czech Republic); 0.1 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309294
309297,Mucopolysaccharidosis type 4A,15.0 (Europe); 0.15 (Canada); 0.38 (Germany); 0.12 (Germany); 1.4 (United Arab Emirates); 0.46 (United Arab Emirates); 0.497 (Australia); 0.153 (Australia); 0.48 (Canada); 0.29 (Sweden); 0.029 (United States); 0.11 (United States); 0.0848 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309297
309310,Mucopolysaccharidosis type 4B,0.001 (United States); 0.004 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309310
309147,Hyper-beta-alaninemia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309147
309152,GM2 gangliosidosis,0.87 (Sweden); 5.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=309152
300547,Autosomal recessive infantile hypercalcemia,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300547
300552,Follicular cholangitis and pancreatitis,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300552
300557,Carcinoma of the ampulla of Vater,0.59 (France); 0.0 (Europe); 0.57 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300557
300564,Combined pulmonary fibrosis-emphysema syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300564
300570,Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300570
300573,Polymicrogyria due to TUBB2B mutation,36.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300573
300576,Oligodontia-cancer predisposition syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300576
300496,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300496
300501,Painful orbital and systemic neurofibromas-marfanoid habitus syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300501
300504,Onychocytic matricoma,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300504
300512,Onychomatricoma,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300512
300525,Pseudohypoaldosteronism type 2D,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300525
300530,Pseudohypoaldosteronism type 2E,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300530
300536,DDOST-CDG,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300536
300865,Primary cutaneous anaplastic large cell lymphoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300865
300857,T-cell/histiocyte rich large B cell lymphoma,0.023 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300857
300878,Hairy cell leukemia variant,0.22 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300878
300895,ALK-positive anaplastic large cell lymphoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300895
300605,Juvenile amyotrophic lateral sclerosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300605
300755,Laminopathy with striated muscle involvement,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300755
300751,Familial dilated cardiomyopathy with conduction defect due to LMNA mutation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300751
300763,Laminopathy with lipodystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300763
300758,Laminopathy with peripheral neuropathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300758
300842,Indolent B-cell non-Hodgkin lymphoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300842
300766,Laminopathy with premature aging,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300766
300903,ALK-negative anaplastic large cell lymphoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300903
300912,Marginal zone lymphoma,2.8 (France); 7.0 (Europe); 0.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300912
306431,Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306431
306550,FADD-related immunodeficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306550
306553,Myospherulosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306553
306542,Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306542
306547,Porencephaly-microcephaly-bilateral congenital cataract syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306547
306530,Congenital hereditary facial paralysis-variable hearing loss syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306530
306527,Isolated hereditary congenital facial paralysis,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306527
306516,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis,200.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306516
306511,Autosomal recessive spastic paraplegia type 48,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306511
306498,PTEN hamartoma tumor syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306498
306504,Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306504
306644,Complication after organ transplantation,9.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306644
306577,Hereditary sodium channelopathy-related small fibers neuropathy,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306577
306558,Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=306558
298644,Disorder of thiamine metabolism and transport,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=298644
300179,Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300179
300319,Charcot-Marie-Tooth disease type 2P,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300319
300324,Persistent polyclonal B-cell lymphocytosis,154.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300324
300313,Congenital cataract-hearing loss-severe developmental delay syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300313
300298,Severe congenital hypochromic anemia with ringed sideroblasts,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300298
300305,11p15.4 microduplication syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300305
300284,Connective tissue disorder due to lysyl hydroxylase-3 deficiency,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300284
300293,Transient infantile hypertriglyceridemia and hepatosteatosis,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300293
300385,Pituitary carcinoma,0.04 (Europe); 0.87 (Europe); 0.0 (Worldwide); 0.026 (Austria); 0.041 (Belgium); 0.014 (Bulgaria); 0.037 (Czech Republic); 0.009 (Estonia); 0.019 (Finland); 0.033 (Germany); 0.099 (Ireland); 0.052 (Italy); 0.016 (Latvia); 0.025 (Lithuania); 0.063 (Malta); 0.025 (Norway); 0.008 (Portugal); 0.021 (Slovakia); 0.006 (Slovenia); 0.021 (Spain); 0.006 (Switzerland); 0.015 (Netherlands); 0.036 (United Kingdom); 0.135 (Croatia); 0.213 (Iceland); 0.171 (Poland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300385
300493,Sagliker syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300493
300373,X-linked acrogigantism,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300373
300382,Progeroid and marfanoid aspect-lipodystrophy syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300382
300345,Autosomal systemic lupus erythematosus,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300345
300359,PLCG2-associated antibody deficiency and immune dysregulation,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300359
300333,Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300333
464724,Fever-associated acute infantile liver failure syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464724
464738,Basel-Vanagaite-Smirin-Yosef syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464738
464760,Familial cavitary optic disc anomaly,0.0 (Worldwide); 17.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464760
464756,Familial gastric type 1 neuroendocrine tumor,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464756
465508,Symptomatic form of HFE-related hemochromatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=465508
464282,Spastic paraplegia-severe developmental delay-epilepsy syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464282
464288,Short stature-brachydactyly-obesity-global developmental delay syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464288
464306,DYRK1A-related intellectual disability syndrome,54.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464306
464329,Kaposiform lymphangiomatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464329
464321,Multifocal lymphangioendotheliomatosis-thrombocytopenia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464321
464318,Verrucous hemangioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464318
464311,Intellectual disability syndrome due to a DYRK1A point mutation,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464311
464366,NEK9-related lethal skeletal dysplasia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464366
464359,Benign metanephric tumor,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464359
464343,Catastrophic antiphospholipid syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464343
464336,BENTA disease,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464336
464453,Acquired methemoglobinemia,242.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464453
464443,COG6-CGD,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464443
464440,"Primary dystonia, DYT27 type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464440
464370,Neonatal alloimmune neutropenia,16.6 (Poland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464370
464458,Paracetamol poisoning,16.0 (Iceland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=464458
639,Polyneuropathy associated with IgM monoclonal gammopathy with anti-MAG,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=639
662,Lymphedema with yellow nails,400.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=662
537,Toxic epidermal necrolysis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=537
793,SAPHO syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=793
456298,1p35.2 microdeletion syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=456298
456328,X-linked myotubular myopathy-abnormal genitalia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=456328
456312,Infantile multisystem neurologic-endocrine-pancreatic disease,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=456312
456318,Hereditary sensory neuropathy-deafness-dementia syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=456318
454831,Acute radiation syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454831
454836,Avian influenza,826.0 (Worldwide); 0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454836
454887,Corticobasal syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454887
454723,Endometrioid carcinoma of ovary,"0.51 (Korea, Republic of); 0.81 (Europe)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454723
454718,Holmes-Adie syndrome,4.7 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454718
454714,Plasma cell leukemia,0.04 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454714
454821,OBSOLETE: Pleomorphic salivary gland adenoma,2.725 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454821
454750,Isolated tracheoesophageal fistula,4.2 (Australia); 2.2 (Worldwide); 2.2 (Worldwide); 4.2 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454750
454745,Kuru,2700.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454745
453533,Polyendocrine-polyneuropathy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=453533
453521,Autosomal recessive cerebellar ataxia due to CWF19L1 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=453521
454710,Anti-p200 pemphigoid,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454710
454700,Acquired Creutzfeldt-Jakob disease,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454700
451602,Primary cutaneous plasmacytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=451602
451607,Cutaneous pseudolymphoma,0.0 (Worldwide); 60.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=451607
451612,Familial congenital nasolacrimal duct obstruction,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=451612
453499,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=453499
453504,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to a point mutation,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=453504
453510,Congenital insensitivity to pain with severe intellectual disability,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=453510
450322,Polyclonal hyperviscosity syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=450322
449566,Eosinophilic angiocentric fibrosis,52.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449566
449563,IgG4-related ophthalmic disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449563
449291,Symptomatic form of fragile X syndrome in female carriers,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449291
449400,IgG4-related aortitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449400
449395,IgG4-related kidney disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449395
449432,IgG4-related submandibular gland disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449432
449427,IgG4-related pachymeningitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449427
449280,Scedosporiosis,0.1 (Australia); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449280
449285,Snakebite envenomation,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449285
449266,Pleural empyema,13.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=449266
448264,Isolated focal non-epidermolytic palmoplantar keratoderma,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=448264
448251,Progressive autosomal recessive ataxia-deafness syndrome,0.0 (Worldwide); 13.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=448251
448270,Ectopia cordis,0.67 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=448270
448267,Regressive spondylometaphyseal dysplasia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=448267
448010,CAD-CDG,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=448010
447997,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447997
448242,Autosomal recessive brachyolmia,0.0 (Worldwide); 20.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=448242
448237,Zika virus disease,0.0 (Worldwide); 58.8 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=448237
447977,Progressive scapulohumeroperoneal distal myopathy,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447977
447974,Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447974
447980,19p13.3 microduplication syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447980
447954,Combined oxidative phosphorylation defect type 25,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447954
447964,Autosomal dominant Charcot-Marie-Tooth disease type 2V,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447964
447961,Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447961
459033,Ataxia-oculomotor apraxia type 4,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=459033
459051,"Spondyloepiphyseal dysplasia, Stanescu type",7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=459051
459061,Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=459061
459056,Autosomal recessive spastic paraplegia type 75,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=459056
459074,Corpus callosum agenesis-macrocephaly-hypertelorism syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=459074
459070,X-linked intellectual disability-cerebellar hypoplasia-spondylo-epiphyseal dysplasia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=459070
458718,Idiopathic spontaneous coronary artery dissection,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=458718
458758,Composite hemangioendothelioma,39.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=458758
458763,Retiform hemangioendothelioma,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=458763
458768,Papillary intralymphatic angioendothelioma,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=458768
458798,Spinocerebellar ataxia type 41,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=458798
458803,Spinocerebellar ataxia type 42,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=458803
457485,Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457485
457265,Progressive myoclonic epilepsy type 9,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457265
457279,Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457279
457260,X-linked intellectual disability-hypotonia-movement disorder syndrome,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457260
457240,X-linked intellectual disability-short stature-overweight syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457240
457395,Progressive spondyloepimetaphyseal dysplasia-short stature-short fourth metatarsals-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457395
457406,Multiple mitochondrial dysfunctions syndrome type 4,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457406
457375,ITPA-related lethal infantile neurological disorder with cataract and cardiac involvement,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457375
457378,Complex lethal osteochondrodysplasia,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457378
457359,Megalencephaly-severe kyphoscoliosis-overgrowth syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457359
457365,Intellectual disability-muscle weakness-short stature-facial dysmorphism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457365
457284,Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457284
457351,Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457351
457185,Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457185
457083,Isolated splenogonadal fusion,145.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457083
457077,TAFRO syndrome,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457077
457095,Actinomycosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457095
457223,Syndromic sensorineural deafness due to combined oxidative phosphorylation defect,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457223
457212,Progressive essential tremor-speech impairment-facial dysmorphism-intellectual disability-abnormal behavior syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457212
457193,KAT6-related intellectual disability-craniofacial anomalies-cardiac defects syndrome,76.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457193
457205,Infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457205
456369,Polyglucosan body myopathy type 2,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=456369
457050,Autosomal dominant mitochondrial myopathy with exercise intolerance,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=457050
317,Erythrokeratodermia variabilis,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=317
629,Short stature due to growth hormone qualitative anomaly,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=629
248,Autosomal recessive hypohidrotic ectodermal dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=248
1810,Autosomal dominant hypohidrotic ectodermal dysplasia,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1810
3437,Vogt-Koyanagi-Harada disease,0.0 (Worldwide); 3.75 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3437
2032,Idiopathic pulmonary fibrosis,"16.125 (Worldwide); 5.55 (Worldwide); 29.8 (Canada); 15.35 (Canada); 8.6 (Finland); 1.3 (Finland); 8.2 (France); 2.8 (France); 21.2 (Italy); 2.6 (Italy); 5.9 (Japan); 37.0 (Korea, Republic of); 13.0 (Korea, Republic of); 11.6 (United Kingdom); 1.2 (United Kingdom); 6.7 (United States); 2.6 (United States)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2032
1303,Bronchiolitis obliterans,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1303
3348,Tracheobronchopathia osteochondroplastica,0.0 (Worldwide); 400.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3348
2902,Idiopathic chronic eosinophilic pneumonia,0.0 (Worldwide); 0.23 (Iceland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2902
1302,Cryptogenic organizing pneumonia,0.0 (Worldwide); 0.81 (Spain); 0.92 (Greece); 1.1 (Iceland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1302
198,Occipital horn syndrome,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=198
891,Familial exudative vitreoretinopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=891
466677,Scorpion envenomation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466677
466688,Severe intellectual disability-corpus callosum agenesis-facial dysmorphism-cerebellar ataxia syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466688
466695,Supratip dysplasia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466695
466670,Cyanide poisoning,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466670
466650,Exercise-induced malignant hyperthermia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466650
466962,SMARCA4-deficient sarcoma of thorax,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466962
466950,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to WAC point mutation,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466950
466943,WAC-related facial dysmorphism-developmental delay-behavioral abnormalities syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466943
466926,Seizures-scoliosis-macrocephaly syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466926
466934,VPS11-related autosomal recessive hypomyelinating leukodystrophy,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466934
466921,Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466921
466806,Autosomal dominant thrombocytopenia with platelet secretion defect,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466806
466794,Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466794
466791,Macrocephaly-intellectual disability-left ventricular non compaction syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466791
466784,Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466784
466775,Autosomal recessive Charcot-Marie-Tooth disease type 2X,29.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466775
466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466768
466722,Autosomal recessive spastic paraplegia type 77,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466722
466718,Martinique crinkled retinal pigment epitheliopathy,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466718
466703,TMEM199-CDG,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466703
465824,Fetal encasement syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=465824
466026,Class I glucose-6-phosphate dehydrogenase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=466026
468620,Intellectual disability-epilepsy-extrapyramidal syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468620
468631,Microcephalic cortical malformations-short stature due to RTTN deficiency,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468631
467166,Tubulinopathy-associated dysgyria,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=467166
467176,Severe hypotonia-psychomotor developmental delay-strabismus-cardiac septal defect syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=467176
468635,Cryptogenic multifocal ulcerous stenosing enteritis,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468635
468641,Chronic enteropathy associated with SLCO2A1 gene,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468641
468661,Autosomal recessive spastic paraplegia type 74,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468661
468666,Isolated generalized anhidrosis with normal sweat glands,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468666
468678,White-Sutton syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468678
468684,CCDC115-CDG,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468684
468672,Colobomatous macrophthalmia-microcornea syndrome,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468672
468726,Severe primary trimethylaminuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468726
468699,SLC39A8-CDG,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468699
468717,Rhizomelic chondrodysplasia punctata type 5,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=468717
401785,Autosomal recessive spastic paraplegia type 62,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401785
401780,Autosomal recessive spastic paraplegia type 61,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401780
401800,Autosomal recessive spastic paraplegia type 60,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401800
401795,Autosomal recessive spastic paraplegia type 59,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401795
401768,Proximal myopathy with extrapyramidal signs,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401768
401764,Pancytopenia-developmental delay syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401764
401777,Optic atrophy-intellectual disability syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401777
401830,Autosomal recessive spastic paraplegia type 69,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401830
401835,Autosomal recessive spastic paraplegia type 70,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401835
401840,Autosomal recessive spastic paraplegia type 71,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401840
401805,Autosomal recessive spastic paraplegia type 63,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401805
401810,Autosomal recessive spastic paraplegia type 64,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401810
401815,Autosomal recessive spastic paraplegia type 66,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401815
401820,Autosomal recessive spastic paraplegia type 67,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401820
401866,Childhood-onset spasticity with hyperglycinemia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401866
401869,Multiple mitochondrial dysfunctions syndrome type 1,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401869
401874,Multiple mitochondrial dysfunctions syndrome type 2,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401874
401849,Autosomal spastic paraplegia type 72,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401849
401859,Lipoic acid synthetase deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401859
401862,Lipoyl transferase 1 deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401862
402823,Hepatitis delta,40.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=402823
401920,Fibrolamellar hepatocellular carcinoma,0.02 (United States); 0.009 (Austria); 0.019 (Belgium); 0.029 (Bulgaria); 0.029 (Czech Republic); 0.018 (Estonia); 0.002 (Finland); 0.031 (France); 0.019 (Germany); 0.043 (Iceland); 0.022 (Ireland); 0.13 (Italy); 0.022 (Latvia); 0.003 (Norway); 0.005 (Poland); 0.006 (Portugal); 0.008 (Slovakia); 0.009 (Spain); 0.017 (Switzerland); 0.022 (Netherlands); 0.016 (United Kingdom); 0.025 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401920
401911,AXIN2-related attenuated familial adenomatous polyposis,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401911
401901,Huntington disease-like syndrome due to C9ORF72 expansions,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401901
401942,Familial median cleft of the upper and lower lips,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401942
401935,14q24.1q24.3 microdeletion syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401935
401923,9q31.1q31.3 microdeletion syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401923
401959,Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401959
401953,Episodic ataxia with slurred speech,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401953
401948,Hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401948
401945,Moyamoya disease with early-onset achalasia,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401945
401986,1p31p32 microdeletion syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401986
401979,"Autosomal recessive spondylometaphyseal dysplasia, Mégarbané type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401979
401973,MEND syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401973
401964,Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401964
402003,Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=402003
401996,Karyomegalic interstitial nephritis,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401996
402035,Eosinophilic colitis,196.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=402035
402082,Progressive myoclonic epilepsy type 5,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=402082
402364,Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=402364
402041,Autosomal recessive distal renal tubular acidosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=402041
806,Scott syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=806
404473,Severe intellectual disability-progressive spastic diplegia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404473
404463,Multisystemic smooth muscle dysfunction syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404463
404466,Female infertility due to zona pellucida defect,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404466
404451,FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404451
404454,Alacrimia-choreoathetosis-liver dysfunction syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404454
404443,Tatton-Brown-Rahman syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404443
404448,ADNP syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404448
404437,Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404437
404440,Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404440
404560,Familial atypical multiple mole melanoma syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404560
404553,Adenosine deaminase 2 deficiency,0.0 (Worldwide); 48.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404553
404546,DITRA,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404546
404521,Spinal muscular atrophy with respiratory distress type 2,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404521
404507,Chondromyxoid fibroma,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404507
404499,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404499
404493,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404493
404476,Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404476
411527,Central retinal vein occlusion,28.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411527
411536,Mild phosphoribosylpyrophosphate synthetase superactivity,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411536
411543,Severe phosphoribosylpyrophosphate synthetase superactivity,0.0 (Worldwide); 33.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411543
411593,Insulin autoimmune syndrome,404.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411593
411602,Hereditary late-onset Parkinson disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411602
411629,Infantile nephropathic cystinosis,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411629
411493,Pontocerebellar hypoplasia type 10,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411493
411777,Generalized eruptive keratoacanthoma,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411777
411712,Maternal riboflavin deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411712
411788,Familial isolated trichomegaly,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411788
411986,Early-onset epileptic encephalopathy-cortical blindness-intellectual disability-facial dysmorphism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411986
412035,13q12.3 microdeletion syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412035
412022,Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412022
411641,Ocular cystinosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411641
411634,Juvenile nephropathic cystinosis,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411634
411696,Proton-pump inhibitor-responsive esophageal eosinophilia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411696
411709,Renal agenesis,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411709
411703,Pulmonary non-tuberculous mycobacterial infection,6.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=411703
371428,Multicentric osteolysis-nodulosis-arthropathy spectrum,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=371428
371364,Hypotonia-speech impairment-severe cognitive delay syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=371364
391673,Necrotizing enterocolitis,45.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391673
391677,Short stature-optic atrophy-Pelger-Huët anomaly syndrome,39.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391677
391474,Frontorhiny,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391474
391504,Transient neonatal myasthenia gravis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391504
391497,Juvenile myasthenia gravis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391497
391490,Adult-onset myasthenia gravis,31.8 (Serbia); 1.33 (Serbia); 17.0 (United States); 28.0 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391490
391487,STAT1-related autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome,5.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391487
391646,Feingold syndrome type 2,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391646
391641,Feingold syndrome type 1,120.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391641
391665,Homozygous familial hypercholesterolemia,0.5842 (Japan); 0.3194 (Worldwide); 0.22 (Spain); 0.625 (Denmark); 0.33 (Netherlands); 0.125 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391665
391655,Off-periods in Parkinson disease not responding to oral treatment,4.15 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391655
391343,Fatal post-viral neurodegenerative disorder,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391343
391348,Growth and developmental delay-hypotonia-vision impairment-lactic acidosis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391348
391351,SURF1-related Charcot-Marie-Tooth disease type 4,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391351
391366,Growth retardation-mild developmental delay-chronic hepatitis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391366
391372,FOXP1 Syndrome,48.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391372
391376,Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391376
391384,Familial episodic pain syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391384
391389,Familial episodic pain syndrome with predominantly upper body involvement,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391389
391392,Familial episodic pain syndrome with predominantly lower limb involvement,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391392
391397,Hereditary sensory and autonomic neuropathy type 7,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391397
391408,Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391408
391411,Atypical juvenile parkinsonism,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391411
391417,HSD10 disease,37.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391417
391457,"HSD10 disease, neonatal type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391457
391307,Severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391307
391316,Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391316
391327,X-linked calvarial hyperostosis,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391327
391320,East Texas bleeding disorder,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391320
391330,X-linked osteoporosis with fractures,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=391330
398063,Refractory celiac disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398063
398058,Squamous cell carcinoma of the penis,0.57 (Europe); 0.612 (Netherlands); 0.491 (Austria); 0.605 (Belgium); 0.516 (Bulgaria); 0.423 (Croatia); 0.684 (Czech Republic); 0.6 (Estonia); 0.426 (Finland); 0.638 (Germany); 0.682 (Iceland); 0.475 (Ireland); 0.606 (Italy); 0.552 (Latvia); 0.517 (Lithuania); 0.628 (Malta); 0.744 (Norway); 0.396 (Poland); 0.745 (Portugal); 0.499 (Slovakia); 0.45 (Slovenia); 0.791 (Spain); 0.597 (Switzerland); 0.691 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398058
398053,Adenocarcinoma of the penis,0.0 (Europe); 0.006 (Austria); 0.006 (Belgium); 0.003 (Bulgaria); 0.003 (Croatia); 0.004 (Czech Republic); 0.002 (Finland); 0.005 (Germany); 0.003 (Ireland); 0.004 (Italy); 0.005 (Latvia); 0.012 (Lithuania); 0.005 (Norway); 0.003 (Poland); 0.025 (Portugal); 0.004 (Netherlands); 0.006 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398053
398043,Malignant tumor of penis,4.85 (Brazil); 3.5 (Uganda); 1.075 (Europe); 1.21 (United Kingdom); 0.58 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398043
397973,Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397973
397968,Charcot-Marie-Tooth disease type 2R,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397968
397964,Combined immunodeficiency due to MALT1 deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397964
397959,TCR-alpha-beta-positive T-cell deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397959
397951,Microcephaly-thin corpus callosum-intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397951
397946,Autosomal spastic paraplegia type 58,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397946
397941,MAN1B1-CDG,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397941
397937,Polyglucosan body myopathy type 1,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397937
397933,Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397933
397927,Sacral agenesis-abnormal ossification of the vertebral bodies-persistent notochordal canal syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397927
397922,Ferro-cerebro-cutaneous syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397922
397787,Combined immunodeficiency due to IKK2 deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397787
397755,Periodic paralysis with transient compartment-like syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397755
397758,Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397758
397744,Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397744
397750,Periodic paralysis with later-onset distal motor neuropathy,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397750
397725,COASY protein-associated neurodegeneration,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397725
397735,Autosomal dominant Charcot-Marie-Tooth disease type 2U,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397735
397709,Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome,0.0 (Worldwide); 30.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397709
397715,Joubert syndrome with Jeune asphyxiating thoracic dystrophy,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397715
397692,Hereditary isolated aplastic anemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397692
397695,3q27.3 microdeletion syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397695
397623,Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397623
397685,Familial hyperprolactinemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397685
397615,Obesity due to CEP19 deficiency,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397615
397618,Foveal hypoplasia-optic nerve decussation defect-anterior segment dysgenesis syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397618
397596,Activated PI3K-delta syndrome,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397596
397593,Severe neonatal lactic acidosis due to NFS1-ISD11 complex deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397593
397612,Macrocephaly-developmental delay syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397612
397606,PrP systemic amyloidosis,0.0 (Worldwide); 16.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397606
397590,Silver-Russell syndrome due to a point mutation,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397590
397587,Deep dermatophytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=397587
399329,Epiphysiolysis of the hip,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399329
399180,Secondary non-traumatic avascular necrosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399180
399058,Alpha-B crystallin-related late-onset myopathy,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399058
398987,Malignant teratoma of ovary,0.0 (Worldwide); 0.07 (Europe); 0.051 (Austria); 0.052 (Belgium); 0.043 (Bulgaria); 0.056 (Croatia); 0.034 (Czech Republic); 0.074 (Estonia); 0.053 (Finland); 0.042 (Germany); 0.052 (Ireland); 0.039 (Italy); 0.027 (Latvia); 0.017 (Lithuania); 0.031 (Malta); 0.084 (Norway); 0.048 (Poland); 0.045 (Portugal); 0.045 (Slovakia); 0.075 (Slovenia); 0.063 (Spain); 0.084 (Switzerland); 0.082 (Netherlands); 0.056 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398987
399086,Finnish upper limb-onset distal myopathy,0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399086
399081,KLHL9-related early-onset distal myopathy,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399081
399103,Distal nebulin myopathy,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399103
399096,Distal anoctaminopathy,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399096
398934,Malignant epithelial tumor of ovary,9.39 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398934
398961,Mucinous adenocarcinoma of ovary,0.85 (Europe); 0.497 (Austria); 0.883 (Belgium); 0.815 (Croatia); 0.995 (Czech Republic); 0.666 (Germany); 0.469 (Iceland); 0.706 (Ireland); 0.666 (Italy); 0.503 (Latvia); 0.567 (Lithuania); 0.717 (Norway); 0.665 (Poland); 0.49 (Portugal); 0.945 (Slovakia); 0.601 (Slovenia); 0.695 (Spain); 0.563 (Switzerland); 0.76 (Netherlands); 0.815 (United Kingdom); 1.154 (Bulgaria); 1.108 (Estonia); 1.062 (Finland); 1.162 (Malta),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398961
398940,Malignant non-epithelial tumor of ovary,0.43 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398940
398971,Clear cell adenocarcinoma of the ovary,0.32 (Europe); 0.112 (Austria); 0.361 (Belgium); 0.201 (Bulgaria); 0.147 (Croatia); 0.165 (Czech Republic); 0.24 (Estonia); 0.359 (Finland); 0.182 (Germany); 0.383 (Iceland); 0.395 (Ireland); 0.227 (Italy); 0.162 (Latvia); 0.166 (Lithuania); 0.534 (Malta); 0.425 (Norway); 0.118 (Poland); 0.119 (Portugal); 0.273 (Slovakia); 0.388 (Slovenia); 0.343 (Spain); 0.282 (Switzerland); 0.342 (Netherlands); 0.451 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398971
398124,Neonatal lupus erythematosus,5.0 (United States); 5.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398124
398127,Neonatal scleroderma,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398127
398147,Persistent idiopathic facial pain,0.0 (Worldwide); 4.4 (Netherlands); 1.0 (Germany); 30.0 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398147
398156,Oculoauriculofrontonasal syndrome,41.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398156
398166,Focal facial dermal dysplasia,0.0 (Worldwide); 147.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398166
398173,Focal facial dermal dysplasia type II,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398173
398189,Focal facial dermal dysplasia type IV,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398189
398069,Schaaf-Yang syndrome,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398069
398073,Prader-Willi-like syndrome,117.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398073
398079,SIM1-related Prader-Willi-like syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398079
398088,Hereditary cryohydrocytosis with normal stomatin,53.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398088
398097,Neonatal antiphospholipid syndrome,34.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398097
398109,Neonatal autoimmune hemolytic anemia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398109
398117,Neonatal dermatomyositis,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=398117
435628,Keppen-Lubinsky syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435628
435660,LIPE-related familial partial lipodystrophy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435660
435651,CIDEC-related familial partial lipodystrophy,0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435651
435638,3p25.3 microdeletion syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435638
435804,Short stature-advanced bone age-early-onset osteoarthritis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435804
435845,Lethal neonatal spasticity-epileptic encephalopathy syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435845
435930,Colobomatous optic disc-macular atrophy-chorioretinopathy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435930
435819,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutation,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435819
435953,Progeroid features-hepatocellular carcinoma predisposition syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435953
435988,Chronic atrial and intestinal dysrhythmia syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435988
435934,COG2-CDG,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435934
435938,X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435938
436141,HIDEA syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436141
436144,Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436144
435998,Autosomal recessive intermediate Charcot-Marie-Tooth disease type D,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435998
436003,Contractures-developmental delay-Pierre Robin syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436003
436159,Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436159
436169,Thrombomodulin-related bleeding disorder,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436169
436166,Periodic fever-infantile enterocolitis-autoinflammatory syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436166
436182,Microcephalic primordial dwarfism-insulin resistance syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436182
436174,Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436174
436245,Retinitis pigmentosa-juvenile cataract-short stature-intellectual disability syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436245
436242,Familial atrial tachyarrhythmia-infra-Hisian cardiac conduction disease,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436242
436274,Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=436274
437552,Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=437552
438178,Fatty acyl-CoA reductase 1 deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438178
438159,STAT3-related early-onset multisystem autoimmune disease,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438159
438134,PCNA-related progressive neurodegenerative photosensitivity syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438134
438117,Steel syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438117
438114,RARS-related autosomal recessive hypomyelinating leukodystrophy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438114
438075,Ketoacidosis due to monocarboxylate transporter-1 deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438075
438279,Human infection by orthopoxvirus,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438279
438274,GCGR-related hyperglucagonemia,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438274
438266,Progressive encephalomyelitis with rigidity and myoclonus,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438266
438216,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438216
438213,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438213
438207,Severe autosomal recessive macrothrombocytopenia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=438207
439232,AApoAIV amyloidosis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439232
439212,Early-onset myopathy-areflexia-respiratory distress-dysphagia syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439212
439218,KCNQ2-related epileptic encephalopathy,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439218
439196,Zinc-responsive necrolytic acral erythema,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439196
439167,Placental insufficiency,33.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439167
439822,PDE4D haploinsufficiency syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439822
439254,ITM2B amyloidosis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439254
439854,Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439854
439897,Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439897
439881,Plastic bronchitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=439881
440354,Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome,0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=440354
440713,Isolated sedoheptulokinase deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=440713
440727,Combined hamartoma of the retina and retinal pigment epithelium,120.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=440727
440731,L-ferritin deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=440731
440706,Ribose-5-P isomerase deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=440706
443084,Baroreflex failure,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443084
443073,Charcot-Marie-Tooth disease type 2S,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443073
442835,Non-specific early-onset epileptic encephalopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=442835
442582,AH amyloidosis,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=442582
443197,X-linked erythropoietic protoporphyria,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443197
3008,Pyruvate carboxylase deficiency,0.4 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3008
443192,Classic stiff person syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443192
595,Centronuclear myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=595
298,Mitochondrial neurogastrointestinal encephalomyopathy,0.1 (Europe); 0.3 (Israel); 0.5 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=298
396,Chronic hiccup,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=396
443236,Postural orthostatic tachycardia syndrome due to NET deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443236
552,MODY,0.0 (Europe); 10.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=552
854,Non-malignant and non-cirrhotic portal vein thrombosis,3.7 (Sweden); 0.7 (Sweden); 0.0 (Europe); 2.75 (Italy); 1.72 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=854
443098,Hyperostosis cranialis interna,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443098
443087,"46,XY difference of sex development due to testicular 17,20-desmolase deficiency",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443087
130,Brugada syndrome,20.0 (Europe); 75.0 (South East Asia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=130
277,Severe combined immunodeficiency due to adenosine deaminase deficiency,0.3 (Europe); 0.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=277
443162,NDE1-related microhydranencephaly,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443162
443804,Focal stiff limb syndrome,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443804
443811,PGM3-CDG,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443811
443950,DNAJB2-related Charcot-Marie-Tooth disease type 2,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443950
443988,Ventriculomegaly-cystic kidney disease,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443988
444092,Autoimmune interstitial lung disease-arthritis syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444092
444099,Autosomal dominant spastic paraplegia type 73,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444099
444138,Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444138
444002,11q22.2q22.3 microdeletion syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444002
443995,Mandibulofacial dysostosis with alopecia,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=443995
444048,"46,XX ovarian dysgenesis-short stature syndrome",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444048
444013,Combined oxidative phosphorylation defect type 23,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444013
444069,Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444069
444051,20q11.2 microdeletion syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444051
444077,Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444077
444072,Cerebellar-facial-dental syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444072
444463,Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome due to TPP2 deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444463
444490,Familial chylomicronemia syndrome,0.1 (United States); 0.97 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444490
444458,Combined oxidative phosphorylation defect type 24,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444458
445110,Limb-girdle muscular dystrophy due to POMK deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=445110
445062,Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=445062
445038,3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=445038
445018,Combined immunodeficiency due to LRBA deficiency,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=445018
447731,NIK deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447731
447737,Combined immunodeficiency due to DOCK2 deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447737
447881,Idiopathic dropped head syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447881
447896,Tremor-ataxia-central hypomyelination syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447896
447893,Hypomyelination-cerebellar atrophy-hypoplasia of the corpus callosum syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447893
447788,Cerebral visual impairment,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447788
447795,Lipoyl transferase 2 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447795
447784,Mitochondrial pyruvate carrier deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447784
447757,Autosomal dominant spastic paraplegia type 9B,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447757
447753,Autosomal dominant spastic paraplegia type 9A,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447753
447760,Autosomal recessive spastic paraplegia type 9B,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=447760
412066,PRKAR1B-related neurodegenerative dementia with intermediate filaments,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412066
412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412057
412181,Epidermolysis bullosa simplex due to BP230 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412181
412069,AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412069
412189,Epidermolysis bullosa simplex due to exophilin 5 deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412189
412217,Dystonia-aphonia syndrome,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=412217
418959,Squamous cell carcinoma of the stomach,0.0 (Worldwide); 0.115 (Europe); 0.063 (Austria); 0.025 (Belgium); 0.08 (Bulgaria); 0.034 (Croatia); 0.092 (Czech Republic); 0.176 (Estonia); 0.065 (Finland); 0.08 (France); 0.079 (Germany); 0.043 (Iceland); 0.207 (Ireland); 0.1 (Italy); 0.401 (Latvia); 0.137 (Lithuania); 0.031 (Malta); 0.046 (Norway); 0.04 (Poland); 0.115 (Portugal); 0.111 (Slovakia); 0.1 (Slovenia); 0.128 (Spain); 0.051 (Switzerland); 0.053 (Netherlands); 0.18 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=418959
418945,"Carcinoma of esophagus, salivary gland type",0.004 (Europe); 0.003 (Austria); 0.017 (Belgium); 0.002 (Bulgaria); 0.007 (Czech Republic); 0.009 (Estonia); 0.002 (Finland); 0.004 (Germany); 0.009 (Ireland); 0.001 (Italy); 0.003 (Poland); 0.013 (Slovakia); 0.006 (Slovenia); 0.003 (Spain); 0.002 (Netherlands); 0.005 (France); 0.008 (Portugal); 0.004 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=418945
418951,Undifferentiated carcinoma of esophagus,0.044 (Europe); 0.029 (Austria); 0.077 (Belgium); 0.027 (Bulgaria); 0.006 (Croatia); 0.115 (Czech Republic); 0.037 (Estonia); 0.002 (Finland); 0.118 (France); 0.042 (Germany); 0.085 (Iceland); 0.012 (Ireland); 0.041 (Italy); 0.087 (Latvia); 0.021 (Lithuania); 0.038 (Norway); 0.101 (Poland); 0.021 (Portugal); 0.082 (Slovakia); 0.013 (Slovenia); 0.051 (Spain); 0.023 (Switzerland); 0.025 (Netherlands); 0.039 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=418951
420179,Malan overgrowth syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420179
415286,Bilirubin encephalopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=415286
420789,Autoimmune encephalopathy with parasomnia and obstructive sleep apnea,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420789
420794,Cono-spondylar dysplasia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420794
420702,Autosomal recessive severe congenital neutropenia due to CSF3R deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420702
420728,Combined oxidative phosphorylation defect type 20,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420728
420733,Combined oxidative phosphorylation defect type 21,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420733
420741,RIDDLE syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420741
420492,"Adult-onset cervical dystonia, DYT23 type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420492
420402,Semicircular canal dehiscence syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420402
420429,"Glycogen storage disease due to acid maltase deficiency, late-onset",1.75 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420429
420584,Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome,112.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420584
420699,Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420699
420686,Woolly hair-palmoplantar keratoderma syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420686
420561,Temple-Baraitser syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420561
420573,Severe combined immunodeficiency due to CTPS1 deficiency,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420573
420566,Bleeding disorder due to CalDAG-GEFI deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=420566
423461,Mucolipidosis type III alpha/beta,13.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423461
423470,Mucolipidosis type III gamma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423470
423454,Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423454
423384,Severe congenital neutropenia due to JAGN1 deficiency,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423384
423296,Spinocerebellar ataxia type 38,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423296
423306,Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423306
423479,X-linked intellectual disability-limb spasticity-retinal dystrophy-arginine vasopressin deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423479
422526,Hereditary clear cell renal cell carcinoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=422526
423275,Spinocerebellar ataxia type 40,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423275
424065,Solid pseudopapillary carcinoma of pancreas,0.003 (Europe); 0.003 (Austria); 0.008 (Belgium); 0.003 (Croatia); 0.011 (Czech Republic); 0.005 (France); 0.004 (Germany); 0.005 (Italy); 0.003 (Norway); 0.009 (Spain); 0.002 (Netherlands); 0.001 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424065
424058,Intraductal papillary mucinous carcinoma of pancreas,0.011 (Europe); 0.017 (Belgium); 0.028 (Czech Republic); 0.031 (France); 0.048 (Germany); 0.006 (Ireland); 0.006 (Italy); 0.041 (Norway); 0.006 (Portugal); 0.018 (Spain); 0.028 (Switzerland); 0.016 (Netherlands); 0.001 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424058
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,0.002 (Belgium); 0.006 (Czech Republic); 0.003 (France); 0.001 (Germany); 0.043 (Iceland); 0.001 (Italy); 0.004 (Lithuania); 0.004 (Netherlands); 0.001 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424080
424073,Serous cystadenocarcinoma of pancreas,0.0 (Europe); 0.002 (Belgium); 0.002 (Finland); 0.001 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424073
424107,Congenital myopathy with myasthenic-like onset,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424107
424099,Colobomatous microphthalmia-rhizomelic dysplasia syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424099
424261,TOR1AIP1-related limb-girdle muscular dystrophy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424261
424016,Adenocarcinoma of the anal canal,0.253 (Europe); 0.238 (Austria); 0.226 (Belgium); 0.485 (Bulgaria); 0.076 (Croatia); 0.269 (Czech Republic); 0.24 (Estonia); 0.105 (Finland); 0.09 (France); 0.12 (Germany); 0.256 (Iceland); 0.299 (Ireland); 0.499 (Italy); 0.287 (Latvia); 0.215 (Lithuania); 0.144 (Norway); 0.217 (Poland); 0.406 (Portugal); 0.382 (Slovakia); 0.343 (Spain); 0.135 (Switzerland); 0.12 (Netherlands); 0.26 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424016
424027,Progressive myoclonic epilepsy type 8,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424027
424019,Squamous cell carcinoma of the anal canal,0.81 (Europe); 0.923 (Austria); 0.707 (Belgium); 0.268 (Bulgaria); 0.251 (Croatia); 0.568 (Czech Republic); 0.6 (Estonia); 0.464 (Finland); 1.096 (France); 1.307 (Germany); 0.809 (Iceland); 0.416 (Ireland); 0.872 (Italy); 0.238 (Latvia); 0.153 (Lithuania); 1.071 (Norway); 0.411 (Poland); 0.603 (Portugal); 0.194 (Slovakia); 0.331 (Spain); 1.712 (Switzerland); 0.621 (Netherlands); 1.038 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424019
424039,Squamous cell carcinoma of pancreas,0.023 (Europe); 0.044 (Austria); 0.006 (Belgium); 0.027 (Bulgaria); 0.028 (Croatia); 0.045 (Czech Republic); 0.028 (Estonia); 0.012 (Finland); 0.015 (France); 0.032 (Germany); 0.034 (Ireland); 0.019 (Italy); 0.06 (Latvia); 0.058 (Lithuania); 0.003 (Norway); 0.008 (Poland); 0.016 (Portugal); 0.005 (Slovakia); 0.027 (Spain); 0.006 (Switzerland); 0.011 (Netherlands); 0.023 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424039
424053,Mucinous cystadenocarcinoma of the pancreas,0.01 (Europe); 0.0 (Europe); 0.006 (Belgium); 0.002 (Bulgaria); 0.002 (Czech Republic); 0.012 (Finland); 0.003 (France); 0.012 (Germany); 0.019 (Italy); 0.004 (Portugal); 0.024 (Spain); 0.006 (Switzerland); 0.019 (Netherlands); 0.004 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424053
424046,Acinar cell carcinoma of pancreas,0.029 (Europe); 0.049 (Austria); 0.039 (Belgium); 0.034 (Bulgaria); 0.006 (Croatia); 0.044 (Czech Republic); 0.083 (Estonia); 0.024 (Finland); 0.01 (France); 0.058 (Germany); 0.028 (Ireland); 0.039 (Italy); 0.07 (Latvia); 0.027 (Norway); 0.005 (Poland); 0.02 (Portugal); 0.05 (Slovakia); 0.024 (Spain); 0.039 (Switzerland); 0.017 (Netherlands); 0.016 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424046
423968,Squamous cell carcinoma of the small intestine,0.008 (Europe); 0.008 (Austria); 0.008 (Belgium); 0.002 (Bulgaria); 0.006 (Croatia); 0.013 (Czech Republic); 0.002 (Finland); 0.008 (France); 0.004 (Germany); 0.012 (Ireland); 0.007 (Italy); 0.022 (Latvia); 0.003 (Norway); 0.003 (Poland); 0.02 (Portugal); 0.005 (Slovakia); 0.027 (Spain); 0.011 (Switzerland); 0.002 (Netherlands); 0.012 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423968
423994,Squamous cell carcinoma of the colon,0.026 (Europe); 0.072 (Austria); 0.014 (Belgium); 0.035 (Bulgaria); 0.008 (Croatia); 0.022 (Czech Republic); 0.009 (Estonia); 0.014 (Finland); 0.026 (France); 0.028 (Germany); 0.025 (Ireland); 0.041 (Italy); 0.13 (Latvia); 0.037 (Lithuania); 0.003 (Norway); 0.01 (Poland); 0.035 (Portugal); 0.027 (Slovakia); 0.024 (Spain); 0.017 (Switzerland); 0.01 (Netherlands); 0.021 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423994
424002,Squamous cell carcinoma of the rectum,0.113 (Europe); 0.126 (Austria); 0.052 (Belgium); 0.088 (Bulgaria); 0.017 (Croatia); 0.26 (Czech Republic); 0.157 (Estonia); 0.045 (Finland); 0.074 (France); 0.083 (Germany); 0.128 (Iceland); 0.096 (Ireland); 0.149 (Italy); 0.346 (Latvia); 0.116 (Lithuania); 0.071 (Norway); 0.111 (Poland); 0.119 (Portugal); 0.05 (Slovakia); 0.042 (Spain); 0.084 (Switzerland); 0.028 (Netherlands); 0.143 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424002
423786,Undifferentiated carcinoma of stomach,0.211 (Europe); 0.086 (Austria); 0.077 (Belgium); 0.764 (Bulgaria); 0.068 (Croatia); 0.328 (Czech Republic); 2.743 (Estonia); 0.002 (Finland); 0.1 (France); 0.221 (Germany); 0.085 (Iceland); 0.009 (Ireland); 0.399 (Italy); 2.571 (Latvia); 0.877 (Lithuania); 0.251 (Malta); 0.087 (Norway); 0.386 (Poland); 0.072 (Portugal); 0.456 (Slovakia); 0.013 (Slovenia); 0.098 (Spain); 0.045 (Switzerland); 0.02 (Netherlands); 0.032 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423786
423894,Microcephaly-complex motor and sensory axonal neuropathy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=423894
431140,X-linked colobomatous microphthalmia-microcephaly-intellectual disability-short stature syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431140
425120,STING-associated vasculopathy with onset in infancy,0.0 (Worldwide); 9.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=425120
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,0.412 (Europe); 0.715 (Austria); 0.201 (Belgium); 0.219 (Bulgaria); 0.659 (Czech Republic); 0.471 (Estonia); 0.309 (Finland); 0.262 (France); 0.582 (Germany); 0.256 (Iceland); 0.642 (Italy); 0.426 (Lithuania); 0.267 (Norway); 0.481 (Poland); 0.365 (Portugal); 0.154 (Slovakia); 0.471 (Spain); 0.377 (United Kingdom); 0.753 (Croatia); 0.157 (Ireland); 0.206 (Latvia); 0.467 (Switzerland); 0.118 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424943
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,0.015 (Europe); 0.011 (Austria); 0.056 (Czech Republic); 0.046 (Estonia); 0.01 (France); 0.02 (Germany); 0.03 (Bulgaria); 0.043 (Iceland); 0.006 (Ireland); 0.019 (Italy); 0.049 (Latvia); 0.033 (Lithuania); 0.011 (Norway); 0.013 (Poland); 0.016 (Portugal); 0.098 (Slovakia); 0.015 (Spain); 0.028 (Switzerland); 0.005 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424970
424991,Adenocarcinoma of the gallbladder and extrahepatic biliary tract,2.62 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424991
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,0.032 (Europe); 0.026 (Austria); 0.006 (Belgium); 0.027 (Bulgaria); 0.025 (Croatia); 0.124 (Czech Republic); 0.037 (Estonia); 0.026 (Finland); 0.018 (France); 0.055 (Germany); 0.043 (Iceland); 0.018 (Ireland); 0.037 (Italy); 0.005 (Latvia); 0.033 (Lithuania); 0.016 (Norway); 0.015 (Poland); 0.002 (Portugal); 0.077 (Slovakia); 0.042 (Spain); 0.051 (Switzerland); 0.014 (Netherlands); 0.021 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424996
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,0.009 (Europe); 0.009 (Austria); 0.003 (Bulgaria); 0.018 (Czech Republic); 0.009 (Estonia); 0.007 (Finland); 0.008 (France); 0.004 (Germany); 0.019 (Italy); 0.016 (Latvia); 0.004 (Lithuania); 0.003 (Norway); 0.005 (Poland); 0.006 (Portugal); 0.003 (Slovakia); 0.017 (Switzerland); 0.002 (Netherlands); 0.014 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424975
424982,Biliary cystadenocarcinoma,0.002 (Europe); 0.002 (Austria); 0.002 (Belgium); 0.005 (Bulgaria); 0.01 (Czech Republic); 0.009 (Estonia); 0.005 (France); 0.003 (Germany); 0.003 (Italy); 0.005 (Latvia); 0.003 (Norway); 0.002 (Portugal); 0.009 (Spain); 0.002 (Netherlands); 0.001 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=424982
431361,Progressive encephalopathy with leukodystrophy due to DECR deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431361
431353,Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis,0.015 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431353
431341,Patent urachus,1.75 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431341
431344,Urachal sinus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431344
431272,X-linked scapuloperoneal muscular dystrophy,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431272
431329,Autosomal recessive spastic paraplegia type 57,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431329
431255,Scapuloperoneal spinal muscular atrophy,31.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431255
431149,Combined immunodeficiency due to OX40 deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431149
431166,Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=431166
435438,Progressive myoclonic epilepsy type 7,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435438
435387,Autosomal dominant Charcot-Marie-Tooth disease type 2Y,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435387
435329,Familial ossifying fibroma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=435329
434179,Orofaciodigital syndrome type 14,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=434179
504476,Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=504476
504523,Severe combined immunodeficiency due to LAT deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=504523
504530,Combined immunodeficiency due to Moesin deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=504530
26793,Very long chain acyl-CoA dehydrogenase deficiency,0.0 (Europe); 3.2 (Australia); 1.8 (United States); 2.0 (Germany); 2.3 (Israel); 4.3 (Specific population); 0.45 (Czech Republic),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=26793
29072,Hereditary pheochromocytoma-paraganglioma,0.3 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=29072
28378,Tyrosinemia type 2,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=28378
29207,Reactive arthritis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=29207
29073,Multiple myeloma,"3.8 (United States); 6.0 (Worldwide); 11.9 (Europe); 7.7 (France); 2.4 (Europe); 5.6 (United States); 2.0 (Iran, Islamic Republic of); 5.1 (Australia); 6.2 (Denmark)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=29073
29822,Spontaneous periodic hypothermia,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=29822
30391,Isolated biliary atresia,10.6 (Specific population); 2.9 (Europe); 0.0 (Europe); 2.9 (Belgium); 5.9 (France); 11.9 (Germany); 4.2 (Italy); 16.6 (Netherlands); 1.6 (Norway); 1.9 (Spain); 12.6 (Switzerland); 2.3 (United Kingdom); 12.7 (Ukraine); 18.5 (Worldwide); 7.4 (Japan); 7.0 (United States); 32.0 (French Polynesia); 7.0 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=30391
320,Apparent mineralocorticoid excess,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=320
724,Idiopathic acute eosinophilic pneumonia,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=724
230,Dopamine beta-hydroxylase deficiency,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=230
725,Developmental and epileptic encephalopathy with spike-wave activation in sleep,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=725
590,Congenital myasthenic syndrome,0.3 (Europe); 0.92 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=590
404,Familial hyperaldosteronism type II,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=404
756,Pseudohypoaldosteronism type 1,2.12 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=756
162,Congenital cataract-anterior segment dysgenesis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=162
544,Diffuse large B-cell lymphoma,43.0 (Europe); 6.5 (France); 2.79 (Europe); 0.765 (Croatia); 0.298 (Latvia); 2.227 (Austria); 5.51 (Belgium); 1.229 (Bulgaria); 3.304 (Czech Republic); 3.815 (Estonia); 1.244 (Finland); 4.586 (Germany); 4.559 (Iceland); 3.458 (Ireland); 6.47 (Italy); 2.984 (Lithuania); 2.827 (Malta); 5.115 (Norway); 1.673 (Poland); 2.635 (Portugal); 3.259 (Slovakia); 4.773 (Slovenia); 4.78 (Spain); 6.328 (Switzerland); 6.478 (Netherlands); 4.931 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544
545,Follicular lymphoma,37.0 (Europe); 3.95 (France); 2.192 (Europe); 0.348 (Bulgaria); 0.72 (Estonia); 0.579 (Finland); 0.363 (Latvia); 0.277 (Lithuania); 0.368 (Poland); 1.52 (Austria); 3.04 (Belgium); 1.665 (Croatia); 1.687 (Czech Republic); 2.456 (Germany); 2.769 (Iceland); 2.08 (Ireland); 2.541 (Italy); 1.759 (Malta); 3.298 (Norway); 1.364 (Portugal); 1.046 (Slovakia); 1.389 (Slovenia); 2.375 (Spain); 2.916 (Switzerland); 2.977 (Netherlands); 2.766 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=545
88,Idiopathic aplastic anemia,0.4 (Europe); 0.27 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88
102,Multiple system atrophy,3.7 (Europe); 3.5 (Worldwide); 1.8 (Worldwide); 0.7 (Iceland); 3.4 (Iceland); 2.1 (Sweden); 4.4 (United Kingdom); 0.6 (United States); 1.9 (France); 0.11 (Russian Federation); 4.9 (Italy); 10.3 (Japan); 2.3 (Faroe Islands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=102
824,Primary myelofibrosis,1.0 (Europe); 3.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=824
748,Mendelian susceptibility to mycobacterial diseases,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=748
729,Polycythemia vera,1.9 (Europe); 30.0 (Europe); 30.0 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=729
25980,X-linked myopathy with excessive autophagy,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=25980
26137,Juvenile temporal arteritis,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=26137
26106,Hereditary diffuse gastric cancer,1.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=26106
505395,Ventilator-induced diaphragmatic dysfunction,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505395
25968,Self-limited childhood occipital epilepsy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=25968
26790,Pseudomyxoma peritonei,0.1 (Worldwide); 0.2 (Netherlands); 0.0 (Worldwide); 2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=26790
26792,Short chain acyl-CoA dehydrogenase deficiency,0.0 (Worldwide); 2.0 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=26792
26791,Multiple acyl-CoA dehydrogenase deficiency,0.47 (United States); 0.0 (Europe); 0.5 (Israel); 1.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=26791
49,Penile agenesis,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=49
227,Diphallia,0.02 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=227
674,Accessory pancreas,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=674
266,Autosomal dominant limb-girdle muscular dystrophy type 1A,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=266
353,Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5,0.2 (Europe); 0.13 (United Kingdom); 0.18 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=353
219,Delta-sarcoglycan-related limb-girdle muscular dystrophy R6,0.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=219
641,Multifocal motor neuropathy,1.5 (Worldwide); 0.16 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641
119,Beta-sarcoglycan-related limb-girdle muscular dystrophy R4,0.07 (United Kingdom); 0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=119
603,"Distal myopathy, Welander type",100.0 (Sweden); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=603
505227,Combined immunodeficiency due to GINS1 deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505227
505237,Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505237
588,Muscle-eye-brain disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=588
899,Walker-Warburg syndrome,0.03 (United Kingdom); 1.65 (Europe); 0.0 (Europe); 1.2 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=899
505216,3-methylglutaconic aciduria type 9,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505216
272,"Congenital muscular dystrophy, Fukuyama type",2.8 (Japan); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=272
505208,3-methylglutaconic aciduria type 8,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505208
268,Dysferlin-related limb-girdle muscular dystrophy R2,0.13 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=268
263,Limb-girdle muscular dystrophy,0.81 (Netherlands); 2.27 (United Kingdom); 0.0 (Europe); 1.55 (Japan); 2.32 (Worldwide); 5.7 (Egypt); 6.9 (Spain); 1.1 (Ireland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=263
600,Vocal cord and pharyngeal distal myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600
505248,Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505248
609,Tibial muscular dystrophy,6.0 (Europe); 20.0 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=609
602,GNE myopathy,1.0 (Worldwide); 66.7 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=602
505242,Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505242
508093,MEPAN syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508093
508533,Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508533
508542,Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508542
508512,Intrauterine growth restriction-congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508512
508529,Intermediate epidermolysis bullosa simplex with cardiomyopathy,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508529
508523,Hyperphenylalaninemia due to DNAJC12 deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508523
508488,8q24.3 microdeletion syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508488
508476,Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508476
508501,Oral-facial-digital syndrome with short stature and brachymesophalangy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508501
508498,Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=508498
505652,CDKL5-deficiency disorder,0.0 (Worldwide); 0.21 (Australia); 2.36 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505652
506307,Stromme syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=506307
506358,Gabriele-de Vries syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=506358
506353,Autosomal recessive complex spastic paraplegia due to Kennedy pathway dysfunction,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=506353
495274,Charcot-Marie-Tooth disease type 2T,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=495274
495844,C11ORF73-related autosomal recessive hypomyelinating leukodystrophy,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=495844
495818,9q33.3q34.11 microdeletion syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=495818
495879,Congenital agenesis of the scrotum,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=495879
495875,Congenital labioscrotal agenesis-cerebellar malformation-corneal dystrophy-facial dysmorphism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=495875
495930,Familial monosomy 7 syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=495930
496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,39.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=496641
496686,Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome,0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=496686
496689,Kyphoscoliosis-lateral tongue atrophy-hereditary spastic paraplegia syndrome,0.0 (Worldwide); 12.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=496689
496693,Omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=496693
496751,EVEN-plus syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=496751
496756,Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=496756
496790,Ocular anomalies-axonal neuropathy-developmental delay syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=496790
494433,MIRAGE syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494433
494439,Retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494439
494424,Extracranial carotid artery aneurysm,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494424
494428,Idiopathic pleuroparenchymal fibroelastosis,0.0 (Worldwide); 37.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494428
494444,DIAPH1-related sensorineural hearing loss-thrombocytopenia syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494444
494344,RERE-related neurodevelopmental syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494344
494547,Squamous cell carcinoma of the hypopharynx,1.27 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494547
494541,Childhood-onset benign chorea with striatal involvement,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494541
494526,Infantile-onset generalized dyskinesia with orofacial involvement,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494526
494550,Squamous cell carcinoma of the larynx,4.61 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=494550
500180,Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500180
500188,X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500188
68,Amoebiasis due to free-living amoebae,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=68
781,Q fever,0.03 (United States); 3.0 (Australia); 0.0 (Europe); 0.16 (Europe); 0.08 (Belgium); 0.26 (Bulgaria); 0.4 (Croatia); 0.32 (Cyprus); 0.04 (Finland); 0.26 (France); 0.26 (Germany); 0.1 (Greece); 0.64 (Hungary); 0.06 (Ireland); 0.07 (Latvia); 0.04 (Luxembourg); 0.1 (Malta); 0.18 (Netherlands); 0.2 (Portugal); 0.1 (Romania); 0.1 (Slovenia); 0.0 (Sweden); 0.1 (United Kingdom); 0.05 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=781
500150,Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500150
500159,Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500159
500163,Witteveen-Kolk syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500163
302,Inherited epidermodysplasia verruciformis,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=302
297,Tick-borne encephalitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=297
182,Chromomycosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=182
128,Diphyllobothriasis,0.88 (France); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=128
210,Cyclosporiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=210
76,Strongyloidiasis,0.0 (Worldwide); 0.06 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=76
74,Angiostrongyliasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=74
108,Babesiosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=108
78,Ankylostomiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=78
500135,Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500135
500144,Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500144
500055,Hao-Fountain syndrome due to 16p13.2 microdeletion,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500055
500095,Tall stature-intellectual disability-renal anomalies syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500095
500062,Infantile-onset periodic fever-panniculitis-dermatosis syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500062
129,Pseudopelade of Brocq,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=129
123,Björnstad syndrome,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=123
898,Wagner disease,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=898
500478,Squamous cell carcinoma of the oropharynx,3.12 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500478
518,Acute megakaryoblastic leukemia,0.0 (Europe); 0.02 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=518
318,Acute erythroid leukemia,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=318
514,Acute monoblastic/monocytic leukemia,0.13 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=514
517,Acute myelomonocytic leukemia,0.0 (Europe); 0.17 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=517
505,Graham Little-Piccardi-Lassueur syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=505
346,Quinquaud folliculitis decalvans,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=346
222,Erosive pustular dermatosis of the scalp,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=222
202,Crandall syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=202
170,Woolly hair,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=170
500548,Osteosclerotic metaphyseal dysplasia,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500548
169,Ringed hair disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=169
500533,Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500533
168,Loose anagen syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=168
500545,Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500545
345,Dissecting cellulitis of the scalp,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=345
591,Furuncular myiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=591
723,Pneumocystosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=723
472,Isosporiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=472
401,Hymenolepiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=401
400,Cystic echinococcosis,1.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=400
500464,Squamous cell carcinoma of the nasal cavity and paranasal sinuses,0.35 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=500464
520,Acute promyelocytic leukemia,0.28 (United States); 0.11 (Europe); 0.3 (France); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=520
450,Heterotaxia,10.0 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=450
529,Roch-Leri mesosomatous lipomatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529
224,Neonatal diabetes mellitus,1.1 (Europe); 1.1 (Italy); 1.12 (Germany); 0.62 (Austria); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=224
826,Sporotrichosis,0.0 (Worldwide); 2500.0 (Mexico); 54.0 (Peru),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=826
879,Tungiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=879
502363,Squamous cell carcinoma of the oral cavity,3.51 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=502363
502366,Squamous cell carcinoma of the lip,1.02 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=502366
502423,Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=502423
502430,Weiss-Kruszka Syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=502430
502434,STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=502434
502437,4q25 proximal deletion syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=502437
502444,Alkaline ceramidase 3 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=502444
91,Aromatase deficiency,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91
785,Estrogen resistance syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=785
873,Desmoid tumor,0.3 (Europe); 0.33 (Finland); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=873
679,Malignant atrophic papulosis,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=679
901,Wells syndrome,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=901
703,Bullous pemphigoid,2.17 (France); 1.34 (Germany); 4.3 (United Kingdom); 1.21 (Switzerland); 25.0 (Europe); 25.93 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=703
841,Sebocystomatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=841
817,Peeling skin syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=817
867,Familial multiple trichoepithelioma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=867
735,Porokeratosis of Mibelli,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=735
497906,Childhood-onset basal ganglia degeneration syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=497906
659,Mutilating palmoplantar keratoderma with periorificial keratotic plaques,73.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=659
737,Porokeratosis plantaris palmaris et disseminata,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=737
497623,C12ORF65-related combined oxidative phosphorylation defect,0.0 (Worldwide); 30.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=497623
523,Hereditary leiomyomatosis and renal cell cancer,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=523
497757,MME-related autosomal dominant Charcot Marie Tooth disease type 2,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=497757
497764,Spinocerebellar ataxia type 43,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=497764
530,Lipoid proteinosis,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=530
497188,Diffuse intrinsic pontine glioma,0.056 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=497188
454,Acquired ichthyosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=454
617,Congenital primary megaureter,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617
488,Urachal cyst,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488
105,Atresia of urethra,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=105
237,Duplication of urethra,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=237
721,Gray platelet syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=721
722,Hypoplasminogenemia,0.16 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=722
853,Fetal and neonatal alloimmune thrombocytopenia,39.6307 (Worldwide); 66.6667 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=853
498359,Aquagenic palmoplantar keratoderma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498359
465,Congenital plasminogen activator inhibitor type 1 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=465
310,Reflex epilepsy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=310
498251,Menstrual cycle-dependent periodic fever,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498251
1332,Medullary thyroid carcinoma,5.0 (Europe); 0.17 (United States); 0.22 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1332
877,Neuroendocrine neoplasm,3.2 (Norway); 5.25 (United States); 2.53 (Europe); 35.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=877
73,Gorham-Stout disease,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73
498228,Phyllodes tumor of the prostate,90.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498228
728,Relapsing polychondritis,0.35 (United States); 0.35 (Worldwide); 0.0 (Worldwide); 0.071 (United Kingdom); 0.52 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=728
467,Non-acquired combined pituitary hormone deficiency,29.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=467
142,Anaplastic thyroid carcinoma,0.17 (Europe); 0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=142
143,Parathyroid carcinoma,0.02 (Europe); 0.0 (Europe); 0.28 (Europe); 0.0 (United States); 0.015 (Austria); 0.027 (Belgium); 0.013 (Bulgaria); 0.037 (Croatia); 0.015 (Czech Republic); 0.009 (Estonia); 0.045 (Finland); 0.017 (Germany); 0.043 (Iceland); 0.031 (Ireland); 0.052 (Italy); 0.011 (Latvia); 0.008 (Lithuania); 0.031 (Malta); 0.016 (Norway); 0.005 (Poland); 0.008 (Portugal); 0.005 (Slovakia); 0.006 (Slovenia); 0.045 (Spain); 0.011 (Switzerland); 0.015 (Netherlands); 0.037 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=143
786,Generalized glucocorticoid resistance syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=786
1461,Criss-cross heart,0.8 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1461
875,Primary pediatric heart tumor,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=875
615,Familial atrial myxoma,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=615
874,Primary adult heart tumor,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=874
499009,Congenital syphilis,1.3 (Europe); 15.7 (United States); 15.7 (United States); 1.3 (Europe); 26.6 (Bulgaria); 1.3 (Czech Republic); 1.04 (Denmark); 1.1 (Greece); 1.7 (Hungary); 1.1 (Italy); 4.6 (Lithuania); 1.9 (Poland); 5.4 (Portugal); 2.5 (Romania); 0.3 (Sweden); 0.3 (Germany); 0.8 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=499009
1330,Partial atrioventricular septal defect,20.0 (Europe); 30.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1330
1677,Familial idiopathic dilatation of the right atrium,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1677
498497,Short rib-polydactyly syndrome type 5,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498497
720,Pili bifurcati,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=720
671,Primary cutis verticis gyrata,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=671
864,Trichofolliculoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=864
498602,Sugarman brachydactyly,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498602
247,Inherited arrhythmogenic cardiomyopathy,43.5 (Italy); 20.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=247
498693,MYBPC1-related autosomal recessive non-lethal arthrogryposis multiplex congenita syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498693
444,Marie Unna hereditary hypotrichosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=444
2221,Acquired hypertrichosis lanuginosa,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2221
498474,Hyaline fibromatosis syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498474
499,Kerion celsi,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=499
498485,Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498485
573,Monilethrix,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=573
498488,Overgrowth syndrome with 2q37 translocation,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=498488
525,Lichen planopilaris,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=525
700,Alopecia totalis,10.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=700
840,Syringocystadenoma papilliferum,730.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=840
315,Erythrokeratoderma ''en cocardes'',0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=315
409,Hyperkeratosis lenticularis perstans,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=409
41,Dyschromatosis symmetrica hereditaria,300.0 (Worldwide); 0.0 (Worldwide); 1.5 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=41
122,Birt-Hogg-Dubé syndrome,0.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=122
38,Acrokeratoelastoidosis of Costa,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=38
39,Acromelanosis,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=39
316,Progressive symmetric erythrokeratodermia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=316
658,Non-histaminic angioedema,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=658
3282,Multifocal atrial tachycardia,0.67 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3282
188,Systemic capillary leak syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=188
303,Dystrophic epidermolysis bullosa,0.572 (Europe); 0.6 (Spain); 0.39 (Australia); 0.14 (United States); 0.28 (Romania); 0.83 (Netherlands); 1.41 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=303
305,Junctional epidermolysis bullosa,0.0 (Worldwide); 0.0 (Europe); 0.08 (Sweden); 0.07 (Ireland); 0.02 (Finland); 0.38 (Italy); 0.07 (Australia); 0.02 (Japan); 0.22 (United States); 0.04 (United States); 0.07 (South Africa); 0.93 (Netherlands); 0.21 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=305
3406,Ulerythema ophryogenesis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=3406
2908,Kindler epidermolysis bullosa,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2908
81,Antisynthetase syndrome,3.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=81
563,Peripartum cardiomyopathy,30.0 (Worldwide); 36.0 (United States); 89.0 (Singapore); 5.0 (Japan); 334.0 (Haiti); 100.0 (South Africa); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=563
764,Pyomyositis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=764
779,Reynolds syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=779
838,Susac syndrome,304.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=838
889,Cutaneous small vessel vasculitis,2.7 (Norway); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=889
482,Kimura disease,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=482
486811,Prenatal-onset spinal muscular atrophy with congenital bone fractures,0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=486811
486815,Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=486815
485418,EMILIN-1-related connective tissue disease,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=485418
485421,MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=485421
485405,16p12.1p12.3 triplication syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=485405
485350,CLCN4-related X-linked intellectual disability syndrome,0.0 (Worldwide); 38.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=485350
485358,Propylthiouracil embryofetopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=485358
482606,X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=482606
482601,Adenylosuccinate synthetase-like 1-related distal myopathy,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=482601
31828,Digitalis poisoning,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31828
480864,Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480864
31837,Pulmonary venoocclusive disease,0.015 (France); 0.015 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31837
480907,X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480907
480898,Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480898
480880,X-linked female restricted facial dysmorphism-short stature-choanal atresia-intellectual disability,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480880
31740,Hypersensitivity pneumonitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31740
480556,Isolated neonatal sclerosing cholangitis,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480556
31709,Infantile convulsions and choreoathetosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31709
31826,Ethylene glycol poisoning,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31826
480851,Hereditary thrombocytopenia with early-onset myelofibrosis,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480851
31827,Paraquat poisoning,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31827
31824,Colchicine poisoning,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31824
480682,POGLUT1-related limb-girdle muscular dystrophy R21,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480682
31825,Methanol poisoning,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31825
481665,USP18 deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=481665
482077,HTRA1-related autosomal dominant cerebral small vessel disease,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=482077
481152,PYCR2-related microcephaly-progressive leukoencephalopathy,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=481152
481662,Familial Chilblain lupus,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=481662
480476,Progressive familial intrahepatic cholestasis type 5,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480476
480491,MYO5B-related progressive familial intrahepatic cholestasis,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480491
480483,Progressive familial intrahepatic cholestasis type 4,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480483
480528,Lethal hydranencephaly-diaphragmatic hernia syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480528
480536,MSH3-related attenuated familial adenomatous polyposis,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480536
480520,Caroli syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=480520
477814,Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477814
477781,Primary condylar hyperplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477781
477787,Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477787
478029,Combined oxidative phosphorylation defect type 29,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=478029
478042,Combined oxidative phosphorylation defect type 30,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=478042
477993,Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477993
477857,Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477857
477817,PMP22-RAI1 contiguous gene duplication syndrome,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477817
477831,Kosaki overgrowth syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477831
478049,Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=478049
478664,Hereditary sensory and autonomic neuropathy type 8,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=478664
477650,Fibroblastic rheumatism,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477650
477661,IL21-related infantile inflammatory bowel disease,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477661
477684,Combined oxidative phosphorylation defect type 26,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477684
477673,Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477673
477749,Pontine autosomal dominant microangiopathy with leukoencephalopathy,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477749
477742,Nodular fasciitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477742
477774,Combined oxidative phosphorylation defect type 27,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=477774
476119,Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=476119
476113,Combined immunodeficiency due to TFRC deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=476113
476126,Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=476126
476406,Congenital generalized hypercontractile muscle stiffness syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=476406
476394,PMP2-related Charcot-Marie-Tooth disease type 1,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=476394
493342,Vibratory urticaria,37.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=493342
488642,TELO2-related intellectual disability-neurodevelopmental disorder,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488642
488647,DDX41-related hematologic malignancy predisposition syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488647
488650,"Distal myopathy, Tateyama type",0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488650
488618,Transketolase deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488618
488627,Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488627
488632,TBCK-related intellectual disability syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488632
488635,Early-onset epilepsy-intellectual disability-brain anomalies syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488635
488239,Acute macular neuroretinopathy,101.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488239
488232,Split-foot malformation-mesoaxial polydactyly syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488232
488333,Autosomal dominant Charcot-Marie-Tooth disease type 2W,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488333
488280,14q32 duplication syndrome,33.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488280
488437,SIX2-related frontonasal dysplasia,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488437
488434,"Camptodactyly syndrome, Guadalajara type 3",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488434
488613,Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488613
488594,Autosomal recessive spastic paraplegia type 76,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488594
488197,Familial progressive retinal dystrophy-iris coloboma-congenital cataract syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488197
488168,Microcephaly-congenital cataract-psoriasiform dermatitis syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488168
488191,Female infertility due to oocyte meiotic arrest,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=488191
487796,Takenouchi-Kosaki syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=487796
487814,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=487814
487809,Pediatric collagenous gastritis,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=487809
487825,Pierpont syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=487825
31205,Rat-bite fever,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31205
31204,Nocardiosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31204
31202,Melioidosis,0.0 (Worldwide); 50.0 (Australia); 50.0 (Thailand),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31202
31150,Tangier disease,185.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31150
31043,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement,110.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31043
31112,Dermatofibrosarcoma protuberans,10.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=31112
30924,Primary hypomagnesemia with secondary hypocalcemia,100.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=30924
30925,Hereditary arginine vasopressin deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=30925
476084,BVES-related limb-girdle muscular dystrophy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=476084
476096,Erythrokeratodermia-cardiomyopathy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=476096
476093,Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=476093
71278,Congenital brain dysgenesis due to glutamine synthetase deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71278
71279,CANOMAD syndrome,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71279
71271,Split hand-split foot-deafness syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71271
71272,Sandifer syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71272
71273,Renal nutcracker syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71273
71274,Disseminated peritoneal leiomyomatosis,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71274
71275,Rh deficiency syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71275
71276,Silent sinus syndrome,558.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71276
71277,Classic glucose transporter type 1 deficiency syndrome,0.26 (Norway); 1.11 (Australia); 0.538 (Worldwide); 1.2 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71277
71212,Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency,10.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71212
71211,Neuromyelitis optica spectrum disorder,"0.73 (Martinique); 0.054 (Austria); 0.1877 (Worldwide); 2.071 (Worldwide); 0.7 (Austria); 0.08 (United Kingdom); 1.43 (United Kingdom); 0.09 (Netherlands); 0.063 (Spain); 0.89 (Spain); 0.07 (Denmark); 1.09 (Denmark); 0.079 (Sweden); 1.04 (Sweden); 0.132 (Hungary); 1.91 (Hungary); 0.037 (Australia); 0.7 (Australia); 0.07 (United States); 3.9 (United States); 0.495 (India); 0.495 (Canada); 2.6 (India); 3.42 (Japan); 0.39 (Malaysia); 1.94 (Malaysia); 1.51 (Iran, Islamic Republic of); 0.053 (Cuba); 0.52 (Cuba); 10.0 (Martinique); 0.285 (Costa rica)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71211
71267,Dentinogenesis imperfecta-short stature-hearing loss-intellectual disability syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71267
71213,Retinal capillary malformation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71213
71198,Rare pulmonary hypertension,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71198
558411,Idiopathic gastroparesis,11.4 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=558411
70591,Chronic thromboembolic pulmonary hypertension,0.0 (Worldwide); 4.2 (Europe); 5.1 (United States); 1.9 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70591
70592,Transient predisposition to invasive pyogenic bacterial infection,49.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70592
70589,Bronchopulmonary dysplasia,13.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70589
70595,Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70595
70596,Congenital Epstein-Barr virus infection,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70596
70593,Immunodeficiency due to selective anti-polysaccharide antibody deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70593
70594,Dopa-responsive dystonia due to sepiapterin reductase deficiency,43.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70594
70578,Adult acute respiratory distress syndrome,64.0 (United States); 51.0 (United States); 11.5 (Iceland); 7.2 (Spain); 4.9 (Finland); 13.5 (Sweden); 13.5 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70578
70573,Small cell lung cancer,12.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70573
70568,Post-transplant lymphoproliferative disease,26.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70568
70588,Meconium aspiration syndrome,2.44 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70588
70472,"Congenital lactic acidosis, Saguenay-Lac-Saint-Jean type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70472
70567,Cholangiocarcinoma,4.2 (Worldwide); 2.1 (Worldwide); 1.0 (United States); 113.0 (Thailand); 5.5 (Japan); 0.1 (Australia); 4.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70567
70482,Carcinoma of esophagus,"7.0 (Worldwide); 7.1 (Europe); 6.67 (Europe); 12.2 (Europe); 5.5 (United States); 9.8 (Worldwide); 6.873 (France); 10.82 (United Kingdom); 3.9 (India); 20.0 (China); 2.3 (Africa); 9.0 (Japan); 3.9 (Canada); 8.0 (Russian Federation); 13.0 (Latin America); 0.34 (Iran, Islamic Republic of); 3.293 (Austria); 7.892 (Belgium); 1.194 (Bulgaria); 3.281 (Croatia); 3.718 (Czech Republic); 3.473 (Estonia); 3.83 (Finland); 5.854 (Germany); 4.772 (Iceland); 7.2 (Ireland); 3.612 (Italy); 3.372 (Latvia); 3.468 (Lithuania); 2.575 (Malta); 3.592 (Norway); 2.414 (Poland); 4.592 (Portugal); 4.54 (Slovakia); 3.904 (Slovenia); 4.777 (Spain); 6.413 (Switzerland); 8.362 (Netherlands)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70482
70476,Vernal keratoconjunctivitis,151.0 (Italy); 45.5 (Finland); 49.5 (Sweden); 26.0 (Netherlands); 20.0 (France); 11.0 (Norway); 32.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70476
70475,Radiation proctitis,35.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70475
69744,Circumscribed palmoplantar hypokeratosis,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69744
69745,Warty dyskeratoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69745
69735,Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69735
69736,Bilateral acute depigmentation of the iris,62.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69736
69737,Bosley-Salih-Alorainy syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69737
69739,Athabaskan brainstem dysgenesis syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69739
69663,Low phospholipid-associated cholelithiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69663
69665,Intrahepatic cholestasis of pregnancy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69665
69723,Tyrosinemia type 3,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69723
69126,PAPA syndrome,53.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69126
69087,Naegeli-Franceschetti-Jadassohn syndrome,0.035 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69087
69125,Anonychia with flexural pigmentation,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69125
69088,Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69088
69083,"Ectodermal dysplasia with natal teeth, Turnpenny type",0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69083
69082,Odonto-tricho-ungual-digito-palmar syndrome,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69082
69085,Limb-mammary syndrome,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69085
69084,Pure hair and nail ectodermal dysplasia,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69084
69077,Rhabdoid tumor,500.0 (Worldwide); 0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69077
69076,Familial renal glucosuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69076
69078,Liposarcoma,1.0 (Europe); 0.59 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69078
69061,Idiopathic steroid-sensitive nephrotic syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69061
69063,Congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69063
67048,3-methylglutaconic aciduria type 4,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67048
69028,Dysostosis with brachydactyly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=69028
67046,3-methylglutaconic aciduria type 1,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67046
67047,3-methylglutaconic aciduria type 3,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67047
67044,Thrombocytopenia with congenital dyserythropoietic anemia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67044
67045,X-linked intellectual disability with isolated growth hormone deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67045
67042,Late-onset retinal degeneration,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67042
67043,Amoebic keratitis,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67043
67039,Segmental odontomaxillary dysplasia,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67039
67041,Hyaluronidase deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67041
67038,B-cell chronic lymphocytic leukemia,48.0 (Europe); 7.05 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67038
67036,Autosomal dominant optic atrophy and cataract,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=67036
66646,Cutaneous mastocytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66646
66637,Diaphanospondylodysostosis,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66637
66634,Dilated cardiomyopathy with ataxia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66634
66633,Sensorineural hearing loss-early graying-essential tremor syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66633
66631,CEDNIK syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66631
66630,Congenital pseudoarthrosis of the clavicle,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66630
66629,Goldberg-Shprintzen megacolon syndrome,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66629
66628,Obesity due to congenital leptin deficiency,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66628
66627,Tenosynovial giant cell tumor,20.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66627
66625,Cerebrooculonasal syndrome,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66625
66624,PANDAS,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66624
66529,Tako-Tsubo cardiomyopathy,0.0 (Worldwide); 2.98 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66529
66518,Short fifth metacarpals-insulin resistance syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=66518
65283,Timothy syndrome,56.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65283
65282,Carvajal syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65282
562639,Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=562639
65285,Lhermitte-Duclos disease,220.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65285
65287,Beta-ureidopropionase deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65287
65286,3q29 microdeletion syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65286
65681,Vaginal atresia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65681
65288,Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65288
65683,Isolated focal cortical dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65683
65682,Benign recurrent intrahepatic cholestasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65682
65720,Arthrogryposis-severe scoliosis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65720
65684,Monomelic amyotrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65684
65748,Multiple self-healing squamous epithelioma,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65748
65743,Autosomal dominant multiple pterygium syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65743
65759,Carpenter syndrome,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65759
65753,Charcot-Marie-Tooth disease type 1,17.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=65753
64744,IgG4-related thyroid disease,1.06 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64744
64745,Pruritic urticarial papules and plaques of pregnancy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64745
64746,Autosomal dominant Charcot-Marie-Tooth disease type 2,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64746
64747,X-linked Charcot-Marie-Tooth disease,1.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64747
64748,Dejerine-Sottas syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64748
64749,Charcot-Marie-Tooth disease type 4,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64749
562509,Heme oxygenase-1 deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=562509
64752,Hereditary sensory and autonomic neuropathy type 5,0.0 (Europe); 0.035 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64752
64753,Spinocerebellar ataxia with axonal neuropathy type 2,0.11 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64753
64754,Nevus comedonicus syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64754
562528,Congenital limbs-face contractures-hypotonia-developmental delay syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=562528
64755,Becker nevus syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64755
562559,Anterior maxillary protrusion-strabismus-intellectual disability syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=562559
562569,TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=562569
64542,"Acrofacial dysostosis, Kennedy-Teebi type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64542
64280,Childhood absence epilepsy,5.0 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64280
64720,Leiomyosarcoma,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64720
64739,Ovarian hyperstimulation syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64739
64734,Iridocorneal endothelial syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64734
64743,Hepatoportal sclerosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64743
64742,Pleuropulmonary blastoma,0.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64742
64741,Pulmonary blastoma,350.0 (Worldwide); 0.0 (Worldwide); 0.0 (Europe); 0.002 (Belgium); 0.005 (Finland); 0.001 (Germany); 0.002 (Italy); 0.002 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64741
63259,Iniencephaly,50.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63259
63442,Angel-shaped phalango-epiphyseal dysplasia,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63442
63273,Distal myopathy with posterior leg and anterior hand involvement,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63273
63275,Pemphigoid gestationis,0.2 (Germany); 0.05 (France); 0.18 (Kuwait); 0.693 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63275
63454,Pattern dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63454
63455,Paraneoplastic pemphigus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63455
63443,Rare epithelial tumor of stomach,18.6 (Europe); 49.17 (Europe); 7.5 (United States); 24.0 (United States); 11.2 (United Kingdom); 3.9 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63443
63446,Acrocapitofemoral dysplasia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63446
63862,Schisis association,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=63862
60040,Megalencephaly-capillary malformation-polymicrogyria syndrome,170.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60040
60039,Pudendal nerve entrapment syndrome,0.0 (Worldwide); 16.67 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60039
60041,Congenital heart block,4.54 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60041
60032,Recurrent respiratory papillomatosis,4.0 (Netherlands); 0.16 (Netherlands); 2.34 (United States); 0.76 (Denmark); 1.42 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60032
60033,Idiopathic bronchiectasis,1.8 (Finland); 29.0 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60033
59303,Neonatal ichthyosis-sclerosing cholangitis syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=59303
59305,Gestational trophoblastic neoplasm,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=59305
59306,McLeod neuroacanthocytosis syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=59306
59298,Schilder disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=59298
60015,Enlarged parietal foramina,4.3 (Europe); 3.7 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60015
564003,Osteochondrosis of the metatarsal bone,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=564003
60025,Pulmonary alveolar microlithiasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60025
563991,Osteochondrosis of the tarsal bone,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=563991
60026,Pulmonary nodular lymphoid hyperplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60026
564178,Primary hypomagnesemia-refractory seizures-intellectual disability syndrome,0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=564178
60030,Loeys-Dietz syndrome,52.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60030
59315,Rhombencephalosynapsis,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=59315
60014,Argyria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60014
57196,Medial condensing osteitis of the clavicle,58.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=57196
563690,Furuncular myiasis due to Cordylobia rodhaini,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=563690
57145,SUNCT syndrome,6.7 (Europe); 6.7 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=57145
563684,Furuncular myiasis due to Dermatobia hominis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=563684
563687,Furuncular myiasis due to Cordylobia anthropophaga,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=563687
56970,Human prion disease,0.15 (Europe); 0.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=56970
56425,Cold agglutinin disease,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=56425
59181,Sorsby pseudoinflammatory fundus dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=59181
59135,Laing distal myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=59135
58017,Classic hairy cell leukemia,0.29 (Europe); 3.12 (Europe); 0.33 (United States); 0.29 (United Kingdom); 0.24 (Israel); 0.47 (Iceland); 0.035 (Hong Kong); 0.37 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=58017
57782,Mazabraud syndrome,54.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=57782
55595,TNP03-related limb-girdle muscular dystrophy D2,64.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=55595
55596,HNRNPDL-related limb-girdle muscular dystrophy D3,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=55596
54595,Craniopharyngioma,1.0 (Worldwide); 2.0 (Europe); 0.19 (United States); 0.17 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54595
54368,Sarcocystosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54368
54370,Primary membranoproliferative glomerulonephritis,16.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54370
54272,Hepatocellular adenoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54272
56304,Atelosteogenesis type II,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=56304
56305,Atelosteogenesis type III,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=56305
56044,Carcinoma of gallbladder and extrahepatic biliary tract,12.0 (Worldwide); 5.3 (Japan); 1.5 (United States); 14.0 (Poland); 1.27 (France); 0.0 (Europe); 4.37 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=56044
55880,Chondrosarcoma,0.24 (Europe); 0.0 (Europe); 3.55 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=55880
55881,Adamantinoma,0.01 (Europe); 0.0 (Worldwide); 0.11 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=55881
55654,Hypotrichosis simplex,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=55654
565858,Craniosynostosis-microretrognathia-severe intellectual disability syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=565858
565788,Infantile inflammatory bowel disease with neurological involvement,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=565788
79213,Mucopolysaccharidosis,"4.5 (Netherlands); 3.9 (Australia); 4.8 (Portugal); 3.53 (Germany); 2.22 (Sweden); 3.08 (Norway); 1.77 (Denmark); 1.81 (Poland); 3.72 (Czech Republic); 2.29 (Tunisia); 2.04 (Taiwan, Province of China); 4.05 (Estonia); 0.0 (Worldwide); 0.0 (Europe); 1.53 (Japan); 1.56 (Switzerland); 1.25 (Brazil); 16.9 (Saudi Arabia); 1.35 (Korea, Republic of); 0.98 (United States); 0.267 (United States); 1.04 (Brazil)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79213
565899,POMGNT2-related limb-girdle muscular dystrophy R24,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=565899
565909,Calpain-3-related limb-girdle muscular dystrophy D4,0.0 (Worldwide); 47.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=565909
79233,Hypoxanthine guanine phosphoribosyltransferase partial deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79233
79230,HJV or HAMP-related hemochromatosis,74.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79230
79237,Galactokinase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79237
566067,CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=566067
79234,Crigler-Najjar syndrome type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79234
79235,Crigler-Najjar syndrome type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79235
79189,Peroxisome biogenesis disorder,2.0 (United States); 0.0 (United States); 0.2 (Japan); 0.0 (Japan); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79189
565624,Combined oxidative phosphorylation defect type 39,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=565624
565612,Primary triglyceride deposit cardiomyovasculopathy,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=565612
79201,Glycogen storage disease,1.51 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79201
565782,Methotrexate toxicity,3.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=565782
79157,2-methylbutyryl-CoA dehydrogenase deficiency,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79157
79156,Seizures-intellectual disability due to hydroxylysinuria syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79156
79155,Hydroxykynureninuria,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79155
79154,2-aminoadipic 2-oxoadipic aciduria,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79154
79153,Idiopathic trachyonychia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79153
79152,Disseminated superficial actinic porokeratosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79152
79151,Acrokeratosis verruciformis of Hopf,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79151
79149,Dermochondrocorneal dystrophy,0.0 (Worldwide); 15.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79149
79148,Elastosis perforans serpiginosa,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79148
79147,Familial reactive perforating collagenosis,0.0 (Worldwide); 50.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79147
79145,Dowling-Degos disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79145
79144,Isolated congenital onychodysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79144
79143,Isolated congenital anonychia,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79143
79172,Creatine deficiency syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79172
79168,Disorder of bile acid synthesis,0.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79168
79158,Cerebral organic aciduria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79158
79159,Isobutyryl-CoA dehydrogenase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79159
79107,Developmental malformations-deafness-dystonia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79107
566231,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=566231
79106,Eiken syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79106
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,0.0 (United States); 0.0 (Japan); 2.47 (United States); 2.4 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=566243
79118,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79118
79113,Mandibulofacial dysostosis-microcephaly syndrome,107.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79113
79102,Thyrotoxic periodic paralysis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79102
79105,Myxofibrosarcoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79105
79099,Interstitial granulomatous dermatitis with arthritis,53.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79099
79098,Sympathetic ophthalmia,0.03 (United Kingdom); 0.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79098
79101,Hyperprolinemia type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79101
566192,Congenital autosomal recessive small-platelet thrombocytopenia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=566192
79100,Atrophoderma vermiculata,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79100
79095,Congenital bile acid synthesis defect type 4,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79095
79094,Grange syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79094
566175,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=566175
79097,Folinic acid-responsive seizures,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79097
79096,Pyridoxal phosphate-responsive seizures,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79096
79138,Bickerstaff brainstem encephalitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79138
79139,Japanese encephalitis,0.65 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79139
79140,Cutaneous neuroendocrine carcinoma,0.27 (Worldwide); 4.0 (Europe); 0.13 (Europe); 0.86 (Europe); 0.06 (Finland); 2.7 (United States); 0.22 (Denmark); 0.378 (France); 0.13 (United Kingdom); 1.8 (Australia); 2.0 (New Zealand); 4.0 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79140
79141,Hereditary painful callosities,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79141
79134,DEND syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79134
79135,Episodic ataxia type 3,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79135
79136,Episodic ataxia type 4,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79136
79137,Generalized epilepsy-paroxysmal dyskinesia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79137
79129,Trichodysplasia-amelogenesis imperfecta syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79129
79133,Focal facial dermal dysplasia type I,81.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79133
79124,Hepatic veno-occlusive disease-immunodeficiency syndrome,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79124
79126,Acute interstitial pneumonia,3.8 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79126
79127,Respiratory bronchiolitis-interstitial lung disease syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79127
79128,Lymphoid interstitial pneumonia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79128
77293,Chronic visceral acid sphingomyelinase deficiency,0.4 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77293
77295,Odontoleukodystrophy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77295
77261,Gaucher disease type 3,0.05 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77261
77292,Infantile neurovisceral acid sphingomyelinase deficiency,0.25 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77292
77298,Anophthalmia/microphthalmia-esophageal atresia syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77298
77299,Microphthalmia-brain atrophy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77299
77296,Morgagni-Stewart-Morel syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77296
77297,Majeed syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77297
567502,B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=567502
77300,Auricular abnormalities-cleft lip with or without cleft palate-ocular abnormalities syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77300
77301,Monosomy 9q22.3 syndrome,42.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77301
567550,Idiopathic multidrug-resistant nephrotic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=567550
567548,Idiopathic steroid-resistant nephrotic syndrome,0.2582 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=567548
567546,Idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=567546
567544,Idiopathic non-lupus full-house nephropathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=567544
79083,PPARG-related familial partial lipodystrophy,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79083
79078,IgG4-related dacryoadenitis and sialadenitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79078
79076,Juvenile polyposis of infancy,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79076
79087,Acquired partial lipodystrophy,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79087
79086,Acquired generalized lipodystrophy,0.0 (Worldwide); 1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79086
79085,AKT2-related familial partial lipodystrophy,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79085
79084,"Familial partial lipodystrophy, Köbberling type",20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79084
567983,Parenteral nutrition-associated cholestasis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=567983
79093,Foix-Alajouanine syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79093
79091,Hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79091
79088,Localized lipodystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79088
75327,North Carolina macular dystrophy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75327
75373,Progressive bifocal chorioretinal atrophy,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75373
75374,Bradyopsia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75374
75376,Familial drusen,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75376
75377,Central areolar choroidal dystrophy,3.33 (France); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75377
75378,Oligocone trichromacy,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75378
75381,Cystoid macular dystrophy,97.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75381
75382,Oguchi disease,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75382
75389,Brain malformation-congenital heart disease-postaxial polydactyly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75389
566841,Liver adenomatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=566841
75391,Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75391
75392,Periodontal Ehlers-Danlos syndrome,62.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75392
75496,B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome,0.0 (Worldwide); 34.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75496
75497,X-linked Ehlers-Danlos syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75497
75508,Angioosteohypotrophic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75508
75563,X-linked sideroblastic anemia,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75563
566943,Mueller-Weiss syndrome,277.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=566943
75565,Tropical endomyocardial fibrosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75565
75564,Acquired idiopathic sideroblastic anemia,0.0 (Europe); 0.09 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75564
75567,Primary progressive freezing gait,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75567
75566,Loeffler endocarditis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75566
75857,6q terminal deletion syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75857
75840,Ullrich congenital muscular dystrophy,0.13 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75840
77240,Primary lymphedema,16.7 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77240
75858,MORM syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75858
77258,Trichorhinophalangeal syndrome type 1,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77258
77260,Gaucher disease type 2,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77260
77259,Gaucher disease type 1,1.0 (Europe); 2.48 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=77259
73271,Bleeding diathesis due to a collagen receptor defect,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73271
73263,Zygomycosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73263
73267,Non-24-hour sleep-wake syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73267
73256,Central neurocytoma,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73256
73260,Paracoccidioidomycosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73260
73246,Visceral neuropathy-brain anomalies-facial dysmorphism-developmental delay syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73246
569821,Congenital primary lymphedema of Gordon,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=569821
73423,Acute ackee fruit intoxication,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73423
569816,CELSR1-related late-onset primary lymphedema,0.0 (Worldwide); 11.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=569816
73272,Growth delay due to insulin-like growth factor type 1 deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73272
73273,Growth delay due to insulin-like growth factor I resistance,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73273
75326,Familial isolated retinal arteriolar tortuosity,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75326
75325,Osteosclerosis-ichthyosis-premature ovarian failure syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75325
75249,Familial isolated restrictive cardiomyopathy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75249
75234,Cholesteryl ester storage disease,2.5 (Germany); 0.8 (Specific population); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75234
75233,Wolman disease,0.19 (Australia); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=75233
568065,EPHB4-related lymphatic-related hydrops fetalis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=568065
568062,PIEZO1-related generalized lymphatic dysplasia with non-immune hydrops fetalis,0.0 (Worldwide); 10.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=568062
71493,Familial thrombocytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71493
71505,Cancer-associated retinopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71505
568056,Warts-immunodeficiency-lymphedema-anogenital dysplasia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=568056
568051,GJC2-related late-onset primary lymphedema,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=568051
71289,Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71289
71526,Obesity due to pro-opiomelanocortin deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71526
71528,Obesity due to prohormone convertase I deficiency,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71528
71529,Obesity due to melanocortin 4 receptor deficiency,50.0 (France); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71529
569164,Angiomatoid fibrous histiocytoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=569164
71517,Rapid-onset dystonia-parkinsonism,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71517
71518,Benign paroxysmal torticollis of infancy,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71518
71519,Psychogenic movement disorders,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=71519
569274,Multiple mitochondrial dysfunctions syndrome type 5,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=569274
569290,Multiple mitochondrial dysfunctions syndrome type 6,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=569290
569248,Microcystic stromal tumor,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=569248
73229,HANAC syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73229
73224,Kidney tubulopathy-dilated cardiomyopathy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73224
73245,Spinal muscular atrophy-Dandy-Walker malformation-cataracts syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73245
73230,Ossification anomalies-psychomotor developmental delay syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73230
73217,Müllerian aplasia,0.0 (Finland); 10.0 (Finland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73217
73223,Global developmental delay-osteopenia-ectodermal defect syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=73223
40366,Acitretin/etretinate embryopathy,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=40366
40923,Eales disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=40923
39812,Graft versus host disease,5.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=39812
530849,Familial apolipoprotein A5 deficiency,0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=530849
39041,Omenn syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=39041
530838,KRT1-related diffuse nonepidermolytic keratoderma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=530838
39044,Uveal melanoma,0.5 (Europe); 0.0 (Europe); 6.0 (Europe); 0.03 (Africa),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=39044
530792,RELA fusion-positive ependymoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=530792
38874,Dihydropyrimidinuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=38874
37748,Schnitzler syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=37748
37612,Episodic ataxia type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=37612
37553,Andersen-Tawil syndrome,0.1 (Europe); 0.0 (Worldwide); 0.08 (United Kingdom); 0.1 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=37553
37202,Interstitial cystitis,0.0 (Europe); 10.6 (Finland); 30.0 (United States); 0.66 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=37202
37042,Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome,195.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=37042
36913,Autoimmune hypoparathyroidism,"0.0 (Worldwide); 0.0 (Worldwide); 0.013 (Korea, Republic of); 0.023 (Denmark)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36913
36899,Myoclonus-dystonia syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36899
531151,9q21.13 microdeletion syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=531151
530983,Lamb-Shaffer syndrome,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=530983
530995,Mixed phenotype acute leukemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=530995
41751,Bietti crystalline dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=41751
42062,Iminoglycinuria,6.67 (Europe); 6.68 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=42062
35705,Neurometabolic disorder due to serine deficiency,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35705
35706,Glutaric acidemia type 3,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35706
35704,L-Arginine:glycine amidinotransferase deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35704
35710,Glucose-galactose malabsorption,0.0 (Worldwide); 0.22 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35710
35737,Morning glory disc anomaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35737
35708,Aromatic L-amino acid decarboxylase deficiency,140.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35708
35689,Primary lateral sclerosis,1.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35689
35701,3-hydroxy-3-methylglutaryl-CoA synthase deficiency,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35701
35698,Mitochondrial DNA depletion syndrome,0.0 (Worldwide); 0.5 (Israel); 1.1 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35698
35612,Nanophthalmos,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35612
35173,X-linked dominant chondrodysplasia punctata,0.25 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35173
35687,Erdheim-Chester disease,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35687
35664,ALDH18A1-related De Barsy syndrome,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35664
35656,Coenzyme Q10 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35656
35107,Desmosterolosis,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35107
35125,Epidermal nevus syndrome,400.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35125
35122,Congenital sucrase-isomaltase deficiency,20.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35122
35121,Lysosomal acid phosphatase deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35121
36387,Genetic epilepsy with febrile seizure plus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36387
36388,Paraneoplastic neurologic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36388
36397,Adiposis dolorosa,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36397
36412,Hypocomplementemic urticarial vasculitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36412
36426,Stevens-Johnson syndrome,0.36 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36426
36355,Bleeding disorder due to P2Y12 defect,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36355
36386,Hereditary sensory and autonomic neuropathy type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36386
36234,Bacterial toxic-shock syndrome,3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36234
36236,Staphylococcal scalded skin syndrome,0.01 (Germany); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36236
36238,Staphylococcal necrotizing pneumonia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36238
36237,Bullous impetigo,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36237
36273,Gastric linitis plastica,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36273
36258,Buerger disease,16.0 (Worldwide); 10.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36258
35808,Malignant sex cord stromal tumor of ovary,1.85 (Europe); 0.13 (Europe); 0.1 (United States); 0.0 (Worldwide); 0.05 (Finland); 0.043 (Iceland); 0.074 (Ireland); 0.069 (Italy); 0.094 (Malta); 0.045 (Portugal); 0.063 (Slovenia); 0.039 (Spain); 0.073 (Switzerland); 0.093 (Netherlands); 0.089 (United Kingdom); 0.133 (Austria); 0.102 (Belgium); 0.367 (Bulgaria); 0.152 (Croatia); 0.314 (Czech Republic); 0.296 (Estonia); 0.135 (Germany); 0.401 (Latvia); 0.236 (Lithuania); 0.12 (Norway); 0.232 (Poland); 0.212 (Slovakia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35808
35807,Malignant germ cell tumor of ovary,0.08 (Europe); 2.3 (Europe); 0.2 (United States); 0.0 (Worldwide); 0.072 (Austria); 0.07 (Belgium); 0.089 (Bulgaria); 0.093 (Croatia); 0.087 (Czech Republic); 0.062 (Finland); 0.065 (Germany); 0.085 (Iceland); 0.065 (Ireland); 0.065 (Italy); 0.081 (Latvia); 0.095 (Lithuania); 0.09 (Norway); 0.098 (Poland); 0.064 (Portugal); 0.075 (Slovenia); 0.072 (Spain); 0.051 (Switzerland); 0.061 (Netherlands); 0.064 (United Kingdom); 0.157 (Estonia); 0.126 (Malta); 0.141 (Slovakia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35807
35878,Hyperinsulinism-hyperammonemia syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35878
35858,Imerslund-Gräsbeck syndrome,0.5 (Finland); 0.5 (Norway); 0.0 (Worldwide); 0.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35858
35909,Combined deficiency of factor V and factor VIII,"0.5 (Europe); 1.0 (Iran, Islamic Republic of)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35909
35889,Acute opioid intoxication,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35889
36204,Intestinal lymphangiectasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=36204
35981,Polymicrogyria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35981
33572,5-oxoprolinase deficiency,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33572
33543,Kleine-Levin syndrome,0.0 (Europe); 0.18 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33543
33475,Meningococcal meningitis,0.0 (Europe); 2.3 (France); 2.7 (New Zealand); 0.8 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33475
33445,Neuroectodermal melanolysosomal disease,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33445
33408,Bullous lichen planus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33408
535458,Familial GPIHBP1 deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=535458
33402,Pediatric hepatocellular carcinoma,0.0 (Worldwide); 0.15 (Europe); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33402
34217,Naxos disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34217
33577,Nodular non-suppurative panniculitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33577
33574,Glutamate-cysteine ligase deficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33574
33573,Gamma-glutamyl transpeptidase deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33573
33110,Autosomal agammaglobulinemia,100.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33110
33111,Granulomatous slack skin,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33111
33108,Lethal multiple pterygium syndrome,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33108
33067,"Metaphyseal chondrodysplasia, Jansen type",16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33067
33069,Dravet syndrome,3.3 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33069
33001,Lymphedema-distichiasis syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33001
33355,Reticular dysgenesis,0.03 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33355
535453,Familial lipase maturation factor 1 deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=535453
33364,Trichothiodystrophy,0.0 (Worldwide); 201.0 (Worldwide); 0.12 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33364
33276,Kaposi sarcoma,0.34 (Europe); 0.0 (Europe); 2.11 (Europe); 0.051 (Austria); 0.075 (Belgium); 0.099 (Bulgaria); 0.092 (Czech Republic); 0.065 (Estonia); 0.014 (Finland); 0.076 (Germany); 0.027 (Norway); 0.043 (Poland); 0.05 (Slovakia); 0.056 (Slovenia); 0.133 (Croatia); 0.111 (Ireland); 0.108 (Latvia); 0.112 (Lithuania); 0.597 (Malta); 0.915 (Portugal); 0.546 (Spain); 0.163 (Switzerland); 0.278 (Netherlands); 0.192 (United Kingdom); 1.363 (Iceland); 1.142 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33276
33314,Jessner lymphocytic infiltration of the skin,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33314
33208,Idiopathic hypersomnia,0.0 (Worldwide); 30.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33208
33226,Waldenström macroglobulinemia,0.81 (Europe); 2.05 (France); 0.38 (United States); 0.55 (United Kingdom); 0.31 (Spain); 0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=33226
35069,Infantile neuroaxonal dystrophy,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35069
35093,Non-syndromic sagittal craniosynostosis,20.7 (Australia); 20.7 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35093
35078,T-B+ severe combined immunodeficiency due to JAK3 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35078
35062,Severe disseminated cytomegalovirus infection in immunocompetent patients,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=35062
34520,Congenital muscular dystrophy with integrin alpha-7 deficiency,0.03 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34520
34514,Telethonin-related limb-girdle muscular dystrophy R7,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34514
34515,FKRP-related limb-girdle muscular dystrophy R9,0.0 (Europe); 0.43 (United Kingdom); 1.85 (Norway),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34515
34516,DNAJB6-related limb-girdle muscular dystrophy D1,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34516
34587,Danon disease,84.0 (Worldwide); 0.0 (Worldwide); 0.05 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34587
34592,Immunodeficiency by defective expression of MHC class I,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34592
34528,Autosomal dominant primary hypomagnesemia with hypocalciuria,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34528
34533,Corneal dystrophy,110.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=34533
536516,Myopathic Ehlers-Danlos syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=536516
536471,Spondylodysplastic Ehlers-Danlos syndrome,0.0 (Worldwide); 24.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=536471
536467,B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome,41.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=536467
536545,Kyphoscoliotic Ehlers-Danlos syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=536545
536532,Classical-like Ehlers-Danlos syndrome type 2,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=536532
537072,PLG-related hereditary angioedema with normal C1Inh,105.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=537072
32960,Tumor necrosis factor receptor 1 associated periodic syndrome,0.0 (Worldwide); 0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=32960
52530,Pseudo-von Willebrand disease,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52530
52688,Myelodysplastic syndrome,1.5 (Europe); 5.02 (Europe); 4.15 (Germany); 7.0 (Germany); 6.4 (France); 1.35 (Japan); 3.35 (United States); 5.4 (Greece); 8.5 (United Kingdom); 3.5 (Sweden); 0.5 (Romania); 8.1 (Spain); 15.0 (United States); 0.0 (Europe); 1.95 (Poland); 6.2 (Poland); 3.8 (Switzerland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52688
538096,Autosomal recessive lethal neonatal axonal sensorimotor polyneuropathy,0.0 (Worldwide); 13.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538096
52503,X-linked creatine transporter deficiency,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52503
538101,Congenital axonal neuropathy with encephalopathy,0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538101
52430,Inclusion body myopathy with Paget disease of bone and frontotemporal dementia,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52430
52416,Mantle cell lymphoma,0.8 (United States); 3.5 (Europe); 1.05 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52416
52427,Retinitis punctata albescens,0.125 (Worldwide); 0.175 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52427
52417,MALT lymphoma,0.3 (Europe); 1.59 (United States); 4.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52417
52056,Ulnar/fibula ray defect-brachydactyly syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52056
52055,Corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52055
52368,Mohr-Tranebjaerg syndrome,91.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52368
53271,Muenke syndrome,3.33 (Worldwide); 0.0 (Worldwide); 2.3 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53271
53296,Familial cutaneous collagenoma,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53296
53347,Brody myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53347
52994,Orbital leiomyoma,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52994
53035,Caroli disease,0.1 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53035
52759,Vasculitis,6.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52759
52901,Isolated follicle stimulating hormone deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52901
538863,Classic pyoderma gangrenosum,0.0 (Worldwide); 0.0 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538863
538756,Familial multiple discoid fibromas,44.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538756
538574,Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538574
53583,Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53583
53540,Goldmann-Favre syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53540
53372,Hereditary geniospasm,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53372
53351,X-linked dystonia-parkinsonism,0.0 (Europe); 0.31 (Philippines),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53351
54247,Posterior cortical atrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54247
538934,X-linked lymphoproliferative disease due to XIAP deficiency,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538934
54251,Aseptic abscess syndrome,49.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54251
538931,X-linked lymphoproliferative disease due to SAP deficiency,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538931
54057,Thrombotic thrombocytopenic purpura,0.0 (Worldwide); 0.35 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54057
54028,Plummer-Vinson syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=54028
53719,Wyburn-Mason syndrome,0.0 (Worldwide); 90.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53719
53721,Spinal arteriovenous metameric syndrome,45.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53721
53715,Familial tumoral calcinosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53715
53696,Arthrogryposis-anterior horn cell disease syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53696
538872,Vegetative pyoderma gangrenosum,0.0 (Worldwide); 0.0 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538872
53697,Gnathodiaphyseal dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53697
538869,Bullous pyoderma gangrenosum,0.0 (Worldwide); 0.0 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538869
538866,Pustular pyoderma gangrenosum,0.0 (Worldwide); 0.0 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538866
53693,GRACILE syndrome,2.0 (Finland); 0.0 (Finland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=53693
48818,Aceruloplasminemia,0.1 (Japan); 0.09 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48818
49041,IgG4-related retroperitoneal fibrosis,0.35 (Europe); 0.0 (Finland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=49041
48918,Focal myositis,115.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48918
49382,Achromatopsia,2.7 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=49382
49042,Dentinogenesis imperfecta,14.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=49042
538958,Combined immunodeficiency due to CD70 deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538958
48431,Congenital cataracts-facial dysmorphism-neuropathy syndrome,170.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48431
538963,Combined immunodeficiency due to ITK deficiency,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=538963
48435,Postinfectious vasculitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48435
48686,Primary effusion lymphoma,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48686
48652,Phelan-McDermid syndrome,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48652
50809,Talo-patello-scaphoid osteolysis,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50809
50810,Microlissencephaly-micromelia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50810
50811,Lipodystrophy-intellectual disability-deafness syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50811
50812,Zellweger-like syndrome without peroxisomal anomalies,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50812
50814,Craniolenticulosutural dysplasia,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50814
50815,Branchiogenic deafness syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50815
49566,Acquired purpura fulminans,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=49566
49827,Thiamine-responsive megaloblastic anemia syndrome,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=49827
50251,Pleural mesothelioma,3.1 (Europe); 1.9 (Europe); 0.8 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50251
50945,Blomstrand lethal chondrodysplasia,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50945
50944,Schöpf-Schulz-Passarge syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50944
51083,Familial short QT syndrome,0.0 (Worldwide); 80.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=51083
50839,Cat-scratch disease,6.6 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50839
50918,Kikuchi-Fujimoto disease,0.0 (Worldwide); 1052.0 (Worldwide); 0.278 (Martinique),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=50918
52054,Craniosynostosis-intracranial calcifications syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52054
52022,Potocki-Shaffer syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52022
52047,Braddock syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=52047
51577,Cobblestone lissencephaly,1.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=51577
51608,Generalized arterial calcification of infancy,0.0 (Worldwide); 300.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=51608
51188,Ethylmalonic encephalopathy,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=51188
541423,Growth delay-intellectual disability-hepatopathy syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=541423
51208,Formiminoglutamic aciduria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=51208
51636,WHIM syndrome,65.0 (Worldwide); 0.0 (Worldwide); 0.023 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=51636
51890,Anterior cutaneous nerve entrapment syndrome,0.0 (Worldwide); 55.6 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=51890
542306,GNB5-related intellectual disability-cardiac arrhythmia syndrome,0.0 (Worldwide); 22.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542306
542301,Combined immunodeficiency due to CARMIL2 deficiency,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542301
542310,Leukoencephalopathy with calcifications and cysts,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542310
42642,PFAPA syndrome,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=42642
42665,Tietz syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=42665
542323,CAR T cell therapy-associated cytokine release syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542323
43117,Acute tricyclic antidepressant poisoning,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=43117
542585,Auditory neuropathy-optic atrophy syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542585
43116,Serotonin syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=43116
542592,Necrobiosis lipoidica,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542592
43393,Lambert-Eaton myasthenic syndrome,0.06 (Netherlands); 1.0 (Europe); 0.35 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=43393
43119,Acute poisoning by drugs with membrane-stabilizing effect,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=43119
542643,Livedoid vasculopathy,1.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542643
42775,PHACE syndrome,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=42775
42738,Severe congenital neutropenia,"0.4 (Europe); 0.4 (Europe); 0.07 (Worldwide); 1.0 (Sweden); 0.0 (Sweden); 0.6 (France); 0.077 (Iran, Islamic Republic of); 25.7 (China)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=42738
43115,Hereditary myopathy with lactic acidosis due to ISCU deficiency,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=43115
45448,Miyoshi myopathy,0.22 (Japan); 0.26 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=45448
543470,Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=543470
45453,Incessant infant ventricular tachycardia,1.5 (Europe); 0.0 (Europe); 0.3 (United Kingdom); 0.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=45453
45452,Idiopathic neonatal atrial flutter,1.5 (Europe); 2.1 (United Kingdom); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=45452
542657,Isolated hyperchlorhidrosis,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=542657
44890,Gastrointestinal stromal tumor,"13.0 (Europe); 1.0 (Europe); 1.0 (Worldwide); 1.9 (Korea, Republic of); 14.5 (Hong Kong); 1.82 (Hong Kong); 1.5 (United States); 12.9 (Sweden)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=44890
45358,Congenital fibrosis of extraocular muscles,0.0 (Europe); 0.43 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=45358
46487,Epidermolysis bullosa acquisita,0.03 (Europe); 0.02 (France); 0.05 (Germany); 0.05 (Singapore); 0.0 (Europe); 0.008 (Serbia); 0.284 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46487
544254,SYNGAP1-related developmental and epileptic encephalopathy,57.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544254
46488,Linear IgA dermatosis,0.1 (Germany); 0.069 (Kuwait); 0.026 (Singapore); 0.3 (Germany); 0.207 (Kuwait); 0.078 (Singapore),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46488
46485,Superficial pemphigus,1.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46485
46486,Mucous membrane pemphigoid,0.13 (France); 0.2 (Germany); 0.0 (Europe); 2.456 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46486
46348,Paroxysmal extreme pain disorder,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46348
46484,Oligodendroglial tumor,0.35 (Europe); 0.0 (Worldwide); 0.24 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46484
46059,Lathosterolosis,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46059
46135,Primary central nervous system lymphoma,0.44 (United States); 0.26 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46135
46724,Cerebral arteriovenous malformation,6.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46724
46627,Char syndrome,109.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46627
46532,Hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=46532
48372,Nodular regenerative hyperplasia of the liver,0.34 (Spain); 3.1 (Spain); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48372
48162,Lewis-Sumner syndrome,0.9 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48162
544493,Streptococcus pneumoniae-associated hemolytic uremic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544493
48104,Pyoderma gangrenosum,1.0 (United States); 0.91 (United Kingdom); 0.0 (Worldwide); 0.33 (Spain); 0.74 (Worldwide); 0.517 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48104
544503,RNF13-related severe early-onset epileptic encephalopathy,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544503
47612,Felty syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=47612
544482,Infection-related hemolytic uremic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544482
47159,Proximal renal tubular acidosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=47159
544488,Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544488
544469,PRUNE1-related neurological syndrome,48.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544469
544472,Atypical hemolytic uremic syndrome with complement gene abnormality,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544472
47045,Familial cold urticaria,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=47045
544628,Atypical Fanconi syndrome-neonatal hyperinsulinism syndrome,0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544628
544602,Congenital myopathy with reduced type 2 muscle fibers,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544602
48377,Subcorneal pustular dermatosis,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=48377
544578,"Congenital primary megaureter, refluxing and obstructed form",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=544578
555402,NAD(P)HX dehydratase deficiency,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=555402
555434,Fibrohistiocytic inflammatory pseudotumor of the liver,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=555434
555407,NAD(P)HX epimerase deficiency,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=555407
68367,Rare inborn errors of metabolism,3.3 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=68367
555437,Lymphoplasmacytic inflammatory pseudotumor of the liver,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=555437
555874,Congenital tricuspid valve dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=555874
555877,FLNA-related X-linked myxomatous valvular dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=555877
555905,IgA pemphigus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=555905
556030,Early-onset familial hypoaldosteronism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=556030
556037,Late-onset familial hypoaldosteronism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=556037
556985,Early-onset calcifying leukoencephalopathy-skeletal dysplasia,0.0 (Worldwide); 13.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=556985
556955,Pancreatic agenesis-holoprosencephaly syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=556955
557064,Neonatal epileptic encephalopathy due to glutaminase deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=557064
557056,Spastic ataxia-dysarthria due to glutaminase deficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=557056
557003,Oculoskeletodental syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=557003
90065,Acquired aneurysmal subarachnoid hemorrhage,10.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90065
90066,Pneumonia caused by Pseudomonas aeruginosa infection,50.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90066
90068,Cocaine intoxication,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90068
90061,Non-infectious posterior uveitis,18.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90061
90062,Acute liver failure,20.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90062
519388,Autosomal recessive anterior segment dysgenesis,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=519388
90064,Acute peripheral arterial occlusion,16.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90064
90073,Hepatitis B reinfection following liver transplantation,2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90073
90076,Partial deep dermal and full thickness burns,10.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90076
90069,Systemic monochloroacetate poisoning,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90069
90050,Retinopathy of prematurity,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90050
90045,Hereditary folate malabsorption,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90045
90052,Recurrent hepatitis C virus induced liver disease in liver transplant recipients,7.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90052
90051,Sepsis in premature infants,32.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90051
90041,Gaisböck syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90041
90039,Hemoglobin D disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90039
90044,Familial pseudohyperkalemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90044
90042,Primary familial polycythemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90042
90058,Spinal cord injury,3.57 (Canada); 32.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90058
90060,Diffuse alveolar hemorrhage,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90060
90059,Sudden sensorineural hearing loss,40.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90059
90053,Complications after hematopoietic stem cell transplantation,0.65 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90053
90056,Moderate and severe traumatic brain injury,37.8 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90056
90024,"Deafness with labyrinthine aplasia, microtia, and microdontia",56.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90024
90023,Primary immunodeficiency syndrome due to P14/LAMTOR2 deficiency,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90023
90003,Inflammatory pseudotumor of the liver,140.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90003
90037,Drug-induced autoimmune hemolytic anemia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90037
90038,Shiga toxin-associated hemolytic uremic syndrome,2.1 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90038
90035,Paroxysmal cold hemoglobinuria,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90035
90036,Mixed-type autoimmune hemolytic anemia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90036
90031,Non-spherocytic hemolytic anemia due to hexokinase deficiency,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90031
90033,"Autoimmune hemolytic anemia, warm type",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90033
90026,Primary erythromelalgia,1.1 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90026
90030,Hemolytic anemia due to glutathione reductase deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90030
89936,X-linked hypophosphatemia,1.89 (Norway); 1.54 (United Kingdom); 1.66 (Europe); 4.5 (Worldwide); 2.14 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=89936
89844,"Lissencephaly syndrome, Norman-Roberts type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=89844
89843,Dystrophic epidermolysis bullosa pruriginosa,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=89843
89842,"Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=89842
90001,X-linked cone dysfunction syndrome with myopia,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90001
90000,Erythema elevatum diutinum,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90000
89938,Bartter syndrome type 4,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=89938
89937,Autosomal dominant hypophosphatemic rickets,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=89937
90340,Blau syndrome,0.06 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90340
90342,Xeroderma pigmentosum variant,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90342
90348,Autosomal dominant cutis laxa,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90348
90349,Autosomal recessive cutis laxa type 1,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90349
90350,Autosomal recessive cutis laxa type 2,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90350
90354,Brittle cornea syndrome,65.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90354
90362,Primary intestinal lymphangiectasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90362
90289,Localized scleroderma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90289
90301,Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90301
90291,Systemic sclerosis,"15.4 (Europe); 230.0 (Spain); 27.7 (Spain); 8.8 (United Kingdom); 17.3 (France); 110.0 (Greece); 15.4 (Greece); 72.0 (Japan); 4.6 (Japan); 30.0 (United States); 44.3 (Canada); 204.0 (Australia); 23.3 (Australia); 1.09 (Taiwan, Province of China); 5.63 (Taiwan, Province of China); 22.2 (Italy); 1.7 (Italy)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90291
90308,Klippel-Trénaunay syndrome,0.007 (United States); 0.007 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90308
90280,Chilblain lupus,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90280
90281,Discoid lupus erythematosus,3.56 (United States); 3.2 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90281
90186,Meige disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90186
90285,Lupus erythematosus panniculitis,0.07 (United States); 0.315 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90285
90283,Lupus erythematosus tumidus,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90283
90080,Scarring in glaucoma filtration surgical procedures,22.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90080
90078,Invasive infections due to vancomycin-resistant enterococci,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90078
90103,Charcot-Marie-Tooth disease-deafness-intellectual disability syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90103
514980,ATP13A2-related parkinsonism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=514980
90081,AIDS wasting syndrome,20.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90081
90117,"Hereditary motor and sensory neuropathy, Okinawa type",120.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90117
90114,Autosomal dominant intermediate Charcot-Marie-Tooth disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90114
88673,Hepatocellular carcinoma,"6.2 (United States); 15.0 (Europe); 6.264 (France); 2.106 (United Kingdom); 5.129 (Germany); 5.212 (Spain); 9.266 (Italy); 15.0 (Greece); 5.0 (Canada); 5.0 (Oceania); 12.5 (Latin America); 35.0 (China); 29.0 (Japan); 49.0 (Korea, Republic of); 99.0 (Mongolia); 16.0 (Africa); 3.221 (Europe); 5.296 (Austria); 2.275 (Belgium); 1.697 (Bulgaria); 2.762 (Croatia); 2.979 (Czech Republic); 1.487 (Estonia); 3.382 (Finland); 1.278 (Iceland); 1.045 (Ireland); 1.933 (Latvia); 1.146 (Lithuania); 1.627 (Norway); 0.925 (Poland); 2.345 (Portugal); 2.762 (Slovakia); 6.649 (Switzerland); 1.127 (Netherlands)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88673
88644,"Autosomal recessive ataxia, Beauce type",57.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88644
88659,Autosomal dominant progressive nephropathy with hypertension,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88659
88661,Amelogenesis imperfecta,7.1 (United States); 90.0 (India); 142.0 (Sweden); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88661
88637,Hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88637
88639,Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88639
88642,Congenital insensitivity to pain-anosmia-neuropathic arthropathy,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88642
88643,Obesity-colitis-hypothyroidism-cardiac hypertrophy-developmental delay syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88643
88635,Vacuolar myopathy with sarcoplasmic reticulum protein aggregates,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88635
88621,Ichthyosis-prematurity syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88621
88628,Posterior column ataxia-retinitis pigmentosa syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88628
88629,Tritanopia,4.8 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88629
88630,Terminal osseous dysplasia-pigmentary defects syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88630
88620,Isolated congenital anosmia,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88620
88619,Familial acute necrotizing encephalopathy,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88619
88618,S-adenosylhomocysteine hydrolase deficiency,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88618
87884,Non-syndromic genetic deafness,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=87884
87876,Sialidosis type 2,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=87876
87503,Mal de Meleda,1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=87503
86923,"Hereditary palmoplantar keratoderma, Gamborg-Nielsen type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86923
86920,Dermatopathia pigmentosa reticularis,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86920
86919,Keratosis palmaris et plantaris-clinodactyly syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86919
86918,Diffuse palmoplantar keratoderma-acrocyanosis syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86918
86915,Lymphedema-atrial septal defects-facial changes syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86915
522077,Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=522077
86913,Myoclonic epilepsy in non-progressive encephalopathies,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86913
86914,Lymphedema-cerebral arteriovenous anomaly-primary pulmonary hypertension syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86914
86909,Myoclonic epilepsy of infancy,106.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86909
521450,LAMA5-related multisystemic syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521450
521445,Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521445
521438,Congenital vertebral-cardiac-renal anomalies syndrome,0.0 (Worldwide); 4.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521438
86900,Interdigitating dendritic cell sarcoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86900
521432,Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521432
86902,Follicular dendritic cell sarcoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86902
521426,PLAA-associated neurodevelopmental disorder,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521426
86896,Histiocytic sarcoma,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86896
521414,Autosomal dominant Charcot-Marie-Tooth disease type 2DD,51.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521414
521258,Xq25 microduplication syndrome,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521258
521305,Proximal myopathy with focal depletion of mitochondria,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521305
521308,Frontonasal dysplasia-bifid nose-upper limb anomalies syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521308
521390,Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521390
521406,Dystonia-parkinsonism-hypermanganesemia syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521406
89838,Autosomal recessive generalized epidermolysis bullosa simplex,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=89838
521411,Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521411
521219,Mirizzi syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521219
88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,0.0 (Worldwide); 0.0 (Worldwide); 0.07 (United States); 0.4 (Ireland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88949
88950,UMOD-related autosomal dominant tubulointerstitial kidney disease,1.7 (Austria); 9.0 (United Kingdom); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88950
88991,Rare congenital non-syndromic heart malformation,7.8 (Europe); 223.0 (Canada),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88991
88924,Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88924
88917,X-linked Alport syndrome,1.25 (Sweden); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=88917
93256,Fragile X-associated tremor/ataxia syndrome,0.0 (United States); 6.3 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93256
528105,Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=528105
528091,Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=528091
528084,Non-specific syndromic intellectual disability,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=528084
93262,Crouzon syndrome-acanthosis nigricans syndrome,0.1 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93262
93260,Pfeiffer syndrome type 3,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93260
93259,Pfeiffer syndrome type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93259
93258,Pfeiffer syndrome type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93258
93271,"Short rib-polydactyly syndrome, Verma-Naumoff type",5.2 (United Arab Emirates); 0.0 (United Arab Emirates),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93271
93269,"Short rib-polydactyly syndrome, Majewski type",34.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93269
93267,Cloverleaf skull-multiple congenital anomalies syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93267
93282,"Spondyloepimetaphyseal dysplasia, PAPSS2 type",17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93282
93283,"Spondyloepiphyseal dysplasia, Kimberley type",1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93283
93279,Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93279
93274,Thanatophoric dysplasia type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93274
93108,Renal dysplasia,0.0 (Europe); 43.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93108
527497,NKX6-2-related autosomal recessive hypomyelinating leukodystrophy,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=527497
93101,Renal hypoplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93101
93110,Posterior urethral valve,2.0 (Europe); 4.125 (Europe); 6.4 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93110
93109,Congenital megacalycosis,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93109
527450,Severe myopia-generalized joint laxity-short stature syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=527450
91547,Relapsing fever,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91547
93100,"Renal agenesis, unilateral",0.0 (Europe); 50.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93100
527468,Diaphragmatic hernia-short bowel-asplenia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=527468
92050,Congenital tufting enteropathy,0.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=92050
93160,Hypocalcemic vitamin D-resistant rickets,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93160
93164,Transient pseudohypoaldosteronism,152.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93164
93114,Autosomal dominant intermediate Charcot-Marie-Tooth disease type E,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93114
93111,HNF1B-related autosomal dominant tubulointerstitial kidney disease,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93111
93126,Pauci-immune glomerulonephritis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93126
93172,"Renal dysplasia, unilateral",0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93172
93173,"Renal dysplasia, bilateral",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93173
93322,Isolated tibial hemimelia,0.1 (Europe); 0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93322
93321,Isolated radial hemimelia,2.5 (Worldwide); 2.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93321
93320,Isolated ulnar hemimelia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93320
93323,Isolated fibular hemimelia,1.1033 (Worldwide); 1.1033 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93323
93329,Autosomal recessive omodysplasia,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93329
93335,Postaxial polydactyly type B,43.5 (Mexico); 43.5 (Mexico),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93335
93334,Postaxial polydactyly type A,15.7 (Mexico); 15.7 (Mexico),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93334
93333,Pelviscapular dysplasia,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93333
93337,Polydactyly of an index finger,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93337
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=527276
93346,"Spondyloepimetaphyseal dysplasia congenita, Strudwick type",30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93346
93347,Anauxetic dysplasia,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93347
93356,"Spondyloepimetaphyseal dysplasia, Missouri type",14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93356
93351,"Spondyloepimetaphyseal dysplasia, Irapa type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93351
93352,"Spondyloepimetaphyseal dysplasia, Shohat type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93352
93284,Spondyloepiphyseal dysplasia tarda,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93284
93296,Achondrogenesis type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93296
93298,Achondrogenesis type 1B,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93298
93297,Hypochondrogenesis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93297
93299,Achondrogenesis type 1A,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93299
93302,"Brachyolmia, Maroteaux type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93302
93307,Multiple epiphyseal dysplasia type 4,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93307
93308,Multiple epiphyseal dysplasia type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93308
93311,Multiple epiphyseal dysplasia type 5,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93311
93314,"Spondylometaphyseal dysplasia, Kozlowski type",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93314
93315,"Spondylometaphyseal dysplasia, 'corner fracture' type",30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93315
93316,"Spondylometaphyseal dysplasia, Schmidt type",7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93316
93317,"Spondylometaphyseal dysplasia, Sedaghatian type",9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93317
529962,17q24.2 microdeletion syndrome,0.0 (Worldwide); 19.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529962
529864,Secondary erythromelalgia,0.0 (Worldwide); 0.2 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529864
529852,Combined hepatocellular carcinoma and cholangiocarcinoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529852
90673,Hypothyroidism due to TSH receptor mutations,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90673
90674,Isolated thyroid-stimulating hormone deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90674
529831,Letrozole toxicity,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529831
529808,Chronic bilirubin encephalopathy,0.0 (Canada); 0.0 (Denmark); 0.0 (United States); 1.49 (Canada); 1.4 (Denmark); 1.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529808
90658,Charcot-Marie-Tooth disease type 1E,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90658
529799,Acute bilirubin encephalopathy,0.0 (United Kingdom); 0.87 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529799
90791,Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency,68.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90791
90790,Congenital lipoid adrenal hyperplasia due to STAR deficency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90790
529980,Inflammatory bowel disease-recurrent sinopulmonary infections syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529980
529977,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529977
529965,Intellectual disability-autism-speech apraxia-craniofacial dysmorphism syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529965
529970,Male infertility due to acephalic spermatozoa,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529970
90400,Scleromyxedema without monoclonal gammopathy,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90400
90625,Rare X-linked non-syndromic sensorineural deafness type DFN,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90625
90635,Rare autosomal dominant non-syndromic sensorineural deafness type DFNA,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90635
90636,Rare autosomal recessive non-syndromic sensorineural deafness type DFNB,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90636
529468,Monoclonal mast cell activation syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529468
529574,Duane retraction syndrome with congenital deafness,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529574
90398,Localized lichen myxedematosus with mixed features of different subtypes,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90398
90399,Localized lichen myxedematosus with monoclonal gammopathy or systemic symptoms,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90399
90368,Hypotrichosis simplex of the scalp,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90368
90390,Anonychia-onychodystrophy syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90390
90652,Otopalatodigital syndrome type 2,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90652
529665,Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=529665
90647,Jervell and Lange-Nielsen syndrome,0.3 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90647
90641,Rare mitochondrial non-syndromic sensorineural deafness,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90641
91387,Familial thoracic aortic aneurysm and aortic dissection,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91387
91396,Isolated cryptophthalmia,0.0 (Worldwide); 30.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91396
91378,Hereditary angioedema,5.0 (Europe); 1.4 (Denmark); 1.51 (Norway); 1.09 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91378
91385,Acquired angioedema,0.11 (Denmark); 200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91385
91412,Marcus-Gunn syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91412
91397,Isolated ankyloblepharon filiforme adnatum,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91397
91411,Congenital ptosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91411
91355,Sheehan syndrome,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91355
91359,Chronic pneumonitis of infancy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91359
91496,Snowflake vitreoretinal degeneration,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91496
91495,Persistent hyperplastic primary vitreous,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91495
91494,Macular coloboma-cleft palate-hallux valgus syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91494
91546,Lyme disease,177.5 (Europe); 16.6 (France); 21.9 (Worldwide); 12.37 (Hungary); 36.0 (Sweden); 100.0 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91546
91500,Tubulointerstitial nephritis and uveitis syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91500
91498,Familial congenital palsy of trochlear nerve,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91498
91481,Ring dermoid of cornea,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91481
91416,Isolated congenital alacrima,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91416
91414,Pilomatrixoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91414
91127,Adenovirus infection in immunocompromised patients,18.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91127
91130,Cardiomyopathy-hypotonia-lactic acidosis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91130
91131,DK1-CDG,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91131
91132,Ichthyosis-hypotrichosis syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91132
90793,Congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90793
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,7.0 (Europe); 7.0 (Worldwide); 6.4 (France); 9.2 (Italy); 8.7 (Sweden); 6.2 (United States); 4.2 (New Zealand); 6.4 (Croatia); 6.2 (Estonia); 4.5 (Singapore); 6.5 (Switzerland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90794
90795,Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency,0.75 (Europe); 0.47 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90795
90796,"46,XY difference of sex development due to isolated 17,20-lyase deficiency",15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90796
90797,Partial androgen insensitivity syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90797
90970,Primary lipodystrophy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=90970
91347,TSH-secreting pituitary adenoma,0.28 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91347
91349,Non-functioning pituitary adenoma,1.05 (Worldwide); 2.55 (Europe); 0.0 (Europe); 4.0 (Finland); 1.1 (Sweden); 94.0 (Belgium); 80.5 (Switzerland); 77.6 (United Kingdom); 68.0 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91349
91350,Pituitary deficiency due to Rathke cleft cysts,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91350
91136,Acquired monoclonal Ig light chain-associated Fanconi syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91136
91135,Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91135
91138,Cryoglobulinemic vasculitis,1.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91138
91137,Immunotactoid or fibrillary glomerulopathy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91137
91139,Simple cryoglobulinemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=91139
79396,"Autosomal dominant generalized epidermolysis bullosa simplex, severe form",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79396
79397,Epidermolysis bullosa simplex with mottled pigmentation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79397
79394,Congenital ichthyosiform erythroderma,0.5 (Spain); 0.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79394
79395,Keratoderma hereditarium mutilans with ichthyosis,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79395
79373,Ectodermal dysplasia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79373
79399,"Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79399
79401,PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79401
79400,Localized epidermolysis bullosa simplex,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79400
79403,Junctional epidermolysis bullosa with pyloric atresia,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79403
79402,Intermediate generalized junctional epidermolysis bullosa,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79402
79405,Junctional epidermolysis bullosa inversa,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79405
79404,Severe generalized junctional epidermolysis bullosa,0.17 (Worldwide); 0.04 (United States); 0.4 (Netherlands); 0.07 (Italy); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79404
79406,Late-onset junctional epidermolysis bullosa,37.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79406
79409,Recessive dystrophic epidermolysis bullosa inversa,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79409
79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",0.3 (United States); 1.3 (Europe); 0.963 (Europe); 0.2222 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79408
79411,Self-improving dystrophic epidermolysis bullosa,52.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79411
79410,"Localized dystrophic epidermolysis bullosa, pretibial form",40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79410
79452,Milroy disease,0.0 (Worldwide); 3.0 (Israel),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79452
79447,X-linked lethal multiple pterygium syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79447
79456,Diffuse cutaneous mastocytosis,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79456
79457,Maculopapular cutaneous mastocytosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79457
79455,Cutaneous mastocytoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79455
79435,Oculocutaneous albinism type 4,1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79435
79434,Oculocutaneous albinism type 1B,1.3 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79434
79433,Oculocutaneous albinism type 3,0.0 (Worldwide); 11.7647 (Africa),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79433
79432,Oculocutaneous albinism type 2,"58.34 (Specific population); 2.55 (Worldwide); 71.43 (Tanzania, United Republic of); 2.78 (United States); 48.52 (Africa)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79432
79431,Oculocutaneous albinism type 1A,1.3 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79431
79430,Hermansky-Pudlak syndrome,0.15 (Worldwide); 55.0 (Puerto rico),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79430
79445,Pseudopseudohypoparathyroidism,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79445
79444,Pseudohypoparathyroidism type 1C,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79444
79443,Pseudohypoparathyroidism type 1A,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79443
79478,Griscelli syndrome type 3,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79478
79479,Pemphigus vegetans,0.391 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79479
79481,Pemphigus foliaceus,1.001 (Germany),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79481
79493,Brooke-Spiegler syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79493
79477,Griscelli syndrome type 2,102.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79477
79476,Griscelli syndrome type 1,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79476
79473,Variegate porphyria,0.008 (Europe); 0.32 (Europe); 0.012 (France); 0.48 (France); 0.006 (Finland); 0.24 (Finland); 0.016 (Ireland); 0.64 (Ireland); 0.006 (Italy); 0.24 (Netherlands); 0.24 (Italy); 0.006 (Netherlands); 0.007 (Norway); 0.28 (Norway); 0.004 (Spain); 0.16 (Spain); 0.011 (Sweden); 0.44 (Sweden); 0.026 (Switzerland); 1.04 (Switzerland); 0.008 (United Kingdom); 0.32 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79473
79269,Sanfilippo syndrome type A,0.32 (Europe); 1.16 (Netherlands); 0.88 (Australia); 0.47 (Czech Republic); 1.62 (Estonia); 1.4 (Worldwide); 0.62 (Sweden); 0.052 (United States); 0.19 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79269
79257,GM1 gangliosidosis type 3,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79257
79256,GM1 gangliosidosis type 2,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79256
79255,GM1 gangliosidosis type 1,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79255
79254,Classic phenylketonuria,6.0 (Worldwide); 6.34 (Europe); 6.0 (Worldwide); 6.34 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79254
79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,150.0 (Worldwide); 0.0 (Worldwide); 4.1 (Israel); 8.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79259
79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,1.0 (Europe); 1.7 (Italy); 0.0 (Worldwide); 1.5 (Israel),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79258
79246,Pyruvate dehydrogenase phosphatase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79246
79253,Mild phenylketonuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79253
79240,Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79240
79241,Biotinidase deficiency,1.6 (Worldwide); 0.0 (Worldwide); 1.5 (United States); 1.6 (Brazil); 1.6 (Europe); 2.0 (Sweden); 3.2 (Italy); 0.0 (Italy); 1.4 (Austria); 5.0 (Hungary); 3.0 (Turkey); 0.0069 (China); 11.58 (Czech Republic),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79241
79238,Galactose epimerase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79238
79239,Classic galactosemia,"2.1 (Europe); 3.0 (Netherlands); 2.3 (United Kingdom); 4.3 (Ireland); 0.13 (Japan); 0.25 (China); 20.8 (Iran, Islamic Republic of); 0.0 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79239
79244,Pyruvate dehydrogenase E2 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79244
79242,Holocarboxylase synthetase deficiency,0.5 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79242
79243,Pyruvate dehydrogenase E1-alpha deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79243
79298,Diazoxide-resistant focal hyperinsulinism,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79298
79301,Congenital bile acid synthesis defect type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79301
79293,Familial LCAT deficiency,70.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79293
79292,Fish-eye disease,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79292
79278,Autosomal erythropoietic protoporphyria,0.012 (Europe); 0.92 (Europe); 0.006 (France); 0.46 (France); 0.007 (Italy); 0.62 (Ireland); 0.018 (Netherlands); 0.54 (Italy); 0.036 (Norway); 1.39 (Netherlands); 0.003 (Poland); 2.77 (Norway); 0.003 (Spain); 0.15 (Poland); 0.018 (Sweden); 0.23 (Spain); 0.035 (Switzerland); 1.39 (Sweden); 0.033 (United Kingdom); 2.7 (Switzerland); 2.54 (United Kingdom); 1.75 (Slovenia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79278
79279,Alpha-N-acetylgalactosaminidase deficiency type 1,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79279
79280,Alpha-N-acetylgalactosaminidase deficiency type 2,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79280
79281,Alpha-N-acetylgalactosaminidase deficiency type 3,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79281
79282,"Methylmalonic acidemia with homocystinuria, type cblC",500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79282
79283,"Methylmalonic acidemia with homocystinuria, type cblD",17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79283
79284,Methylmalonic acidemia with homocystinuria type cblF,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79284
79270,Sanfilippo syndrome type B,0.2 (Europe); 0.42 (Netherlands); 0.72 (Portugal); 0.47 (Australia); 0.02 (Czech Republic); 0.05 (Sweden); 0.014 (United States); 0.05 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79270
79271,Sanfilippo syndrome type C,0.21 (Netherlands); 0.12 (Portugal); 0.07 (Australia); 0.42 (Czech Republic); 5.0 (Europe); 0.34 (Sweden); 4.0E-4 (United States); 0.015 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79271
79272,Sanfilippo syndrome type D,0.1 (Netherlands); 0.1 (Australia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79272
79273,Hereditary coproporphyria,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79273
79276,Acute intermittent porphyria,0.013 (Europe); 0.54 (Europe); 0.012 (France); 0.55 (France); 0.011 (Italy); 0.5 (Italy); 0.013 (Finland); 0.59 (Finland); 0.018 (Netherlands); 0.81 (Netherlands); 0.014 (Norway); 0.63 (Norway); 0.016 (Poland); 0.72 (Poland); 0.014 (Spain); 0.63 (Spain); 0.051 (Sweden); 10.0 (Sweden); 0.022 (Switzerland); 0.99 (Switzerland); 0.016 (United Kingdom); 0.72 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79276
79277,Congenital erythropoietic porphyria,200.0 (Worldwide); 0.065 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79277
79333,COG7-CDG,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79333
79332,B4GALT1-CDG,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79332
79330,MOGS-CDG,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79330
79329,MGAT2-CDG,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79329
79328,ALG9-CDG,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79328
79327,ALG1-CDG,57.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79327
79326,ALG2-CDG,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79326
79325,ALG8-CDG,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79325
79324,ALG12-CDG,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79324
79323,MPDU1-CDG,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79323
79322,DPM1-CDG,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79322
79321,ALG3-CDG,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79321
79320,ALG6-CDG,54.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79320
79319,MPI-CDG,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79319
79318,PMM2-CDG,1.73 (Italy); 0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79318
79314,L-2-hydroxyglutaric aciduria,0.0 (Worldwide); 140.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79314
79315,D-2-hydroxyglutaric aciduria,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79315
79312,Vitamin B12-unresponsive methylmalonic acidemia type mut-,450.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79312
79310,Vitamin B12-responsive methylmalonic acidemia type cblA,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79310
79306,Progressive familial intrahepatic cholestasis type 1,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79306
79304,Progressive familial intrahepatic cholestasis type 2,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79304
79305,Progressive familial intrahepatic cholestasis type 3,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79305
79302,Congenital bile acid synthesis defect type 3,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79302
79303,Congenital bile acid synthesis defect type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79303
79361,Inherited epidermolysis bullosa,1.9 (Europe); 0.8 (Europe); 0.96 (Croatia); 1.9 (United States); 0.8 (United States); 0.59 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79361
79351,"3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form",15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79351
79350,"3-phosphoserine phosphatase deficiency, infantile/juvenile form",8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79350
79347,"Chondrodysplasia punctata, Toriello type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79347
79345,Brachytelephalangic chondrodysplasia punctata,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79345
85191,Singleton-Merten dysplasia,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85191
85188,"Metaphyseal dysplasia, Braun-Tinschert type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85188
85193,Idiopathic juvenile osteoporosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85193
85192,Calvarial doughnut lesions-bone fragility syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85192
85194,Spondylo-ocular syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85194
85197,Genochondromatosis type 1,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85197
85199,Craniosynostosis-anal anomalies-porokeratosis syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85199
85198,Dysspondyloenchondromatosis,16.0 (Worldwide); 0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85198
85201,Genitopatellar syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85201
85203,Acropectoral syndrome,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85203
85202,Keutel syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85202
85273,"X-linked intellectual disability, Abidi type",8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85273
85212,Fetal Gaucher disease,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85212
85274,Syndromic X-linked intellectual disability 7,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85274
85275,Microphthalmia-ankyloblepharon-intellectual disability syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85275
85276,"X-linked intellectual disability, Armfield type",6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85276
85277,"X-linked intellectual disability, Cantagrel type",30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85277
85278,Christianson syndrome,1.7241 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85278
85279,KDM5C-related syndromic X-linked intellectual disability,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85279
85280,X-linked intellectual disability-cubitus valgus-dysmorphism syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85280
85282,MEHMO syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85282
85283,"X-linked intellectual disability, Miles-Carpenter type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85283
85284,BRESEK syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85284
85285,"X-linked intellectual disability, Schimke type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85285
85286,"X-linked intellectual disability, Shashi type",9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85286
85287,"X-linked intellectual disability, Siderius type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85287
85288,"X-linked intellectual disability, Stocco Dos Santos type",1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85288
85293,"X-linked intellectual disability, Cabezas type",24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85293
85292,X-linked spinocerebellar ataxia type 4,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85292
85290,"X-linked intellectual disability, Wilson type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85290
85317,X-linked intellectual disability-hypogammaglobulinemia-progressive neurological deterioration syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85317
85297,X-linked spinocerebellar ataxia type 3,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85297
85295,"HSD10 disease, atypical type",5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85295
85294,X-linked epilepsy-learning disabilities-behavior disorders syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85294
85321,"Deafness-intellectual disability syndrome, Martin-Probst type",0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85321
85320,X-linked intellectual disability-macrocephaly-macroorchidism syndrome,0.0 (Worldwide); 12.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85320
85319,X-linked intellectual disability-epilepsy-progressive joint contractures-dysmorphism syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85319
85325,"X-linked intellectual disability, Stevenson type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85325
85324,"X-linked intellectual disability, Shrimpton type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85324
85323,"X-linked intellectual disability, Seemanova type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85323
85322,"X-linked intellectual disability, Pai type",1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85322
85329,X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85329
85326,"X-linked intellectual disability, Stoll type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85326
85327,X-linked intellectual disability-acromegaly-hyperactivity syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85327
85332,X-linked intellectual disability-retinitis pigmentosa syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85332
85336,"X-linked neurodegenerative syndrome, Hamel type",11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85336
85334,"X-linked neurodegenerative syndrome, Bertini type",0.0 (Worldwide); 7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85334
85335,Fried syndrome,0.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85335
85410,Oligoarticular juvenile idiopathic arthritis,20.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85410
85414,Systemic-onset juvenile idiopathic arthritis,3.1 (Worldwide); 0.6 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85414
85338,X-linked intellectual disability-ataxia-apraxia syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85338
85408,Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis,8.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85408
85443,AL amyloidosis,"6.459 (Germany); 5.127 (Worldwide); 1.044 (Worldwide); 5.5311 (Europe); 1.1177 (Europe); 5.77 (Austria); 1.166 (Austria); 5.54 (Belgium); 1.122 (Belgium); 5.892 (Bulgaria); 1.174 (Bulgaria); 5.801 (Croatia); 1.156 (Croatia); 4.299 (Cyprus); 0.894 (Cyprus); 5.462 (Czech Republic); 1.109 (Czech Republic); 5.568 (Denmark); 1.124 (Denmark); 5.51 (Estonia); 1.107 (Estonia); 5.885 (Finland); 1.187 (Finland); 5.692 (France); 1.152 (France); 1.294 (Germany); 6.219 (Greece); 1.254 (Greece); 5.418 (Hungary); 1.088 (Hungary); 4.643 (Iceland); 0.948 (Iceland); 4.448 (Ireland); 0.913 (Ireland); 6.538 (Italy); 1.329 (Italy); 5.71 (Latvia); 1.123 (Latvia); 5.809 (Liechtenstein); 1.174 (Liechtenstein); 5.61 (Lithuania); 1.109 (Lithuania); 4.653 (Luxembourg); 0.968 (Luxembourg); 5.641 (Malta); 1.147 (Malta); 5.672 (Netherlands); 1.146 (Netherlands); 4.977 (Norway); 1.018 (Norway); 5.134 (Poland); 1.044 (Poland); 6.216 (Portugal); 1.25 (Portugal); 5.537 (Romania); 1.107 (Romania); 4.76 (Slovakia); 0.968 (Slovakia); 5.756 (Slovenia); 1.167 (Slovenia); 5.864 (Spain); 1.193 (Spain); 5.667 (Sweden); 1.141 (Sweden); 5.316 (United Kingdom); 1.078 (United Kingdom); 3.222 (Brazil); 0.672 (Brazil); 5.215 (Canada); 1.076 (Canada); 7.108 (Japan); 1.43 (Japan); 4.569 (Russian Federation); 0.93 (Russian Federation); 4.822 (Korea, Republic of); 0.997 (Korea, Republic of); 4.852 (Taiwan, Province of China); 1.001 (Taiwan, Province of China); 4.842 (United States); 0.991 (United States); 6.0 (Argentina)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85443
85442,Short stature-pituitary and cerebellar defects-small sella turcica syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85442
85446,Wild type ABeta2M amyloidosis,4.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85446
85445,AA amyloidosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85445
85436,Psoriasis-related juvenile idiopathic arthritis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85436
85435,Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis,4.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85435
85438,Enthesitis-related juvenile idiopathic arthritis,5.7 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85438
85458,Cerebral Amyloid Angiopathy,350.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85458
85453,X-linked reticulate pigmentary disorder,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85453
86788,X-linked severe congenital neutropenia,45.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86788
86309,DPAGT1-CDG,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86309
85448,AGel amyloidosis,475.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85448
85447,ATTRV30M amyloidosis,90.0 (Portugal); 0.1 (Japan); 3.75 (Sweden); 97.5 (Sweden); 0.69 (Cyprus); 3.7 (Cyprus); 0.0 (Worldwide); 3.0 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85447
85451,ATTRV122I amyloidosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85451
85450,Hereditary amyloidosis with primary renal involvement,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85450
86812,POMT1-related limb-girdle muscular dystrophy R11,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86812
86813,Helicoid peripapillary chorioretinal degeneration,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86813
86814,Benign adult familial myoclonic epilepsy,2.8 (Japan); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86814
86789,Isolated patella aplasia/hypoplasia,0.0 (Worldwide); 5.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86789
86797,Atypical lichen myxedematosus,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86797
86820,Familial avascular necrosis of femoral head,5.0 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86820
86821,Lissencephaly type 3-familial fetal akinesia sequence syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86821
86822,Lissencephaly type 3-metacarpal bone dysplasia syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86822
86823,Lissencephaly with cerebellar hypoplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86823
86816,Congenital analbuminemia,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86816
86817,Hemolytic anemia due to adenylate kinase deficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86817
86818,Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86818
512034,Large granular lymphocyte leukemia,0.02 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=512034
86843,Acute panmyelosis with myelofibrosis,0.06 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86843
86841,Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86841
86839,Myelodysplastic neoplasm with increased blasts,0.0 (Worldwide); 0.15 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86839
86836,Refractory cytopenia with multilineage dysplasia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86836
86834,Juvenile myelomonocytic leukemia,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86834
86830,"Chronic myeloproliferative disease, unclassifiable",0.53 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86830
86829,Chronic neutrophilic leukemia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86829
86855,Plasmacytoma,0.0 (Worldwide); 0.34 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86855
512260,Congenital cerebellar ataxia due to RNU12 mutation,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=512260
86854,Splenic marginal zone lymphoma,0.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86854
86852,B-cell prolymphocytic leukemia,0.05 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86852
86850,Myeloid sarcoma,0.0 (Worldwide); 0.02 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86850
86849,Acute basophilic leukemia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86849
86846,Therapy related acute myeloid leukemia and myelodysplastic syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86846
86845,Acute myeloid leukaemia with myelodysplasia-related features,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86845
86872,T-cell large granular lymphocyte leukemia,0.4 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86872
86873,Aggressive NK-cell leukemia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86873
86870,Blastic plasmacytoid dendritic cell neoplasm,12.0 (Europe); 0.03 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86870
86871,T-cell prolymphocytic leukemia,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86871
86867,Nodal marginal zone B-cell lymphoma,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86867
86864,Heavy chain disease,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86864
86886,Angioimmunoblastic T-cell lymphoma,0.05 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86886
86893,Nodular lymphocyte predominant Hodgkin lymphoma,0.12 (Worldwide); 0.095 (Europe); 0.0 (Worldwide); 0.041 (Austria); 0.006 (Bulgaria); 0.099 (Czech Republic); 0.037 (Estonia); 0.097 (Germany); 0.074 (Ireland); 0.038 (Latvia); 0.008 (Lithuania); 0.013 (Poland); 0.055 (Portugal); 0.053 (Slovakia); 0.056 (Slovenia); 0.092 (United Kingdom); 0.128 (Belgium); 0.285 (Finland); 0.124 (Italy); 0.226 (Norway); 0.14 (Spain); 0.135 (Switzerland); 0.133 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86893
86884,Subcutaneous panniculitis-like T-cell lymphoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86884
86880,Enteropathy-associated T-cell lymphoma,0.0111 (United States); 0.1 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86880
86882,Hepatosplenic T-cell lymphoma,0.03 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86882
86875,Adult T-cell leukemia/lymphoma,3.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86875
86879,Extranodal nasal NK/T cell lymphoma,2.25 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86879
79502,Punctate palmoplantar keratoderma type 2,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79502
79503,Ichthyosis hystrix of Curth-Macklin,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79503
79507,Hypotonia-failure to thrive-microcephaly syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79507
79499,Autosomal dominant deafness-onychodystrophy syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79499
79500,DOORS syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79500
79501,Punctate palmoplantar keratoderma type 1,437.0 (Worldwide); 1.17 (Croatia); 3.3 (Slovenia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79501
79665,Gardner syndrome,9.1 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79665
79651,Mild hyperphenylalaninemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79651
79644,Autosomal recessive hyperinsulinism due to Kir6.2 deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79644
83317,Scrub typhus,"7.2 (Korea, Republic of); 0.3 (Japan); 0.0 (Worldwide)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83317
83330,Proximal spinal muscular atrophy type 1,0.26 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83330
83315,Murine typhus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83315
83316,Pseudotyphus of California,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83316
83419,Proximal spinal muscular atrophy type 3,0.6623 (Italy); 0.61 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83419
83420,Proximal spinal muscular atrophy type 4,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83420
83418,Proximal spinal muscular atrophy type 2,2.0 (Europe); 2.0322 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83418
83313,Boutonneuse fever,24.2 (France); 9.8 (Portugal); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83313
83314,Epidemic typhus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83314
83311,Rocky Mountain spotted fever,0.24 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83311
83312,Rickettsialpox,800.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83312
83469,Desmoplastic small round cell tumor,300.0 (Worldwide); 0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83469
83468,Solitary bone cyst,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83468
83467,Morvan syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83467
83465,Narcolepsy type 2,0.0 (Worldwide); 20.3 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83465
83476,West-Nile encephalitis,0.92 (United States); 0.0 (Worldwide); 0.036 (Europe); 0.02 (Austria); 0.17 (Croatia); 0.66 (Greece); 0.16 (Hungary); 0.07 (Italy); 0.12 (Romania),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83476
83473,Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome,62.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83473
83472,CAMOS syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83472
83471,T-cell immunodeficiency with thymic aplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83471
83452,Complex regional pain syndrome,26.2 (Netherlands); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83452
83451,Florid cemento-osseous dysplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83451
83450,Regional odontodysplasia,140.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83450
83463,Microtia,38.0 (Specific population); 13.0 (Europe); 0.0 (Europe); 15.5 (Worldwide); 0.0 (Worldwide); 3.7 (France); 0.0 (France); 1.2 (Italy); 0.0 (Italy); 2.1 (Sweden); 0.0 (Sweden); 22.0 (United States); 0.0 (United States); 43.4 (Finland); 0.0 (Finland); 174.0 (Ecuador); 83.0 (Chile),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83463
83461,Congenital primary aphakia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83461
83454,Glomuvenous malformation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83454
83453,Vulvovaginal gingival syndrome,380.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83453
514352,Congenital brachyesophagus-intrathoracic stomach-vertebral anomalies syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=514352
83619,Macrostomia-preauricular tags-external ophthalmoplegia syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83619
83620,Enteric anendocrinosis,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83620
83628,LUMBAR syndrome,54.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83628
83601,Steroid-responsive encephalopathy associated with autoimmune thyroiditis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83601
83616,Rubella panencephalitis,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83616
83617,Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83617
83594,Eastern equine encephalitis,0.01 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83594
83595,Colorado tick fever,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83595
83597,Acute disseminated encephalomyelitis,0.6 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83597
83600,Encephalitis lethargica,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83600
83482,Mycoplasma encephalitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83482
83483,La Crosse encephalitis,1.91 (Canada); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83483
83484,St. Louis encephalitis,0.38 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83484
83593,Western equine encephalitis,0.02 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83593
84085,Hinman syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84085
84081,Senior-Boichis syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84081
84090,Fibronectin glomerulopathy,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84090
84064,Syndromic diarrhea,116.0 (Worldwide); 0.0 (Worldwide); 0.1 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84064
513436,Autosomal recessive spastic paraplegia type 78,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=513436
83639,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83639
83629,Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83629
513456,Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=513456
83642,Microcytic anemia with liver iron overload,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83642
85163,Hypomyelination-congenital cataract syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85163
85164,Camptodactyly-tall stature-scoliosis-hearing loss syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85164
85146,"Neurogenic scapuloperoneal syndrome, Kaeser type",15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85146
85162,Facial onset sensory and motor neuronopathy,47.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85162
85138,Addison disease,54.0 (Specific population); 12.5 (Europe); 14.0 (Norway); 9.3 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85138
85128,Bothnia retinal dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85128
85136,Cystic leukoencephalopathy without megalencephaly,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85136
85110,Familial encephalopathy with neuroserpin inclusion bodies,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85110
85112,Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85112
84132,Desmin-related myopathy with Mallory body-like inclusions,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84132
84142,Isaacs syndrome,150.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84142
84093,Hereditary thermosensitive neuropathy,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=84093
85186,Endosteal sclerosis-cerebellar hypoplasia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85186
85184,"Craniometadiaphyseal dysplasia, wormian bone type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85184
85179,Infantile osteopetrosis with neuroaxonal dysplasia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85179
85175,Astley-Kendall dysplasia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85175
85174,Pseudodiastrophic dysplasia,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85174
85173,IMAGe syndrome,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85173
85172,"Microcephalic osteodysplastic dysplasia, Saul-Wilson type",4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85172
85170,"Mesomelic dysplasia, Savarirayan type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85170
85169,Familial digital arthropathy-brachydactyly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85169
85168,Craniofacial conodysplasia,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85168
85167,Spondylometaphyseal dysplasia-cone-rod dystrophy syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85167
85166,"Platyspondylic dysplasia, Torrance type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85166
85165,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=85165
603448,Cerebellar hypoplasia-intellectual disability-congenital microcephaly-dystonia-anemia-growth retardation syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=603448
603515,Isolated female hypospadias,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=603515
603494,Coloboma-osteopetrosis-microphthalmia-macrocephaly-albinism-deafness syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=603494
603689,KLHL7-related Bohring-Opitz-like syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=603689
603684,KLHL7-related Bohring-Opitz-like and Crisponi/Cold-induced sweating-like overlap syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=603684
610573,CLCN6-related childhood-onset progressive neurodegeneration-peripheral neuropathy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=610573
610569,KIAA1109-related early lethal congenital brain malformations-arthrogryposis syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=610569
604680,Symptomatic form of X-linked centronuclear myopathy in female carriers,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=604680
611256,Pontocerebellar hypoplasia type 12,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=611256
611237,Parkinsonism with polyneuropathy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=611237
611247,Pontocerebellar hypoplasia type 11,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=611247
611216,Aplastic anemia-intellectual disability-dwarfism syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=611216
611223,EN1-related dorsoventral syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=611223
611201,Oculogastrointestinal-neurodevelopmental syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=611201
613267,Pontocerebellar hypoplasia type 13,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=613267
98085,"46,XY difference of sex development",0.06 (Denmark); 6.4 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98085
613274,Pontocerebellar hypoplasia type 14,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=613274
98249,Ehlers-Danlos syndrome,0.9 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98249
600668,CCNK-related neurodevelopmental disorder-severe intellectual disability-facial dysmorphism syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600668
600663,NRXN1-related severe neurodevelopmental disorder-motor stereotypies-chronic constipation-sleep-wake cycle disturbance,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600663
600691,Combined deficiency of factor VII and factor X,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600691
600731,Clark-Baraitser syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600731
98287,Histiocytic and dendritic cell tumor,0.05 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98287
98293,Hodgkin lymphoma,2.4 (Europe); 46.9 (Europe); 2.8 (United States); 0.25 (Japan); 0.25 (China),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98293
98292,Mastocytosis,3.0 (Europe); 9.59 (Denmark); 10.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98292
98274,Myeloproliferative neoplasm,3.07 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98274
98277,Acute myeloid leukemia with recurrent genetic anomaly,0.11 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98277
98275,Myelodysplastic/myeloproliferative disease,0.29 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98275
98267,Genetic non-syndromic obesity,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98267
601028,Non-syndromic anorectal malformation with rectovaginal fistula,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=601028
601033,Non-syndromic anorectal malformation with H-type fistula,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=601033
601008,Non-syndromic anorectal malformation with anal stenosis,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=601008
601013,Non-syndromic anorectal malformation with pouch colon,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=601013
601018,Non-syndromic anorectal malformation with rectal atresia,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=601018
601023,Non-syndromic anorectal malformation with rectal stenosis,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=601023
600984,Non-syndromic anorectal malformation with rectovesical fistula,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600984
600993,Non-syndromic anorectal malformation with vestibular fistula,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600993
600998,Non-syndromic cloacal malformation,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600998
601002,Non-syndromic anorectal malformation without fistula,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=601002
600961,Non-syndromic anorectal malformation with rectourethral fistula,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600961
600952,Non-syndromic anorectal malformation with perineal fistula,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600952
97245,Congenital myopathy,3.8 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97245
97244,Rigid spine syndrome,0.0 (Worldwide); 0.0 (Worldwide); 0.13 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97244
97242,Congenital muscular dystrophy,0.0 (Europe); 0.563 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97242
97261,GRFoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97261
97253,Neuroendocrine tumor of pancreas,0.22 (United States); 1.27 (Japan); 2.69 (Japan); 0.21 (France); 0.21 (Europe); 27.5 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97253
97249,Pontocerebellar hypoplasia type 3,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97249
97279,Insulinoma,0.12 (Ireland); 0.25 (Worldwide); 0.56 (Japan); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97279
97278,PPoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97278
97285,Thyroid lymphoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97285
97283,Somatostatinoma,0.0025 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97283
97282,VIPoma,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97282
97280,Glucagonoma,0.005 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97280
97290,Familial papillary thyroid carcinoma with renal papillary neoplasia,2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97290
97286,Carney-Stratakis syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97286
97292,Cardiogenic shock,40.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97292
97335,Osgood-Schlatter disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97335
97297,Bohring-Opitz syndrome,46.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97297
97330,Thoracic outlet syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97330
97339,Dural sinus malformation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97339
97336,Panner disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97336
97337,Sinding-Larsen-Johansson disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97337
97341,Persistent placoid maculopathy,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97341
97340,Hunter-McAlpine syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97340
97360,Robinow syndrome,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97360
97355,Caribbean parkinsonism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97355
97361,"Renal hypoplasia, unilateral",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97361
97362,"Renal hypoplasia, bilateral",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97362
97363,Unilateral multicystic dysplastic kidney,23.2 (Worldwide); 14.8 (Europe); 45.4 (United Kingdom); 25.0 (Japan); 108.0 (Saudi Arabia); 24.4 (Finland); 41.0 (United States); 60.3 (Switzerland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97363
97364,Bilateral multicystic dysplastic kidney,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97364
97548,Right sided atrial isomerism,0.0 (France); 16.67 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97548
97560,Primary membranous glomerulonephritis,0.8103 (Worldwide); 0.9194 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97560
96181,Maternal uniparental disomy of chromosome 6 syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96181
96178,Ring chromosome 16 syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96178
96177,Ring chromosome 15 syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96177
96176,Ring chromosome 13 syndrome,1.72 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96176
96188,Maternal uniparental disomy of chromosome 22 syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96188
96187,Maternal uniparental disomy of chromosome 21 syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96187
96186,Maternal uniparental disomy of chromosome 20 syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96186
96184,Temple syndrome due to maternal uniparental disomy of chromosome 14,64.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96184
96192,Paternal uniparental disomy of chromosome 7 syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96192
96253,Cushing disease,4.0 (Europe); 0.2 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96253
96264,"49,XXXXY syndrome",0.55 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96264
96263,"48,XXXY syndrome",1.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96263
96334,Kagami-Ogata syndrome due to paternal uniparental disomy of chromosome 14,0.0 (Worldwide); 37.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96334
97214,Eisenmenger syndrome,0.2 (Belgium); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97214
97234,Glycogen storage disease due to phosphoglycerate mutase deficiency,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97234
97239,Reducing body myopathy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97239
97240,Zebra body myopathy,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97240
97229,Riboflavin transporter deficiency,109.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97229
97230,Solar urticaria,3.1 (United Kingdom); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97230
97232,Fingerprint body myopathy,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97232
600194,Factor V Atlanta bleeding disorder,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=600194
97678,Maternal uniparental disomy of chromosome 13 syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97678
97593,Pseudohypoparathyroidism,0.67 (Italy); 0.34 (Japan); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97593
97564,Pauci-immune glomerulonephritis without ANCA,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97564
97563,Pauci-immune glomerulonephritis with ANCA,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97563
97685,17q11 microdeletion syndrome,170.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=97685
95707,Idiopathic isolated micropenis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95707
95706,Non-syndromic posterior hypospadias,19.25 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95706
95702,X-linked adrenal hypoplasia congenita,8.0 (Worldwide); 8.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95702
95715,Congenital hypothyroidism due to transplacental passage of TSH-binding inhibitory antibodies,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95715
95716,Familial thyroid dyshormonogenesis,2.67 (Worldwide); 4.0 (Europe); 4.0 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95716
95713,Athyreosis,3.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95713
95714,Primary congenital hypothyroidism without thyroid developmental anomaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95714
95711,Congenital hypothyroidism due to developmental anomaly,21.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95711
95712,Thyroid ectopia,14.3 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95712
95613,Pituitary apoplexy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95613
95700,Familial adrenal hypoplasia with absent pituitary luteinizing hormone,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95700
95699,Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency,0.75 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95699
95626,Acquired arginine vasopressin deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95626
95506,Primary hypophysitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95506
95496,Pituitary stalk interruption syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95496
95494,"Combined pituitary hormone deficiencies, genetic forms",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95494
95433,Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome,0.0 (Worldwide); 3.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95433
95434,Autosomal recessive cerebellar ataxia-movement disorder syndrome,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95434
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,"0.19 (Worldwide); 0.0 (Worldwide); 0.8 (Taiwan, Province of China); 0.189 (Germany); 0.19 (United States)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95455
95157,Acute hepatic porphyria,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95157
95159,Hepatoerythropoietic porphyria,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95159
95428,COG8-CDG,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95428
95427,Secondary short bowel syndrome,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95427
95409,Acute adrenal insufficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95409
95432,Primary progressive aphasia,7.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95432
95430,Congenital tracheomalacia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95430
95429,Angioma serpiginosum,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95429
94091,Mills syndrome,0.12 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94091
94093,Neuroleptic malignant syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94093
94122,"Cerebellar ataxia, Cayman type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94122
94124,Spinocerebellar ataxia with axonal neuropathy type 1,0.0 (Worldwide); 9.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94124
94145,Autosomal dominant cerebellar ataxia type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94145
94147,Spinocerebellar ataxia type 7,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94147
94148,Autosomal dominant cerebellar ataxia type III,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94148
94064,Deafness-infertility syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94064
94063,12q14 microdeletion syndrome,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94063
94066,Severe intellectual disability-epilepsy-anal anomalies-distal phalangeal hypoplasia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94066
94065,15q24 microdeletion syndrome,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94065
94068,Spondyloepiphyseal dysplasia congenita,1.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94068
94083,Partington syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94083
94086,Blue diaper syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94086
94088,Hereditary renal hypouricemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94088
94087,Cytophagic histiocytic panniculitis,0.0 (Worldwide); 100.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94087
94090,Pseudohypoparathyroidism type 2,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94090
94089,Pseudohypoparathyroidism type 1B,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94089
96175,Ring chromosome 11 syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96175
96173,Ring chromosome 9 syndrome,31.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96173
96172,Ring chromosome 3 syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96172
96171,Ring chromosome 2 syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96171
96170,Emanuel syndrome,350.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96170
96169,Koolen-De Vries syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96169
96168,Monosomy 13q34 syndrome,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96168
96167,Recombinant 8 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96167
96148,Distal deletion 10q syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96148
96147,Kleefstra syndrome due to 9q34 microdeletion,86.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96147
96125,Distal deletion 6p syndrome,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96125
96121,7q11.23 microduplication syndrome,163.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96121
96102,Distal duplication 10q syndrome,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96102
96095,3q26 microduplication syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96095
96092,8p inverted duplication/deletion syndrome,3.9 (Italy); 60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96092
96078,16p13.3 microduplication syndrome,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96078
96061,Mosaic trisomy 8 syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96061
95717,Idiopathic congenital hypothyroidism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95717
95719,Thyroid hemiagenesis,25.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95719
95720,Thyroid hypoplasia,3.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95720
96055,Tetrasomy 21 syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=96055
597623,IRF2BPL-related regressive neurodevelopmental disorder-dystonia-seizures syndrome,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597623
597733,Oculocutaneous albinism type 8,0.0 (Worldwide); 2.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597733
597738,Luscan-Lumish syndrome,0.0 (Worldwide); 11.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597738
597887,ALPI-related inflammatory bowel disease,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597887
93555,Mixed cryoglobulinemia type III,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93555
93554,Mixed cryoglobulinemia type II,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93554
597939,Euthyroid dysprealbuminemic hyperthyroxinemia,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597939
597743,SETD2-related microcephaly-severe intellectual disability-multiple congenital anomalies syndrome,0.0 (Worldwide); 12.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597743
597746,Blepharophimosis-intellectual disability syndrome/genitopatellar overlap syndrome,122.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597746
93552,Pediatric systemic lupus erythematosus,1.1 (United States); 0.7 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93552
597874,MTHFS-related developmental delay-microcephaly-short stature-epilepsy syndrome,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597874
598216,Upper tract urothelial carcinoma,0.0 (Worldwide); 1.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=598216
598603,Facial dysmorphism-hypertrichosis-epilepsy-intellectual disability/developmental delay-gingival overgrowth syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=598603
598363,Multisystem inflammatory syndrome in children and adults,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=598363
93561,ALys amyloidosis,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93561
93571,Dense deposit disease,0.25 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93571
597201,TRIM22-related inflammatory bowel disease,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=597201
93474,Scheie syndrome,0.2 (Canada); 0.07 (United Kingdom); 0.2 (Canada); 0.07 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93474
93476,Hurler-Scheie syndrome,0.24 (United Kingdom); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93476
93473,Hurler syndrome,"0.5 (Europe); 0.76 (United Kingdom); 0.64 (Germany); 0.38 (Denmark); 0.0 (Denmark); 1.05 (Portugal); 0.06 (Taiwan, Province of China); 0.93 (Australia); 0.7 (Europe); 0.07 (United States); 0.26 (United States)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93473
93398,Genochondromatosis type 2,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93398
599373,STXBP1-related encephalopathy,1.0885 (Denmark); 282.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599373
93403,Syndactyly type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93403
599376,Hypomyelination of early myelinating structures,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599376
93402,Syndactyly type 1,25.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93402
93405,Syndactyly type 4,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93405
93404,Syndactyly type 3,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93404
599480,Acquired hemophilia A,0.0 (Europe); 0.1505 (Europe); 0.0 (United Kingdom); 0.141 (United Kingdom); 0.3063 (Spain); 0.0829 (Spain); 0.0 (Germany); 0.6 (Germany); 0.0 (Australia); 0.12 (Australia); 0.0 (Japan); 0.097 (Japan); 0.0 (Switzerland); 0.45 (Switzerland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599480
599485,Acquired hemophilia B,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599485
93406,Syndactyly type 5,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93406
599490,Acquired factor V deficiency,0.0 (Worldwide); 200.0 (Worldwide); 0.029 (Australia); 0.009 (Singapore),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599490
93409,"Brachydactyly-syndactyly, Zhao type",2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93409
599495,Acquired factor VII deficiency,83.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599495
599501,Acquired factor X deficiency,77.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599501
599507,Acquired factor XI deficiency,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599507
599513,Acquired factor XIII deficiency,95.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599513
599519,Factor V short isoforms-related bleeding disorder,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599519
93420,FGFR3-related chondrodysplasia,8.1 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93420
599579,Factor V Amsterdam bleeding disorder,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599579
93360,"Spondyloepimetaphyseal dysplasia with joint laxity, leptodactylic type",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93360
93358,Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93358
93357,SPONASTRIME dysplasia,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93357
599082,CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=599082
93372,Familial hypocalciuric hypercalcemia type 1,74.1 (United States); 5.5 (Worldwide); 1.3 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93372
93382,Brachydactyly type A6,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93382
93383,Brachydactyly type B,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93383
93387,Brachydactyly type E,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93387
93388,Brachydactyly type A1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93388
93384,Brachydactyly type C,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93384
93396,Brachydactyly type A2,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93396
93397,Brachydactyly type A7,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93397
93394,Brachydactyly type A4,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93394
595356,Localized dystrophic epidermolysis bullosa,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=595356
94059,Uremic pruritus,35.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94059
94058,Neovascular glaucoma,24.4 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94058
94056,Isolated humero-ulnar synostosis,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=94056
93976,Anotia,0.03 (Specific population); 0.028 (Europe); 0.0 (Europe); 0.04 (France); 0.0 (France); 0.03 (Italy); 0.0 (Italy); 0.02 (Sweden); 0.0 (Sweden); 0.02 (United States); 0.0 (United States); 0.02 (Finland); 0.0 (Finland); 0.05 (Chile); 0.0 (Chile),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93976
93932,FG syndrome type 1,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93932
93930,Bladder exstrophy,2.8 (Spain); 0.0 (Europe); 0.0 (Europe); 2.8 (United States); 3.05 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93930
93928,Isolated epispadias,2.4 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93928
93929,Cloacal exstrophy,0.75 (Europe); 0.0 (Europe); 0.6 (United States); 0.5 (Spain); 0.54 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93929
93926,Midline interhemispheric variant of holoprosencephaly,0.0 (Worldwide); 0.0 (Worldwide); 2.778 (Romania),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93926
93924,Lobar holoprosencephaly,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93924
93925,Alobar holoprosencephaly,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93925
93921,Full schwannomatosis,0.0 (Worldwide); 0.058 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93921
93953,Familial thyroglossal duct cyst,22.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93953
93952,"X-linked intellectual disability, Hedera type",9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93952
595133,Perivascular epithelioid cell neoplasm,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=595133
93947,"X-linked intellectual disability, Golabi-Ito-Hall type",3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93947
93946,Hamel cerebro-palato-cardiac syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93946
93941,Laryngotracheoesophageal cleft type 4,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93941
93940,Laryngotracheoesophageal cleft type 3,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93940
93939,Laryngotracheoesophageal cleft type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93939
93938,Laryngotracheoesophageal cleft type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93938
93616,Hemoglobin H disease,8.7 (United States); 0.1 (United States); 1200.0 (South East Asia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93616
93622,Dent disease type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93622
93623,Dent disease type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93623
93672,Juvenile dermatomyositis,0.295 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93672
93685,Unicentric Castleman disease,0.0 (Worldwide); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93685
93890,Rare developmental defect during embryogenesis,3.3 (France); 2.42 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93890
93591,Infantile nephronophthisis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93591
93598,Primary hyperoxaluria type 1,0.015 (Netherlands); 0.29 (Netherlands); 1.0 (Switzerland); 0.2 (Switzerland); 0.83 (France); 0.1 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93598
93583,Congenital thrombotic thrombocytopenic purpura,0.0 (Worldwide); 0.0 (Worldwide); 123.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93583
93585,Immune-mediated thrombotic thrombocytopenic purpura,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93585
93610,Distal renal tubular acidosis with anemia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93610
596759,Combined immunodeficiency due to RELA haploinsufficiency,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=596759
93608,Autosomal dominant distal renal tubular acidosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93608
93607,Autosomal recessive proximal renal tubular acidosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93607
596937,Portosinusoidal vascular disease,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=596937
596448,IgG4-related systemic disease,0.0 (Worldwide); 0.0 (Worldwide); 0.0 (Japan); 1.026 (Japan); 0.576 (Denmark); 0.6885 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=596448
93600,Primary hyperoxaluria type 3,50.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93600
93599,Primary hyperoxaluria type 2,10.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93599
93606,Nephrogenic syndrome of inappropriate antidiuresis,21.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93606
596753,VEXAS syndrome,37.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=596753
93605,Bartter syndrome type 3,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93605
99094,Laubry-Pezzi syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99094
99063,Shone complex,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99063
99125,Congenital total pulmonary venous return anomaly,8.0 (United States); 9.0 (Worldwide); 9.0 (Worldwide); 8.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99125
99095,Congenital Gerbode defect,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99095
99147,Acquired von Willebrand syndrome,300.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99147
592873,Acute transverse myelitis with anti-MOG antibodies,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=592873
99141,Lymphedema-posterior choanal atresia syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99141
99329,"48,XYYY syndrome",10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99329
99330,"49,XYYYY syndrome",8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99330
99657,"Primary dystonia, DYT2 type",0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99657
99429,Complete androgen insensitivity syndrome,3.0 (Europe); 0.83 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99429
99642,"Spondyloepimetaphyseal dysplasia, Handigodu type",0.0 (Worldwide); 234.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99642
99646,Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99646
99688,Dermotrichic syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99688
592574,Menke-Hennekam syndrome,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=592574
592564,GNAO1-related developmental delay-seizures-movement disorder spectrum,75.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=592564
592570,TRAF7-associated heart defect-digital anomalies-facial dysmorphism-motor and speech delay syndrome,55.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=592570
99672,Fried's tooth and nail syndrome,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99672
99718,Leber plus disease,0.04 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99718
590539,Isolated melanotic schwannoma,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=590539
99725,Pituitary gigantism,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99725
589821,Congenital-onset Steinert myotonic dystrophy,0.0 (Worldwide); 2.1 (Canada); 0.94 (Italy); 47.6 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589821
589827,Juvenile-onset Steinert myotonic dystrophy,0.0 (Worldwide); 1.64 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589827
589824,Childhood-onset Steinert myotonic dystrophy,0.0 (Worldwide); 1.29 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589824
589833,Late-onset Steinert myotonic dystrophy,0.0 (Worldwide); 8.14 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589833
589830,Adult-onset Steinert myotonic dystrophy,0.0 (Worldwide); 12.54 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589830
589905,PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589905
589856,Choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589856
99710,Punctate acrokeratoderma freckle-like pigmentation,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99710
99750,Atypical progressive supranuclear palsy syndrome,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99750
99749,Kostmann syndrome,45.0 (Worldwide); 0.0 (Worldwide); 0.0425 (Brazil),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99749
99748,Pontiac fever,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99748
99757,Embryonal rhabdomyosarcoma,0.048 (Austria); 0.091 (Belgium); 0.034 (Bulgaria); 0.054 (Croatia); 0.011 (Czech Republic); 0.055 (Estonia); 0.005 (Finland); 0.046 (Germany); 0.089 (Ireland); 0.045 (Italy); 0.032 (Latvia); 0.046 (Lithuania); 0.057 (Norway); 0.035 (Poland); 0.051 (Portugal); 0.074 (Slovakia); 0.088 (Slovenia); 0.051 (Spain); 0.051 (Switzerland); 0.093 (Netherlands); 0.053 (United Kingdom); 0.128 (Iceland); 0.126 (Malta),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99757
99756,Alveolar rhabdomyosarcoma,0.018 (Austria); 0.054 (Belgium); 0.03 (Bulgaria); 0.017 (Croatia); 0.02 (Czech Republic); 0.009 (Estonia); 0.002 (Finland); 0.033 (Germany); 0.085 (Iceland); 0.062 (Ireland); 0.039 (Italy); 0.005 (Latvia); 0.021 (Lithuania); 0.063 (Malta); 0.035 (Norway); 0.02 (Poland); 0.02 (Portugal); 0.029 (Slovakia); 0.044 (Slovenia); 0.027 (Spain); 0.045 (Switzerland); 0.036 (Netherlands); 0.039 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99756
99734,Myotonia fluctuans,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99734
99731,Isolated sulfite oxidase deficiency,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99731
99735,Myotonia permanens,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99735
99736,Acetazolamide-responsive myotonia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99736
99741,King-Denborough syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99741
99742,Amish lethal microcephaly,200.0 (Specific population); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99742
99745,Typhoid,3.0 (Europe); 274.0 (South East Asia); 53.0 (Latin America); 50.0 (Africa); 0.0 (North America); 15.0 (Oceania); 0.2 (France); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99745
98818,Landau-Kleffner syndrome,0.4 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98818
98815,Self-limited epilepsy with autonomic seizures,0.8 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98815
98813,Hypohidrotic ectodermal dysplasia with immunodeficiency,0.2 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98813
98811,Paroxysmal exertion-induced dyskinesia,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98811
98810,Paroxysmal non-kinesigenic dyskinesia,0.1 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98810
98809,Paroxysmal kinesigenic dyskinesia,0.6 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98809
98808,Autosomal dominant dopa-responsive dystonia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98808
98807,"Primary dystonia, DYT13 type",0.0 (Worldwide); 8.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98807
98838,Primary mediastinal large B-cell lymphoma,5.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98838
98833,Acute myeloblastic leukemia without maturation,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98833
98834,Acute myeloblastic leukemia with maturation,0.02 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98834
98831,Acute myeloid leukemia with 11q23 abnormalities,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98831
98832,Acute myeloid leukemia with minimal differentiation,0.01 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98832
98829,Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22),0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98829
98827,Unclassified myelodysplastic syndrome,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98827
98826,Myelodysplastic neoplasm with low blasts,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98826
98823,Chronic myelomonocytic leukemia,0.68 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98823
98824,Atypical chronic myeloid leukemia,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98824
98851,Mast cell leukemia,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98851
98848,Indolent systemic mastocytosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98848
98850,Aggressive systemic mastocytosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98850
98849,Systemic mastocytosis with associated hematologic neoplasm,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98849
98844,"Classic Hodgkin lymphoma, mixed cellularity type",0.42 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98844
98843,"Classic Hodgkin lymphoma, nodular sclerosis type",1.28 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98843
98846,"Classic Hodgkin lymphoma, lymphocyte-depleted type",0.04 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98846
98845,"Classic Hodgkin lymphoma, lymphocyte-rich type",0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98845
98842,Lymphomatoid papulosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98842
98841,Anaplastic large cell lymphoma,2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98841
589608,"Linear hypopigmentation and craniofacial asymmetry with acral, ocular and brain anomalies",7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589608
589595,Mixed phenotype acute leukemia with t(v;11q23.3),0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589595
98868,Southeast Asian ovalocytosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98868
98869,Congenital dyserythropoietic anemia type I,0.0 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98869
589618,Dystonia 28,160.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589618
98870,Congenital dyserythropoietic anemia type III,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98870
589534,Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2),0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589534
98863,X-linked Emery-Dreifuss muscular dystrophy,0.13 (United Kingdom); 1.0 (Worldwide); 1.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98863
589527,Spinocerebellar ataxia type 45,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589527
589547,"GRIN2B-related developmental delay, intellectual disability and autism spectrum disorder",98.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589547
589542,Myeloid/lymphoid neoplasm associated with JAK2 rearrangement,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589542
589442,Short stature-skeletal dysplasia-retinal degeneration-intellectual disability-sensorineural hearing loss syndrome,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589442
589435,Spondylometaphyseal dysplasia-corneal dystrophy syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589435
589522,Spinocerebellar ataxia type 46,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589522
589515,PUM1-associated developmental disability-ataxia-seizure syndrome,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589515
98856,Charcot-Marie-Tooth disease type 2B1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98856
98881,Familial dysfibrinogenemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98881
98879,Hemophilia B,"3.0 (Europe); 1.0 (Albania); 0.44 (Algeria); 0.54 (Argentina); 0.2 (Armenia); 0.665 (Austria); 0.16 (Azerbaijan); 0.015 (Bangladesh); 0.84 (Belarus); 1.32 (Belgium); 1.155 (Belize); 0.045 (Bolivia); 0.265 (Bosnia and Herzegovina); 0.535 (Brazil); 0.775 (Bulgaria); 0.795 (Chile); 0.405 (Colombia); 0.645 (Costa rica); 1.625 (Croatia); 0.49 (Cuba); 3.195 (Cyprus); 1.045 (Czech Republic); 1.56 (Denmark); 0.165 (Dominican Republic); 0.25 (Ecuador); 0.955 (Egypt); 0.31 (El Salvador); 0.065 (Eritrea); 0.24 (Estonia); 1.235 (Finland); 0.5 (Georgia); 0.885 (Germany); 1.075 (Greece); 0.075 (Guatemala); 0.17 (Honduras); 2.115 (Hungary); 0.695 (Iceland); 0.095 (India); 0.01 (Indonesia); 0.98 (Iran, Islamic Republic of); 0.545 (Iraq); 1.06 (Italy); 0.495 (Korea, Republic of); 0.76 (Latvia); 0.57 (Lithuania); 0.235 (Luxembourg); 3.205 (North Macedonia); 0.5 (Malaysia); 0.77 (Malta); 0.29 (Mexico); 0.37 (Moldova, Republic of); 0.15 (Mongolia); 0.2 (Morocco); 0.065 (Nepal); 1.035 (Netherlands); 1.855 (New Zealand); 0.005 (Nigeria); 1.975 (Norway); 0.24 (Pakistan); 0.84 (Palestinian Territory, occupied); 0.24 (Peru); 0.1 (Philippines); 0.85 (Poland); 0.93 (Portugal); 2.265 (Qatar); 0.73 (Russian Federation); 0.15 (Saudi Arabia); 0.04 (Senegal); 0.715 (Serbia); 0.045 (Sierra leone); 0.545 (Singapore); 0.995 (Israel); 0.32 (Jamaica); 0.745 (Jordan); 0.13 (Kenya); 0.33 (Lebanon); 0.33 (Nicaragua); 0.585 (Panama); 0.375 (Paraguay); 0.76 (Romania); 1.28 (Slovakia); 0.82 (Slovenia); 0.525 (South Africa); 0.765 (Spain); 0.065 (Sri Lanka); 0.115 (Sudan); 1.85 (Sweden); 1.375 (Switzerland); 0.085 (Thailand); 0.02 (Togo); 0.37 (Tunisia); 0.31 (Turkey); 0.01 (Ukraine); 2.08 (United Kingdom); 0.36 (Uruguay); 0.285 (Uzbekistan); 1.18 (Venezuela); 0.14 (Viet Nam); 0.35 (Zimbabwe); 1.665 (Worldwide); 2.44 (France)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98879
98873,Congenital dyserythropoietic anemia type II,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98873
98878,Hemophilia A,"4.85 (Worldwide); 11.25 (Worldwide); 10.5 (France); 7.0 (United States); 8.0 (Europe); 1.58 (Africa); 7.6 (Albania); 2.8 (Algeria); 4.5 (Argentina); 5.0 (Armenia); 6.8 (Australia); 4.3 (Austria); 8.0 (Azerbaijan); 0.2 (Bangladesh); 5.1 (Belarus); 6.0 (Belgium); 2.2 (Belize); 0.1 (Bolivia); 2.6 (Bosnia and Herzegovina); 3.7 (Brazil); 6.8 (Bulgaria); 7.3 (Canada); 5.3 (Chile); 0.2 (China); 2.6 (Colombia); 3.0 (Costa rica); 8.5 (Croatia); 2.7 (Cuba); 5.2 (Cyprus); 6.1 (Czech Republic); 6.2 (Denmark); 1.8 (Dominican Republic); 2.5 (Ecuador); 4.4 (Egypt); 3.0 (El Salvador); 0.7 (Eritrea); 2.8 (Estonia); 4.6 (Finland); 5.0 (Germany); 6.5 (Greece); 1.0 (Guatemala); 2.6 (Honduras); 8.3 (Hungary); 19.3 (Iceland); 0.7 (India); 0.1 (Indonesia); 5.6 (Iran, Islamic Republic of); 1.8 (Iraq); 9.2 (Ireland); 5.4 (Israel); 4.7 (Italy); 3.6 (Jamaica); 3.3 (Japan); 3.5 (Jordan); 1.1 (Kenya); 3.0 (Korea, Republic of); 4.9 (Latvia); 1.5 (Lebanon); 0.7 (Lesotho); 4.1 (Lithuania); 5.4 (Luxembourg); 8.1 (North Macedonia); 3.3 (Malaysia); 3.3 (Malta); 2.2 (Mexico); 4.7 (Moldova, Republic of); 1.4 (Mongolia); 1.0 (Morocco); 0.6 (Nepal); 9.3 (Netherlands); 11.0 (New Zealand); 3.7 (Nicaragua); 0.025 (Nigeria); 6.1 (Norway); 0.8 (Pakistan); 2.7 (Palestinian Territory, occupied); 6.6 (Panama); 1.2 (Paraguay); 1.6 (Peru); 0.9 (Philippines); 5.6 (Poland); 4.9 (Portugal); 7.9 (Qatar); 6.4 (Romania); 3.3 (Russian Federation); 0.5 (Saudi Arabia); 0.8 (Senegal); 3.7 (Serbia); 0.1 (Sierra leone); 4.0 (Singapore); 8.6 (Slovakia); 8.2 (Slovenia); 3.0 (South Africa); 3.8 (Spain); 0.6 (Sri Lanka); 0.85 (Sudan); 7.7 (Sweden); 7.1 (Switzerland); 1.8 (Thailand); 0.02 (Togo); 2.2 (Tunisia); 3.1 (Turkey); 0.35 (Ukraine); 10.4 (United Kingdom); 4.9 (Uruguay); 3.8 (Uzbekistan); 4.9 (Venezuela); 1.0 (Viet Nam); 2.3 (Zimbabwe); 4.4 (Georgia)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98878
98895,Becker muscular dystrophy,2.0 (Europe); 2.7 (United Kingdom); 3.64 (United Kingdom); 2.5 (United States); 2.4 (United States); 2.2 (Europe); 1.53 (Worldwide); 2.47 (Italy); 3.94 (Egypt); 0.91 (Japan); 0.07 (South Africa); 1.59 (Ireland); 1.42 (Puerto rico),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98895
98896,Duchenne muscular dystrophy,9.9 (Worldwide); 4.14 (United Kingdom); 14.0 (United States); 12.0 (Netherlands); 10.5 (Canada); 9.7 (United Kingdom); 8.2 (Ireland); 1.7 (Italy); 4.26 (Ireland); 2.8 (Worldwide); 7.66 (Egypt); 3.56 (Japan); 0.47 (South Africa); 2.75 (Denmark); 2.59 (Puerto rico),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98896
98902,Amish nemaline myopathy,0.0 (Europe); 200.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98902
98890,Early-onset X-linked optic atrophy,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98890
98893,Congenital muscular dystrophy type 1B,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98893
98892,Periventricular nodular heterotopia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98892
98912,"Late-onset distal myopathy, Markesbery-Griggs type",0.0 (Worldwide); 11.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98912
98916,Acute inflammatory demyelinating polyradiculoneuropathy,3.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98916
98908,Neutral lipid storage disease with myopathy,36.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98908
98907,Neutral lipid storage disease with ichthyosis,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98907
98909,Desminopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98909
98933,"Multiple system atrophy, parkinsonian type",2.4 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98933
98934,Huntington disease-like 2,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98934
98919,Miller Fisher syndrome,0.1 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98919
98920,Spinal muscular atrophy with respiratory distress type 1,128.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98920
98938,Colobomatous microphthalmia,19.0 (United Kingdom); 19.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98938
98949,Complete cryptophthalmia,0.0 (Worldwide); 15.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98949
98950,Partial cryptophthalmia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98950
98948,Congenital symblepharon,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98948
98957,Gelatinous drop-like corneal dystrophy,0.33 (Japan); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98957
98955,Lisch epithelial corneal dystrophy,36.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98955
98954,Meesmann corneal dystrophy,250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98954
98964,Lattice corneal dystrophy type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98964
98963,Granular corneal dystrophy type II,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98963
98962,Granular corneal dystrophy type I,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98962
98961,Reis-Bücklers corneal dystrophy,81.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98961
98960,Thiel-Behnke corneal dystrophy,173.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98960
98959,Subepithelial mucinous corneal dystrophy,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98959
98971,Posterior amorphous corneal dystrophy,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98971
98972,Central cloudy dystrophy of François,24.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98972
98973,Posterior polymorphous corneal dystrophy,1.0 (Czech Republic); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98973
98974,Fuchs endothelial corneal dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98974
98967,Schnyder corneal dystrophy,115.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98967
98969,Macular corneal dystrophy,1.0 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98969
98970,Fleck corneal dystrophy,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98970
98976,Congenital glaucoma,2.2 (Europe); 2.9 (Belgium); 6.6 (France); 2.8 (Malta); 3.6 (Italy); 5.6 (Netherlands); 0.8 (Norway); 0.9 (Portugal); 6.5 (Spain); 2.2 (United Kingdom); 3.0 (Ukraine); 0.0 (Europe); 1.5 (Switzerland); 1.4 (Poland); 4.1 (Ireland); 4.1 (Germany); 2.8 (Croatia); 3.4 (Austria),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98976
98977,Juvenile glaucoma,2.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98977
99000,Adult-onset foveomacular vitelliform dystrophy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99000
99013,Spastic paraplegia type 7,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99013
99014,X-linked Charcot-Marie-Tooth disease type 5,0.0 (Worldwide); 9.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99014
99015,Spastic paraplegia type 2,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99015
585867,Acute myeloid leukemia with t(9;22)(q34.1;q11.2),4.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585867
585877,B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585877
585909,B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2),0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585909
585936,B-lymphoblastic leukemia/lymphoma with hyperdiploidy,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585936
585942,B-lymphoblastic leukemia/lymphoma with hypodiploidy,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585942
585918,B-lymphoblastic leukemia/lymphoma with t(v;11q23.3),0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585918
585929,B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1),0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585929
99027,Adult-onset autosomal dominant leukodystrophy,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99027
585956,B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3),0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585956
585948,B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3),0.0 (Western Asia); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=585948
586130,Sporadic fatal insomnia,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=586130
99042,Congenitally uncorrected transposition of the great arteries with coarctation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99042
99050,Abnormal origin of right or left pulmonary artery from the aorta,200.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99050
98606,Syndromic orbital border hypoplasia,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98606
98555,Microphthalmia-anophthalmia-coloboma,8.3 (Europe); 0.0 (Europe); 2.9 (Belgium); 0.0 (Belgium); 9.8 (Austria); 0.0 (Austria); 36.4 (Denmark); 0.0 (Denmark); 7.3 (France); 0.0 (France); 5.8 (Germany); 0.0 (Germany); 17.7 (Hungary); 0.0 (Hungary); 3.6 (Ireland); 0.0 (Ireland); 11.0 (Italy); 0.0 (Italy); 25.9 (Malta); 0.0 (Malta); 11.1 (Netherlands); 0.0 (Netherlands); 6.4 (Norway); 0.0 (Norway); 2.4 (Poland); 0.0 (Poland); 13.1 (Croatia); 0.0 (Croatia); 14.4 (Spain); 0.0 (Spain); 12.3 (Switzerland); 0.0 (Switzerland); 3.9 (United Kingdom); 0.0 (United Kingdom); 12.9 (Ukraine); 0.0 (Ukraine); 5.2 (Portugal); 0.0 (Portugal); 18.0 (United States); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98555
98676,Autosomal recessive isolated optic atrophy,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98676
98673,"Autosomal dominant optic atrophy, classic form",2.0 (Worldwide); 10.0 (Denmark); 2.86 (United Kingdom); 83.33 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98673
98672,Autosomal dominant optic atrophy,10.0 (Denmark); 2.5 (United Kingdom); 3.3 (Worldwide); 83.0 (Specific population),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98672
98627,Posterior corneal dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98627
98626,Stromal corneal dystrophy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98626
98625,Superficial corneal dystrophy,13.8 (United States); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98625
583856,Isolated splenic vein thrombosis,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=583856
583861,Isolated mesenteric vein thrombosis,1.6 (Europe); 0.5 (Finland); 2.7 (Sweden); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=583861
98715,Uveitis,17.0 (Europe); 38.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98715
98723,Hypoplastic right heart syndrome,3.3 (Europe); 2.9 (Belgium); 19.8 (Denmark); 2.0 (France); 5.8 (Germany); 3.3 (Hungary); 3.6 (Ireland); 1.4 (Italy); 24.1 (Malta); 5.8 (Netherlands); 6.5 (Norway); 0.5 (Poland); 12.6 (Switzerland); 3.9 (United Kingdom); 9.5 (Ukraine); 0.6 (Spain); 1.68 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98723
583097,Congenital infiltrating lipomatosis of the face,59.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=583097
98791,Alpha-thalassemia-intellectual disability syndrome linked to chromosome 16,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98791
98806,"Primary dystonia, DYT6 type",0.0 (Worldwide); 53.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98806
98805,"Primary dystonia, DYT4 type",0.0 (Worldwide); 22.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98805
98784,Autosomal dominant nocturnal frontal lobe epilepsy,100.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98784
98764,Spinocerebellar ataxia type 27A,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98764
98763,Spinocerebellar ataxia type 14,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98763
98766,Spinocerebellar ataxia type 5,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98766
98765,Spinocerebellar ataxia type 4,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98765
98760,Spinocerebellar ataxia type 8,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98760
98759,Spinocerebellar ataxia type 17,100.0 (Worldwide); 0.0 (Worldwide); 0.047 (Japan); 0.16 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98759
98762,Spinocerebellar ataxia type 12,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98762
98761,Spinocerebellar ataxia type 10,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98761
98772,Spinocerebellar ataxia type 19/22,12.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98772
98771,Spinocerebellar ataxia type 18,26.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98771
98773,Spinocerebellar ataxia type 21,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98773
98768,Spinocerebellar ataxia type 13,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98768
98767,Spinocerebellar ataxia type 11,51.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98767
98769,Spinocerebellar ataxia type 15/16,80.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98769
580933,Lethal brain and heart developmental defects,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=580933
98755,Spinocerebellar ataxia type 1,1.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98755
98756,Spinocerebellar ataxia type 2,1.5 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98756
98757,Spinocerebellar ataxia type 3,1.5 (Worldwide); 1.0 (Portugal); 5.5 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98757
98758,Spinocerebellar ataxia type 6,0.0 (Worldwide); 1.7 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98758
580572,Intraductal tubulopapillary neoplasm of pancreas,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=580572
98306,Familial partial lipodystrophy,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98306
576278,SATB2-associated syndrome,171.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=576278
573253,Split cord malformation type II,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=573253
574957,Mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=574957
574918,Predisposition to severe viral infection due to IRF7 deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=574918
98375,Autoimmune hemolytic anemia,2.02 (Europe); 2.02 (United States); 11.0 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98375
573278,Split cord malformation,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=573278
98482,Idiopathic inflammatory myopathy,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98482
572385,Brachydactyly type B1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572385
572361,Blepharophimosis-ptosis-epicanthus inversus syndrome type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572361
98428,Secondary polycythemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98428
572428,Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572428
98434,Hereditary combined deficiency of vitamin K-dependent clotting factors,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98434
572543,RFVT2-related riboflavin transporter deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572543
572550,RFVT3-related riboflavin transporter deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572550
572773,Microcephaly-short stature-limb abnormalities syndrome,29.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572773
572798,WARS2-related combined oxidative phosphorylation defect,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572798
572761,DONSON-related microcephaly-short stature-limb abnormalities spectrum,51.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572761
572768,Microcephaly-micromelia syndrome,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572768
98523,Non-syndromic pontocerebellar hypoplasia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98523
572013,Posterior-predominant lissencephaly-broad flat pons and medulla-midline crossing defects syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572013
572333,Blepharophimosis-ptosis-epicanthus inversus syndrome plus,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572333
572354,Blepharophimosis-ptosis-epicanthus inversus syndrome type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=572354
570762,Infective endocarditis,0.0 (Europe); 3.38 (France); 1.8 (Denmark); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=570762
570491,QRSL1-related combined oxidative phosphorylation defect,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=570491
570470,Ricin poisoning,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=570470
570438,HHV-8-associated multicentric Castleman disease,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=570438
570431,Idiopathic multicentric Castleman disease,0.0 (Worldwide); 0.0 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=570431
570422,Galactose mutarotase deficiency,0.0 (Worldwide); 0.4 (Worldwide); 1.2 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=570422
570371,Bartter syndrome type 5,0.0 (Worldwide); 15.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=570371
98497,Genetic peripheral neuropathy,40.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98497
104075,Adenocarcinoma of the small intestine,0.588 (Europe); 0.517 (Austria); 0.734 (Belgium); 0.174 (Bulgaria); 0.308 (Croatia); 0.464 (Czech Republic); 0.36 (Estonia); 0.574 (Finland); 0.657 (France); 0.551 (Germany); 0.724 (Iceland); 0.564 (Ireland); 0.79 (Italy); 0.265 (Latvia); 0.277 (Lithuania); 0.377 (Malta); 0.788 (Norway); 0.219 (Poland); 0.743 (Portugal); 0.462 (Slovakia); 0.4 (Slovenia); 0.477 (Spain); 0.76 (Switzerland); 0.626 (Netherlands); 0.679 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=104075
104008,Short bowel syndrome,2.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=104008
103918,Tropical pancreatitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=103918
103910,Congenital enterocyte heparan sulfate deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=103910
103908,Congenital sodium diarrhea,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=103908
103909,Trehalase deficiency,7700.0 (Greenland); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=103909
103907,Chronic diarrhea due to glucoamylase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=103907
102724,Acute myeloid leukemia with t(8;21)(q22;q22) translocation,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=102724
101997,Primary immunodeficiency,"0.0 (Europe); 6.8 (Norway); 11.0 (France); 3.6 (Spain); 2.6 (Netherlands); 1.84 (United Kingdom); 1.79 (Italy); 1.38 (Germany); 2.0 (Turkey); 1.33 (Poland); 5.6 (Australia); 4.9 (New Zealand); 1.1 (Korea, Republic of); 4.5 (Oman)",http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101997
101685,Rare non-syndromic intellectual disability,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101685
101959,Chronic primary adrenal insufficiency,0.4 (Europe); 14.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101959
101150,Autosomal recessive dopa-responsive dystonia,50.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101150
101111,Spinocerebellar ataxia type 25,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101111
101112,Spinocerebellar ataxia type 26,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101112
101109,Spinocerebellar ataxia type 28,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101109
101110,Spinocerebellar ataxia type 20,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101110
101108,Spinocerebellar ataxia type 23,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101108
101330,Porphyria cutanea tarda,0.6 (Europe); 4.0 (Europe); 1.0 (Norway); 10.0 (Sweden),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101330
101085,Charcot-Marie-Tooth disease type 1F,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101085
101081,Charcot-Marie-Tooth disease type 1A,82.37 (Norway); 15.2 (United Kingdom); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101081
101082,Charcot-Marie-Tooth disease type 1B,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101082
101083,Charcot-Marie-Tooth disease type 1C,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101083
101077,X-linked Charcot-Marie-Tooth disease type 3,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101077
101078,X-linked Charcot-Marie-Tooth disease type 4,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101078
101075,X-linked Charcot-Marie-Tooth disease type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101075
101076,X-linked Charcot-Marie-Tooth disease type 2,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101076
101102,Charcot-Marie-Tooth disease type 2H,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101102
101101,Charcot-Marie-Tooth disease type 2B2,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101101
101097,Autosomal recessive Charcot-Marie-Tooth disease with hoarseness,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101097
101041,Familial hypofibrinogenemia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101041
101046,Autosomal dominant epilepsy with auditory features,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101046
101068,Congenital stromal corneal dystrophy,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101068
101009,Autosomal dominant spastic paraplegia type 29,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101009
101010,Autosomal spastic paraplegia type 30,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101010
101011,Autosomal dominant spastic paraplegia type 31,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101011
101016,Romano-Ward syndrome,40.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101016
101039,Female restricted epilepsy with intellectual disability,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101039
101028,Transaldolase deficiency,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101028
100984,Autosomal dominant spastic paraplegia type 3,0.14 (Portugal); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100984
100980,Autosomal dominant pure spastic paraplegia,4.4 (Norway); 0.9 (Ireland); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100980
100979,Autosomal dominant complex spastic paraplegia,1.0 (Norway); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100979
100978,Cloverleaf skull-asphyxiating thoracic dysplasia syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100978
100991,Autosomal dominant spastic paraplegia type 10,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100991
100989,Autosomal dominant spastic paraplegia type 8,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100989
100988,Autosomal dominant spastic paraplegia type 6,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100988
100986,Autosomal recessive spastic paraplegia type 5A,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100986
100985,Autosomal dominant spastic paraplegia type 4,0.91 (Portugal),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100985
100999,Autosomal dominant spastic paraplegia type 19,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100999
101000,Autosomal recessive spastic paraplegia type 20,36.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101000
100997,X-linked spastic paraplegia type 16,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100997
100998,Autosomal dominant spastic paraplegia type 17,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100998
100995,Autosomal recessive spastic paraplegia type 14,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100995
100996,Autosomal recessive spastic paraplegia type 15,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100996
100993,Autosomal dominant spastic paraplegia type 12,27.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100993
100994,Autosomal dominant spastic paraplegia type 13,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100994
101007,Autosomal recessive spastic paraplegia type 27,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101007
101008,Autosomal recessive spastic paraplegia type 28,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101008
101005,Autosomal recessive spastic paraplegia type 25,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101005
101006,Autosomal recessive spastic paraplegia type 26,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101006
101003,Autosomal recessive spastic paraplegia type 23,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101003
101004,Autosomal recessive spastic paraplegia type 24,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101004
101001,Autosomal recessive spastic paraplegia type 21,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101001
100088,Rare thyroid carcinoma,3.65 (Europe); 61.7 (Europe); 12.2 (United States); 3.1 (Worldwide); 12.7 (Worldwide); 2.733 (United Kingdom); 12.86 (Italy); 7.679 (Austria); 3.74 (Belgium); 2.921 (Bulgaria); 8.329 (Croatia); 6.382 (Czech Republic); 4.803 (Estonia); 6.375 (Finland); 5.526 (Germany); 2.45 (Ireland); 4.563 (Latvia); 7.905 (Lithuania); 6.344 (Malta); 4.472 (Norway); 4.488 (Poland); 8.628 (Portugal); 3.991 (Slovakia); 5.649 (Slovenia); 5.162 (Spain); 6.39 (Switzerland); 2.373 (Netherlands),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100088
100085,Primary hepatic neuroendocrine carcinoma,0.2 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100085
100087,Rare thyroid tumor,3.2 (Worldwide); 5.0 (Europe); 5.7 (Italy); 5.35 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100087
100924,Porphyria due to ALA dehydratase deficiency,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100924
100973,FRAXE intellectual disability,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100973
100974,FRAXF syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100974
100976,Bathing suit ichthyosis,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100976
100054,F12-related hereditary angioedema with normal C1Inh,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100054
100051,Hereditary angioedema type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100051
100057,Renin-angiotensin-aldosterone system-blocker-induced angioedema,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100057
100070,Progressive non-fluent aphasia,2.5 (Europe); 0.7 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100070
100073,Neurogenic thoracic outlet syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100073
100075,Neuroendocrine tumor of stomach,3.2 (Europe); 1.7 (United States); 0.7 (United Kingdom); 0.5 (Japan),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100075
100071,Mosaic trisomy 3 syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100071
100020,Myelodysplastic neoplasm with increased blasts type 2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100020
100019,Myelodysplastic neoplasm with increased blasts type 1,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100019
100022,Extramedullary soft tissue plasmacytoma,0.1 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100022
100021,Primary plasmacytoma of the bone,0.15 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100021
100024,Mu-heavy chain disease,35.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100024
100026,Gamma-heavy chain disease,120.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100026
100025,Alpha-heavy chain disease,400.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100025
100043,Autosomal dominant intermediate Charcot-Marie-Tooth disease type A,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100043
100044,Autosomal dominant intermediate Charcot-Marie-Tooth disease type B,37.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100044
100045,Autosomal dominant intermediate Charcot-Marie-Tooth disease type C,0.0 (Worldwide); 35.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100045
100046,Autosomal dominant intermediate Charcot-Marie-Tooth disease type D,0.0 (Worldwide); 12.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100046
100050,Hereditary angioedema type 1,1.54 (Italy); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100050
100012,Lissencephaly with cerebellar hypoplasia type B,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100012
100013,Lissencephaly with cerebellar hypoplasia type C,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100013
100008,ACys amyloidosis,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100008
100006,"ABeta amyloidosis, Dutch type",250.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=100006
99995,Complex regional pain syndrome type 1,5.46 (United States); 20.57 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99995
99994,Complex regional pain syndrome type 2,0.82 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99994
99989,Intermediate DEND syndrome,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99989
99981,Apnea of prematurity,8.5 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99981
99978,Klatskin tumor,1.5 (United States); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99978
99977,Squamous cell carcinoma of the esophagus,3.357 (Europe); 0.0 (Europe); 5.42 (Europe); 5.2 (Worldwide); 2.026 (Austria); 3.881 (Belgium); 0.801 (Bulgaria); 2.79 (Croatia); 2.315 (Czech Republic); 3.122 (Estonia); 2.325 (Finland); 5.069 (France); 4.172 (Germany); 2.215 (Iceland); 3.443 (Ireland); 2.623 (Italy); 2.896 (Latvia); 2.922 (Lithuania); 1.256 (Malta); 1.706 (Norway); 1.996 (Poland); 3.734 (Portugal); 3.866 (Slovakia); 3.234 (Slovenia); 3.544 (Spain); 3.778 (Switzerland); 3.139 (Netherlands); 4.186 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99977
99976,Adenocarcinoma of the esophagus,3.264 (Europe); 0.0 (Europe); 5.55 (Europe); 0.7 (Worldwide); 1.235 (Austria); 3.918 (Belgium); 0.364 (Bulgaria); 0.485 (Croatia); 1.28 (Czech Republic); 0.305 (Estonia); 1.5 (Finland); 1.681 (France); 1.636 (Germany); 2.471 (Iceland); 3.736 (Ireland); 0.947 (Italy); 0.39 (Latvia); 0.526 (Lithuania); 1.319 (Malta); 0.315 (Poland); 0.829 (Portugal); 0.578 (Slovakia); 0.651 (Slovenia); 2.612 (Switzerland); 5.196 (Netherlands); 6.592 (United Kingdom); 1.848 (Norway); 1.178 (Spain),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99976
99971,Well-differentiated liposarcoma,0.51 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99971
99969,Pleomorphic liposarcoma,0.05 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99969
99970,Dedifferentiated liposarcoma,0.27 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99970
99967,Myxoid/round cell liposarcoma,0.1 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99967
99966,Atypical teratoid rhabdoid tumor,0.0 (Worldwide); 1.38 (Austria),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99966
643549,Hao-Fountain syndrome,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=643549
99955,Charcot-Marie-Tooth disease type 4B1,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99955
99956,Charcot-Marie-Tooth disease type 4B2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99956
99948,Charcot-Marie-Tooth disease type 4A,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99948
99947,Autosomal dominant Charcot-Marie-Tooth disease type 2A2,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99947
99950,Charcot-Marie-Tooth disease type 4D,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99950
99949,Charcot-Marie-Tooth disease type 4C,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99949
99952,Charcot-Marie-Tooth disease type 4F,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99952
99954,Charcot-Marie-Tooth disease type 4H,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99954
99953,Charcot-Marie-Tooth disease type 4G,0.0 (Worldwide); 10.0 (Czech Republic),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99953
99940,Autosomal dominant Charcot-Marie-Tooth disease type 2F,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99940
99939,Autosomal dominant Charcot-Marie-Tooth disease type 2E,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99939
99941,Autosomal dominant Charcot-Marie-Tooth disease type 2G,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99941
99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99944
99946,Autosomal dominant Charcot-Marie-Tooth disease type 2A1,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99946
99945,Autosomal dominant Charcot-Marie-Tooth disease type 2L,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99945
99931,Idiopathic pulmonary hemosiderosis,0.0425 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99931
99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,44.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99938
99925,Invasive mole,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99925
99926,Gestational choriocarcinoma,0.0 (Worldwide); 0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99926
99927,Hydatidiform mole,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99927
99928,Placental site trophoblastic tumor,0.02 (Europe); 0.86 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99928
99918,Streptococcal toxic-shock syndrome,0.1 (France); 0.2 (United States); 0.33 (Sweden); 0.23 (Denmark),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99918
99917,"Theca steroid-producing cell malignant tumor of ovary, not further specified",0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99917
99916,Malignant Sertoli-Leydig cell tumor of the ovary,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99916
99915,Malignant granulosa cell tumor of the ovary,0.12 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99915
99919,Staphylococcal toxic-shock syndrome,0.0 (Worldwide); 0.58 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99919
99912,Ovarian dysgerminoma,0.0 (Worldwide); 0.04 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99912
99901,Acyl-CoA dehydrogenase 9 deficiency,23.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99901
99905,Streptobacillary rat-bite fever,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99905
99903,Spirillary rat-bite fever,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99903
99892,ACTH-dependent Cushing syndrome,0.55 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99892
99898,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency,0.0 (Worldwide); 31.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99898
99879,Familial isolated hyperparathyroidism,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99879
99880,Hyperparathyroidism-jaw tumor syndrome,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99880
99889,Cushing syndrome due to ectopic ACTH secretion,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99889
99885,Isolated permanent neonatal diabetes mellitus,0.38 (Europe); 0.0 (Europe); 0.38 (United Kingdom); 0.38 (Poland); 0.38 (Netherlands); 0.46 (Slovakia); 0.4 (United States); 18.0 (Oman),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99885
99886,Transient neonatal diabetes mellitus,0.3 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99886
99865,Spermatocytic seminoma,0.03 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99865
99868,Thymic carcinoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99868
99867,Thymoma,0.14 (Europe); 1.22 (Europe); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99867
99869,Thymic neuroendocrine carcinoma,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99869
99849,Glycogen storage disease due to muscle beta-enolase deficiency,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99849
99845,Genetic recurrent myoglobinuria,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99845
99846,Autosomal dominant myoglobinuria,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99846
99843,Leukocyte adhesion deficiency type II,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99843
99844,Leukocyte adhesion deficiency type III,40.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99844
99853,Ovarioleukodystrophy,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99853
99852,Ravine syndrome,38.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99852
99832,Resistance to thyrotropin-releasing hormone syndrome,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99832
99829,Yellow fever,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99829
99828,Dengue fever,0.0 (Worldwide); 714.0 (Worldwide); 0.5 (Europe); 0.0 (Europe); 1.14 (Austria); 0.98 (Belgium); 0.033 (Croatia); 0.58 (Estonia); 0.98 (Finland); 0.36 (France); 0.96 (Germany); 0.14 (Hungary); 0.32 (Ireland); 0.14 (Italy); 0.34 (Latvia); 0.15 (Lithuania); 0.04 (Luxembourg); 0.22 (Malta); 0.1 (Portugal); 0.07 (Slovakia); 0.22 (Slovenia); 0.26 (Spain); 1.7 (Sweden); 0.72 (United Kingdom); 1.26 (Norway); 0.0 (Greece),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99828
99827,Crimean-Congo hemorrhagic fever,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99827
99842,Leukocyte adhesion deficiency type I,0.1 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99842
99812,LIG4 syndrome,28.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99812
99824,Lassa fever,0.0 (Worldwide); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99824
99825,Nipah virus disease,556.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99825
99826,Marburg hemorrhagic fever,500.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99826
99798,Oligodontia,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99798
99802,Hemimegalencephaly,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99802
99803,Haddad syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99803
99806,Oculootodental syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99806
99807,PEHO-like syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99807
99810,Familial porencephaly,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99810
99789,Dentin dysplasia type I,1.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99789
99791,Dentin dysplasia type II,19.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99791
99792,Dentin dysplasia-sclerotic bones syndrome,1.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99792
99772,Cleft velum,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99772
99771,Bifid uvula,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99771
99776,Mosaic trisomy 9 syndrome,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=99776
631073,Autosomal recessive spastic paraplegia type 82,5.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631073
631076,Autosomal recessive spastic paraplegia type 83,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631076
631079,Autosomal recessive spastic paraplegia type 84,2.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631079
631082,Autosomal recessive spastic paraplegia type 85,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631082
631068,Autosomal dominant spastic paraplegia type 80,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631068
631106,Spinocerebellar ataxia type 49,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631106
631103,Spinocerebellar ataxia type 48,50.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631103
631095,Spinocerebellar ataxia type 44,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631095
631088,Autosomal recessive spastic paraplegia type 87,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631088
631085,Autosomal recessive spastic paraplegia type 86,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631085
631248,Mitchell Syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=631248
634475,Mosaic NF2-related schwannomatosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=634475
634492,Mosaic schwannomatosis,0.0 (Worldwide); 0.7928 (United Kingdom); 1.4502 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=634492
634461,Mosaic neurofibromatosis type 1,0.0 (Worldwide); 24.4618 (Finland),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=634461
633228,Isolated proximal femoral focal deficiency,1.55 (Worldwide); 1.55 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=633228
637064,Isolated optic nerve aplasia,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=637064
637061,Isolated optic nerve hypoplasia,25.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=637061
637051,Borna virus encephalitis,18.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=637051
636945,Invasive candidiasis,0.0 (Europe); 2.5 (France),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=636945
636941,Vascular Ehlers-Danlos-polymicrogyria syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=636941
636955,Endemic pemphigus foliaceus,0.0 (Europe); 0.4 (Tunisia),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=636955
636950,Glaucomatocyclitic crisis disease,0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=636950
641829,Neonatal compartment syndrome,60.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641829
641496,Childhood-onset schizophrenia,0.0 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641496
641390,PsAPASH syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641390
641380,PAPASH syndrome,20.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641380
641385,PASS syndrome,16.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641385
641368,Autosomal recessive hyper-IgE syndrome due to ZNF341 deficiency,61.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641368
641353,Infantile neurodegeneration-progressive spasticity-intellectual disability-white matter lesions syndrome,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641353
641361,Neurodevelopmental delay-hypotonia-cerebellar ataxia-cardiac conduction defects syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641361
641350,Immunotherapy induced hypophysitis,12.8074 (Europe); 0.0 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=641350
642099,"Spondyloepimetaphyseal dysplasia with joint laxity, Beighton type",30.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=642099
642085,EXOC6B-related spondyloepimetaphyseal dysplasia with joint laxity,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=642085
633004,KDM3B-related intellectual disability-facial dysmorphism-short stature syndrome,17.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=633004
633014,SLC12A2-related developmental delay-intellectual disability-sensorineural deafness syndrome,13.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=633014
633124,Invasive scopulariopsis infection,0.05 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=633124
633028,CPE-related Prader-Willi-like syndrome,8.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=633028
615970,Chronic intervillositis of unknown etiology,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=615970
617408,Classic eosinophilic pustular folliculitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617408
617304,Amniotic fluid embolism,0.0 (United Kingdom),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617304
617294,Twin anemia-polycythemia sequence,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617294
617301,Selective intrauterine growth restriction,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617301
617297,Twin-reversed arterial perfusion sequence,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617297
621758,Fibrosis-neurodegeneration-cerebral angiomatosis syndrome,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=621758
620371,Gitelman-like kidney tubulopathy due to mitochondrial DNA mutation,14.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620371
620368,EGF-related primary hypomagnesemia with intellectual disability,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620368
620363,Primary hypomagnesemia-generalized seizures-intellectual disability-obesity syndrome,11.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620363
620205,Non-syndromic bicoronal and sagittal craniosynostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620205
620212,Non-syndromic pansynostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620212
620192,Non-syndromic metopic and sagittal craniosynostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620192
620198,Non-syndromic bicoronal and metopic craniosynostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620198
620178,Non-syndromic bilambdoid craniosynostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620178
620186,Non-syndromic unicoronal and sagittal craniosynostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620186
620158,Non-syndromic non-specific multisutural craniosynostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620158
620139,Non-syndromic unifrontosphenoidal craniosynostosis,0.0136 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620139
620146,Non-syndromic unisquamosal craniosynostosis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620146
620102,Non-syndromic unicoronal craniosynostosis,0.1049 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620102
620113,Non-syndromic unilambdoid craniosynostosis,0.0442 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=620113
624268,Non-specific autoimmune cerebellar ataxia without characteristic antibodies,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=624268
624199,Non-specific autoimmune brainstem encephalitis with characteristic antibodies,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=624199
624190,Paraneoplastic isolated brainstem encephalitis,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=624190
624244,Postinfectious cerebellitis,0.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=624244
624216,Non-specific autoimmune brainstem encephalitis without characteristic antibodies,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=624216
623789,Body integrity dysphoria,0.11 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=623789
623801,Acute flaccid myelitis,0.0 (Worldwide); 1.12 (Australia); 0.06 (Netherlands); 0.04 (United States),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=623801
624166,Non-specific autoimmune supratentorial encephalitis with characteristic antibodies,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=624166
624178,Non-specific autoimmune supratentorial encephalitis without characteristic antibodies,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=624178
623615,Autoimmune limbic encephalitis,1.7 (Europe); 0.25 (Europe),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=623615
623626,Paraneoplastic cerebellar degeneration,0.9553 (Europe); 0.2225 (Europe); 0.6869 (France); 0.16 (France); 1.2236 (Italy); 0.285 (Italy),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=623626
622925,X-linked severe syndromic thoracic aortic aneurysm and dissection,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=622925
618891,Chronic neurovisceral acid sphingomyelinase deficiency,0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=618891
617910,Conjunctival malignant melanoma,32.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617910
617916,Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia,100.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617916
617919,F12-associated cold autoinflammatory syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=617919
619941,Congenital neutropenia-combined immunodeficiency due to MKL1 deficiency,3.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=619941
619367,SAMD9L-associated autoinflammatory syndrome,6.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=619367
619953,Familial hyperinflammatory lymphoproliferative immunodeficiency,7.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=619953
619948,Early-onset autoimmunity-autoinflammation-immunodeficiency syndrome due to SOCS1 haploinsufficiency,10.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=619948
619979,Developmental delay-immunodeficiency-leukoencephalopathy-hypohomocysteinemia syndrome,4.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=619979
619363,NOCARH syndrome,15.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=619363
619233,Hereditary persistence of fetal hemoglobin-intellectual disability syndrome,9.0 (Worldwide); 0.0 (Worldwide),http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=619233
